{
  "questions": [
    {
      "body": "Are deletions of chromosomal regulatory boundaries associated with congenital disease?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25315429"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Yes. Enhancer adoption caused by deletions of regulatory boundaries may contribute to a substantial minority of copy-number variation phenotypes and should thus be taken into account in their medical interpretation."
      ], 
      "exact_answer": "yes", 
      "concepts": [
        "http://www.disease-ontology.org/api/metadata/DOID:0080014", 
        "http://www.disease-ontology.org/api/metadata/DOID:1086", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D002872"
      ], 
      "type": "yesno", 
      "id": "587f56c392a5b8ad44000001", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 86, 
          "text": "Deletions of chromosomal regulatory boundaries are associated with congenital disease.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25315429", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 1404, 
          "offsetInEndSection": 1638, 
          "text": "Our results suggest that enhancer adoption caused by deletions of regulatory boundaries may contribute to a substantial minority of copy-number variation phenotypes and should thus be taken into account in their medical interpretation", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25315429", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 85, 
          "text": "Deletions of chromosomal regulatory boundaries are associated with congenital disease", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25315429", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 87, 
          "text": "Deletions of chromosomal regulatory boundaries are associated with congenital disease.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25315429", 
          "endSection": "title"
        }
      ]
    }, 
    {
      "body": "What is the role of the UBC9 enzyme in the protein sumoylation pathway?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25191977", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23078246", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23708104", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23628505", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22525038", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21390240", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27425617", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20800867", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24991007", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19826484", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15087395", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19323834", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26889037", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27142163", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25311713", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23097446", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20561671", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15546615", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21510985", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17698038", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23187003", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22904261", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26582473", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16862185", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18617892", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11867732", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20865051", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21444718", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21278366", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25097219", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23381475", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21518767", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26826302", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25637535"
      ], 
      "triples": [], 
      "ideal_answer": [
        "The small ubiquitin-like modifier (SUMO) pathway in eukaryotes is an essential post-translational modification required for a variety of cellular processes, development and organelle biogenesis. SUMO-conjugating enzyme (Ubc9) is the sole conjunction enzyme in the SUMO pathway."
      ], 
      "exact_answer": [
        [
          "SUMO-conjugating enzyme"
        ]
      ], 
      "concepts": [
        "http://www.uniprot.org/uniprot/UBC9_ARATH", 
        "http://www.uniprot.org/uniprot/UBC9_YEAST", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D058207", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004798", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D025841", 
        "http://www.uniprot.org/uniprot/UBC9_MESAU", 
        "http://www.uniprot.org/uniprot/UBC9_ICTTR", 
        "http://www.uniprot.org/uniprot/UBC9_DICDI", 
        "http://www.uniprot.org/uniprot/UBC9_XENLA", 
        "http://amigo.geneontology.org/amigo/term/GO:0016925", 
        "http://www.uniprot.org/uniprot/UBC9_CHICK", 
        "http://www.uniprot.org/uniprot/UBC9_MOUSE", 
        "http://www.uniprot.org/uniprot/UBC9_SCHPO", 
        "http://www.uniprot.org/uniprot/UBC9_HUMAN"
      ], 
      "type": "factoid", 
      "id": "58a5b1fe60087bc10a000024", 
      "snippets": [
        {
          "offsetInBeginSection": 117, 
          "offsetInEndSection": 335, 
          "text": "Among the proteins involved in the sumoylation pathway, Ubc9 is the sole E2-conjugating enzyme required for sumoylation and plays a central role by interacting with almost all of the partners required for sumoylation. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25191977", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 933, 
          "offsetInEndSection": 1032, 
          "text": "We also found a marked rise in levels of Ubc9, the only SUMO conjugation enzyme identified so far. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23078246", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 98, 
          "offsetInEndSection": 279, 
          "text": "Ubiquitin-conjugating enzyme 9 (Ubc9), the sole conjugating enzyme for sumoylation, regulates protein function and plays an important role in sumoylation-mediated cellular pathways.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23708104", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1026, 
          "offsetInEndSection": 1166, 
          "text": "We observed steady-state expression of SUMO1-3, SUMO-conjugated enzyme-UBC9 and deSUMOylating enzymes - SENPs, throughout normal gestation. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23628505", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 282, 
          "text": "The small ubiquitin-like modifier (SUMO) pathway in eukaryotes is an essential post-translational modification required for a variety of cellular processes, development and organelle biogenesis. SUMO-conjugating enzyme (Ubc9) is an important conjunction enzyme in the SUMO pathway. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22525038", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1174, 
          "offsetInEndSection": 1669, 
          "text": "Western blot analysis, EMSA, ELISA, confocal microscopy and immunoprecipitation demonstrated that drastic tissue hypoxia, elevated levels of proteins conjugated by small ubiquitin-related modifier-1 (SUMO-1), Ubc9 (the only known conjugating enzyme for the sumoylation pathway) or HIF-1\u03b1, augmented sumoylation of HIF-1\u03b1, nucleus-bound translocation and enhanced transcriptional activity of HIF-1\u03b1 in RVLM neurons took place preferentially during the pro-life phase of experimental brain death. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21390240", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 116, 
          "offsetInEndSection": 333, 
          "text": "Among the proteins involved in the sumoylation pathway, Ubc9 is the sole E2-conjugating enzyme required for sumoylation and plays a central role by interacting with almost all of the partners required for sumoylation.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25191977", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 309, 
          "offsetInEndSection": 436, 
          "text": "UBC9 is the only E2 conjugating enzyme involved in this process, and loss of UBC9 completely abolishes the SUMOylation pathway.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27425617", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 235, 
          "text": "Here we have identified host cell proteins involved with the cellular SUMOylation pathway, SUMO-1 (small ubiquitin-like modifier) and UBC9, a SUMO-1 conjugating enzyme that interact with classical swine fever virus (CSFV) Core protein.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20800867", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 97, 
          "offsetInEndSection": 278, 
          "text": "Ubiquitin-conjugating enzyme 9 (Ubc9), the sole conjugating enzyme for sumoylation, regulates protein function and plays an important role in sumoylation-mediated cellular pathways.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23708104", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 341, 
          "offsetInEndSection": 573, 
          "text": "In this study, we found that the SUMOylation pathway was involved in the DENV life cycle, since DENV replication was reduced by silencing the cellular gene Ubc9, which encodes the sole E2-conjugating enzyme required for SUMOylation.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26889037", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 202, 
          "offsetInEndSection": 349, 
          "text": "Here we demonstrate that the synaptic diffusion of Ubc9, the sole conjugating enzyme of the sumoylation pathway, is regulated by synaptic activity.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25311713", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 257, 
          "text": "The SUMO pathway parallels the classical ubiquitinylation pathway with three discrete steps: activation involving the enzyme E1, conjugation involving the E2 enzyme UBC9, and substrate modification through the cooperative association of UBC9 and E3 ligases.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15546615", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 92, 
          "text": "RAP80 interacts with the SUMO-conjugating enzyme UBC9 and is a novel target for sumoylation.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17698038", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 117, 
          "offsetInEndSection": 334, 
          "text": "Among the proteins involved in the sumoylation pathway, Ubc9 is the sole E2-conjugating enzyme required for sumoylation and plays a central role by interacting with almost all of the partners required for sumoylation.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25191977", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 134, 
          "offsetInEndSection": 273, 
          "text": "Although there are multiple E2 enzymes required for ubiquitination, there is only one E2-conjugating enzyme for sumoylation, which is Ubc9.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20561671", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 492, 
          "offsetInEndSection": 709, 
          "text": "Consistent with a role of sumoylation in inhibiting Tec1 activity, specifically increasing sumoylation of Tec1 by fusing it to the sumoylating enzyme Ubc9 leads to a dramatic decrease of Tec1 transcriptional activity.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19826484", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 131, 
          "text": "Ubc9 is an E2-conjugating enzyme required for sumoylation and has been implicated in regulating several critical cellular pathways.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15087395", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 901, 
          "offsetInEndSection": 1132, 
          "text": "We also exposed placental explants to hypoxia to study the effect on the SUMOylation pathway.We observed steady-state expression of SUMO1-3, SUMO-conjugated enzyme-UBC9 and deSUMOylating enzymes - SENPs, throughout normal gestation", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23628505", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 143, 
          "text": "It has been reported that ubiquitin-conjugating enzyme 9 (Ubc9), the unique enzyme2 in the sumoylation pathway, is up-regulated in many cancers", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23187003", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 117, 
          "offsetInEndSection": 333, 
          "text": "Among the proteins involved in the sumoylation pathway, Ubc9 is the sole E2-conjugating enzyme required for sumoylation and plays a central role by interacting with almost all of the partners required for sumoylation", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25191977", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 203, 
          "offsetInEndSection": 349, 
          "text": "Here we demonstrate that the synaptic diffusion of Ubc9, the sole conjugating enzyme of the sumoylation pathway, is regulated by synaptic activity", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25311713", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 174, 
          "offsetInEndSection": 416, 
          "text": "Here, we investigated inhibition of sumoylation as a novel antifibrotic approach.Sumoylation was inhibited by siRNA-mediated knockdown of the Small Ubiquitin-like MOdifiers (SUMO) E2-conjugating enzyme Ubc9, which is essential for sumoylation", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22904261", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 234, 
          "text": "Here we have identified host cell proteins involved with the cellular SUMOylation pathway, SUMO-1 (small ubiquitin-like modifier) and UBC9, a SUMO-1 conjugating enzyme that interact with classical swine fever virus (CSFV) Core protein", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20800867", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 347, 
          "offsetInEndSection": 566, 
          "text": "A new pathway that contributes to mutant CFTR degradation is mediated by the small heat shock protein, Hsp27, which cooperates with Ubc9, the E2 enzyme for SUMOylation, to selectively conjugate mutant CFTR with SUMO-2/3", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26582473", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 420, 
          "offsetInEndSection": 749, 
          "text": "Using transfection of Ets-1 wildtype (WT) or its sumoylation deficient version (Ets-1 K15R/K227R), as well as WT or mutant proteins of the SUMO pathway, we further demonstrated that the E2 SUMO-conjugating enzyme Ubc9 and a E3 SUMO ligase, PIASy, can enhance Ets-1 sumoylation, while a SUMO protease, SENP1, can desumoylate Ets-1", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16862185", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 485, 
          "offsetInEndSection": 863, 
          "text": "The results show that basal SUMO modification is required for stimuli-induced p100 phosphorylation and that blocking SUMOylation of p100, either by site-directed mutation or by short interfering RNA-targeted diminution of E2 SUMO-conjugating enzyme Ubc9, inhibits various physiological stimuli-induced p100 processing and ultimate activation of the alternative NF-kappaB pathway", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18617892", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 290, 
          "offsetInEndSection": 482, 
          "text": "Sumoylation proceeds via an enzymatic pathway that is mechanistically analogous to ubiquitination, but requires a different E1-activating enzyme and Ubc9, a SUMO-specific E2-conjugating enzyme", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11867732", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 151, 
          "text": "SUMO-conjugating enzyme E2 UBC9 mediates viral immediate-early protein SUMOylation in crayfish to facilitate reproduction of white spot syndrome virus.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23097446", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 526, 
          "offsetInEndSection": 695, 
          "text": "OBJECTIVE: To determine the role of ubiquitin-conjugating enzyme 9 (UBC9), a small ubiquitin-like modifier-conjugating enzyme, in cardiomyocyte protein quality control. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25097219", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 521, 
          "offsetInEndSection": 695, 
          "text": "Ubiquitin-conjugating enzyme             9 (Ubc9), the sole conjugating enzyme for sumoylation, regulates protein function             and plays a key role in tumorigenesis. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23381475", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 311, 
          "offsetInEndSection": 438, 
          "text": "UBC9 is the only E2 conjugating enzyme involved in this process, and loss of UBC9 completely abolishes the SUMOylation pathway.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27425617", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 203, 
          "offsetInEndSection": 350, 
          "text": "Here we demonstrate that the synaptic diffusion of Ubc9, the sole conjugating enzyme of the sumoylation pathway, is regulated by synaptic activity.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25311713", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 290, 
          "offsetInEndSection": 483, 
          "text": "Sumoylation proceeds via an enzymatic pathway that is mechanistically analogous to ubiquitination, but requires a different E1-activating enzyme and Ubc9, a SUMO-specific E2-conjugating enzyme.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11867732", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1130, 
          "offsetInEndSection": 1624, 
          "text": "Western blot analysis, EMSA, ELISA, confocal microscopy and immunoprecipitation demonstrated that drastic tissue hypoxia, elevated levels of proteins conjugated by small ubiquitin-related modifier-1 (SUMO-1), Ubc9 (the only known conjugating enzyme for the sumoylation pathway) or HIF-1\u03b1, augmented sumoylation of HIF-1\u03b1, nucleus-bound translocation and enhanced transcriptional activity of HIF-1\u03b1 in RVLM neurons took place preferentially during the pro-life phase of experimental brain death.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21390240", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 343, 
          "offsetInEndSection": 575, 
          "text": "In this study, we found that the SUMOylation pathway was involved in the DENV life cycle, since DENV replication was reduced by silencing the cellular gene Ubc9, which encodes the sole E2-conjugating enzyme required for SUMOylation.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26889037", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 168, 
          "offsetInEndSection": 311, 
          "text": "In this study, we revisited the role of Tax SUMOylation using a strategy based on the targeting of Ubc9, the unique E2 SUMO-conjugating enzyme.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24991007", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 933, 
          "offsetInEndSection": 1155, 
          "text": "Taken together, these findings provide evidence for regulated sumoylation as a mechanism to modulate the activity of Tec1 and validate Ubc9 fusion-directed sumoylation as a useful approach for studying protein sumoylation.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19826484", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 353, 
          "offsetInEndSection": 518, 
          "text": "We report that the high risk HPVE6 proteins reduce the intracellular quantity of the sole SUMO conjugation enzyme, Ubc9, concomitant with decreased host sumoylation.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21510985", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 996, 
          "offsetInEndSection": 1135, 
          "text": "We observed steady-state expression of SUMO1-3, SUMO-conjugated enzyme-UBC9 and deSUMOylating enzymes - SENPs, throughout normal gestation.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23628505", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 69, 
          "text": "As the sole E2 enzyme for SUMOylation, Ubc9 is predominantly nuclear.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25637535", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 135, 
          "offsetInEndSection": 397, 
          "text": "Expression of small ubiquitin-like modifier (SUMO) molecules, SUMO E1 activating enzymes SAE1 and SAE2, SUMO E2 conjugating enzyme UBC9, and de-sumoylation enzyme sentrin/SUMO-specific proteases (SENP)1 was immunolocalized in rat intervertebral disc (IVD) cells.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26826302", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Can the Micro-C XL method achieve mononucleosome resolution?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/27723753"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Yes. Micro-C XL is an improved method for analysis of chromosome folding at mononucleosome resolution."
      ], 
      "exact_answer": "yes", 
      "concepts": [], 
      "type": "yesno", 
      "id": "587dfde9ae05ffb474000001", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 105, 
          "text": "We present Micro-C XL, an improved method for analysis of chromosome folding at mononucleosome resolution", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27723753", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 106, 
          "text": "We present Micro-C XL, an improved method for analysis of chromosome folding at mononucleosome resolution.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27723753", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 86, 
          "text": "Micro-C XL: assaying chromosome conformation from the nucleosome to the entire genome.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27723753", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 413, 
          "offsetInEndSection": 538, 
          "text": "Micro-C XL provides a single assay to interrogate chromosome folding at length scales from the nucleosome to the full genome.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27723753", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Can Diabetes be caused by a defect in a potassium chanel?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/27118464", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25931474", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24827651", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15746700"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Mutations in the KATP channel can lead to neonatal diabetes.", 
        "Mutations in KATP channel genes can result in hypo- or hypersecretion of insulin, as in neonatal diabetes mellitus and congenital hyperinsulinism, respectively."
      ], 
      "exact_answer": "yes", 
      "concepts": [
        "http://www.disease-ontology.org/api/metadata/DOID:9351", 
        "http://www.biosemantics.org/jochem#http://www.biosemantics.org/jochem#:4277521", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D003920", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011188", 
        "http://www.biosemantics.org/jochem#4277521", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D003921", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016640", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D003924", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D003923", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D003922", 
        "http://www.disease-ontology.org/api/metadata/DOID:11717", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011189", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D024681", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D015221"
      ], 
      "type": "yesno", 
      "id": "58a0a28a78275d0c4a000051", 
      "snippets": [
        {
          "offsetInBeginSection": 146, 
          "offsetInEndSection": 306, 
          "text": "Mutations in KATP channel genes can result in hypo- or hypersecretion of insulin, as in neonatal diabetes mellitus and congenital hyperinsulinism, respectively.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27118464", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 307, 
          "offsetInEndSection": 472, 
          "text": "To date, all patients affected by neonatal diabetes due to a mutation in the pore-forming subunit of the channel (Kir6.2, KCNJ11) are heterozygous for the mutation. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27118464", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 479, 
          "offsetInEndSection": 571, 
          "text": "e report the first clinical case of neonatal diabetes caused by a homozygous KCNJ11 mutation", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27118464", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 106, 
          "text": "Diffuse congenital hyperinsulinism in infancy (CHI-D) arises from mutations inactivating the KATP channel;", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25931474", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 178, 
          "text": "We report a case of a 6-week-old infant with diabetes mellitus based on a genetic defect in the sulfonylurea receptor 1 (SUR1), an ATP-sensitive potassium (KATP) channel protein.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24827651", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1094, 
          "offsetInEndSection": 1150, 
          "text": "In diabetes, vascular KATP channel function is impaired.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15746700", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which fimA genotypes are associated with disease?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26387644", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26937292", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26600627", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24466164", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23646850", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23264452", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22466890", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22549664", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22053966", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20219603"
      ], 
      "triples": [], 
      "ideal_answer": [
        "FimA has been characterized as an important virulence factor for P. gingivalis, and many studies, both animal experiments and clinical investigations, have characterized fimA genotypes II, Ib, and IV to be associated with disease (periodontitis and cardiovascular disease)"
      ], 
      "exact_answer": [
        [
          "genotypes II"
        ], 
        [
          "genotypes Ib"
        ], 
        [
          "genotypes IV"
        ]
      ], 
      "concepts": [], 
      "type": "list", 
      "id": "58a94483ee23e0236b000003", 
      "snippets": [
        {
          "offsetInBeginSection": 476, 
          "offsetInEndSection": 750, 
          "text": " FimA has been characterized as an important virulence factor for P. gingivalis, and many studies, both animal experiments and clinical investigations, have characterized fimA genotypes II, Ib, and IV to be associated with disease (periodontitis and cardiovascular disease) ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26387644", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 11, 
          "offsetInEndSection": 179, 
          "text": "Long fimbriae (FimA) are important virulence factors of Porphyromonas gingivalis. Based on the diversity of the fimA gene, this species is classified into 6 genotypes. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20219603", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 782, 
          "offsetInEndSection": 1066, 
          "text": " In cases of chronic apical periodontitis, P. gingivalis variant type IV was the most prevalent (24%), followed by types I (20%), II (16%), and III (8%). In acute abscess samples, variant type II was the most prevalent (12%), followed by types III and IV (8% of each) and type I (4%).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20219603", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 959, 
          "offsetInEndSection": 1082, 
          "text": "We show that P. gingivalis strains with genotype I and II of FimA are efficient in interaction with saliva or S. gordonii. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22053966", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1238, 
          "offsetInEndSection": 1435, 
          "text": "A strong association between Porphyromonas gingivalis fimA genotypes II and Ib and chronic periodontitis exists in the Spanish population. The most prevalent genotype in periodontal patients is II.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22549664", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1022, 
          "offsetInEndSection": 1206, 
          "text": "Our results suggest that the presence of P. gingivalis is associated with periodontal diseases, and that the type II, IV and Ib/II combination are the most common among fimA genotypes.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22466890", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1218, 
          "offsetInEndSection": 1361, 
          "text": "Statistical analysis, however, revealed that a more significant correlation was found between periodontitis and the occurrence of type Ib fimA.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23264452", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1667, 
          "offsetInEndSection": 1755, 
          "text": " Type II of fimA was the most prevalent genotype of P. gingivalis in patients with AgP. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23646850", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1211, 
          "offsetInEndSection": 1409, 
          "text": "The population of Tregs further decreased in patients with type II FimA compared with the other types. P.gingivlias FimA genotype II was the dominant type associated with decreased Treg population. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24466164", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1099, 
          "offsetInEndSection": 1220, 
          "text": "A trend toward a greater frequency of FimA II genotype in patients with moderate and severe periodontitis was determined.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26600627", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1251, 
          "offsetInEndSection": 1441, 
          "text": "The fimA type Ib genotype of P. gingivalis was found to play a critical role in the destruction of peri-implant tissue, suggesting that it may be a distinct risk factor for peri-implantitis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26937292", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Is rucaparib used for ovarian cancer treatment?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/27141062", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27141070", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27022037", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27702817", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27716873", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27908594", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27940438", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23729402", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27087632", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26281686", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24962512", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27002934"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Yes, rucaparib is a PARP inhibitor that is used for ovarian cancer treatment."
      ], 
      "exact_answer": "yes", 
      "concepts": [
        "http://www.disease-ontology.org/api/metadata/DOID:2394", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013812", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D024221", 
        "http://www.disease-ontology.org/api/metadata/DOID:4001"
      ], 
      "type": "yesno", 
      "id": "588485bbe56acf517600000b", 
      "snippets": [
        {
          "offsetInBeginSection": 1323, 
          "offsetInEndSection": 1607, 
          "text": "While olaparib is the first PARP inhibitor to receive approval for ovarian cancer treatment, others including rucaparib and niraparib are clearly effective in this disease and, within the next year or two, the results of ongoing randomised trials will clarify their respective roles. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27141062", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1219, 
          "offsetInEndSection": 1359, 
          "text": "Similar trials with other PARP inhibitors (rucaparib, niraparib and veliparib) are in progress and include non-BRCA-mutated ovarian cancer. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27141070", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1570, 
          "offsetInEndSection": 1840, 
          "text": "IMPLICATIONS FOR PRACTICE: The poly(ADP-ribose) polymerase (PARP) inhibitor olaparib has recently received approval from the Food and Drug Administration (FDA) and European Medicines Agency (EMA), with a second agent (rucaparib) likely to be approved in the near future.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27022037", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 99, 
          "text": "Ovarian Cancers Harbour Defects in Non-Homologous End Joining Resulting in Resistance to Rucaparib.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27702817", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 1256, 
          "offsetInEndSection": 1413, 
          "text": "There are a number of other PARP inhibitors in late phase clinical development in ovarian cancer including rucaparib, niraparib, veliparib, and talazoparib. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27716873", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 145, 
          "text": "Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27908594", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 3353, 
          "offsetInEndSection": 3757, 
          "text": "INTERPRETATION: In patients with BRCA mutant or BRCA wild-type and LOH high platinum-sensitive ovarian carcinomas treated with rucaparib, progression-free survival was longer than in patients with BRCA wild-type LOH low carcinomas. Our results suggest that assessment of tumour LOH can be used to identify patients with BRCA wild-type platinum-sensitive ovarian cancers who might benefit from rucaparib. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27908594", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 61, 
          "text": "Genomic LOH May Predict Rucaparib Response in Ovarian Cancer.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27940438", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 102, 
          "text": "High LOH is associated with response to the PARP inhibitor rucaparib in BRCA wild-type ovarian cancer.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27940438", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 128, 
          "text": "Therapeutic potential of the poly(ADP-ribose) polymerase inhibitor rucaparib for the treatment of sporadic human ovarian cancer.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23729402", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 1317, 
          "offsetInEndSection": 1600, 
          "text": "While olaparib is the first PARP inhibitor to receive approval for ovarian cancer treatment, others including rucaparib and niraparib are clearly effective in this disease and, within the next year or two, the results of ongoing randomised trials will clarify their respective roles.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27141062", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1596, 
          "offsetInEndSection": 1762, 
          "text": "These results support further clinical evaluation of rucaparib either as a single agent or as an adjunct to chemotherapy for the treatment of sporadic ovarian cancer.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23729402", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 170, 
          "text": "Here, we investigate the potential role of the PARP inhibitor rucaparib (CO-338, formerly known as AG014699 and PF-01367338) for the treatment of sporadic ovarian cancer.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23729402", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 501, 
          "offsetInEndSection": 704, 
          "text": "Rucaparib received US FDA Breakthrough Therapy designation for treatment of platinum-sensitive BRCA-mutated advanced ovarian cancer patients who received greater than two lines of platinum-based therapy.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27087632", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1605, 
          "offsetInEndSection": 1771, 
          "text": "These results support further clinical evaluation of rucaparib either as a single agent or as an adjunct to chemotherapy for the treatment of sporadic ovarian cancer.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23729402", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 124, 
          "offsetInEndSection": 650, 
          "text": "Ongoing clinical trials are assessing the efficacy of rucaparib alone or in combination with other cytotoxic drugs, mainly in breast and ovarian cancer patients with mutations in the breast cancer associated (BRCA) genes.PURPOSE: We aimed to establish whether the multidrug efflux transporters ABCG2 (BCRP) and ABCB1 (P-gp, MDR1) affect the oral availability and brain penetration of rucaparib in mice.RESULTS: In vitro, rucaparib was efficiently transported by both human ABCB1 and ABCG2, and very efficiently by mouse Abcg2.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24962512", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 127, 
          "text": "Therapeutic potential of the poly(ADP-ribose) polymerase inhibitor rucaparib for the treatment of sporadic human ovarian cancer", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23729402", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 169, 
          "text": "Here, we investigate the potential role of the PARP inhibitor rucaparib (CO-338, formerly known as AG014699 and PF-01367338) for the treatment of sporadic ovarian cancer", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23729402", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1605, 
          "offsetInEndSection": 1805, 
          "text": "These results support further clinical evaluation of rucaparib either as a single agent or as an adjunct to chemotherapy for the treatment of sporadic ovarian cancer.<CopyrightInformation>\u00a92013 AACR</", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23729402", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 112, 
          "offsetInEndSection": 619, 
          "text": "Ongoing clinical trials are assessing the efficacy of rucaparib alone or in combination with other cytotoxic drugs, mainly in breast and ovarian cancer patients with mutations in the breast cancer associated (BRCA) genes.We aimed to establish whether the multidrug efflux transporters ABCG2 (BCRP) and ABCB1 (P-gp, MDR1) affect the oral availability and brain penetration of rucaparib in mice.In vitro, rucaparib was efficiently transported by both human ABCB1 and ABCG2, and very efficiently by mouse Abcg2", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24962512", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 171, 
          "text": "Here, we investigate the potential role of the PARP inhibitor rucaparib (CO-338, formerly known as AG014699 and PF-01367338) for the treatment of sporadic ovarian cancer. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23729402", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1323, 
          "offsetInEndSection": 1606, 
          "text": "While olaparib is the first PARP inhibitor to receive approval for ovarian cancer treatment, others including rucaparib and niraparib are clearly effective in this disease and, within the next year or two, the results of ongoing randomised trials will clarify their respective roles.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27141062", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 253, 
          "offsetInEndSection": 570, 
          "text": "We investigated the efficacy and safety of single-agent rucaparib in germline (g) BRCA mutation carriers with advanced breast and ovarian cancers.Phase II, open-label, multicentre trial of rucaparib in proven BRCA-1/2 mutation carriers with advanced breast and or ovarian cancer, WHO PS 0-1 and normal organ function.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27002934", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1605, 
          "offsetInEndSection": 1806, 
          "text": "These results support further clinical evaluation of rucaparib either as a single agent or as an adjunct to chemotherapy for the treatment of sporadic ovarian cancer.<CopyrightInformation>\u00a92013 AACR</C", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23729402", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1190, 
          "offsetInEndSection": 1329, 
          "text": "Similar trials with other PARP inhibitors (rucaparib, niraparib and veliparib) are in progress and include non-BRCA-mutated ovarian cancer.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27141070", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 504, 
          "offsetInEndSection": 707, 
          "text": "Rucaparib received US FDA Breakthrough Therapy designation for treatment of platinum-sensitive BRCA-mutated advanced ovarian cancer patients who received greater than two lines of platinum-based therapy.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27087632", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 129, 
          "text": "Therapeutic potential of the poly(ADP-ribose) polymerase inhibitor rucaparib for the treatment of sporadic human ovarian cancer.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23729402", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 1605, 
          "offsetInEndSection": 1772, 
          "text": "These results support further clinical evaluation of rucaparib either as a single agent or as an adjunct to chemotherapy for the treatment of sporadic ovarian cancer..", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23729402", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is the role of cohesins at the IFNG locus?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/19458616"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Cohesins form cell-type-specific long-range chromosomal cis-interactions at the developmentally regulated IFNG locus. Hence, the ability of cohesin to constrain chromosome topology is used not only for the purpose of sister chromatid cohesion, but also to dynamically define the spatial conformation of specific loci. This new aspect of cohesin function is probably important for normal development and disease."
      ], 
      "concepts": [
        "http://www.uniprot.org/uniprot/IFNG_MACMU", 
        "http://www.uniprot.org/uniprot/IFNG_LAMGL", 
        "http://www.uniprot.org/uniprot/IFNG_MACFA", 
        "http://www.uniprot.org/uniprot/IFNG_NUMME", 
        "http://www.uniprot.org/uniprot/IFNG_PANTR", 
        "http://www.uniprot.org/uniprot/IFNG_PAPAN", 
        "http://www.uniprot.org/uniprot/IFNG_PERMA", 
        "http://www.uniprot.org/uniprot/IFNG_PHACO", 
        "http://www.uniprot.org/uniprot/IFNG_PHOSU", 
        "http://www.uniprot.org/uniprot/IFNG_RABIT"
      ], 
      "type": "summary", 
      "id": "588533cee56acf5176000014", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 87, 
          "text": "Cohesins form chromosomal cis-interactions at the developmentally regulated IFNG locus.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19458616", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 828, 
          "offsetInEndSection": 1310, 
          "text": "Here we show that cohesin forms the topological and mechanistic basis for cell-type-specific long-range chromosomal interactions in cis at the developmentally regulated cytokine locus IFNG. Hence, the ability of cohesin to constrain chromosome topology is used not only for the purpose of sister chromatid cohesion, but also to dynamically define the spatial conformation of specific loci. This new aspect of cohesin function is probably important for normal development and disease", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19458616", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 823, 
          "offsetInEndSection": 1012, 
          "text": "Here we show that cohesin forms the topological and mechanistic basis for cell-type-specific long-range chromosomal interactions in cis at the developmentally regulated cytokine locus IFNG.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19458616", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 86, 
          "text": "Cohesins form chromosomal cis-interactions at the developmentally regulated IFNG locus", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19458616", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 828, 
          "offsetInEndSection": 1016, 
          "text": "Here we show that cohesin forms the topological and mechanistic basis for cell-type-specific long-range chromosomal interactions in cis at the developmentally regulated cytokine locus IFNG", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19458616", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 88, 
          "text": "Cohesins form chromosomal cis-interactions at the developmentally regulated IFNG locus.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19458616", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 828, 
          "offsetInEndSection": 1017, 
          "text": "Here we show that cohesin forms the topological and mechanistic basis for cell-type-specific long-range chromosomal interactions in cis at the developmentally regulated cytokine locus IFNG.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19458616", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Describe Wellens' Syndrome.", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/27041816", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27473406", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27951539", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27609724", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25954534", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18394847", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21106319", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21267975", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23420731", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17720261", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26432739", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18649894", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16380872", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21699846", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12442245", 
        "http://www.ncbi.nlm.nih.gov/pubmed/2357882", 
        "http://www.ncbi.nlm.nih.gov/pubmed/14708424", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25161778"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Wellens Syndrome (WS) is a condition characterized by typical changes in ECG, which are biphasic T-wave inversions (less common) or symmetric and deeply inverted T waves (including 75%) in lead V2-V3 chest derivations."
      ], 
      "concepts": [], 
      "type": "summary", 
      "id": "589a246578275d0c4a00002e", 
      "snippets": [
        {
          "offsetInBeginSection": 1, 
          "offsetInEndSection": 233, 
          "text": "NTRODUCTION: Wellens Syndrome (WS) is a condition characterized by typical changes in ECG, which are biphasic T-wave inversions (less common) or symmetric and deeply inverted T waves (including 75%) in lead V2-V3 chest derivations. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27041816", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 207, 
          "text": "BACKGROUND: Reperfusion after coronary occlusion (myocardial infarction, MI), as in Wellens' syndrome, is often represented on ECG as T-wave inversion in the leads overlying the affected myocardial wall(s). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27473406", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 201, 
          "offsetInEndSection": 394, 
          "text": "Her presentation was concerning for acute coronary syndrome, Wellens syndrome in particular, given the elevated troponin levels, lack of ST segment changes, and characteristic T-wave findings. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27951539", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 55, 
          "text": "Omnious T-wave inversions: Wellens' syndrome revisited.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27609724", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 154, 
          "text": "Wellens' syndrome is characterized by T-wave changes in electrocardiogram (EKG) during pain-free period in a patient with intermittent angina chest pain. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27609724", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 314, 
          "text": "We describe a case of a 42-year-old man, with a previous episode of angina and a normal ECG and serum cardiac markers, and a two months later finding of biphasic T wave in leads V2-V3 and deeply inverted T wave in V4-V5 at a asymptomatic occupational evaluation. This is a typical ECG pattern of Wellens' syndrome.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25954534", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 518, 
          "offsetInEndSection": 859, 
          "text": "Whereas the Wellens' syndrome is characterized by symmetrically inverted T-waves with preserved R waves in the precordial leads suggestive of impending myocardial infarction due to a critical proximal left anterior descending stenosis, the pseudo-Wellens' syndrome caused by coronary artery spasm has also rarely been reported in literature.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26432739", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 243, 
          "text": "The Wellens electrocardiogram (ECG) pattern of dynamic T-wave inversion in the anterior leads is observed in clinical conditions characterized by reversible left ventricular (LV) dysfunction (stunned myocardium), either ischemic or nonischemic", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21699846", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 218, 
          "text": "Wellens Syndrome (WS) is a condition characterized by typical changes in ECG, which are biphasic T-wave inversions (less common) or symmetric and deeply inverted T waves (including 75%) in lead V2-V3 chest derivations.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27041816", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 113, 
          "offsetInEndSection": 260, 
          "text": "The initial electrocardiogram (ECG) showed biphasic T-waves in V2-V4, which was recognized as Wellens' syndrome, or acute coronary T-wave syndrome.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18394847", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which human disease is associated with mutated UBQLN2", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/27477512", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27480424", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27834214", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27400686", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25398946", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26075709"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Ggene mutations in UBQLN2 cause dominant inheritance of amyotrophic lateral sclerosis (ALS)."
      ], 
      "exact_answer": [
        [
          "ALS", 
          "amyotrophic lateral sclerosis"
        ]
      ], 
      "concepts": [], 
      "type": "factoid", 
      "id": "58bc5e2202b8c60953000002", 
      "snippets": [
        {
          "offsetInBeginSection": 851, 
          "offsetInEndSection": 1039, 
          "text": "Finally, we found that mutations in UBQLN2, which lead to neurodegeneration in humans, are defective in chaperone binding, impair aggregate clearance, and cause cognitive deficits in mice.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27477512", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1008, 
          "offsetInEndSection": 1051, 
          "text": "UBQLN2 mutations are detected in ALS cases.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27480424", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 87, 
          "text": "C9ORF72 and UBQLN2 mutations are causes of amyotrophic lateral sclerosis in New Zealand", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27480424", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 93, 
          "text": "Missense mutations in ubiquilin 2 (UBQLN2) cause ALS with frontotemporal dementia (ALS-FTD). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27834214", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 519, 
          "text": "Amyotrophic Lateral Sclerosis (ALS) is the most frequent motor neuron disease in adults. Classical ALS is characterized by the death of upper and lower motor neurons leading to progressive paralysis. Approximately 10\u00a0% of ALS patients have familial form of the disease. Numerous different gene mutations have been found in familial cases of ALS, such as mutations in superoxide dismutase 1 (SOD1), TAR DNA-binding protein 43 (TDP-43), fused in sarcoma (FUS), C9ORF72, ubiquilin-2 (UBQLN2), optineurin (OPTN) and others.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27400686", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 157, 
          "text": "A mutation in the ubiquilin 2 gene (UBQLN2) was recently identified as a cause of X-linked amyotrophic lateral sclerosis (ALS)/frontotemporal dementia (FTD) ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25398946", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 100, 
          "offsetInEndSection": 258, 
          "text": "Interest in the proteins has been heightened by the discovery that gene mutations in UBQLN2 cause dominant inheritance of amyotrophic lateral sclerosis (ALS).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26075709", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which ApoE isoform is associated with hyperlipoproteinemia?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25328986", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22981543", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21467726", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11076954", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11701639", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9649566", 
        "http://www.ncbi.nlm.nih.gov/pubmed/2804053", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8198763", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18823563", 
        "http://www.ncbi.nlm.nih.gov/pubmed/2341812", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21716749", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10419818", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15630629", 
        "http://www.ncbi.nlm.nih.gov/pubmed/6578216", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8175773", 
        "http://www.ncbi.nlm.nih.gov/pubmed/1730728", 
        "http://www.ncbi.nlm.nih.gov/pubmed/7635945", 
        "http://www.ncbi.nlm.nih.gov/pubmed/3585172", 
        "http://www.ncbi.nlm.nih.gov/pubmed/2048769", 
        "http://www.ncbi.nlm.nih.gov/pubmed/2609136", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11163021"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Type III hyperlipoproteinemia (HLP) is characterized by the accumulation of remnant lipoproteins in the plasma and it is associated with ApoE2 isoform. ApoE2 binds poorly to low density lipoprotein receptors, resulting in defective remnant lipoprotein clearance."
      ], 
      "exact_answer": [
        [
          "ApoE2 isoform", 
          "Apolipoprotein E2 isoform"
        ]
      ], 
      "concepts": [
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D006951", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D053329", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D006952", 
        "http://www.disease-ontology.org/api/metadata/DOID:3145", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011973"
      ], 
      "type": "factoid", 
      "id": "58b6bd2622d300530900000c", 
      "snippets": [
        {
          "offsetInBeginSection": 557, 
          "offsetInEndSection": 860, 
          "text": "ApoE2 which differs from apoE3 by the single amino acid substitution Arg158Cys located near the LDLR recognition site exhibits impaired binding to the receptor and an inability to promote clearance of TG-rich lipoprotein remnant particles; this isoform is associated with Type-III hyperlipoproteinemia. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25328986", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 12, 
          "offsetInEndSection": 557, 
          "text": "Type III hyperlipoproteinemia (HLP), a disorder associated with a high incidence of premature cardiovascular diseases, is characterized by the accumulation of remnant lipoproteins in the plasma. The primary genetic defect in patients with type III HLP is the presence of apolipoprotein E2 (apoE2), an isoform of apoE, and accumulation of remnant lipoproteins in the plasma has been thought to be attributable to the presence of apoE2, which bind poorly to low density lipoprotein receptors, resulting in defective remnant lipoprotein clearance. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22981543", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 321, 
          "offsetInEndSection": 470, 
          "text": "ApoE2 polymorphism is well known for its relationship to type III hyperlipoproteinemia, and the common apoE2 isoform is encoded by the R158C allele. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21467726", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 171, 
          "offsetInEndSection": 359, 
          "text": "Reduced expression of the LDLR is believed to be a precipitating factor in the pathogenesis of type III hyperlipoproteinemia (HLP) in some humans homozygous for the apoE2 allele (APOE*2). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11076954", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 935, 
          "offsetInEndSection": 1140, 
          "text": "Overall, the 2.3-fold normal level of LDLR message in heterozygotes completely ameliorates type III HLP caused by the homozygosity for the human APOE*2 allele, normalizing their plasma lipoprotein profile.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11076954", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 757, 
          "offsetInEndSection": 1175, 
          "text": "Isoform (allele)-specific effects include the association of apoE2 with the genetic disorder type III hyperlipoproteinemia and with both increased and decreased risk for atherosclerosis and the association of apoE4 with increased risk for both atherosclerosis and Alzheimer's disease, impaired cognitive function, and reduced neurite outgrowth; isoform-specific differences in cellular signaling events may also exist.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11701639", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 134, 
          "text": "Type III hyperlipoproteinemia and spontaneous atherosclerosis in mice resulting from gene replacement of mouse Apoe with human Apoe*2.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9649566", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 202, 
          "offsetInEndSection": 309, 
          "text": "Mice expressing human apoE2 (2/2) have virtually all the characteristics of type III hyperlipoproteinemia. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9649566", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 137, 
          "offsetInEndSection": 377, 
          "text": "ApoE has three major genetically determined isoproteins in plasma, designated apoE-2, apoE-3 and apoE-4, with homozygosity for the allele coding for apoE-2 being associated with dysbetalipoproteinemia or type III hyperlipoproteinemia (HLP).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2804053", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 115, 
          "text": "Type III hyperlipoproteinemia typically is associated with homozygosity for apolipoprotein (apo) E2(Arg158----Cys).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1730728", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 156, 
          "offsetInEndSection": 271, 
          "text": "ApoE is a polymorphic protein, and homozygosity for the E2 allele is associated with type III hyperlipoproteinemia.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6578216", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 227, 
          "text": "Homozygosity for the apolipoprotein (apo) E variant apoE2(158 Arg----Cys) invariably gives rise to dysbetalipoproteinemia, and when associated with obesity or a gene for hyperlipidemia, results in type III hyperlipoproteinemia.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2341812", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 138, 
          "offsetInEndSection": 378, 
          "text": "ApoE has three major genetically determined isoproteins in plasma, designated apoE-2, apoE-3 and apoE-4, with homozygosity for the allele coding for apoE-2 being associated with dysbetalipoproteinemia or type III hyperlipoproteinemia (HLP).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2804053", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1389, 
          "offsetInEndSection": 1565, 
          "text": "From the data of a high association of apo E4 allele and cardiovascular disease with hypercholesterolemia, apo E isoform may be one of the determinants of hyperlipoproteinemia.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8198763", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 756, 
          "offsetInEndSection": 1172, 
          "text": "Isoform (allele)-specific effects include the association of apoE2 with the genetic disorder type III hyperlipoproteinemia and with both increased and decreased risk for atherosclerosis and the association of apoE4 with increased risk for both atherosclerosis and Alzheimers disease, impaired cognitive function, and reduced neurite outgrowth; isoform-specific differences in cellular signaling events may also exist", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11701639", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 136, 
          "offsetInEndSection": 478, 
          "text": "Whereas the association of the apo E2 isoform with primary dysbetalipoproteinemia and hyperlipoproteinemia type III is well established, the plasma- and LDL-cholesterol lowering effects of apo E2 and the phenomenon of apo E4 raising these parameters on the development of coronary heart disease is still a matter of controversial discussion. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2048769", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 207, 
          "offsetInEndSection": 557, 
          "text": "The primary genetic defect in patients with type III HLP is the presence of apolipoprotein E2 (apoE2), an isoform of apoE, and accumulation of remnant lipoproteins in the plasma has been thought to be attributable to the presence of apoE2, which bind poorly to low density lipoprotein receptors, resulting in defective remnant lipoprotein clearance. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22981543", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 249, 
          "offsetInEndSection": 379, 
          "text": "In the normal population, ApoE3 isoform is the most prevalent, and ApoE2 or E4 is frequently associated with hyperlipoproteinemia.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21716749", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 557, 
          "offsetInEndSection": 859, 
          "text": "ApoE2 which differs from apoE3 by the single amino acid substitution Arg158Cys located near the LDLR recognition site exhibits impaired binding to the receptor and an inability to promote clearance of TG-rich lipoprotein remnant particles; this isoform is associated with Type-III hyperlipoproteinemia.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25328986", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 246, 
          "offsetInEndSection": 372, 
          "text": "In the normal population apo E3 isoform is most prevalent and apo E2 or E4 is frequently associated with hyperlipoproteinemia.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8198763", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1394, 
          "offsetInEndSection": 1570, 
          "text": "From the data of a high association of apo E4 allele and cardiovascular disease with hypercholesterolemia, apo E isoform may be one of the determinants of hyperlipoproteinemia.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8198763", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 379, 
          "offsetInEndSection": 505, 
          "text": "We describe a new variant of apoE, apoE-1Harrisburg, which is, in contrast to apoE-2, dominantly associated with type III HLP.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2804053", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 321, 
          "offsetInEndSection": 469, 
          "text": "ApoE2 polymorphism is well known for its relationship to type III hyperlipoproteinemia, and the common apoE2 isoform is encoded by the R158C allele.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21467726", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 156, 
          "text": "Type III hyperlipoproteinemia is characterized by delayed chylomicron and VLDL remnant catabolism and is associated with homozygosity for the apoE-2 allele.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7635945", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 228, 
          "offsetInEndSection": 429, 
          "text": "The association of the E2/2 phenotype with type IV/V hyperlipoproteinemia rather than type III hyperlipoproteinemia in identical twin brothers led us to investigate the primary structure of their apoE.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2341812", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 290, 
          "offsetInEndSection": 402, 
          "text": "ApoE2 is defective in binding and homozygosity for apoE2 is associated with type III hyperlipoproteinemia (HLP).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11163021", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 304, 
          "offsetInEndSection": 486, 
          "text": "Homozygous carriers of apoE2 have an increased risk to develop type III hyperlipoproteinemia, whereas apoE4 is associated with elevated levels of low-density lipoprotein cholesterol.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15630629", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 276, 
          "offsetInEndSection": 407, 
          "text": "Patients homozygous for apolipoprotein E2 are predisposed to type III hyperlipoproteinemia, and apoE2 may be protective against AD.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10419818", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Could hypophosphatemic rickets cause craniosynostosis?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26824597", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23348263", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23466123", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22220162", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19242361", 
        "http://www.ncbi.nlm.nih.gov/pubmed/6265607", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27303470", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26510652", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25014884", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9069051", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17551721"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Yes, hypophosphatemic rickets could cause craniosynostosis."
      ], 
      "exact_answer": "yes", 
      "concepts": [
        "http://www.disease-ontology.org/api/metadata/DOID:10609", 
        "http://www.disease-ontology.org/api/metadata/DOID:2340", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012279", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D003398", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D063730", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D053098", 
        "http://www.disease-ontology.org/api/metadata/DOID:0050445", 
        "http://www.disease-ontology.org/api/metadata/DOID:0050948", 
        "http://www.disease-ontology.org/api/metadata/DOID:0050949", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D010294", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005624"
      ], 
      "type": "yesno", 
      "id": "58b9585c22d3005309000010", 
      "snippets": [
        {
          "offsetInBeginSection": 10, 
          "offsetInEndSection": 177, 
          "text": "This study examines a series of patients with hypophosphatemic rickets and craniosynostosis to characterize the clinical course and associated craniofacial anomalies. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26824597", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 73, 
          "text": "Hypophosphatemic rickets and craniosynostosis: a multicenter case series.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26824597", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 185, 
          "offsetInEndSection": 330, 
          "text": "A 20-year retrospective review identified patients with hypophosphatemic rickets and secondary craniosynostosis at 3 major craniofacial centers. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26824597", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1244, 
          "offsetInEndSection": 1549, 
          "text": "Secondary craniosynostosis develops postnatally due to metabolic or mechanical factors. The most common metabolic cause is hypophosphatemic rickets, which has a variety of etiologies. Head shape changes occur later and with a more heterogeneous presentation compared with that of primary craniosynostosis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26824597", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1513, 
          "offsetInEndSection": 1651, 
          "text": "Patients with multisutural involvement or X-linked hypophosphatemic rickets had a significant delay in presentation for craniosynostosis. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23348263", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 466, 
          "text": "Craniosynostosis can be gene-linked, or caused by metabolic diseases, such as rickets, which results from a deficiency or impaired metabolism of vitamin D, magnesium, phosphorus or calcium leading to hypomineralization of the bone. X-linked dominant hypophosphatemic rickets (XLHR) is the most prevalent genetic type of hypophosphatemic rickets and is caused by germ line mutations in the PHEX-gene. In XLHR, only few case reports of craniosynostosis were described.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23466123", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 86, 
          "text": "Papilledema in the setting of x-linked hypophosphatemic rickets with craniosynostosis.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22220162", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 165, 
          "offsetInEndSection": 277, 
          "text": "Case report of a 3-year-old female presenting with papilledema resulting from craniosynostosis secondary to XLH.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22220162", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 55, 
          "text": "X-linked hypophosphatemic rickets and craniosynostosis.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19242361", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 333, 
          "offsetInEndSection": 599, 
          "text": "X-linked hypophosphatemic (XLH) rickets is the most common form of metabolic rickets, and there have been reports linking XLH rickets to craniosynostosis. A clinical report of a patient with XLH rickets and craniosynostosis is presented with a review of literature. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19242361", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 758, 
          "offsetInEndSection": 845, 
          "text": "This may be the reason for the common association of craniosynostosis and XLH rickets. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19242361", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 287, 
          "text": "Craniosynostosis and associated craniofacial deformities, such as frontal bossing, often occur as symptoms of vitamin D-resistant rickets in children. Similar skull deformities develop in mice with X-linked dominant hypophosphatemia, the most common form of vitamin D-resistant rickets. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6265607", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 914, 
          "offsetInEndSection": 1191, 
          "text": "The x-linked hypophosphatemic mouse is an animal model that can be used to study the role of vitamin D-resistant rickets in the development of craniosynostosis, to relate craniosynostosis to the development of associated skull deformities, and to test new treatment procedures.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6265607", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 449, 
          "offsetInEndSection": 627, 
          "text": "Craniosynostosis secondary to rickets is rarely reported, but since neither rickets nor craniosynostosis is a reportable disease, the exact incidence of both diseases is unknown.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27303470", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 331, 
          "offsetInEndSection": 485, 
          "text": "X-linked hypophosphatemic (XLH) rickets is the most common form of metabolic rickets, and there have been reports linking XLH rickets to craniosynostosis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19242361", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 485, 
          "offsetInEndSection": 595, 
          "text": "A clinical report of a patient with XLH rickets and craniosynostosis is presented with a review of literature.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19242361", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 176, 
          "offsetInEndSection": 328, 
          "text": "METHODS A 20-year retrospective review identified patients with hypophosphatemic rickets and secondary craniosynostosis at 3 major craniofacial centers.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26824597", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 94, 
          "text": "Bilateral coronal and sagittal synostosis in X-linked hypophosphatemic rickets: a case report.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23466123", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 152, 
          "text": "X-linked hypophosphatemic rickets and sagittal craniosynostosis: three patients requiring operative cranial expansion: case series and literature review", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26510652", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 54, 
          "text": "X-linked hypophosphatemic rickets and craniosynostosis", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19242361", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 333, 
          "offsetInEndSection": 486, 
          "text": "X-linked hypophosphatemic (XLH) rickets is the most common form of metabolic rickets, and there have been reports linking XLH rickets to craniosynostosis", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19242361", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 582, 
          "text": "The recent observations of two new cases of X-linked hypophosphatemic rickets associated with premature closure of the sagittal suture prompted a review of similar cases seen in this institution.To review the clinical records and skull radiographs of 28 children with hypophosphatemic rickets in order to investigate the frequency and type of craniosynostosis and other cranial vault changes seen in these conditions and to review the literature for relevant findings.Clinical and imaging records were reviewed on 28 patients with hypophosphatemic rickets, all younger than 18 years", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17551721", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1344, 
          "offsetInEndSection": 1606, 
          "text": "Those with multisutural synostosis presented at a significantly older age than patients with sagittal or bicoronal synostosis.Patients with multisutural involvement or X-linked hypophosphatemic rickets had a significant delay in presentation for craniosynostosis", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23348263", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 85, 
          "text": "Papilledema in the setting of x-linked hypophosphatemic rickets with craniosynostosis", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22220162", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 510, 
          "text": "INTRODUCTION TO THE OPHTHALMIC LITERATURE OF AN UNUSUAL CAUSE OF PAPILLEDEMA AND SUBSEQUENT OPTIC ATROPHY: X-linked hypophosphatemic rickets (XLH).Case report of a 3-year-old female presenting with papilledema resulting from craniosynostosis secondary to XLH.Early intervention with craniofacial surgery prevented the development of optic atrophy.Children with XLH should be screened for ophthalmic evidence of elevated intracranial pressure to aid early intervention and prevention of permanent loss of vision", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22220162", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1503, 
          "offsetInEndSection": 1654, 
          "text": "CONCLUSIONS: Patients with multisutural involvement or X-linked hypophosphatemic rickets had a significant delay in presentation for craniosynostosis. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23348263", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 232, 
          "text": "Craniosynostosis can be gene-linked, or caused by metabolic diseases, such as rickets, which results from a deficiency or impaired metabolism of vitamin D, magnesium, phosphorus or calcium leading to hypomineralization of the bone. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23466123", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 151, 
          "offsetInEndSection": 286, 
          "text": "Similar skull deformities develop in mice with X-linked dominant hypophosphatemia, the most common form of vitamin D-resistant rickets.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6265607", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 48, 
          "text": "Craniosynostosis in vitamin D-resistant rickets.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6265607", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 231, 
          "text": "Craniosynostosis can be gene-linked, or caused by metabolic diseases, such as rickets, which results from a deficiency or impaired metabolism of vitamin D, magnesium, phosphorus or calcium leading to hypomineralization of the bone.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23466123", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 56, 
          "text": "X-linked hypophosphatemic rickets and craniosynostosis.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19242361", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 333, 
          "offsetInEndSection": 487, 
          "text": "X-linked hypophosphatemic (XLH) rickets is the most common form of metabolic rickets, and there have been reports linking XLH rickets to craniosynostosis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19242361", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 74, 
          "text": "Hypophosphatemic rickets and craniosynostosis: a multicenter case series.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26824597", 
          "endSection": "title"
        }
      ]
    }, 
    {
      "body": "Is vortioxetine effective for treatment of depression?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26546771", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26358483", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26464458", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26641142", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26679430", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25350320", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24676550", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24524096", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27067232", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24570588", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25851751", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25418918", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26525043", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22963932", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23252878", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24787143", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25260373", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24424707", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25087600", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26035185", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24684240", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26346592", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25907797", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25249164", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25562777", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24871704", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26035186", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25650503", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26316764", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26020712", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25874839", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25893002", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27139079"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Yes. Vortioxetine is the most recently approved medication for the treatment of major depressive disorder."
      ], 
      "exact_answer": "yes", 
      "concepts": [
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D003863", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D003866"
      ], 
      "type": "yesno", 
      "id": "589a246878275d0c4a000030", 
      "snippets": [
        {
          "offsetInBeginSection": 316, 
          "offsetInEndSection": 424, 
          "text": "Vortioxetine is the most recently approved medication for the treatment of major depressive disorder (MDD). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26546771", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 66, 
          "text": "[Vortioxetine: a new antidepressant to treat depressive episodes].", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26358483", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 179, 
          "text": "Vortioxetine is a new antidepressant, which mechanism of action is multimodal, targeting the 5-HT1A, 5-HT1B, 5-HT1D, 5-HT3, 5-HT7\u00a0receptors and the serotonin transporter (5-HTT). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26358483", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 334, 
          "offsetInEndSection": 990, 
          "text": "In short-term studies (8\u00a0weeks), vortioxetine is more efficacious than placebo in decreasing depressive symptoms as measured by the MADRS total score, response rate (vortioxetine: 53.2% vs placebo: 35.2%) and remission rate (vortioxetine: 29.2% vs placebo: 19.3%). In a long-term study (52\u00a0weeks), vortioxetine is also superior to placebo in preventing relapses and recurrences. Moreover, in second line treatment, after failure of a first line selective serotonin reuptake inhibitor (SSRI) or serotonin norepinephrin reuptake inhibitor (SNRI), vortioxetine is superior to agomelatine in improving depressive symptoms and achieving response and remission. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26358483", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1027, 
          "offsetInEndSection": 1386, 
          "text": "Against this background, we feature the novel antidepressants vortioxetine, vilazodone and milnacipran/levomilnacipran with regard to their serotonin receptor targets such as the 5-HT1A, 5-HT3 and 5-HT7 which may account for their specific effects on certain symptoms of depression (e.g. cognition and anxiety) as well as a characteristic side-effect profile.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26464458", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 990, 
          "offsetInEndSection": 1139, 
          "text": "CONCLUSION: Vortioxetine dominated venlafaxine XR in South Korea and is a relevant treatment option for MDD patients initiating or switching therapy.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26641142", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 60, 
          "text": "Vortioxetine: a New Treatment for Major Depressive Disorder.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26679430", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 143, 
          "text": "INTRODUCTION: Vortioxetine is a structurally novel medication that has recently been approved for treatment of major depressive disorder (MDD).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26679430", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1433, 
          "offsetInEndSection": 1584, 
          "text": "EXPERT OPINION: Results of placebo-controlled trials suggest efficacy and an overall safety profile comparable to existing first-line antidepressants. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26679430", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1941, 
          "offsetInEndSection": 2132, 
          "text": "The authors suggest that vortioxetine is currently a good second-line antidepressant option and shows promise, pending additional long-term data, to become a first-line antidepressant option.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26679430", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 264, 
          "offsetInEndSection": 428, 
          "text": "Clinical studies indicate that vortioxetine is effective in the treatment of major depression, though there is no suggestion of superiority over active comparators.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24570588", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 486, 
          "offsetInEndSection": 694, 
          "text": "Vortioxetine has been effective in various animal models of depression and anxiety and clinical studies have shown the antidepressant and antianxiety properties of vortioxetine in a dose range of 5-20 mg/day.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24524096", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 913, 
          "offsetInEndSection": 1068, 
          "text": "Vortioxetine was significantly more effective than was placebo, with a standardized mean difference (SMD) of\u00a0-0.118 (95% CIs,\u00a0-0.203 to\u00a0-0.033, P\u00a0=\u00a00.007).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25851751", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 45, 
          "text": "Vortioxetine for the treatment of depression.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24676550", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 51, 
          "text": "Vortioxetine for the treatment of major depression.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24524096", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 248, 
          "text": "Vortioxetine (Lu-AA-21004; 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine hydrobromide) is a novel orally active molecule that is being investigated by Lundbeck and Takeda for the treatment of major depression and generalized anxiety disorders.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24524096", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 135, 
          "text": "Vortioxetine (Lu AA21004) is a multi-modal antidepressant in clinical development for the treatment of major depressive disorder (MDD).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22963932", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 178, 
          "text": "A randomized, double-blind, fixed-dose study comparing the efficacy and tolerability of vortioxetine 2.5 and 10\u2009mg in acute treatment of adults with generalized anxiety disorder.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24424707", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 489, 
          "offsetInEndSection": 697, 
          "text": "Vortioxetine has been effective in various animal models of depression and anxiety and clinical studies have shown the antidepressant and antianxiety properties of vortioxetine in a dose range of 5-20 mg/day.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24524096", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 678, 
          "offsetInEndSection": 1177, 
          "text": "Secondary endpoints included response and remission rates, anxiety symptoms(Hamilton Anxiety Rating Scale), Clinical Global Impression, overall functioning (Sheehan Disability Scale), health-related quality of life(EuroQol 5 Dimensions), productivity (work limitation questionnaire) and family functioning (Depression and Family Functioning Scale).RESULTS: Primary endpoint noninferiority was established and vortioxetine (n = 252) was superior to agomelatine (n = 241) by 2.2 MADRS points (p<0.01).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25087600", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 711, 
          "text": "Vortioxetine (Lu AA21004) is an antidepressant with a mechanism of action thought to be related to a combination of 2 pharmacologic actions: direct modulation of several receptors and inhibition of the serotonin transporter.To evaluate the efficacy of vortioxetine 10 and 20 mg once daily in outpatients with major depressive disorder.This 8-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study was conducted from July 2010 to January 2012 among adults with a primary diagnosis of recurrent major depressive disorder (DSM-IV-TR).Eligible subjects were randomized in 1:1:1 ratio to 1 of 3 treatment arms: vortioxetine 10 mg, vortioxetine 20 mg, or placebo once daily for 8 weeks.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26035185", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 188, 
          "offsetInEndSection": 478, 
          "text": "Vortioxetine (Lu AA21004) is a new antidepressant that combines a number of neurotransmitter reuptake and receptor effects that have been thought to predict efficacy as a treatment for depressive and anxiety disorders.This review summarizes the pharmacology and neurobiology of vortioxetine", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24684240", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1723, 
          "offsetInEndSection": 2190, 
          "text": "In the study of elderly patients, vortioxetine 5 mg (n = 136) improved 12-item Health Status Questionnaire scores significantly more than placebo (n = 148) for the domains of health perception (10.4, P &lt; 0.0001, SES of 0.54), mental health (7.9, P &lt; 0.001, SES of 0.44), and energy (6.4, P &lt; 0.05, SES of 0.28) (FAS, mixed model for repeated measures).Vortioxetine yielded significant, meaningful HRQoL improvements in 6 MDD studies of 6 to 8 weeks duration.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26346592", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 324, 
          "offsetInEndSection": 749, 
          "text": "All references included were published between 1999 and 2014.All studies that included humans and were published in English, with data describing vortioxetine for the treatment of MDD, were reviewed.Vortioxetine is a novel multimodal antidepressant agent, which inhibits the 5-HT transporter protein, acts as a 5-HT3 antagonist, 5-HT1A receptor agonist, 5-HT7 receptor antagonist, and a partial agonist of the 5-HT1B receptor", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24676550", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 489, 
          "offsetInEndSection": 696, 
          "text": "Vortioxetine has been effective in various animal models of depression and anxiety and clinical studies have shown the antidepressant and antianxiety properties of vortioxetine in a dose range of 5-20 mg/day", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24524096", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 355, 
          "text": "Vortioxetine is an antidepressant with multimodal activity which has shown efficacy in major depressive disorder (MDD) patients in six of ten short-term, randomized, placebo-controlled trials (completed end 2012).We performed meta-regression analyses to indirectly compare vortioxetine to seven marketed antidepressants with different mechanisms of action", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25249164", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 661, 
          "offsetInEndSection": 1043, 
          "text": "Data were available from 51 human trials involving vortioxetine, and included a total of 7,666 healthy volunteers and patients with a diagnosis of major depressive disorder (MDD) or generalized anxiety disorder who were exposed to at least 1 dose of vortioxetine for a total of 2,743 patient-years.Vortioxetine was effective in treating MDD in the United States at a dose of 20 mg/d", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25562777", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 386, 
          "text": "Vortioxetine is a recently approved multimodal antidepressant with anxiolytic properties in preclinical studies.This double-blind, placebo-controlled study assessed the efficacy and tolerability of vortioxetine in subjects with a primary diagnosis of generalized anxiety disorder.Subjects (n\u2009=\u2009457) were randomized 1:1:1 to treatment with placebo or vortioxetine 2.5 or 10\u2009mg once daily", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24424707", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1359, 
          "offsetInEndSection": 1744, 
          "text": "There was a significant difference for nausea between the two groups (OR=3.01, 95 % CI=2.22-4.09, Z=7.08, P=0.00001), but no significant differences were observed for the other four adverse effects.CONCLUSIONS: For the treatment of major depressive disorder, our results show that a dose of 5 mg/day vortioxetine was more effective, but more easily induced nausea, compared to placebo.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24871704", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 114, 
          "text": "The efficacy and safety of 5 mg/d Vortioxetine compared to placebo for major depressive disorder: A meta-analysis.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24871704", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 142, 
          "text": "Vortioxetine: a meta-analysis of 12 short-term, randomized, placebo-controlled clinical trials for the treatment of major depressive disorder.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25350320", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 141, 
          "text": "Vortioxetine in the treatment of adult patients with major depressive disorder: a meta-analysis of randomized double-blind controlled trials.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25260373", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 489, 
          "offsetInEndSection": 698, 
          "text": "Vortioxetine has been effective in various animal models of depression and anxiety and clinical studies have shown the antidepressant and antianxiety properties of vortioxetine in a dose range of 5-20 mg/day. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24524096", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 266, 
          "offsetInEndSection": 430, 
          "text": "Clinical studies indicate that vortioxetine is effective in the treatment of major depression, though there is no suggestion of superiority over active comparators.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24570588", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1432, 
          "offsetInEndSection": 1642, 
          "text": "The incidence of treatment-emergent adverse events was significantly higher in the duloxetine group than in the vortioxetine group.Duloxetine was more effective but less well-tolerated than vortioxetine in MDD.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27067232", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 2085, 
          "offsetInEndSection": 2676, 
          "text": "There was no significant difference in discontinuation rates between vortioxetine and comparators owing to inefficacy (OR 0.983, 95% CI 0.585 to 1.650), whereas discontinuation owing to AEs was significantly less common in the vortioxetine than in the comparator group (OR 0.728, 95% CI 0.554 to 0.957).Studies examining the role of vortioxetine in the treatment of MDD are limited.Although our results suggest that vortioxetine may be an effective treatment option for MDD, they should be interpreted and translated into clinical practice with caution, as the meta-analysis was based on a l", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25350320", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 285, 
          "offsetInEndSection": 533, 
          "text": "We performed a meta-analysis to increase the statistical power of these studies and enhance our current understanding of the role of vortioxetine in the treatment of MDD.We performed an extensive search of databases and the clinical trial registry.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25350320", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 419, 
          "text": "BACKGROUND: Vortioxetine is a recently approved multimodal antidepressant with anxiolytic properties in preclinical studies.OBJECTIVE: This double-blind, placebo-controlled study assessed the efficacy and tolerability of vortioxetine in subjects with a primary diagnosis of generalized anxiety disorder.METHODS: Subjects (n\u2009=\u2009457) were randomized 1:1:1 to treatment with placebo or vortioxetine 2.5 or 10\u2009mg once daily.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24424707", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1524, 
          "offsetInEndSection": 1735, 
          "text": "Vortioxetine significantly improved objective and subjective measures of cognitive function in adults with recurrent MDD and these effects were largely independent of its effect on improving depressive symptoms.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24787143", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1545, 
          "offsetInEndSection": 1731, 
          "text": "Furthermore, a statistically significant number of patients with MDD who were on vortioxetine have achieved a greater than or equal to 50% reduction in depression symptoms from baseline.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25260373", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 152, 
          "text": "BACKGROUND: Vortioxetine is a novel multimodal compound that has recently been approved by the FDA for the treatment of major depressive disorder (MDD).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25260373", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 2471, 
          "offsetInEndSection": 2717, 
          "text": "Although our results suggest that vortioxetine may be an effective treatment option for MDD, they should be interpreted and translated into clinical practice with caution, as the meta-analysis was based on a limited number of heterogeneous RCTs..", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25350320", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1284, 
          "offsetInEndSection": 1427, 
          "text": "Vortioxetine is an effective agent for the treatment of MDD, but it does not have any clear advantages over other available treatment options..", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24676550", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1827, 
          "offsetInEndSection": 1941, 
          "text": "Vortioxetine was significantly more effective than placebo for acute treatment of major depressive disorder (MDD).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25874839", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1566, 
          "offsetInEndSection": 1645, 
          "text": "Duloxetine was more effective but less well-tolerated than vortioxetine in MDD.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27067232", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which server is used for simulation of macromolecular diffusional association?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25883142"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Macromolecular interactions play a crucial role in biological systems. Simulation of diffusional association (SDA) is a software for carrying out Brownian dynamics simulations that can be used to study the interactions between two or more biological macromolecules. webSDA allows users to run Brownian dynamics simulations with SDA to study bimolecular association and encounter complex formation, to compute association rate constants, and to investigate macromolecular crowding using atomically detailed macromolecular structures. webSDA facilitates and automates the use of the SDA software, and offers user-friendly visualization of results.", 
        "webSDA allows users to run Brownian dynamics simulations with SDA to study bimolecular association and encounter complex formation, to compute association rate constants, and to investigate macromolecular crowding using atomically detailed macromolecular structures. webSDA currently has three modules: 'SDA docking' to generate structures of the diffusional encounter complexes of two macromolecules, 'SDA association' to calculate bimolecular diffusional association rate constants, and 'SDA multiple molecules' to simulate the diffusive motion of hundreds of macromolecules.", 
        "Simulation of diffusional association (SDA) is a software for carrying out Brownian dynamics simulations that can be used to study the interactions between two or more biological macromolecules. webSDA allows users to run Brownian dynamics simulations with SDA to study bimolecular association and encounter complex formation, to compute association rate constants, and to investigate macromolecular crowding using atomically detailed macromolecular structures."
      ], 
      "exact_answer": [
        [
          "webSDA"
        ]
      ], 
      "concepts": [
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D003198", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D056004", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D039301"
      ], 
      "type": "factoid", 
      "id": "589480b47d9090f353000007", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 72, 
          "text": "webSDA: a web server to simulate macromolecular diffusional association.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25883142", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 645, 
          "text": "Macromolecular interactions play a crucial role in biological systems. Simulation of diffusional association (SDA) is a software for carrying out Brownian dynamics simulations that can be used to study the interactions between two or more biological macromolecules. webSDA allows users to run Brownian dynamics simulations with SDA to study bimolecular association and encounter complex formation, to compute association rate constants, and to investigate macromolecular crowding using atomically detailed macromolecular structures. webSDA facilitates and automates the use of the SDA software, and offers user-friendly visualization of results.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25883142", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 642, 
          "offsetInEndSection": 952, 
          "text": "webSDA currently has three modules: 'SDA docking' to generate structures of the diffusional encounter complexes of two macromolecules, 'SDA association' to calculate bimolecular diffusional association rate constants, and 'SDA multiple molecules' to simulate the diffusive motion of hundreds of macromolecules.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25883142", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 71, 
          "offsetInEndSection": 950, 
          "text": "Simulation of diffusional association (SDA) is a software for carrying out Brownian dynamics simulations that can be used to study the interactions between two or more biological macromolecules. webSDA allows users to run Brownian dynamics simulations with SDA to study bimolecular association and encounter complex formation, to compute association rate constants, and to investigate macromolecular crowding using atomically detailed macromolecular structures. webSDA facilitates and automates the use of the SDA software, and offers user-friendly visualization of results. webSDA currently has three modules: SDA docking to generate structures of the diffusional encounter complexes of two macromolecules, SDA association to calculate bimolecular diffusional association rate constants, and SDA multiple molecules to simulate the diffusive motion of hundreds of macromolecules.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25883142", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 71, 
          "text": "webSDA: a web server to simulate macromolecular diffusional association", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25883142", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 73, 
          "text": "webSDA: a web server to simulate macromolecular diffusional association.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25883142", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 266, 
          "offsetInEndSection": 532, 
          "text": "webSDA allows users to run Brownian dynamics simulations with SDA to study bimolecular association and encounter complex formation, to compute association rate constants, and to investigate macromolecular crowding using atomically detailed macromolecular structures.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25883142", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 646, 
          "offsetInEndSection": 956, 
          "text": "webSDA currently has three modules: 'SDA docking' to generate structures of the diffusional encounter complexes of two macromolecules, 'SDA association' to calculate bimolecular diffusional association rate constants, and 'SDA multiple molecules' to simulate the diffusive motion of hundreds of macromolecules.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25883142", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Can beans induce apoptosis?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26769089", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22524832", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15302513", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23194196", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15527074", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23394551", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26290674", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25997867", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24952025", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23027830", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19723093", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22916808"
      ], 
      "triples": [], 
      "ideal_answer": [
        "White kidney bean lectin  has been shown to exert anti-proliferative and apoptotic effects on cancer cells"
      ], 
      "exact_answer": "yes", 
      "concepts": [
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D017209"
      ], 
      "type": "yesno", 
      "id": "58bca1c202b8c6095300000b", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 413, 
          "text": "A 60-kDa glucosamine binding lectin, white kidney bean lectin (WKBL), was purified from Phaseolus vulgaris cv. white kidney beans, by application of anion exchange chromatography on Q-Sepharose, affinity chromatography on Affi-gel blue gel, and FPLC-size exclusion on Superdex 75. The anti-proliferative activity of WKBL on HONE1 cells and HepG2 cells was stronger than the activity on MCF7 cells and WRL68 cells ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26769089", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 153, 
          "text": "Treatment of human stomach cancer KATO III cells with hot-water extracts from adzuki beans led to their growth inhibition as well as apoptosis induction.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15527074", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 227, 
          "text": "Stimulation of dendritic cell maturation and induction of apoptosis in leukemia cells by a heat-stable extract from azuki bean (Vigna angularis), a promising immunopotentiating food and dietary supplement for cancer prevention.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22524832", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 226, 
          "text": "Human gut flora-fermented nondigestible fraction from cooked bean ( Phaseolus vulgaris L.) modifies protein expression associated with apoptosis, cell cycle arrest, and proliferation in human adenocarcinoma colon cancer cells.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23194196", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 218, 
          "offsetInEndSection": 461, 
          "text": "This paper reports the effect of fermentation products (FP) by hgf (FP-hgf) from NDF of cooked beans on survival and protein expression associated with apoptosis, cell cycle arrest, and proliferation in human adenocarcinoma colon cancer cells.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23194196", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 147, 
          "text": "PHA-E is a natural product extracted from red kidney beans, and it has been reported to induce cell apoptosis by blocking EGFR in lung cancer cells", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23394551", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 132, 
          "text": "A Glucosamine-Specific Lectin from Green Dragon No. 8 Beans (Phaseolus vulgaris) Induced Apoptosis on Nasopharyngeal Carcinoma Cells", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26290674", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 148, 
          "text": "PHA-E is a natural product extracted from red kidney beans, and it has been reported to induce cell apoptosis by blocking EGFR in lung cancer cells.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23394551", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 344, 
          "text": "The anticancer activity of \u03b4-tocotrienol, a bioactive vitamin E present in whole grain cereals, annatto beans and palm fruit, is strongly dependent on its effect on the induction of apoptosis. \u03b4-Tocotrienol-induced apoptosis is associated with consistent induction in the expression of the proapoptotic protein Bcl-2-associated X protein (Bax).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25997867", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1077, 
          "offsetInEndSection": 1316, 
          "text": "NDF of cooked common beans inhibited colon carcinogenesis at an early stage by inducing cell cycle arrest of colon cells and morphological changes linked to apoptosis, thus confirming previous results obtained with gene expression studies.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24952025", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 921, 
          "offsetInEndSection": 1025, 
          "text": "Azuki extract also inhibited the growth of human leukemia U937 cells, leading to induction of apoptosis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22524832", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 121, 
          "text": "Fermentation product of soybean, black bean, and green bean mixture induces apoptosis in a wide variety of cancer cells.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23027830", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 138, 
          "text": "A non-digestible fraction of the common bean (Phaseolus vulgaris L.) induces cell cycle arrest and apoptosis during early carcinogenesis.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24952025", 
          "endSection": "title"
        }
      ]
    }, 
    {
      "body": "What is the function of transthyretin in cerebrospinal fluid?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25737004", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25784853", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25311081", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25009532", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24160776", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19682646", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12553433", 
        "http://www.ncbi.nlm.nih.gov/pubmed/1519448", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11294981", 
        "http://www.ncbi.nlm.nih.gov/pubmed/7965021", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9630636", 
        "http://www.ncbi.nlm.nih.gov/pubmed/2309926", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12182890", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23579071", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19075702", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16325339", 
        "http://www.ncbi.nlm.nih.gov/pubmed/3601096", 
        "http://www.ncbi.nlm.nih.gov/pubmed/7553078", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10718550"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Transthyretin (TTR) is a protein synthesized in the choroid plexus, which forms the blood-cerebrospinal fluid barrier.  TTR is the physiological carrier of thyroxine (T4) and retinol from the blood into the cerebrospinal fluid and their distribution in the brain. The transport of T4 is important for normal development of the brain."
      ], 
      "concepts": [
        "http://www.uniprot.org/uniprot/TTHY_TILRU", 
        "http://www.uniprot.org/uniprot/TTHY_MACEU", 
        "http://www.uniprot.org/uniprot/TTHY_CROPO", 
        "http://www.uniprot.org/uniprot/TTHY_SMIMA", 
        "http://www.uniprot.org/uniprot/TTHY_MACGI", 
        "http://www.uniprot.org/uniprot/TTHY_BOVIN", 
        "http://www.uniprot.org/uniprot/TTHY_SHEEP", 
        "http://www.uniprot.org/uniprot/TTHY_MONDO", 
        "http://www.uniprot.org/uniprot/TTHY_PIG", 
        "http://www.uniprot.org/uniprot/TTHY_HUMAN", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D002555"
      ], 
      "type": "summary", 
      "id": "58b6a42522d300530900000b", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 452, 
          "text": "Transthyretin (TTR) is a protein that binds and distributes thyroid hormones (THs). TTR synthesised in the liver is secreted into the bloodstream and distributes THs around the body, whereas TTR synthesised in the choroid plexus is involved in movement of thyroxine from the blood into the cerebrospinal fluid and the distribution of THs in the brain. This is important because an adequate amount of TH is required for normal development of the brain. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25737004", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 204, 
          "offsetInEndSection": 847, 
          "text": "The choroid plexus forms the blood-cerebrospinal fluid barrier. In reptiles, birds and mammals, the main protein synthesized and secreted by the choroid plexus is a thyroid hormone distributor protein: transthyretin. This transthyretin is secreted into the cerebrospinal fluid and moves thyroid hormones from the blood into the cerebrospinal fluid. Maximal transthyretin synthesis in the choroid plexus occurs just prior to the period of rapid brain growth, suggesting that choroid plexus-derived transthyretin moves thyroid hormones from blood into cerebrospinal fluid just prior to when thyroid hormones are required for rapid brain growth. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25784853", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 129, 
          "text": "Transthyretin (TTR) is a visceral protein, which facilitates the transport of thyroid hormones in blood and cerebrospinal fluid. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25311081", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 291, 
          "offsetInEndSection": 702, 
          "text": "Serum TH binding proteins play a major role for the availability of TH since only free hormone concentrations may dictate cellular uptake. One of these proteins, transthyretin is also present in the cerebrospinal fluid (CSF) after being secreted by the choroid plexus. Entry routes into the brain like the blood-brain-barrier (BBB) and the blood-CSF-barrier will be explicated regarding fetal and adult status. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25009532", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 148, 
          "offsetInEndSection": 426, 
          "text": "Some POPs, i.e., hydroxylated metabolites of polychlorinated biphenyls (OH-PCBs), pentachlorophenol (PCP), and perfluorooctane sulfonate (PFOS), compete with thyroxin (T4) for binding sites on transthyretin (TTR), a T4 transport protein found in plasma and cerebrospinal fluid. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24160776", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 182, 
          "text": "Transthyretin (TTR), a plasma and cerebrospinal fluid protein secreted by the liver and choroid plexus, is mainly known as the physiological carrier of thyroxine (T(4)) and retinol. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19682646", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 134, 
          "offsetInEndSection": 305, 
          "text": "The secretion of transthyretin by the choroid plexus into the cerebrospinal fluid may have an important function in the transport of thyroxine from the blood to the brain.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1519448", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 417, 
          "offsetInEndSection": 548, 
          "text": "This transthyretin is secreted into the cerebrospinal fluid and moves thyroid hormones from the blood into the cerebrospinal fluid.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25784853", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1488, 
          "offsetInEndSection": 1775, 
          "text": "Thyroid hormones enter the choroid plexus via thyroid hormone transmembrane transporters and leave the choroid plexus to enter the cerebrospinal fluid via either thyroid hormone transmembrane transporters or via choroid plexus-derived transthyretin secreted into the cerebrospinal fluid.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25784853", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 421, 
          "offsetInEndSection": 551, 
          "text": "This transthyretin is secreted into the cerebrospinal fluid and moves thyroid hormones from the blood into the cerebrospinal fluid", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25784853", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 553, 
          "offsetInEndSection": 845, 
          "text": "Maximal transthyretin synthesis in the choroid plexus occurs just prior to the period of rapid brain growth, suggesting that choroid plexus-derived transthyretin moves thyroid hormones from blood into cerebrospinal fluid just prior to when thyroid hormones are required for rapid brain growth", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25784853", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1499, 
          "offsetInEndSection": 1785, 
          "text": "Thyroid hormones enter the choroid plexus via thyroid hormone transmembrane transporters and leave the choroid plexus to enter the cerebrospinal fluid via either thyroid hormone transmembrane transporters or via choroid plexus-derived transthyretin secreted into the cerebrospinal fluid", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25784853", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 127, 
          "text": "Transthyretin (TTR) is a visceral protein, which facilitates the transport of thyroid hormones in blood and cerebrospinal fluid", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25311081", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 96, 
          "text": "Transthyretin (TTR) is a plasma and cerebrospinal fluid (CSF)-circulating homotetrameric protein", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23579071", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 148, 
          "offsetInEndSection": 424, 
          "text": "Some POPs, i.e., hydroxylated metabolites of polychlorinated biphenyls (OH-PCBs), pentachlorophenol (PCP), and perfluorooctane sulfonate (PFOS), compete with thyroxin (T4) for binding sites on transthyretin (TTR), a T4 transport protein found in plasma and cerebrospinal fluid", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24160776", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 173, 
          "text": "Transthyretin (TTR) is a homotetrameric serum and cerebrospinal fluid protein that transports both thyroxine (T(4)) and the retinol-retinol binding protein complex (holoRBP)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19075702", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 87, 
          "text": "Dose-dependent transthyretin inhibition of T4 uptake from cerebrospinal fluid in sheep.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16325339", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 135, 
          "offsetInEndSection": 306, 
          "text": "The secretion of transthyretin by the choroid plexus into the cerebrospinal fluid may have an important function in the transport of thyroxine from the blood to the brain.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1519448", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 888, 
          "offsetInEndSection": 1086, 
          "text": "High-affinity cellular binding sites for TTR have been described; however, their function and that of choroid plexus synthesis of TTR and transport of T4 into the cerebrospinal fluid remain unclear.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10718550", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 172, 
          "text": "Transthyretin is the major thyroxine-binding protein in the plasma of rodents, and the main thyroxine-binding protein in the cerebrospinal fluid of both rodents and humans.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12182890", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 421, 
          "offsetInEndSection": 552, 
          "text": "This transthyretin is secreted into the cerebrospinal fluid and moves thyroid hormones from the blood into the cerebrospinal fluid.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25784853", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1499, 
          "offsetInEndSection": 1786, 
          "text": "Thyroid hormones enter the choroid plexus via thyroid hormone transmembrane transporters and leave the choroid plexus to enter the cerebrospinal fluid via either thyroid hormone transmembrane transporters or via choroid plexus-derived transthyretin secreted into the cerebrospinal fluid.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25784853", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Can you define iatrogenic disease?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26386902", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17470323", 
        "http://www.ncbi.nlm.nih.gov/pubmed/2173098", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8133999", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17497458", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17091219", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19063792", 
        "http://www.ncbi.nlm.nih.gov/pubmed/3961454", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20650043", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10979347", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18176826", 
        "http://www.ncbi.nlm.nih.gov/pubmed/2534534", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24719163", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25660151", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21610562", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26767158", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21481093", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22197283", 
        "http://www.ncbi.nlm.nih.gov/pubmed/133304", 
        "http://www.ncbi.nlm.nih.gov/pubmed/2240392", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8608668", 
        "http://www.ncbi.nlm.nih.gov/pubmed/355046", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8420729", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12561154", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8642152", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18242414", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25600788"
      ], 
      "triples": [], 
      "ideal_answer": [
        "An iatrogenic disease is one that arises from treatment of another illness, such as an arrythmia that results from surgery or and hospital aquired infection in an immunocompromised patient."
      ], 
      "exact_answer": [
        [
          "illness caused by treatment"
        ]
      ], 
      "concepts": [
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D007049"
      ], 
      "type": "factoid", 
      "id": "58a342e760087bc10a00001c", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 120, 
          "text": "Iatrogenic neurologic deficits after lumbar spine surgery are rare complications, but important to recognize and manage.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26386902", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 174, 
          "offsetInEndSection": 399, 
          "text": "However, we analyze its etiology in order to determine if it is from iatrogenic causes. This syndrome can be categorized as follows: mistaken diagnoses, transoperative error, technique error, poor application, poor indication", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17470323", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 548, 
          "offsetInEndSection": 863, 
          "text": "However, the clinical events that occur during iatrogenic immunosuppression (transplantation and cancer therapy) and as a result of immunocompromise due to human immunodeficiency virus infection are currently promoting our understanding of the epidemiology of CMV disease and the definition of its clinical spectrum", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2173098", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 142, 
          "text": "The authors observed one case of an iatrogenic subarachnoid-pleural fistula secondary to the resection of an upper lobe carcinoma of the lung.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8133999", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 192, 
          "text": "Radiological procedures require the intravascular administration of iodinated contrast media, which are becoming a great source of an iatrogenic disease known as contrast-induced nephropathy. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17497458", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 135, 
          "offsetInEndSection": 273, 
          "text": "Many studies have reported that AED therapy is associated with metabolic bone disease and is a major iatrogenic risk factor for fractures.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17091219", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 673, 
          "offsetInEndSection": 750, 
          "text": " The aetiology of arrhythmias can be either iatrogenic, such as postsurgical,", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19063792", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 89, 
          "text": "Iatrogenic diseases are defined as illnesses due to diagnostic or therapeutic procedures.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3961454", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 177, 
          "text": "BACKGROUND: Iatrogenic illness, defined as a disease that results from a diagnostic procedure or from any form of therapy, is a well-recognized phenomenon in clinical practice. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10979347", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 90, 
          "text": "Iatrogenic diseases are defined as illnesses due to diagnostic or therapeutic procedures. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3961454", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 477, 
          "text": "Iatrogenic illness, defined as a disease that results from a diagnostic procedure or from any form of therapy, is a well-recognized phenomenon in clinical practice.To study and evaluate major cardiac iatrogenic disease as the cause of admission to the intensive cardiac care unit in the modern era.We assessed 64 critically ill patients suffering from major cardiac iatrogenic problems among a total of 2,559 patients admitted to the intensive cardiac care unit during 3 years.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10979347", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 265, 
          "offsetInEndSection": 436, 
          "text": "Iatrogenic disease was defined as adverse drug reactions according to the World Health Organization Definition and complications induced by non-drug medical interventions.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20650043", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 164, 
          "text": "Iatrogenic illness, defined as a disease that results from a diagnostic procedure or from any form of therapy, is a well-recognized phenomenon in clinical practice.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10979347", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 480, 
          "offsetInEndSection": 553, 
          "text": "Iatrogenic illness was defined as any problem that resulted from therapy.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10979347", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 895, 
          "offsetInEndSection": 980, 
          "text": "An iatrogenic event was defined as \"an adverse event related to a medical procedure\".", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25600788", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1402, 
          "offsetInEndSection": 1608, 
          "text": "Patients with colorectal cancer who had splenectomy as a result of iatrogenic damage of the spleen while undergoing resection of the sigmoid or rectum for adenocarcinoma had a significantly worse prognosis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18176826", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1243, 
          "offsetInEndSection": 1635, 
          "text": "Intraoperative aortic dissection remains a rare and unpredictable complication of cardiac surgery, with worse outcomes than spontaneous aortic dissection. Increased age and atheromatous disease at the site of cannulation are significant risk factors for iatrogenic dissection. In this series, off-pump coronary artery bypass did not appear to be a risk factor for iatrogenic aortic dissection", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24719163", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 13, 
          "offsetInEndSection": 392, 
          "text": " Iatrogenic injury to the spleen is not an uncommon complication. Left nephrectomy has been reported as the second commonest cause of iatrogenic splenectomy with a reported incidence between 1.3 and 24%. Iatrogenic splenectomy is associated with significant morbidity and mortality.AIMS: We reviewed the occurrence of iatrogenic splenectomy during left nephrectomy at our centre.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21701137", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 380, 
          "text": "Hallux valgus is a common forefoot pathology often requiring surgical intervention for symptomatic relief. One complication of hallux valgus correction is flexible hallux varus. Iatrogenic flexible hallux varus often requires surgical repair; however, the most advantageous surgical procedure for repair of iatrogenic flexible hallux varus and their sustainability remains unclear", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22197283", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 703, 
          "offsetInEndSection": 833, 
          "text": "The possible interrelationship between such deposition and cranial irradiation and/or i.t. MTX suggests a new iatrogenic disorder.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/417541", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1, 
          "offsetInEndSection": 207, 
          "text": " report of a patient with granulomatous peritonitis following general surgery is presented. Laparoscopy was performed as the final diagnostic procedure. Prevention is the remedy for this iatrogenic problem.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/133304", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 521, 
          "offsetInEndSection": 914, 
          "text": "This report reviews both the medical and surgical literature during the past 15 years of patients treated for pseudomembranous colitis. Analysis of this clinical data has provided us with the opportunity to both define the role of surgery in this disorder and illustrate the necessity for a combined medical and surgical cooperative approach in the early management of this iatrogenic disease.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2240392", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 46, 
          "text": "Iatrogenic problems following gastric surgery.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/355046", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 6, 
          "offsetInEndSection": 238, 
          "text": "difficult to truly define iatrogenic complications in the postsurgical state in that the surgery is a condition originated by physician intervention and thus any problems that occur may be technically considered as physician created", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/355046", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1260, 
          "offsetInEndSection": 1839, 
          "text": "he most severe iatrogenic events were nosocomial infections (49/62 [79%]) and respiratory events (nine of 26 [35%]). Cutaneous injuries were frequent (n=94) but generally minor (89 [95%]), as were medication errors (15/19 [76%]). Most medication errors occurred during administration stage (12/19 [63%]) and were ten-fold errors (nine of 19 [47%]). The major risk factors were low birthweight and gestational age (both p<0.0001), length of stay (p<0.0001), a central venous line (p<0.0001), mechanical ventilation (p=0.0021), and support with continuous positive airwary pressure", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18242414", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Where do the Schwann cells and melanocytes originate from?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25805416", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22170630", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21501576", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19931641", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20454996", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23815504", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9247201", 
        "http://www.ncbi.nlm.nih.gov/pubmed/1967835", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12702775", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18636017", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17652534", 
        "http://www.ncbi.nlm.nih.gov/pubmed/7684712", 
        "http://www.ncbi.nlm.nih.gov/pubmed/6517351", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23858437", 
        "http://www.ncbi.nlm.nih.gov/pubmed/14576682", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8320168", 
        "http://www.ncbi.nlm.nih.gov/pubmed/2685414", 
        "http://www.ncbi.nlm.nih.gov/pubmed/3085152", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10885676", 
        "http://www.ncbi.nlm.nih.gov/pubmed/1504451", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24760871", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9142492", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23347447", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8269857", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8834474", 
        "http://www.ncbi.nlm.nih.gov/pubmed/3425403", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20683859", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10906452", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17631447", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25752517"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Schwann cells and melanocytes originate from the multipotent population of neural crest cells."
      ], 
      "exact_answer": [
        [
          "neural crest cells", 
          "NCC"
        ]
      ], 
      "concepts": [
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008544", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012583", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D039902", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D039904"
      ], 
      "type": "factoid", 
      "id": "58b56fe422d3005309000007", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 419, 
          "text": "The development of the nervous system involves cells remaining within the neural tube (CNS) and a group of cells that delaminate from the dorsal neural tube and migrate extensively throughout the developing embryo called neural crest cells (NCC). These cells are a mesenchymal highly migratory group of cells that give rise to a wide variety of cell derivatives: melanocytes, sensory neurons, bone, Schwann cells, etc. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25805416", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 235, 
          "offsetInEndSection": 460, 
          "text": "Cell types with neural crest ancestry consequently comprise a number of specialized varieties, such as ectodermal neurons, melanocytes and Schwann cells, as well as mesodermal osteoblasts, adipocytes and smooth muscle cells. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22170630", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 294, 
          "text": "Melanocytes, the pigmented cells of the skin, and the glial Schwann cells lining peripheral nerves are developmentally derived from an early and transient ectodermal structure of the vertebrate embryo, the neural crest, which is also at the origin of multiple neural and non-neural cell types. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21501576", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 405, 
          "offsetInEndSection": 608, 
          "text": "Later, SoxE proteins drive the formation of multiple neural crest derivatives including chondrocytes, melanocytes, and cells of the peripheral nervous system, particularly Schwann cells/peripheral glia. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19931641", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 96, 
          "text": "Melanocytes and Schwann cells are derived from the multipotent population of neural crest cells.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20454996", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 909, 
          "offsetInEndSection": 1086, 
          "text": "The present results suggest that the induced hamster melanomas originate from neural crest-derived cells which are able to differentiate into both melanocytes and Schwann cells.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8320168", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 244, 
          "offsetInEndSection": 423, 
          "text": "Melanocytes and Schwann cells both arise from the neural crest during development, and some melanocytes arise directly from Schwann cell precursors lining developing spinal nerves", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23815504", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 227, 
          "text": "Schwann cells, the myelinating glia of the peripheral nervous system (PNS), originate from multipotent neural crest cells that also give rise to other cells, including neurons, melanocytes, chondrocytes, and smooth muscle cells", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24760871", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 270, 
          "text": "In the vertebrate embryo, Schwann cells lining the peripheral nerves originate from the neural crest (NC), a structure that also gives rise to ganglion satellite cells, most of the neurons of the peripheral nervous system, melanocytes, and part of the cranial mesenchyme", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1967835", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 909, 
          "offsetInEndSection": 1085, 
          "text": "The present results suggest that the induced hamster melanomas originate from neural crest-derived cells which are able to differentiate into both melanocytes and Schwann cells", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8320168", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 901, 
          "offsetInEndSection": 1215, 
          "text": "Thus, the nevus cells shared a common nature with epidermal melanocytes and Schwann cells which originate from the neural crest; however, the former cells were somewhat different from the latter two kinds and from benign and malignant tumors derived from these cells in the expression of these antigenic substances", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2685414", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 292, 
          "text": "Melanocytes, the pigmented cells of the skin, and the glial Schwann cells lining peripheral nerves are developmentally derived from an early and transient ectodermal structure of the vertebrate embryo, the neural crest, which is also at the origin of multiple neural and non-neural cell types", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21501576", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 508, 
          "offsetInEndSection": 823, 
          "text": "Furthermore, although both populations are initially part of the Foxd3 lineage, hypaxial melanocytes lose Foxd3 at late stages upon separation from the nerve, whereas we recently found that epaxial melanocytes segregate earlier from Foxd3-positive neural progenitors while still residing in the dorsal neural tube. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23858437", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 136, 
          "text": "Reversal of developmental restrictions in neural crest lineages: transition from Schwann cells to glial-melanocytic precursors in vitro.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12702775", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 228, 
          "text": "Schwann cells, the myelinating glia of the peripheral nervous system (PNS), originate from multipotent neural crest cells that also give rise to other cells, including neurons, melanocytes, chondrocytes, and smooth muscle cells.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24760871", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 271, 
          "text": "In the vertebrate embryo, Schwann cells lining the peripheral nerves originate from the neural crest (NC), a structure that also gives rise to ganglion satellite cells, most of the neurons of the peripheral nervous system, melanocytes, and part of the cranial mesenchyme.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1967835", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 901, 
          "offsetInEndSection": 1216, 
          "text": "Thus, the nevus cells shared a common nature with epidermal melanocytes and Schwann cells which originate from the neural crest; however, the former cells were somewhat different from the latter two kinds and from benign and malignant tumors derived from these cells in the expression of these antigenic substances.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2685414", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1501, 
          "offsetInEndSection": 1737, 
          "text": "Other already committed cells are the angioblasts forming the endothelial lining of the blood vessels, the neural crest cells differentiating into melanocytes and Schwann cells, and the blood-derived cells like chrondro- or osteoclasts.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3425403", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 243, 
          "text": "The dorsal neural tube first generates neural crest cells that exit the neural primordium following an epithelial-to-mesenchymal conversion to become sympathetic ganglia, Schwann cells, dorsal root sensory ganglia, and melanocytes of the skin.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20683859", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1024, 
          "offsetInEndSection": 1228, 
          "text": "We show here that neural crest cells arising from the neural tube located at the level of somites 47-53 can differentiate both in vitro and in vivo into melanocytes and Schwann cells but not into neurons.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10906452", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 270, 
          "offsetInEndSection": 369, 
          "text": "This capacity may be due to the common origin of Schwann cells and melanocytes in the neural crest.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1504451", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 244, 
          "offsetInEndSection": 424, 
          "text": "Melanocytes and Schwann cells both arise from the neural crest during development, and some melanocytes arise directly from Schwann cell precursors lining developing spinal nerves.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23815504", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 160, 
          "text": "In the vertebrate embryo, multiple cell types originate from a common structure, the neural crest (NC), which forms at the dorsal tips of the neural epithelium.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17631447", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Please list 3 diseases associated with the PIEZO2 gene.", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/27714920", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27843126", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24726473", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23487782"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Recently, Gordon syndrome has been associated to heterozygous mutations in the piezo-type mechanosensitive ion channel component 2 gene (PIEZO2). Different mutations of this gene also cause distal arthrogryposis type 5 and Marden-Walker syndrome."
      ], 
      "exact_answer": [
        [
          "Gordon syndrome"
        ], 
        [
          "distal arthrogryposis type 5"
        ], 
        [
          "Marden-Walker syndrome"
        ]
      ], 
      "concepts": [
        "http://www.uniprot.org/uniprot/PIEZ2_HUMAN"
      ], 
      "type": "list", 
      "id": "58bd645702b8c60953000010", 
      "snippets": [
        {
          "offsetInBeginSection": 241, 
          "offsetInEndSection": 487, 
          "text": "Recently, Gordon syndrome has been associated to heterozygous mutations in the piezo-type mechanosensitive ion channel component 2 gene (PIEZO2). Different mutations of this gene also cause distal arthrogryposis type 5 and Marden-Walker syndrome.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27714920", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 100, 
          "text": "Mutations in PIEZO2 cause Gordon syndrome, Marden-Walker syndrome, and distal arthrogryposis type 5.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24726473", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 903, 
          "offsetInEndSection": 1117, 
          "text": "Both types of changes in kinetics result in increased channel activity in response to a given mechanical stimulus, suggesting that Distal Arthrogryposis Type 5 can be caused by gain-of-function mutations in PIEZO2.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23487782", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 318, 
          "offsetInEndSection": 588, 
          "text": "Here, we describe two distinct PIEZO2 mutations in patients with a subtype of Distal Arthrogryposis Type 5 characterized by generalized autosomal dominant contractures with limited eye movements, restrictive lung disease, and variable absence of cruciate knee ligaments.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23487782", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 241, 
          "offsetInEndSection": 386, 
          "text": "Recently, Gordon syndrome has been associated to heterozygous mutations in the piezo-type mechanosensitive ion channel component 2 gene (PIEZO2).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27714920", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 794, 
          "offsetInEndSection": 1091, 
          "text": "In contrast, heterozygous gain-of-function missense mutations, mainly localized at the C terminus, cause dominant distal arthrogryposis 3 (DA3), distal arthrogryposis 5 (DA5), or Marden-Walker syndrome (MWKS), which encompass contractures of hands and feet, scoliosis, ophthalmoplegia, and ptosis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27843126", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 192, 
          "text": "Dominant mutations in PIEZO2, which codes for the principal mechanotransduction channel for proprioception and touch sensation, have been found to cause different forms of distal arthrogryposi", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27607563", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Is treatment resistant depression related to vitamin B9?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24519190", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22762295", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18370582", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25229175", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24324965", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23538072", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27655070"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Treatment with SAMe, as well as with various formulations of folates and analogues, appears to be efficacious and well tolerated in reducing depressive symptoms in treatment resistant depression."
      ], 
      "exact_answer": "yes", 
      "concepts": [
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D003863", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D061218", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D003865"
      ], 
      "type": "yesno", 
      "id": "58a337af60087bc10a000016", 
      "snippets": [
        {
          "offsetInBeginSection": 253, 
          "offsetInEndSection": 616, 
          "text": "Suboptimal serum and red blood cell folate levels have been associated with a poorer response to antidepressant therapy, a greater severity of symptoms, later onset of clinical improvement, and overall treatment resistance. This article reviews the evidence for L-methylfolate and folic acid as antidepressive agents in depression and discusses their clinical use", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24519190", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1220, 
          "offsetInEndSection": 1377, 
          "text": "Although further randomized controlled trials in this area appear warranted, SAMe and L-methylfolate may represent a useful addition to the AD armamentarium.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22762295", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 478, 
          "offsetInEndSection": 972, 
          "text": "Patients with depression have consistently been found to have lower levels of serum and red blood cell folate than normal or nondepressed psychiatric patients. Decreased folate levels have been associated with lowered response rates to standard antidepressant pharmacotherapy. Recent studies have shown that augmentation with a folate supplement increases medication response in both treatment-na\u00efve and treatment-resistant depressed patients irrespective of whether there is folate deficiency.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18370582", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 985, 
          "offsetInEndSection": 1223, 
          "text": "Depressed patients with both low and normal folate levels may benefit from augmenting a primary antidepressant medication either initially, at the onset of treatment, or later after some degree of treatment resistance has been recognized.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18370582", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 526, 
          "offsetInEndSection": 768, 
          "text": "The results of this study suggest that intake of vitamin B9 may modulate the total score of Center for Epidemiological Studies Depression Scale (CES-D) and two subscales of the CES-D including depressive affect and interpersonal difficulties.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24324965", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 526, 
          "offsetInEndSection": 769, 
          "text": "The results of this study suggest that intake of vitamin B9 may modulate the total score of Center for Epidemiological Studies Depression Scale (CES-D) and two subscales of the CES-D including depressive affect and interpersonal difficulties. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24324965", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 301, 
          "offsetInEndSection": 459, 
          "text": "This article reviews the metabolic and clinical importance of folate, vitamin B12, and SAMe, as well as clinical trials in relation to depression and dementia", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23538072", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 423, 
          "offsetInEndSection": 554, 
          "text": "In particular, vitamins B1, B3, B6, B9 and B12 are essential for neuronal function and deficiencies have been linked to depression.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27655070", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Where is the protein slitrk1 localized?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/27273464", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25379384", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22703893", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21315458"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Slitrk1 is enriched in postsynaptic fractions and is localized to excitatory synapses. "
      ], 
      "concepts": [], 
      "type": "summary", 
      "id": "58a87bd338c171fb5b000005", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 43, 
          "text": "Slitrk1 is localized to excitatory synapses", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27273464", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 500, 
          "offsetInEndSection": 587, 
          "text": " Slitrk1 is enriched in postsynaptic fractions and is localized to excitatory synapses.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27273464", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 587, 
          "offsetInEndSection": 655, 
          "text": " The porcine SLITRK1 gene is expressed exclusively in brain tissues.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25379384", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 124, 
          "offsetInEndSection": 226, 
          "text": "Six family members exist (Slitrk1-6) and all are highly expressed in the central nervous system (CNS).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21315458", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Describe clinical manifestation of the Harlequin syndrome.", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26513674", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26943985", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26964837", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25933078", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25923501", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17569597", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18769278", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21796071", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22638078", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23726525", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27024906", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24882829", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8250530", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9219751", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16918633", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9555141", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8292878", 
        "http://www.ncbi.nlm.nih.gov/pubmed/2331828"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Harlequin syndrome is characterized by the sudden onset of unilateral facial flushing and sweating, often preceded by exercise, excessive heat, or, rarely, regional anesthesia. It is a rare autonomic disorder due to a hemifacial cutaneous sympathetic denervation."
      ], 
      "concepts": [], 
      "type": "summary", 
      "id": "5895db407d9090f35300000e", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 177, 
          "text": "Harlequin syndrome is characterized by the sudden onset of unilateral facial flushing and sweating, often preceded by exercise, excessive heat, or, rarely, regional anesthesia. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26513674", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 245, 
          "text": "UNLABELLED: Harlequin syndrome (HS) is a rare autonomic disorder due to a hemifacial cutaneous sympathetic denervation. It is characterized by unilateral diminished sweating and flushing of the face even though after heat or prolonged exercise. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26943985", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 236, 
          "offsetInEndSection": 390, 
          "text": "OBSERVATION: A 38-year-old melanoderm man, without any history of surgery or neck trauma, consulted for a strictly right unilateral facial hyperhidrosis. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26964837", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 220, 
          "text": "Harlequin syndrome (HS) is a rare disorder of the sympathetic nervous system which presents with unilateral decreased sweating and flushing of the face, neck, and chest in response to heat, exercise, or emotional factors", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25933078", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 147, 
          "text": "A 42-year-old woman had symptoms of unilateral flushing and sweating of her face during exercise. The clinical diagnosis was 'harlequin syndrome'. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25923501", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 189, 
          "text": "Harlequin sign and harlequin syndrome, which are used interchangeably in the literature, are characterized by sudden onset of hemifacial sweating and flushing, induced by exercise and heat.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17569597", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 138, 
          "text": "Harlequin syndrome is a rare, clinically striking syndrome characterized by distinctly demarcated asymmetric facial flushing and sweating.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27024906", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 188, 
          "text": "Harlequin sign and harlequin syndrome, which are used interchangeably in the literature, are characterized by sudden onset of hemifacial sweating and flushing, induced by exercise and heat", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17569597", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 109, 
          "text": "Harlequin sign (hemifacial flushing and contralateral hypohidrosis) in a 4-year-old girl with Horner syndrome", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16918633", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 250, 
          "offsetInEndSection": 357, 
          "text": "She also exhibited left hemifacial flushing and loss of sweating on the contralateral side (harlequin sign)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16918633", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is the role of the constitutive photomorphogenesis 9 signalosome (CSN)?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23288897", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21317535", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21403132", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21876386", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21051661", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27412572", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27546621", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11731421", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23818606", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26976604", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24286178", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24973710", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27833851", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22956996", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18854373", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16844902", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16310364", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11337588", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15342494", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12368504", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12324474", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16275352", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15867213", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10585392", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17914096", 
        "http://www.ncbi.nlm.nih.gov/pubmed/14502989", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27581057"
      ], 
      "triples": [], 
      "ideal_answer": [
        "The constitutive photomorphogenesis 9 (COP9) signalosome (CSN) is a protein complex involved in the ubiquitin proteasome system and plays a role in regulating the degradation of polyubiquitinated proteins. The mammalian CSN is also involved in embryonic development, in cancer and the DNA damage response, whereas in plants CSN plays a role in innate immunity."
      ], 
      "concepts": [
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012380", 
        "http://amigo.geneontology.org/amigo/term/GO:0008180"
      ], 
      "type": "summary", 
      "id": "58b576b622d3005309000008", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 258, 
          "text": "The family of cullin-RING E3 Ligases (CRLs) and the constitutive photomorphogenesis 9 (COP9) signalosome (CSN) form dynamic complexes that mediate ubiquitylation of 20% of the proteome, yet regulation of their assembly/disassembly remains poorly understood. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26976604", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 190, 
          "text": "The COP9 (constitutive photomorphogenesis 9) signalosome (CSN) is a protein complex involved in the ubiquitin proteasome system and a common host target of diverse pathogens in Arabidopsis. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27581057", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 229, 
          "text": "The COP9 (Constitutive photomorphogenesis 9) signalosome (CSN), a large multiprotein complex that resembles the 19S lid of the 26S proteasome, plays a central role in the regulation of the E3-cullin RING ubiquitin ligases (CRLs).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23288897", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 251, 
          "text": "The mammalian constitutive photomorphogenesis 9 (COP9) signalosome (CSN), a protein complex involved in embryonic development, is implicated in cell cycle regulation and the DNA damage response. Its role in tumor development, however, remains unclear.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21317535", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 44, 
          "text": "COP9 plays a role in plant innate immunity. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21403132", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 342, 
          "text": "The constitutive photomorphogenesis\u00a09 signalosome (COP9 or CSN) is an evolutionarily conserved multiprotein complex found in plants and animals. Because of the homology between the COP9 signalosome and the 19S lid complex of the proteosome, COP9 has been postulated to play a role in regulating the degradation of polyubiquitinated proteins. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21876386", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 464, 
          "offsetInEndSection": 673, 
          "text": "Therefore, it is conceivable that COP9 plays a significant role in cancer, regulating processes relevant to carcinogenesis and cancer progression (e.g., cell cycle control, signal transduction and apoptosis). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21876386", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 251, 
          "text": "The constitutive photomorphogenesis 9 (COP9) signalosome (CSN) plays key roles in many biological processes, such as repression of photomorphogenesis in plants and protein subcellular localization, DNA-damage response, and NF-\u03baB activation in mammals.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23818606", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 267, 
          "offsetInEndSection": 419, 
          "text": "The COP9 (constitutive photomorphogenesis mutant 9) signalosome (CSN) may regulate the UPS, but this has not been tested in a critical vertebrate organ.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21051661", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 194, 
          "text": "The mammalian constitutive photomorphogenesis 9 (COP9) signalosome (CSN), a protein complex involved in embryonic development, is implicated in cell cycle regulation and the DNA damage response.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21317535", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 205, 
          "offsetInEndSection": 378, 
          "text": "Here we show that the production of vascular endothelial growth factor (VEGF) in HeLa and HL-60 cells is directed by the constitutive photomorphogenesis 9 signalosome (CSN).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11731421", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 257, 
          "text": "The family of cullin-RING E3 Ligases (CRLs) and the constitutive photomorphogenesis 9 (COP9) signalosome (CSN) form dynamic complexes that mediate ubiquitylation of 20% of the proteome, yet regulation of their assembly/disassembly remains poorly understood.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26976604", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 272, 
          "text": "CSN6 is one subunit of the constitutive photomorphogenesis 9 (COP9) signalosome (CSN), which is an evolutionarily conserved multiprotein complex found in plants and animals and originally described as a repressor of light-dependent growth and transcription in Arabidopsis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24286178", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 291, 
          "text": "CSN6, a critical subunit of the constitutive photomorphogenesis 9 (COP9) signalosome (CSN), has received attention as a regulator of the degradation of cancer-related proteins such as p53, c-myc and c-Jun, through the ubiquitin-proteasome system, suggesting its importance in cancerogenesis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27546621", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 118, 
          "text": "The COP9 signalosome (CSN) is a complex of eight proteins first identified as a repressor of plant photomorphogenesis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12324474", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 181, 
          "text": "COP10 is a ubiquitin-conjugating enzyme variant (UEV), which is thought to act together with COP1, DET1, and the COP9 signalosome (CSN) in Arabidopsis to repress photomorphogenesis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15342494", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 280, 
          "offsetInEndSection": 432, 
          "text": "The COP9 (constitutive photomorphogenesis mutant 9) signalosome (CSN) may regulate the UPS, but this has not been tested in a critical vertebrate organ.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21051661", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 226, 
          "text": "The COP9 signalosome (CSN) is an evolutionarily conserved multiprotein complex that mediates the repression of photomorphogenesis in the dark in Arabidopsis through the degradation of transcription factors such as HY5 and HYH.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12368504", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 231, 
          "offsetInEndSection": 449, 
          "text": "The COP9 signalosome (CSN), a suppressor of plant photomorphogenesis, associated with multiple cullins and promoted cleavage of the ubiquitin-like protein NEDD8 from Schizosaccharomyces pombe CUL1 in vivo and in vitro.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11337588", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 251, 
          "text": "The constitutive photomorphogenesis 9 (COP9) signalosome (CSN) plays key roles in many biological processes, such as repression of photomorphogenesis in plants and protein subcellular localization, DNA-damage response, and NF-\u00eaB activation in mammals.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23818606", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 248, 
          "text": "Repression of photomorphogenesis in Arabidopsis thaliana requires activity of the COP9 signalosome (CSN), CDD, and COP1 complexes, but how these three complexes work in concert to accomplish this important developmental switch has remained unknown.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16844902", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 250, 
          "text": "The constitutive photomorphogenesis 9 (COP9) signalosome (CSN) plays key roles in many biological processes, such as repression of photomorphogenesis in plants and protein subcellular localization, DNA-damage response, and NF-\u03baB activation in mammals", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23818606", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 207, 
          "offsetInEndSection": 379, 
          "text": "Here we show that the production of vascular endothelial growth factor (VEGF) in HeLa and HL-60 cells is directed by the constitutive photomorphogenesis 9 signalosome (CSN)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11731421", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 228, 
          "text": "The COP9 (Constitutive photomorphogenesis 9) signalosome (CSN), a large multiprotein complex that resembles the 19S lid of the 26S proteasome, plays a central role in the regulation of the E3-cullin RING ubiquitin ligases (CRLs)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23288897", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 271, 
          "text": "CSN6 is one subunit of the constitutive photomorphogenesis 9 (COP9) signalosome (CSN), which is an evolutionarily conserved multiprotein complex found in plants and animals and originally described as a repressor of light-dependent growth and transcription in Arabidopsis", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24286178", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 193, 
          "text": "The mammalian constitutive photomorphogenesis 9 (COP9) signalosome (CSN), a protein complex involved in embryonic development, is implicated in cell cycle regulation and the DNA damage response", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21317535", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 269, 
          "offsetInEndSection": 420, 
          "text": "The COP9 (constitutive photomorphogenesis mutant 9) signalosome (CSN) may regulate the UPS, but this has not been tested in a critical vertebrate organ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21051661", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 240, 
          "text": "The COP9 Signalosome (CSN) is a multiprotein complex that was originally identified in Arabidopsis thaliana as a negative regulator of photomorphogenesis and subsequently shown to be a general eukaryotic regulator of developmental signaling", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18854373", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 247, 
          "text": "Repression of photomorphogenesis in Arabidopsis thaliana requires activity of the COP9 signalosome (CSN), CDD, and COP1 complexes, but how these three complexes work in concert to accomplish this important developmental switch has remained unknown", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16844902", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 180, 
          "text": "COP10 is a ubiquitin-conjugating enzyme variant (UEV), which is thought to act together with COP1, DET1, and the COP9 signalosome (CSN) in Arabidopsis to repress photomorphogenesis", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15342494", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 119, 
          "text": "The constitutive photomorphogenesis 9 signalosome directs vascular endothelial growth factor production in tumor cells.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11731421", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 207, 
          "offsetInEndSection": 381, 
          "text": "Here we show that the production of vascular endothelial growth factor (VEGF) in HeLa and HL-60 cells is directed by the constitutive photomorphogenesis 9 signalosome (CSN). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11731421", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 252, 
          "text": "The constitutive photomorphogenesis 9 (COP9) signalosome (CSN) plays key roles in many biological processes, such as repression of photomorphogenesis in plants and protein subcellular localization, DNA-damage response, and NF-\u03baB activation in mammals. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23818606", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 230, 
          "text": "The COP9 (Constitutive photomorphogenesis 9) signalosome (CSN), a large multiprotein complex that resembles the 19S lid of the 26S proteasome, plays a central role in the regulation of the E3-cullin RING ubiquitin ligases (CRLs). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23288897", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 131, 
          "text": "Plant homologue constitutive photomorphogenesis 9 (COP9) signalosome subunit CSN5 regulates innate immune responses in macrophages.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21403132", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 280, 
          "offsetInEndSection": 433, 
          "text": "The COP9 (constitutive photomorphogenesis mutant 9) signalosome (CSN) may regulate the UPS, but this has not been tested in a critical vertebrate organ. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21051661", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 195, 
          "text": "The mammalian constitutive photomorphogenesis 9 (COP9) signalosome (CSN), a protein complex involved in embryonic development, is implicated in cell cycle regulation and the DNA damage response. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21317535", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 151, 
          "offsetInEndSection": 449, 
          "text": "Recent studies indicate that Int6 is a multifaceted protein involved in the regulation of protein translation and degradation through binding with three complexes: the eukaryotic translation initiation factor 3, the proteasome regulatory lid, and the constitutive photomorphogenesis 9 signalosome. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15867213", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 242, 
          "text": "The COP9 Signalosome (CSN) is a multiprotein complex that was originally identified in Arabidopsis thaliana as a negative regulator of photomorphogenesis and subsequently shown to be a general eukaryotic regulator of developmental signaling. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18854373", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 518, 
          "offsetInEndSection": 662, 
          "text": "In this report we demonstrate a JNK-independent activation of c-Jun in vivo directed by the constitutive photomorphogenesis (COP9) signalosome. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10585392", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 130, 
          "text": "The COP9 signalosome (CSN) is a multiprotein complex that was initially identified in plants as a repressor of photomorphogenesis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14502989", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 960, 
          "offsetInEndSection": 1129, 
          "text": "This study suggests that AtItpk-1 may function as a protein kinase that is involved in photomorphogenesis possibly via interaction with COP9 signalosome under red light.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16310364", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 182, 
          "text": "The Arabidopsis inositol 1,3,4-trisphosphate 5/6 kinase, AtItpk-1, is involved in plant photomorphogenesis under red light conditions, possibly via interaction with COP9 signalosome.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16310364", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 189, 
          "text": "The COP9 (constitutive photomorphogenesis 9) signalosome (CSN) is a protein complex involved in the ubiquitin proteasome system and a common host target of diverse pathogens in Arabidopsis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27581057", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 207, 
          "offsetInEndSection": 380, 
          "text": "Here we show that the production of vascular endothelial growth factor (VEGF) in HeLa and HL-60 cells is directed by the constitutive photomorphogenesis 9 signalosome (CSN).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11731421", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 269, 
          "offsetInEndSection": 421, 
          "text": "The COP9 (constitutive photomorphogenesis mutant 9) signalosome (CSN) may regulate the UPS, but this has not been tested in a critical vertebrate organ.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21051661", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 120, 
          "text": "The constitutive photomorphogenesis 9 signalosome directs vascular endothelial growth factor production in tumor cells.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11731421", 
          "endSection": "title"
        }
      ]
    }, 
    {
      "body": "Is adalimumab effective for hidradenitis suppurativa?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26831295", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27136622", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27799806", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27388530", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21091684", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27518661", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19451504", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19371236", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26801356", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23106519", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24144253", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19213236", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21756155", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20652119", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22644772", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26201313", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25040429", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22013960", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21128923", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23247938", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21457202", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19997689", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18754844", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23670060", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27665300", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20628295", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26470624", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25580790"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Yes, Adalimumab, a recombinant, fully humanized, anti-tumor necrosis factor alpha (anti-TNF-\u03b1) monoclonal antibody, is the only officially approved treatment for the management of moderate-to-severe hidradenitis suppurativa."
      ], 
      "exact_answer": "yes", 
      "concepts": [
        "http://www.disease-ontology.org/api/metadata/DOID:2280", 
        "http://www.biosemantics.org/jochem#4002010", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000068879", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D017497"
      ], 
      "type": "yesno", 
      "id": "58847e36e56acf5176000009", 
      "snippets": [
        {
          "offsetInBeginSection": 1819, 
          "offsetInEndSection": 2061, 
          "text": "If patient is not improved, then Adalimumab 160\u00a0mg at week 0, 80\u00a0mg at week 2; then 40\u00a0mg subcutaneously weekly should be administered (LOE Ib, SOR A). If improvement occurs then therapy should be maintained as long as HS lesions are present.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26831295", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 181, 
          "text": "Reduction in pain scores and improvement in depressive symptoms in patients with hidradenitis suppurativa treated with adalimumab in a phase 2, randomized, placebo-controlled trial.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27136622", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 144, 
          "offsetInEndSection": 241, 
          "text": "Adalimumab treatment for 16 weeks improved HS lesions significantly versus placebo\u00a0(NCT00918255).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27136622", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1406, 
          "offsetInEndSection": 1615, 
          "text": "CONCLUSION: Patients with moderate to severe HS had a high degree of pain and depressive symptoms\u00a0at baseline. Adalimumabtherapy was associated with decreased pain and depressive symptoms compared to baseline.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27136622", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 95, 
          "text": "Spotlight on adalimumab in the treatment of active moderate-to-severe hidradenitis suppurativa.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27799806", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 465, 
          "offsetInEndSection": 1280, 
          "text": "Adalimumab, a recombinant, fully humanized, anti-tumor necrosis factor alpha (anti-TNF-\u03b1) monoclonal antibody, is the only officially approved treatment for the management of moderate-to-severe HS. Case reports, concerning 42 patients who received adalimumab for severe HS (with the standard dose regimen for psoriasis), reported a cumulative response rate of 58% (\u226550% in 23 patients) with a relapse rate of 71% (10 out of 14 patients). The most recent and most well-powered phase III, randomized placebo-controlled trials for the evaluation of the efficacy and safety of adalimumab in treatment of moderate-to-severe HS (PIONEER studies I and II) showed that the Hidradenitis Suppurativa Clinical Response (HiSCR) rate at week 12 was significantly higher for patients randomized to adalimumab compared to placebo.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27799806", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1324, 
          "offsetInEndSection": 1423, 
          "text": "In conclusion, adalimumab, to date, holds the most robust data regarding treatment efficacy in HS. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27799806", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 66, 
          "text": "Adalimumab (Humira) for the Treatment of Hidradenitis Suppurativa.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27388530", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 183, 
          "text": "Adalimumab (Humira\u00ae) is a novel therapy approved by the US Food and Drug Administration, Health Canada, and the European Commission for the treatment of hidradenitis suppurativa (HS).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27388530", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1338, 
          "offsetInEndSection": 1560, 
          "text": "Taken together, these data conclude that treatment of HS with adalimumab is a safe and effective therapy resulting in a significant decrease in abscess and inflammatory nodule counts within the first 12 weeks of treatment.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27388530", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 121, 
          "text": "Effective long-term control of refractory hidradenitis suppurativa with adalimumab after failure of conventional therapy.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21091684", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 49, 
          "text": "Hidradenitis suppurativa managed with adalimumab.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19213236", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 74, 
          "text": "Treatment of severe recalcitrant hidradenitis suppurativa with adalimumab.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19371236", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 75, 
          "text": "Long-term successful adalimumab therapy in severe hidradenitis suppurativa.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19451504", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 106, 
          "text": "Comparing treatment outcome of infliximab and adalimumab in patients with severe hidradenitis suppurativa.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21756155", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 218, 
          "text": "HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26201313", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 149, 
          "text": "Adalimumab in treatment-resistant hidradenitis suppurativa following recurrence after extensive affected area excision: a review of biologics therapy", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24144253", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 139, 
          "text": "Adalimumab (antitumour necrosis factor-\u03b1) treatment of hidradenitis suppurativa ameliorates skin inflammation: an in situ and ex vivo study", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22013960", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 73, 
          "text": "Treatment of severe recalcitrant hidradenitis suppurativa with adalimumab", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19371236", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 115, 
          "offsetInEndSection": 404, 
          "text": "In a phase 2 trial, adalimumab, an antibody against tumor necrosis factor \u03b1, showed efficacy against hidradenitis suppurativa.PIONEER I and II were similarly designed, phase 3 multicenter trials of adalimumab for hidradenitis suppurativa, with two double-blind, placebo-controlled periods.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27518661", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 731, 
          "offsetInEndSection": 853, 
          "text": "Here we report a case of a patient with severe recalcitrant hidradenitis suppurativa successfully treated with adalimumab.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19371236", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 312, 
          "offsetInEndSection": 495, 
          "text": "Recent reports have demonstrated that adalimumab, a tumor necrosis factor (TNF) antagonist, may be effective in the treatment of patients with HS who have failed conventional therapy.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19213236", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1351, 
          "offsetInEndSection": 1437, 
          "text": "Conclusion Adalimumab appears to be an effective and safe treatment for refractory HS.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19451504", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 122, 
          "text": "Effective long-term control of refractory hidradenitis suppurativa with adalimumab after failure of conventional therapy.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21091684", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 50, 
          "text": "Hidradenitis suppurativa managed with adalimumab.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19213236", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 75, 
          "text": "Treatment of severe recalcitrant hidradenitis suppurativa with adalimumab.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19371236", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 63, 
          "text": "Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27518661", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 83, 
          "text": "Adalimumab treatment for hidradenitis suppurativa associated with Crohn's disease.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25580790", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 76, 
          "text": "Long-term successful adalimumab therapy in severe hidradenitis suppurativa.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19451504", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 1352, 
          "offsetInEndSection": 1439, 
          "text": "Conclusion Adalimumab appears to be an effective and safe treatment for refractory HS..", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19451504", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 107, 
          "text": "Comparing treatment outcome of infliximab and adalimumab in patients with severe hidradenitis suppurativa.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21756155", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 731, 
          "offsetInEndSection": 854, 
          "text": "Here we report a case of a patient with severe recalcitrant hidradenitis suppurativa successfully treated with adalimumab..", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19371236", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1272, 
          "offsetInEndSection": 1407, 
          "text": "Adalimumab is suitable for the long-term treatment of hidradenitis suppurativa and presents a further conservative treatment approach..", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21091684", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 220, 
          "text": "HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26201313", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 96, 
          "text": "Spotlight on adalimumab in the treatment of active moderate-to-severe hidradenitis suppurativa.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27799806", 
          "endSection": "title"
        }
      ]
    }, 
    {
      "body": "What is Legg-Calv\u00e9-Perthes Disease", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26780125", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27064472", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20048104", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21606991", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12208918"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Legg-Calve-Perthes disease is  idiopathic avascular necrosis of the hip, usually occurring in pediatric populations.", 
        "Legg-Calv\u00e9-Perthes' (Perthes') disease is a developmental disease of the hip joint that may result in numerous short and long term problems. Legg-Calve-Perthes disease (LCPD) is the insidious onset of idiopathic avascular necrosis of the hip in the pediatric population."
      ], 
      "concepts": [
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D007873", 
        "http://www.disease-ontology.org/api/metadata/DOID:14415"
      ], 
      "type": "summary", 
      "id": "58bc8e5002b8c60953000006", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 204, 
          "text": "Legg-Calv\u00e9-Perthes' (Perthes') disease is a developmental disease of the hip joint that may result in numerous short and long term problems. The etiology of the disease remains largely unknown, but the me", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26780125", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 283, 
          "text": "Legg-Calve-Perthes disease (LCPD) is the insidious onset of idiopathic avascular necrosis of the hip in the pediatric population. The disease encompasses a wide spectrum of pathology, from mild with no long-term sequelae to severe with permanent degenerative change of the hip joint.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27064472", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 106, 
          "text": "BACKGROUND: Legg-Perthes disease is associated with ischemia of the capital femoral epiphysis in children.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12208918", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 12, 
          "offsetInEndSection": 127, 
          "text": "Legg-Calv\u00e9-Perthes disease is a pediatric disorder characterized by osteonecrosis of the proximal femoral epiphysis", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20048104", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 12, 
          "offsetInEndSection": 103, 
          "text": "Legg-Calv\u00e9-Perthes disease is characterized by avascular necrosis of the head of the femur.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21606991", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 12, 
          "offsetInEndSection": 124, 
          "text": "Legg-Calv\u00e9-Perthes disease is a childhood hip disorder that may result in a deformed and poorly functioning hip.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19034171", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is promoted by ERAP1-ERAP2 dimerization?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24928998"
      ], 
      "triples": [], 
      "ideal_answer": [
        "ERAP1-ERAP2 dimerization increases peptide-trimming efficiency. ERAP1-ERAP2 heterodimers produce several mature epitopes more efficiently than a mix of the two enzymes unable to dimerize. Physical interaction with ERAP2 changes basic enzymatic parameters of ERAP1 and improves its substrate-binding affinity. Thus, by bringing the two enzymes in proximity and by producing allosteric effects on ERAP1, dimerization of ERAP1/2 creates complexes with superior peptide-trimming efficacy. Such complexes are likely to enhance Ag presentation by cells displaying coordinated expression of the two enzymes.", 
        "ERAP1-ERAP2 dimerization increases peptide-trimming efficiency.", 
        "The endoplasmic reticulum aminopeptidases (ERAP)1 and ERAP2 play a critical role in the production of final epitopes presented by MHC class I molecules."
      ], 
      "concepts": [
        "http://www.uniprot.org/uniprot/ERAP1_HUMAN", 
        "http://www.uniprot.org/uniprot/ERAP2_HUMAN", 
        "http://www.uniprot.org/uniprot/ERAP2_PONAB", 
        "http://www.uniprot.org/uniprot/ERAP2_BOVIN", 
        "http://www.uniprot.org/uniprot/ERAP1_RAT", 
        "http://www.uniprot.org/uniprot/ERAP1_MOUSE"
      ], 
      "type": "summary", 
      "id": "588800f43b87a8a738000009", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 63, 
          "text": "ERAP1-ERAP2 dimerization increases peptide-trimming efficiency.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24928998", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 335, 
          "offsetInEndSection": 930, 
          "text": "In this study, we produced stabilized ERAP1-ERAP2 heterodimers and found that they produced several mature epitopes more efficiently than a mix of the two enzymes unable to dimerize. Physical interaction with ERAP2 changes basic enzymatic parameters of ERAP1 and improves its substrate-binding affinity. Thus, by bringing the two enzymes in proximity and by producing allosteric effects on ERAP1, dimerization of ERAP1/2 creates complexes with superior peptide-trimming efficacy. Such complexes are likely to enhance Ag presentation by cells displaying coordinated expression of the two enzymes.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24928998", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 333, 
          "offsetInEndSection": 515, 
          "text": "In this study, we produced stabilized ERAP1-ERAP2 heterodimers and found that they produced several mature epitopes more efficiently than a mix of the two enzymes unable to dimerize.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24928998", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 153, 
          "offsetInEndSection": 334, 
          "text": "Formation of heterodimers by ERAP1 and ERAP2 has been proposed to facilitate trimming of epitope precursor peptides, but the effects of dimerization on ERAP function remain unknown.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24928998", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 62, 
          "text": "ERAP1-ERAP2 dimerization increases peptide-trimming efficiency", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24928998", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 335, 
          "offsetInEndSection": 518, 
          "text": "In this study, we produced stabilized ERAP1-ERAP2 heterodimers and found that they produced several mature epitopes more efficiently than a mix of the two enzymes unable to dimerize. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24928998", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 335, 
          "offsetInEndSection": 517, 
          "text": "In this study, we produced stabilized ERAP1-ERAP2 heterodimers and found that they produced several mature epitopes more efficiently than a mix of the two enzymes unable to dimerize.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24928998", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 64, 
          "text": "ERAP1-ERAP2 dimerization increases peptide-trimming efficiency.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24928998", 
          "endSection": "title"
        }
      ]
    }, 
    {
      "body": "What is plantar fasciitis", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/27904584", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27957702", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26655866", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22166747", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15134611", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21916393", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26665894", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25429080", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26184993", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23037146", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21272731", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12756315"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Plantar fascia (PF) disorders like plantar fasciitis commonly cause heel pain and disability and are thought to be degenerative rather than inflammatory in nature"
      ], 
      "exact_answer": [
        [
          "heel pain"
        ]
      ], 
      "concepts": [
        "http://www.disease-ontology.org/api/metadata/DOID:9600", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005208", 
        "http://www.disease-ontology.org/api/metadata/DOID:9598", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D036981"
      ], 
      "type": "factoid", 
      "id": "58bc8e7a02b8c60953000007", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 69, 
          "text": "Plantar fascia (PF) disorders commonly cause heel pain and disability", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27957702", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 12, 
          "offsetInEndSection": 216, 
          "text": "Plantar fasciitis (PF) is a common foot complaint, affects both active sportsmen and physically inactive middle age group. It is believed that PF results from degenerative changes rather than inflammation", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27904584", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 108, 
          "text": "Plantar fasciitis (PF) is present in 10% of the population and is the most common cause of plantar heel pain", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26665894", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 157, 
          "text": "Plantar fasciitis, a chronic degenerative process that causes medial plantar heel pain, is responsible for approximately 1 million physician visits each year", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25429080", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 67, 
          "text": "Plantar fasciitis (PF)is the most common cause of plantar heel pain", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26184993", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 411, 
          "offsetInEndSection": 641, 
          "text": "Plantar fasciitis is the most common cause of heel pain and is estimated to affect 2 million people in the United States alone.For adults suffering from plantar fasciitis, are foot orthoses a viable treatment option to reduce pain", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23037146", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 75, 
          "text": "Plantar fasciitis: a degenerative process (fasciosis) without inflammation.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12756315", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 96, 
          "text": "BACKGROUND: Plantar fasciitis is a common foot disorder that impacts many functional activities.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15134611", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 529, 
          "offsetInEndSection": 792, 
          "text": "The second purpose was to determine whether chronic plantar fasciitis is accompanied by atrophy of plantar intrinsic foot muscles and tibialis posterior.METHODS: Magnetic resonance images were taken bilaterally in eight subjects with unilateral plantar fasciitis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22166747", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 12, 
          "offsetInEndSection": 139, 
          "text": "Plantar fasciitis, a common injury in runners, has been speculated to be associated with weakness of the intrinsic foot muscles", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26655866", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 12, 
          "offsetInEndSection": 77, 
          "text": "Although plantar fasciitis is the most common cause of heel pain,", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19952249", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 229, 
          "text": "Plantar fasciitis, a self-limiting condition, is a common cause of heel pain in adults. It affects more than 1 million persons per year, and two-thirds of patients with plantar fasciitis will seek care from their family physician", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21916393", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 143, 
          "text": "Plantar fasciitis is a common cause of heel pain and is the result of a degenerative process of the plantar fascia at its calcaneal attachment.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21272731", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which is the enzymatic activity of OTULIN?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26503766", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27559085", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26235645", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26085216", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24726327", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24461064", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24726323", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23806334", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23746843"
      ], 
      "triples": [], 
      "ideal_answer": [
        "OTULIN is a deubiquitinase, that specifically cleaves Met1-linked polyUb."
      ], 
      "exact_answer": [
        [
          "deubiquitination"
        ]
      ], 
      "concepts": [], 
      "type": "factoid", 
      "id": "58a9a8631978bbde22000003", 
      "snippets": [
        {
          "offsetInBeginSection": 58, 
          "offsetInEndSection": 79, 
          "text": "deubiquitinase OTULIN", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26503766", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 186, 
          "offsetInEndSection": 230, 
          "text": "OTULIN (FAM105B), encoding a deubiquitinase ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27559085", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 912, 
          "offsetInEndSection": 993, 
          "text": " Otulin/Gumby/FAM105b are by far the most active DUBs acting on these precursors.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26235645", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 991, 
          "offsetInEndSection": 1088, 
          "text": "Removal of ubiquitin chains is mediated by deubiquitinases (DUBs). Two of them, OTULIN and CYLD, ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26085216", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 219, 
          "offsetInEndSection": 291, 
          "text": " are disassembled by the linear ubiquitin-specific deubiquitinase OTULIN", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24726327", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 100, 
          "offsetInEndSection": 131, 
          "text": "deubiquitinases CYLD and OTULIN", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24461064", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 201, 
          "offsetInEndSection": 295, 
          "text": "We recently discovered OTULIN as a deubiquitinase that specifically cleaves Met1-linked polyUb", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24726323", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 343, 
          "offsetInEndSection": 399, 
          "text": "deubiquitinase OTULIN specifically disassembles Met1-Ub.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23806334", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1029, 
          "offsetInEndSection": 1091, 
          "text": " Our data suggest that OTULIN regulates Met1-polyUb signaling.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23746843", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 89, 
          "text": "OTULIN antagonizes LUBAC signaling by specifically hydrolyzing Met1-linked polyubiquitin.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23746843", 
          "endSection": "title"
        }
      ]
    }, 
    {
      "body": "List diseases that could be targeted by disaggregases?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/27255695", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25620563", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26300264", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26312418"
      ], 
      "triples": [], 
      "ideal_answer": [
        "UBQLN2 acts with the HSP70-HSP110 disaggregase machinery to clear protein aggregates via the 26S proteasome. UBQLN2 recognizes client-bound HSP70 and links it to the proteasome to allow for the degradation of aggregated and misfolded proteins. We further show that this process is active in the cell nucleus, where another system for aggregate clearance, autophagy, does not act."
      ], 
      "exact_answer": [
        [
          "ALS", 
          "amyotrophic lateral sclerosis"
        ], 
        [
          "PD", 
          "Parkinson's disease"
        ], 
        [
          "AD", 
          "Alzheimer's disease"
        ], 
        [
          "Prions"
        ]
      ], 
      "concepts": [], 
      "type": "list", 
      "id": "58bc666702b8c60953000004", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 250, 
          "text": "Therapeutic agents are urgently required to cure several common and fatal neurodegenerative disorders caused by protein misfolding and aggregation, including amyotrophic lateral sclerosis (ALS), Parkinson's disease (PD), and Alzheimer's disease (AD).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27255695", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 81, 
          "text": "Human Hsp70 Disaggregase Reverses Parkinson's-Linked \u03b1-Synuclein Amyloid Fibrils.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26300264", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 73, 
          "text": "Disaggregases, molecular chaperones that resolubilize protein aggregates.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26312418", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 91, 
          "text": "The structural basis by which Hsp104 dissolves disordered aggregates and prions is unknown.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25620563", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Can NEECHAM Confusion Scale be used for evaluation of postoperative delirium?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25337310", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23121489", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22441728", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24175169", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19319925", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16732742", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19711147", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15038935", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16351715", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21539718", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18282269", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15792498", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24928237", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17394635", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27576903", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10095647", 
        "http://www.ncbi.nlm.nih.gov/pubmed/1811781", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10701282", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21511473", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11915156", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15077440"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Yes, NEECHAM Confusion Scale can be used for evaluation of postoperative delirium."
      ], 
      "exact_answer": "yes", 
      "concepts": [
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D003693", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D023362", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011569", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000067290", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D063189"
      ], 
      "type": "yesno", 
      "id": "5886222a3b87a8a738000005", 
      "snippets": [
        {
          "offsetInBeginSection": 361, 
          "offsetInEndSection": 473, 
          "text": "Sampling was achieved in a nonrandomized targeted manner and delirium was assessed using NeeCham questionnaire. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25337310", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 106, 
          "text": "Delirium in older patients: a diagnostic study of NEECHAM Confusion Scale in surgical intensive care unit.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23121489", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 148, 
          "text": "AIMS AND OBJECTIVES: To estimate the diagnostic value and determine the feasibility of the NEECHAM Confusion Scale on critically ill older patients.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23121489", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1447, 
          "offsetInEndSection": 1845, 
          "text": "CONCLUSIONS: Findings from this study confirm the good diagnostic value and ease of application of the NEECHAM scale with nonventilated intensive care patients.RELEVANCE TO CLINICAL PRACTICE: The NEECHAM scale can be used to detect delirium during the routine nursing assessment of nonintubated older patients as it requires minimal demand and stress on the patient as well as on the bedside nurse.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23121489", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 540, 
          "offsetInEndSection": 647, 
          "text": "The NEECHAM Confusion Scale and the validated chart review instrument were used for diagnosis of delirium. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22441728", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 344, 
          "offsetInEndSection": 594, 
          "text": "Among the various screening instruments, NEECHAM confusion scale and delirium observation scale appear to be most suitable screening instrument for patients' in general medical and surgical wards, depending on the type of rater (physician or nurse). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24175169", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 662, 
          "offsetInEndSection": 894, 
          "text": "Use of NEECHAM scaling enabled medical staff to identify cases of possible confusion early, indicating that the NEECHAM confusion scale should be useful for the detection of postoperative delirium and confusion in the surgical ward.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15038935", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 109, 
          "text": "Early detection of postoperative delirium and confusion in a surgical ward using the NEECHAM confusion scale.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15038935", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 406, 
          "offsetInEndSection": 696, 
          "text": "In this study, we investigated whether the early detection of postoperative delirium in elderly patients is possible using a simple, useful behavior-assessing scale, the NEECHAM Confusion Scale, and a method for comprehensively evaluating elderly persons' stress related to surgery, E-PASS.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19319925", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 114, 
          "text": "Assessment of the risk of postoperative delirium in elderly patients using E-PASS and the NEECHAM Confusion Scale.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19319925", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 372, 
          "offsetInEndSection": 659, 
          "text": "The aim of this study was to determine which of the two delirium observation screening scales, the NEECHAM Confusion Scale or the Delirium Observation Screening (DOS) scale, has the best discriminative capacity for diagnosing delirium and which is more practical for daily use by nurses.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17394635", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1121, 
          "offsetInEndSection": 1205, 
          "text": "For delirium diagnosis and severity assessment, we used the NEECHAM Confusion Scale.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19319925", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 666, 
          "offsetInEndSection": 898, 
          "text": "Use of NEECHAM scaling enabled medical staff to identify cases of possible confusion early, indicating that the NEECHAM confusion scale should be useful for the detection of postoperative delirium and confusion in the surgical ward.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15038935", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 546, 
          "offsetInEndSection": 684, 
          "text": "The NEECHAM Confusion Scale was performed upon admission and prior to discharge.RESULTS: The incidence of DSM-IV related delirium was 24%.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21539718", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 148, 
          "text": "A comparison of the CAM-ICU and the NEECHAM Confusion Scale in intensive care delirium assessment: an observational study in non-intubated patients.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18282269", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 115, 
          "text": "Predictive value and validation of the NEECHAM Confusion Scale using DSM-IV criteria for delirium as gold standard.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21539718", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 108, 
          "text": "Early detection of postoperative delirium and confusion in a surgical ward using the NEECHAM confusion scale", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15038935", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 375, 
          "offsetInEndSection": 753, 
          "text": "The aim of this study was to determine which of the two delirium observation screening scales, the NEECHAM Confusion Scale or the Delirium Observation Screening (DOS) scale, has the best discriminative capacity for diagnosing delirium and which is more practical for daily use by nurses.The project was conducted on four wards of a university hospital; 87 patients were included", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17394635", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 597, 
          "offsetInEndSection": 909, 
          "text": "In addition, we scored the participants on the NEECHAM Scale and evaluated their postoperative delirium and postoperative arrhythmia.On the nights of Days 4 and 5, the amount of activity of the exposure group was significantly lower and The sympathetic nervous index was significantly lower on the night of Day 5", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21511473", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 422, 
          "offsetInEndSection": 713, 
          "text": "In this study, we investigated whether the early detection of postoperative delirium in elderly patients is possible using a simple, useful behavior-assessing scale, the NEECHAM Confusion Scale, and a method for comprehensively evaluating elderly persons' stress related to surgery, E-PASS. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19319925", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1207, 
          "offsetInEndSection": 1381, 
          "text": "The cut-off value of the NEECHAM score was established as 20 points, and patients showing values less than this after surgery were regarded as having postoperative delirium. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19319925", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 504, 
          "offsetInEndSection": 663, 
          "text": "Identification of delirium was based on evaluation of the level of consciousness with the NEECHAM Confusion Scale and/or a chart-based instrument for delirium.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19711147", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1100, 
          "offsetInEndSection": 1184, 
          "text": "For delirium diagnosis and severity assessment, we used the NEECHAM Confusion Scale.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19319925", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 410, 
          "offsetInEndSection": 777, 
          "text": "In this study, we investigated whether the early detection of postoperative delirium in elderly patients is possible using a simple, useful behavior-assessing scale, the NEECHAM Confusion Scale, and a method for comprehensively evaluating elderly persons' stress related to surgery, E-PASS.The subjects were 160 patients aged more than 75 years who underwent surgery.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19319925", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 280, 
          "offsetInEndSection": 414, 
          "text": "In this study a nursing screening instrument, the NEECHAM confusion scale, was studied for early recognition of delirium ICU patients.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16351715", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1644, 
          "offsetInEndSection": 1775, 
          "text": "The psychometric characteristics and the ease of use of the NEECHAM confusion scale enables ICU nurses to early recognize delirium.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16351715", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 487, 
          "offsetInEndSection": 665, 
          "text": "The trends of the NEECHAM scores in the 3 groups were compared, and the relationship between the NEECHAM scores and suspected clinical risk factors for delirium was investigated.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15038935", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1836, 
          "offsetInEndSection": 2171, 
          "text": "In groups showing an MMSE score of less than 25 or a preoperative NEECHAM score of less than 27, the incidence of postoperative delirium was 76%.CONCLUSION: The results suggest that E-PASS and the NEECHAM score facilitate assessment of the risk of postoperative delirium in elderly patients, contributing to early prevention/treatment.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19319925", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 410, 
          "offsetInEndSection": 700, 
          "text": "In this study, we investigated whether the early detection of postoperative delirium in elderly patients is possible using a simple, useful behavior-assessing scale, the NEECHAM Confusion Scale, and a method for comprehensively evaluating elderly persons' stress related to surgery, E-PASS.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19319925", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 666, 
          "offsetInEndSection": 899, 
          "text": "Use of NEECHAM scaling enabled medical staff to identify cases of possible confusion early, indicating that the NEECHAM confusion scale should be useful for the detection of postoperative delirium and confusion in the surgical ward..", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15038935", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 110, 
          "text": "Early detection of postoperative delirium and confusion in a surgical ward using the NEECHAM confusion scale.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15038935", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 115, 
          "text": "Assessment of the risk of postoperative delirium in elderly patients using E-PASS and the NEECHAM Confusion Scale.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19319925", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 1101, 
          "offsetInEndSection": 1185, 
          "text": "For delirium diagnosis and severity assessment, we used the NEECHAM Confusion Scale.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19319925", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 137, 
          "text": "The Neecham Confusion Scale and the Delirium Observation Screening Scale: capacity to discriminate and ease of use in clinical practice.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17394635", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 375, 
          "offsetInEndSection": 662, 
          "text": "The aim of this study was to determine which of the two delirium observation screening scales, the NEECHAM Confusion Scale or the Delirium Observation Screening (DOS) scale, has the best discriminative capacity for diagnosing delirium and which is more practical for daily use by nurses.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17394635", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is adhesive capsulitis", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25919473", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21885699", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19011582", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27942856", 
        "http://www.ncbi.nlm.nih.gov/pubmed/7754892", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24374758", 
        "http://www.ncbi.nlm.nih.gov/pubmed/3871127", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10890460", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24652474", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19589853", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24283550", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24211154", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10738419", 
        "http://www.ncbi.nlm.nih.gov/pubmed/2702506"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Adhesive capsulitis also known as \"frozen shoulder\" is characterized by painful, gradual loss of active and passive shoulder motion resulting from fibrosis and contracture of the joint capsule."
      ], 
      "concepts": [
        "http://www.disease-ontology.org/api/metadata/DOID:14188"
      ], 
      "type": "summary", 
      "id": "58bca3eb02b8c6095300000d", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 87, 
          "text": "Adhesive capsulitis (frozen shoulder) is a common cause of shoulder pain and disability", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25919473", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 161, 
          "text": "Adhesive capsulitis is characterized by painful, gradual loss of active and passive shoulder motion resulting from fibrosis and contracture of the joint capsule.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21885699", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 104, 
          "text": "Painful stiffening of the shoulder, 'frozen shoulder' is a common cause of shoulder pain and disability.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19011582", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 281, 
          "offsetInEndSection": 439, 
          "text": "Current adhesive capsulitis was defined as restriction of external rotation and one or more additional directional restrictions with history of shoulder pain.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27942856", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 11, 
          "offsetInEndSection": 189, 
          "text": "Adhesive capsulitis is a clinical syndrome of pain and severely decreased joint motion (\"frozen shoulder\") caused by thickening and contraction of the joint capsule and synovium.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7754892", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 154, 
          "text": "Adhesive capsulitis is, in most cases, a self-limiting condition of poorly understood etiology that results in shoulder pain and large mobility deficits. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24374758", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 160, 
          "text": "Adhesive capsulitis of the shoulder is a condition of unknown etiology that results in the development of restriction of active and passive glenohumeral motion.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10738419", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 122, 
          "text": "Adhesive capsulitis of the shoulder is an idiopathic condition characterized clinically by pain and limitation of movement", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2702506", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Describe the applicability of Semantic MediaWiki in the case of FANTOM5", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/27402679"
      ], 
      "triples": [], 
      "ideal_answer": [
        "To make the heterogeneous data set accessible and useful for investigators, a web-based database called Semantic catalog of Samples, Transcription initiation And Regulators (SSTAR) has been developed. SSTAR utilizes the open source wiki software MediaWiki along with the Semantic MediaWiki (SMW) extension, which provides flexibility to model, store, and display a series of data sets produced during the course of the FANTOM5 project. The use of SMW demonstrates the utility of the framework for dissemination of large-scale analysis results. SSTAR is a case study in handling biological data generated from a large-scale research project in terms of maintenance and growth alongside research activities"
      ], 
      "concepts": [
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012660", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D059467"
      ], 
      "type": "summary", 
      "id": "587d36ab859bf79568000001", 
      "snippets": [
        {
          "offsetInBeginSection": 691, 
          "offsetInEndSection": 1389, 
          "text": "To make the heterogeneous data set accessible and useful for investigators, we developed a web-based database called Semantic catalog of Samples, Transcription initiation And Regulators (SSTAR). SSTAR utilizes the open source wiki software MediaWiki along with the Semantic MediaWiki (SMW) extension, which provides flexibility to model, store, and display a series of data sets produced during the course of the FANTOM5 project. Our use of SMW demonstrates the utility of the framework for dissemination of large-scale analysis results. SSTAR is a case study in handling biological data generated from a large-scale research project in terms of maintenance and growth alongside research activities", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27402679", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 882, 
          "offsetInEndSection": 1116, 
          "text": "SSTAR utilizes the open source wiki software MediaWiki along with the Semantic MediaWiki (SMW) extension, which provides flexibility to model, store, and display a series of data sets produced during the course of the FANTOM5 project.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27402679", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 886, 
          "offsetInEndSection": 1120, 
          "text": "SSTAR utilizes the open source wiki software MediaWiki along with the Semantic MediaWiki (SMW) extension, which provides flexibility to model, store, and display a series of data sets produced during the course of the FANTOM5 project.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27402679", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Is there an association between Muenke Syndrome and FGFR3 gene mutation?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26028288", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24168007", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24448525", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24705944", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24686979", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23378035", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19449410", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18000976", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23044018", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22872265", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22016144", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19086028", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15241680", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21403557", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17070479", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22544111", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26740388", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20592905", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16251895", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22446440", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17103449", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18818193", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19755431", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11571861", 
        "http://www.ncbi.nlm.nih.gov/pubmed/14613973", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21233754", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10696568", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19215249", 
        "http://www.ncbi.nlm.nih.gov/pubmed/14963686"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Yes, Muenke syndrome is caused by point mutation (C749G) in the Fibroblast Growth Factor Receptor3 (FGFR3) gene. It affects 1 in 30,000 newborns and accounts for 25% to 30% of genetic causes of craniosynostosis."
      ], 
      "exact_answer": "yes", 
      "concepts": [
        "http://www.uniprot.org/uniprot/FGFR3_CHICK", 
        "http://www.uniprot.org/uniprot/FGFR3_HUMAN", 
        "http://www.uniprot.org/uniprot/FGFR3_PLEWA", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D001244", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D051498", 
        "http://www.disease-ontology.org/api/metadata/DOID:0060703"
      ], 
      "type": "yesno", 
      "id": "5895ec5e7d9090f353000015", 
      "snippets": [
        {
          "offsetInBeginSection": 579, 
          "offsetInEndSection": 810, 
          "text": "RESULTS: Forty-four with a positive FGFR3 mutation, median age 9 years, range 7 months to 52 years were enrolled. In addition, 10 unaffected siblings served as controls (5 males, 5 females; median age, 13 years; range, 3-18 years).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26028288", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 120, 
          "text": "Muenke is a fibroblast growth factor receptor 3 (FGFR-3)-associated syndrome, which was first described in late 1990 s. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24168007", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 275, 
          "offsetInEndSection": 455, 
          "text": "The syndrome is defined molecularly by a unique point mutation c.749C>G in exon 7 of the FGFR3 gene which results to an amino acid substitution p.Pro250Arg of the protein product. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24168007", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 162, 
          "text": "Muenke syndrome caused by point mutation (C749G) in the FGFR3 gene affects 1 in 30,000 newborns and accounts for 25% to 30% of genetic causes of craniosynostosis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24448525", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 78, 
          "text": "Phenotypic variability in two families of Muenke syndrome with FGFR3 mutation.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24705944", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 282, 
          "text": "PURPOSE: There are a number of craniosynostosis syndromes with hearing loss-including Muenke, Apert, Pfeiffer, Crouzon, Beare-Stevenson, Crouzon with acanthosis nigricans, and Jackson-Weiss syndromes-that result from mutations in the fibroblast growth factor receptor (FGFR) genes. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24686979", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 163, 
          "text": "Muenke syndrome is an autosomal dominant craniosynostosis syndrome resulting from a defining point mutation in the Fibroblast Growth Factor Receptor3 (FGFR3) gene.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23378035", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 155, 
          "text": "Talocalcaneal coalition in Muenke syndrome: report of a patient, review of the literature in FGFR-related craniosynostoses, and consideration of mechanism.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23378035", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 331, 
          "offsetInEndSection": 591, 
          "text": "To better understand the pathophysiology of the Muenke syndrome, we present collective findings from several recent studies that have characterized a genetically equivalent mouse model for Muenke syndrome (FgfR3 (P244R)) and compare them with human phenotypes.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22872265", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 407, 
          "offsetInEndSection": 733, 
          "text": "We show in this study that knock-in mice harboring the mutation responsible for the Muenke syndrome (FgfR3(P244R)) display postnatal shortening of the cranial base along with synchondrosis growth plate dysfunction characterized by loss of resting, proliferating and hypertrophic chondrocyte zones and decreased Ihh expression.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22016144", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 408, 
          "offsetInEndSection": 526, 
          "text": "Muenke syndrome is caused by a single defining point mutation in the fibroblast growth factor receptor 3 (FGFR3) gene.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23044018", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 265, 
          "offsetInEndSection": 434, 
          "text": "The Pro250Arg mutation in the FGFR3 gene is found in patients with Muenke syndrome and is one of the most frequently encountered mutations in craniosynostosis syndromes.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21403557", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 60, 
          "text": "Epilepsy in Muenke syndrome: FGFR3-related craniosynostosis.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23044018", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 106, 
          "text": "Muenke syndrome (FGFR3-related craniosynostosis): expansion of the phenotype and review of the literature.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18000976", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 267, 
          "offsetInEndSection": 436, 
          "text": "The Pro250Arg mutation in the FGFR3 gene is found in patients with Muenke syndrome and is one of the most frequently encountered mutations in craniosynostosis syndromes.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21403557", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 150, 
          "text": "PURPOSE: The Muenke syndrome mutation (FGFR3 (P250R)), which was discovered 15 years ago, represents the single most common craniosynostosis mutation.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22872265", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 233, 
          "text": "The heterozygous Pro250Arg substitution mutation in fibroblast growth factor receptor 3 (FGFR3), which increases ligand-dependent signalling, is the most common genetic cause of craniosynostosis in humans and defines Muenke syndrome.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18818193", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 172, 
          "text": "P250R mutation in the FGFR3 gene also known as Muenke syndrome is associated with coronal craniosynostosis, sensorineural deafness, craniofacial, and digital abnormalities.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17103449", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 133, 
          "text": "Muenke syndrome caused by the FGFR3 Pro250Arg mutation is associated with craniosynostosis, hearing loss, and various bony anomalies.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22446440", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 223, 
          "text": "Muenke syndrome is an autosomal dominant disorder characterized by coronal suture craniosynostosis, hearing loss, developmental delay, carpal and tarsal fusions, and the presence of the Pro250Arg mutation in the FGFR3 gene.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18000976", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 183, 
          "text": "Muenke syndrome, defined by heterozygosity for a Pro250Arg substitution in fibroblast growth factor receptor 3 (FGFR3), is the most common genetic cause of craniosynostosis in humans.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19086028", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1041, 
          "offsetInEndSection": 1173, 
          "text": "In addition, sensorineural hearing loss is detected in all FgfR3 (P244R) mutant mice as in the majority of Muenke syndrome patients.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22872265", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 133, 
          "offsetInEndSection": 772, 
          "text": "Genetic testing identifies a pathogenic mutation or chromosomal abnormality in \u223c 21% of cases, but it is likely that further causative mutations remain to be discovered.To identify a shared signature of genetically determined craniosynostosis by comparing the expression patterns in three monogenic syndromes with a control group of patients with non-syndromic sagittal synostosis.Fibroblasts from 10 individuals each with Apert syndrome (FGFR2 substitution S252W), Muenke syndrome (FGFR3 substitution P250R), Saethre-Chotzen syndrome (various mutations in TWIST1) and non-syndromic sagittal synostosis (no mutation detected) were cultured", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19755431", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 581, 
          "offsetInEndSection": 819, 
          "text": "The craniosynostosis syndromes: Apert syndrome, Beare-Stevenson syndrome, Crouzon syndrome, Jackson-Weiss syndrome, Muenke syndrome, Pfeiffer syndrome and Saethre-Chotzen syndrome can be caused by mutation in either FGFR1, FGFR2, or FGFR3", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11571861", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 240, 
          "text": "Identical proline-->arginine gain-of-function mutations in fibroblast growth factor receptor (FGFR) 1 (Pro252Arg), FGFR2 (Pro253Arg) and FGFR3 (Pro250Arg), result in type I Pfeiffer, Apert and Muenke craniosynostosis syndromes, respectively", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14613973", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 267, 
          "offsetInEndSection": 435, 
          "text": "The Pro250Arg mutation in the FGFR3 gene is found in patients with Muenke syndrome and is one of the most frequently encountered mutations in craniosynostosis syndromes", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21403557", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 818, 
          "offsetInEndSection": 1043, 
          "text": "Mutation analysis of FGFR-3 revealed a missense mutation in exon 6, c.749 C>G, with a resultant amino acid change from proline to arginine at codon 250 (P250R), in keeping with Muenke syndrome (Am J Hum Genet 1997;60:555-564)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21233754", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 219, 
          "offsetInEndSection": 441, 
          "text": "In an attempt to delineate functional features separating SCS from Muenkes syndrome, we screened patients presenting with coronal suture synostosis for mutations in the TWIST 1 gene, and for the Pro250Arg mutation in FGFR3", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16251895", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 942, 
          "offsetInEndSection": 1237, 
          "text": "Since the Gly380Arg achondroplasia mutation was recognized, similar observations regarding the conserved nature of FGFR mutations and resulting phenotype have been made regarding other skeletal phenotypes, including hypochondroplasia, thanatophoric dysplasia, and Muenke coronal craniosynostosis", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10696568", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 418, 
          "text": "Mutations in the gene that encodes Fibroblast Growth Factor Receptor 3 (FGFR3) are associated with Achondroplasia (MIM 100800), Hypochondroplasia (MIM 146000), Muenke Syndrome (MIM 602849), Thanatophoric Dysplasia (MIM 187600, MIM 187601) and Lacrimo-Auriculo-Dento-Digital Syndrome (MIM 149730).Here we report a clinical and molecular study in a large cohort of 125 Portuguese patients with these skeletal disorders. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19215249", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 252, 
          "text": "The Muenke syndrome (MS) is characterized by unicoronal or bicoronal craniosynostosis, midfacial hypoplasia, ocular hypertelorism, and a variety of minor abnormalities associated with a mutation in the fibroblast growth factor receptor 3 (FGFR3) gene. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20592905", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 173, 
          "text": "P250R mutation in the FGFR3 gene also known as Muenke syndrome is associated with coronal craniosynostosis, sensorineural deafness, craniofacial, and digital abnormalities. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17103449", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 539, 
          "offsetInEndSection": 808, 
          "text": "METHODS: Fibroblasts from 10 individuals each with Apert syndrome (FGFR2 substitution S252W), Muenke syndrome (FGFR3 substitution P250R), Saethre-Chotzen syndrome (various mutations in TWIST1) and non-syndromic sagittal synostosis (no mutation detected) were cultured. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19755431", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 224, 
          "text": "Muenke syndrome is an autosomal dominant disorder characterized by coronal suture craniosynostosis, hearing loss, developmental delay, carpal and tarsal fusions, and the presence of the Pro250Arg mutation in the FGFR3 gene. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18000976", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 270, 
          "text": "Muenke syndrome, also known as FGFR3-associated coronal synostosis, is defined molecularly by the presence of a heterozygous nucleotide transversion, c.749C>G, encoding the amino acid substitution Pro250Arg, in the fibroblast growth factor receptor type 3 gene (FGFR3). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15241680", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 323, 
          "offsetInEndSection": 487, 
          "text": "In spite of a variable phenotype, Muenke syndrome has been related to a unique mutation on the FGFR3 gene, Pro 250 to Arg, which is characteristic of this disease. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14963686", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 102, 
          "text": "Skeletal analysis of the Fgfr3(P244R) mouse, a genetic model for the Muenke craniosynostosis syndrome.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19086028", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 410, 
          "offsetInEndSection": 528, 
          "text": "Muenke syndrome is caused by a single defining point mutation in the fibroblast growth factor receptor 3 (FGFR3) gene.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23044018", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 61, 
          "text": "Epilepsy in Muenke syndrome: FGFR3-related craniosynostosis.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23044018", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 269, 
          "text": "Muenke syndrome, also known as FGFR3-associated coronal synostosis, is defined molecularly by the presence of a heterozygous nucleotide transversion, c.749C>G, encoding the amino acid substitution Pro250Arg, in the fibroblast growth factor receptor type 3 gene (FGFR3).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15241680", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 141, 
          "text": "The Muenke syndrome mutation (FGFR3 (P250R)), which was discovered 15 years ago, represents the single most common craniosynostosis mutation.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22872265", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which R package is used for visualization of linear and circular karyotypes?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26791998"
      ], 
      "triples": [], 
      "ideal_answer": [
        "The chromDraw graphical tool was developed as a user-friendly graphical tool for visualizing both linear and circular karyotypes based on the same input data matrix. The output graphics, saved in two different formats (EPS and SVG), can be easily imported to and modified in presentation and image-editing computer programs. The tool is freely distributed under GNU General Public License (GPL) and can be installed from Bioconductor or from the chromDraw home page.", 
        "The chromDraw graphical tool was developed as a user-friendly graphical tool for visualizing both linear and circular karyotypes based on the same input data matrix. The tool is freely distributed under GNU General Public License (GPL) and can be installed from Bioconductor or from the chromDraw home page."
      ], 
      "exact_answer": [
        [
          "chromDraw"
        ]
      ], 
      "concepts": [
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D059785"
      ], 
      "type": "factoid", 
      "id": "588f2de394c1512c50000001", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 76, 
          "text": "chromDraw: an R package for visualization of linear and circular karyotypes.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26791998", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 470, 
          "offsetInEndSection": 936, 
          "text": "The chromDraw graphical tool was developed as a user-friendly graphical tool for visualizing both linear and circular karyotypes based on the same input data matrix. The output graphics, saved in two different formats (EPS and SVG), can be easily imported to and modified in presentation and image-editing computer programs. The tool is freely distributed under GNU General Public License (GPL) and can be installed from Bioconductor or from the chromDraw home page.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26791998", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 467, 
          "offsetInEndSection": 632, 
          "text": "The chromDraw graphical tool was developed as a user-friendly graphical tool for visualizing both linear and circular karyotypes based on the same input data matrix.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26791998", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 77, 
          "text": "chromDraw: an R package for visualization of linear and circular karyotypes.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26791998", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 470, 
          "offsetInEndSection": 635, 
          "text": "The chromDraw graphical tool was developed as a user-friendly graphical tool for visualizing both linear and circular karyotypes based on the same input data matrix.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26791998", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Has small pox been eradicated from the world?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/11808015", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10742580", 
        "http://www.ncbi.nlm.nih.gov/pubmed/7013291", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23436190", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11503361", 
        "http://www.ncbi.nlm.nih.gov/pubmed/14969309", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22185830", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22566811"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Yes, small pox has been eradicated.", 
        "smallpox is now eradicated.", 
        "small pox has been eradicated.", 
        "smallpox is now eradicated"
      ], 
      "exact_answer": "yes", 
      "concepts": [
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012900", 
        "http://www.disease-ontology.org/api/metadata/DOID:8736", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012899"
      ], 
      "type": "yesno", 
      "id": "58a1da4e78275d0c4a000059", 
      "snippets": [
        {
          "offsetInBeginSection": 153, 
          "offsetInEndSection": 183, 
          "text": "small pox has been eradicated.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10742580", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 837, 
          "offsetInEndSection": 863, 
          "text": "smallpox is now eradicated", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11808015", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 819, 
          "offsetInEndSection": 1144, 
          "text": "In May 1980 the World Health Assembly in Geneva announced in solemn form the world-wide eradication of the small-pox and gave recommendations to the member countries for concluding measures concerning the small-pox vaccination, the foundation of vaccine reserves and the control of the epidemiological situation in the world.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7013291", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 65, 
          "offsetInEndSection": 182, 
          "text": "As a result of vaccination, diseases such as polio and measles have been controlled and small pox has been eradicated", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10742580", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 144, 
          "offsetInEndSection": 277, 
          "text": "Small pox eradication from the world is the perfect example of the role of mass vaccination of the entire community of the universe. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23436190", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 914, 
          "offsetInEndSection": 1057, 
          "text": "The French owe a lot to this Central Committee of Vaccine, which greatly contributed to fighting small pox and eradicating the disease finally.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11503361", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 144, 
          "offsetInEndSection": 276, 
          "text": "Small pox eradication from the world is the perfect example of the role of mass vaccination of the entire community of the universe.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23436190", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 669, 
          "offsetInEndSection": 868, 
          "text": "Also, the vaccine that Jenner used, which decreased the prevalence of Small Pox worldwide in his own time, and later was used to eradicate Small Pox altogether, is discussed in light of recent data..", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22566811", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 516, 
          "offsetInEndSection": 760, 
          "text": "the only known cases of smallpox happened from an outbreak in Birmingham, England caused by a laboratory accident in the year of 1979. On May the 8 th 1980 the disease was declared as eliminated from the world by the WHO (WHO-Resolution 33.33).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12822115", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Where is Akkermansia muciniphila found?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26100928", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25795669"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Akkermansia muciniphila is a Gram-negative mucin-degrading bacterium that resides in the gastrointestinal tracts of humans and animals.", 
        "RYGB led to altered relative abundances of 31 species (P\u2009<\u20090.05, q\u2009<\u20090.15) within the first 3\u00a0months, including those of Escherichia coli, Klebsiella pneumoniae, Veillonella spp., Streptococcus spp., Alistipes spp., and Akkermansia muciniphila. Main findings are as follows: (1) gut microbiota compositions of cecal and fecal samples were altered in BTBR compared to control mice, indicating that this model may be of utility in understanding gut-brain interactions in ASD; (2) KD consumption caused an anti-microbial-like effect by significantly decreasing total host bacterial abundance in cecal and fecal matter; (3) specific to BTBR animals, the KD counteracted the common ASD phenotype of a low Firmicutes to Bacteroidetes ratio in both sample types; and (4) the KD reversed elevated Akkermansia m However, faeces from the UC cohort had lower proportions of Akkermansia muciniphila and increased diversity within Clostridium cluster XIVa compared to controls.Gut fermentation of NSP and starch is diminished in patients with UC. Specific members of the microbiota such as Akkermansia muciniphila might be decreased in diabetes and when administered to murines exerted antidiabetic effects. In parallel, the antibiotic susceptibility of Akkermansia muciniphila Muc(T) strain was studied and this strain was observed by electron microscopy."
      ], 
      "exact_answer": [
        [
          "Akkermansia muciniphila resides in the gastrointestinal tracts of humans and animals."
        ]
      ], 
      "concepts": [], 
      "type": "factoid", 
      "id": "58bc363622d300530900001f", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 136, 
          "text": "Akkermansia muciniphila is a Gram-negative mucin-degrading bacterium that resides in the gastrointestinal tracts of humans and animals. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25795669", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 11, 
          "offsetInEndSection": 365, 
          "text": "Individuals with obesity and type 2 diabetes differ from lean and healthy individuals in their abundance of certain gut microbial species and microbial gene richness. Abundance of Akkermansia muciniphila, a mucin-degrading bacterium, has been inversely associated with body fat mass and glucose intolerance in mice, but more evidence is needed in humans.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26100928", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Is there alternative polyadenylation during zebrafish development?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/22722342"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Yes. There is extensive alternative polyadenylation during zebrafish development."
      ], 
      "exact_answer": "yes", 
      "concepts": [
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D026723", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D015027", 
        "http://amigo.geneontology.org/amigo/term/GO:0006378", 
        "http://amigo.geneontology.org/amigo/term/GO:1900364", 
        "http://amigo.geneontology.org/amigo/term/GO:1900365", 
        "http://amigo.geneontology.org/amigo/term/GO:1900363"
      ], 
      "type": "yesno", 
      "id": "58963b0278275d0c4a00000c", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 67, 
          "text": "Extensive alternative polyadenylation during zebrafish development.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22722342", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 1145, 
          "offsetInEndSection": 1525, 
          "text": "At 2 h post-fertilization, thousands of unique poly(A) sites appear at locations lacking a typical polyadenylation signal, which suggests a wave of widespread cytoplasmic polyadenylation of mRNA degradation intermediates. Our insights into the identities, formation, and evolution of zebrafish 3' UTRs provide a resource for studying gene regulation during vertebrate development.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22722342", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 68, 
          "text": "Extensive alternative polyadenylation during zebrafish development.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22722342", 
          "endSection": "title"
        }
      ]
    }, 
    {
      "body": "Which NADPH oxidase family member requires interaction with NOXO1 for function?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/27540115", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23957209", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15824103", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20454568", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15507761", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23322165", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26781991", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16911517", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20609497", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16507994", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17583407", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22549734", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17900370", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15507762", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16762923", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16329988", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18929641", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18463161", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17913709"
      ], 
      "triples": [], 
      "ideal_answer": [
        "NADPH oxidase 1 (NOX1) requires interaction with NOXO1 for function."
      ], 
      "exact_answer": [
        [
          "NADPH oxidase 1", 
          "NOX1", 
          "nicotinamide adenine dinucleotide phosphate-oxidase 1"
        ]
      ], 
      "concepts": [
        "http://www.uniprot.org/uniprot/NOXO1_HUMAN", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D019255", 
        "http://amigo.geneontology.org/amigo/term/GO:0043020", 
        "http://www.uniprot.org/uniprot/NOXO1_MOUSE", 
        "http://www.uniprot.org/uniprot/NOXA1_RAT", 
        "http://www.uniprot.org/uniprot/NOXA1_MOUSE", 
        "http://www.biosemantics.org/jochem#4270191"
      ], 
      "type": "factoid", 
      "id": "58a5a51060087bc10a000021", 
      "snippets": [
        {
          "offsetInBeginSection": 203, 
          "offsetInEndSection": 439, 
          "text": "A unique member of this family, Nox1 oxidase, functions as either a canonical or hybrid system using Nox organizing subunit 1 (NoxO1) or p47(phox), respectively, the latter of which is functional in vascular smooth muscle cells (VSMC). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27540115", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 125, 
          "text": "Phosphorylation of Noxo1 at threonine 341 regulates its interaction with Noxa1 and the superoxide-producing activity of Nox1.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23957209", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 12, 
          "offsetInEndSection": 329, 
          "text": "Superoxide production by Nox1, a member of the Nox family NAPDH oxidases, requires expression of its regulatory soluble proteins Noxo1 (Nox organizer 1) and Noxa1 (Nox activator 1) and is markedly enhanced upon cell stimulation with phorbol 12-myristate 13-acetate (PMA), a potent activator of protein kinase C (PKC).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23957209", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 814, 
          "offsetInEndSection": 1430, 
          "text": "Phosphorylation of Thr341 allows Noxo1 to sufficiently interact with Noxa1, an interaction that participates in Nox1 activation. Thus phosphorylation of Noxo1 at Thr341 appears to play a crucial role in PMA-elicited activation of Nox1, providing a molecular link between PKC-mediated signal transduction and Nox1-catalyzed superoxide production. Furthermore, Ser154 in Noxo1 is phosphorylated in both resting and PMA-stimulated cells, and the phosphorylation probably participates in a PMA-independent constitutive activity of Nox1. Ser154 may also be involved in protein kinase A (PKA) mediated regulation of Nox1; ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23957209", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1503, 
          "offsetInEndSection": 1612, 
          "text": "Thus phosphorylation of Noxo1 at Thr341 and at Ser154 appears to regulate Nox1 activity in different manners.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23957209", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 184, 
          "offsetInEndSection": 529, 
          "text": "The activity of other Nox enzymes such as gp91(phox)/Nox2 and Nox1 is known to absolutely require both an organizer protein (p47(phox) or Noxo1) andanactivatorprotein (p67(phox) or Noxa1); for the p47(phox)-dependent activation of these oxidases, treatment of cells with stimulants such as phorbol 12-myristate 13-acetate is also indispensable. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15824103", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 529, 
          "offsetInEndSection": 782, 
          "text": "Studies of cytosolic co-factors showed that the C-terminal cytoplasmic domain of NOX1 was absolutely required for activation with NOXO1 and NOXA1 and that this activity required interaction of the putative NADPH-binding region of this domain with NOXA1.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15507761", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 648, 
          "offsetInEndSection": 755, 
          "text": "Additionally, NADPH oxidase Organizer 1 (NoxO1) is shown to interact with the NADPH-binding region of Nox1.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16329988", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 173, 
          "text": "Activation of the non-phagocytic superoxide-producing NADPH oxidase Nox1, complexed with p22(phox) at the membrane, requires its regulatory soluble proteins Noxo1 and Noxa1.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16762923", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 100, 
          "text": "NOXO1 phosphorylation on serine 154 is critical for optimal NADPH oxidase 1 assembly and activation.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23322165", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 132, 
          "text": "Activation of the superoxide-producing NADPH oxidase Nox1 requires both the organizer protein Noxo1 and the activator protein Noxa1.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16911517", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 373, 
          "offsetInEndSection": 643, 
          "text": "NOX1, an NADPH oxidase homologue that is most abundantly expressed in colon epithelial cells, requires the regulatory subunits NOXO1 (NOX organizing protein 1) and NOXA1 (NOX activating protein 1), as well as the flavocytochrome component p22(phox) for maximal activity.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20454568", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 732, 
          "offsetInEndSection": 917, 
          "text": "Activation of Nox1, an oxidase that is likely involved in host defence at the colon, requires novel proteins homologous to p47phox and p67phox, designated Noxo1 and Noxa1, respectively.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15507762", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 74, 
          "text": "Molecular interaction of NADPH oxidase 1 with betaPix and Nox Organizer 1.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16329988", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 254, 
          "text": "Reactive oxygen species (ROS) production by NADPH oxidase 1 (NOX1), which is mainly expressed in colon epithelial cells, requires the membrane-bound component p22(PHOX) and the cytosolic partners NOX organizer 1 (NOXO1), NOX activator 1 (NOXA1), and Rac1", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23322165", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 373, 
          "offsetInEndSection": 642, 
          "text": "NOX1, an NADPH oxidase homologue that is most abundantly expressed in colon epithelial cells, requires the regulatory subunits NOXO1 (NOX organizing protein 1) and NOXA1 (NOX activating protein 1), as well as the flavocytochrome component p22(phox) for maximal activity", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20454568", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 131, 
          "text": "Activation of the superoxide-producing NADPH oxidase Nox1 requires both the organizer protein Noxo1 and the activator protein Noxa1", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16911517", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 172, 
          "text": "Activation of the non-phagocytic superoxide-producing NADPH oxidase Nox1, complexed with p22(phox) at the membrane, requires its regulatory soluble proteins Noxo1 and Noxa1", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16762923", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 126, 
          "text": "NADPH oxidase 1 (Nox1) is a multicomponent enzyme consisting of p22(phox), Nox organizer 1 (NOXO1), Nox1 activator 1, and Rac1", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18929641", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 330, 
          "text": "UNLABELLED: Superoxide production by Nox1, a member of the Nox family NAPDH oxidases, requires expression of its regulatory soluble proteins Noxo1 (Nox organizer 1) and Noxa1 (Nox activator 1) and is markedly enhanced upon cell stimulation with phorbol 12-myristate 13-acetate (PMA), a potent activator of protein kinase C (PKC). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23957209", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 240, 
          "text": "The p47phox- and NADPH oxidase organiser 1 (NOXO1)-dependent activation of NADPH oxidase 1 (NOX1) mediates endothelial nitric oxide synthase (eNOS) uncoupling and endothelial dysfunction in a streptozotocin-induced murine model of diabetes.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22549734", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 532, 
          "offsetInEndSection": 785, 
          "text": "Studies of cytosolic co-factors showed that the C-terminal cytoplasmic domain of NOX1 was absolutely required for activation with NOXO1 and NOXA1 and that this activity required interaction of the putative NADPH-binding region of this domain with NOXA1.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15507761", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 185, 
          "text": "Nox activator 1 (NoxA1) is a homologue of p67(phox) that acts in conjunction with Nox organizer 1 (NoxO1) to regulate reactive oxygen species (ROS) production by the NADPH oxidase Nox1.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17913709", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 373, 
          "offsetInEndSection": 568, 
          "text": "Nox1 is highly expressed in the colon, and requires two cytosolic regulators, the organizer subunit NoxO1 and the activator subunit NoxA1, as well as the binding of Rac1 GTPase, for its activity.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20609497", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 354, 
          "offsetInEndSection": 508, 
          "text": "Nox1 is highly expressed in the colon, and it requires two cytosolic regulators, NoxO1 and NoxA1, as well as the binding of Rac1 GTPase, for its activity.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18463161", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 255, 
          "text": "Reactive oxygen species (ROS) production by NADPH oxidase 1 (NOX1), which is mainly expressed in colon epithelial cells, requires the membrane-bound component p22(PHOX) and the cytosolic partners NOX organizer 1 (NOXO1), NOX activator 1 (NOXA1), and Rac1.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23322165", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 317, 
          "text": "Superoxide production by Nox1, a member of the Nox family NAPDH oxidases, requires expression of its regulatory soluble proteins Noxo1 (Nox organizer 1) and Noxa1 (Nox activator 1) and is markedly enhanced upon cell stimulation with phorbol 12-myristate 13-acetate (PMA), a potent activator of protein kinase C (PKC).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23957209", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Are alterations in ultraconserved elements implicated in breast cancer?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/18174240", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21331621"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Yes. SNPs in ultraconserved elements (UCEs) might be associated with cancer risk."
      ], 
      "exact_answer": "yes", 
      "concepts": [
        "http://www.disease-ontology.org/api/metadata/DOID:1612", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D001940", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D050436", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000072656", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D001943", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D058922", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D018567", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000069584", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D064726", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D061325", 
        "http://www.disease-ontology.org/api/metadata/DOID:14521", 
        "http://www.disease-ontology.org/api/metadata/DOID:0060548"
      ], 
      "type": "yesno", 
      "id": "587e276be96a600607000001", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 63, 
          "text": "SNPs in ultraconserved elements and familial breast cancer risk", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18174240", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 639, 
          "offsetInEndSection": 822, 
          "text": " In the present study, we investigated the influence of six SNPs within UCEs on familial breast cancer risk. Two out of six SNPs showed an association with familial breast cancer risk", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18174240", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1456, 
          "offsetInEndSection": 1545, 
          "text": "This is the first study indicating that SNPs in UCEs might be associated with cancer risk", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18174240", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 64, 
          "text": "SNPs in ultraconserved elements and familial breast cancer risk.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18174240", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 103, 
          "offsetInEndSection": 244, 
          "text": "Recent studies have indicated that UCEs are not mutation cold regions and likely to be concerned with cancers, including breast cancer (BC). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21331621", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 65, 
          "text": "SNPs in ultraconserved elements and familial breast cancer risk.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18174240", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 93, 
          "text": "Genetic variants in ultraconserved elements and risk of breast cancer in Chinese population.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21331621", 
          "endSection": "title"
        }
      ]
    }, 
    {
      "body": "What is the mechanism of action of Osimertinib?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/27912836", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26620497", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27071706", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26902828", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26720671", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27169328", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27196753", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27923714", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27393507", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27861144", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27649127", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27660466", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26515464", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26898616", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26943236", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27885838", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27835594"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Osimertinib is a third-generation irreversible tyrosine kinase inhibitor of both activating EGFR mutations and resistance-associated T790M point mutation."
      ], 
      "concepts": [
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D045504", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D020228"
      ], 
      "type": "summary", 
      "id": "58848822e56acf517600000c", 
      "snippets": [
        {
          "offsetInBeginSection": 761, 
          "offsetInEndSection": 1004, 
          "text": "In addition, mutations leading to resistance to first-line EGFR and ALK TKIs can now be successfully inhibited by soon to be approved third-generation EGFR TKIs (osimertinib, rociletinib) and second-generation ALK TKIs (ceritinib, alectinib). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26620497", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 308, 
          "offsetInEndSection": 598, 
          "text": "Gefitinib, erlotinib, and afatinib are the EGFR tyrosine kinase inhibitors that are presently in clinical use. Understanding resistance mechanisms has led to the identification of a secondary mutational target, T790M, in more than half of patients, for which osimertinib has been approved. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27912836", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 243, 
          "offsetInEndSection": 429, 
          "text": "Third-generation EGFR TKIs against the T790M mutation have been in active clinical development. These agents include osimertinib, rociletinib, HM61713, ASP8273, EGF816, and PF-06747775. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27071706", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 381, 
          "text": "PURPOSE: Osimertinib (AZD9291) 80\u00a0mg once daily is approved by the US FDA for the treatment of patients with metastatic EGFR T790M-positive NSCLC whose disease has previously progressed on EGFR-TKI therapy. Osimertinib PK was evaluated to define the dose and dosing interval, whether a fixed-dosing approach can be used globally, and the impact of formulation and food on exposure.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26902828", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 540, 
          "offsetInEndSection": 649, 
          "text": "RECENT FINDINGS: Third-generation TKIs in clinical development include osimertinib, rociletinib, and HM61713.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26720671", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 580, 
          "offsetInEndSection": 790, 
          "text": "In this study, we investigated the interaction between ABCB1 and osimertinib, a novel selective, irreversible third-generation EGFR TKI that has recently been approved by the U.S. Food and Drug Administration. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27169328", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1532, 
          "offsetInEndSection": 1758, 
          "text": "Considering that osimertinib is a clinically approved third-generation EGFR TKI, our findings suggest that a combination therapy with osimertinib and conventional anticancer drugs may be beneficial to patients with MDR tumors.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27169328", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 159, 
          "offsetInEndSection": 682, 
          "text": "In our study, we investigated whether osimertinib (AZD9291), a third-generation irreversible tyrosine kinase inhibitor of both activating EGFR mutations and resistance-associated T790M point mutation, could reverse MDR induced by ABCB1 and ABCG2 in vitro, in vivo, and ex vivo Our results showed that osimertinib significantly increased the sensitivity of ABCB1- and ABCG2-overexpressing cells to their substrate chemotherapeutic agents in vitro and in the model of ABCB1-overexpressing KBv200 cell xenograft in nude mice. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27196753", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 542, 
          "offsetInEndSection": 771, 
          "text": "The potency of 1st (erlotinib), 2nd (afatinib) and 3rd (osimertinib and rociletinib) generation EGFR-TKIs was compared in vitro for human lung cancer cell lines and Ba/F3 cells, which exogenously express mutated or wild type EGFR", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26515464", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 409, 
          "offsetInEndSection": 561, 
          "text": "Osimertinib (AZD9291, Tagrisso\u2122), an oral, third-generation EGFR TKI, has been designed to target the EGFR T790M mutation, while sparing wild-type EGFR.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27660466", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 850, 
          "offsetInEndSection": 1003, 
          "text": "Early phase clinical data suggest the third generation EGFR TKIs such as osimertinib, rociletinib, and HM61713 are highly efficacious and well tolerated.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26898616", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 900, 
          "offsetInEndSection": 1039, 
          "text": "We review the rapid clinical development and approval of the third-generation EGFR TKI osimertinib for treatment of NSCLCs with EGFR-T790M.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26943236", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is Bartter syndrome?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/27277374", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25810436", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9203176", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18800266", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23164417", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19915517", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15875219", 
        "http://www.ncbi.nlm.nih.gov/pubmed/1328936", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16953151", 
        "http://www.ncbi.nlm.nih.gov/pubmed/7869998", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10906158", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12920401", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15056980", 
        "http://www.ncbi.nlm.nih.gov/pubmed/6395627", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20127218", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21431899", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21705784", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23342992", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9502562", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24696311", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22142744"
      ], 
      "triples": [], 
      "ideal_answer": [
        "All forms of hereditary Bartter syndrome are characterized by hypokalemia, metabolic alkalosis, and secondary hyperaldosteronism.", 
        "All forms of Bartter syndrome are characterized by hypokalemia, metabolic alkalosis, and secondary hyperaldosteronism"
      ], 
      "concepts": [
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D001477", 
        "http://www.disease-ontology.org/api/metadata/DOID:445", 
        "http://www.disease-ontology.org/api/metadata/DOID:0110144", 
        "http://www.disease-ontology.org/api/metadata/DOID:0110147", 
        "http://www.disease-ontology.org/api/metadata/DOID:0110145", 
        "http://www.disease-ontology.org/api/metadata/DOID:0110146", 
        "http://www.disease-ontology.org/api/metadata/DOID:0110142", 
        "http://www.disease-ontology.org/api/metadata/DOID:0110143"
      ], 
      "type": "summary", 
      "id": "58bcb83d02b8c6095300000f", 
      "snippets": [
        {
          "offsetInBeginSection": 199, 
          "offsetInEndSection": 316, 
          "text": "All forms of Bartter syndrome are characterized by hypokalemia, metabolic alkalosis, and secondary hyperaldosteronism", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25810436", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 198, 
          "text": "The mutations in the CLCNKB gene encoding the ClC-Kb chloride channel are responsible for Bartter syndrome type 3, one of the four variants of Bartter syndrome in the genetically based nomenclature.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25810436", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 183, 
          "text": "Bartter syndrome (BS) is a hereditary disease, with an autosomal recessive or autosomal dominant mode of transmission. It is characterized by salt wasting hypochloraemic, hypokalaemic", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27277374", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 156, 
          "offsetInEndSection": 345, 
          "text": "Bartter syndrome Type III is caused by genetic alterations in the chloride channel kidney B (CLCNKB) gene and often presents in the first 2 years of life, known as classic Bartter syndrome.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23164417", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 155, 
          "text": "Bartter syndrome encompasses a variety of inheritable renal tubular transport disorders characterized by hypokalemia and hypochloremic metabolic alkalosis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23164417", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 528, 
          "offsetInEndSection": 774, 
          "text": "Classic Bartter syndrome and neonatal Bartter syndrome have defects in genes that affect transport channels in the ascending loop of Henle, where as in Gitleman syndrome the defect occurs in the transport channels of the distal convoluted tubule.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18800266", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 110, 
          "text": "Bartter syndrome type III and congenital anomalies of the kidney and urinary tract: an antenatal presentation.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23164417", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 33, 
          "offsetInEndSection": 129, 
          "text": "Bartter's syndrome associated with hydramnios, prematurity, hypercalciuria and nephrocalcinosis.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6395627", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 139, 
          "text": "Bartter syndrome (BS) is a rare renal tubular disorder presenting with hypokalemic metabolic alkalosis, which is classified into five types", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21431899", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 275, 
          "offsetInEndSection": 977, 
          "text": "It has been described in patients with chronic diarrhoea, eating disorders, laxative abuse and primary hyperaldosteronism; also occasionally in Bartter syndrome (BS), in which severe hypokalaemia accompanies significant renal sodium and water losses, though rarely in Gitelman syndrome (GS), in which there is equally severe hypokalaemia, but only modest sodium losses.We hypothesized that hypokalaemic nephropathy may not be due to potassium depletion per se, but persistently elevated circulating levels of aldosterone, possibly with superimposed episodes of renal hypoperfusion.We searched UK and European data sets to retrospectively compare serum and urinary parameters in patients with GS and BS.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21705784", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 188, 
          "text": "Acquired Bartter-like syndrome (BLS), characterized by hypokalemic metabolic alkalosis, hypomagnesemia, hypocalcemia, and normal kidney function, can be induced by diuretics or antibiotics", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23342992", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 15, 
          "offsetInEndSection": 129, 
          "text": "lassic Bartter syndrome is a salt-wasting tubulopathy caused by mutations in the CLCNKB (chloride channel Kb) gene", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24377430", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 33, 
          "offsetInEndSection": 167, 
          "text": "clinical features of two renal tubular disorders characterized by sodium and potassium wasting: Bartter syndrome and Gitelman syndrome", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22282380", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 105, 
          "text": "Bartter syndrome is an autosomic recessive disease characterized by severe polyuria and sodium renal loss", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19915517", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 163, 
          "text": "The term \"Bartter syndrome\" encompasses a group of closely related inherited tubulopathies characterized by markedly reduced NaCl transport by the distal nephron. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15875219", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 115, 
          "offsetInEndSection": 353, 
          "text": " true Bartter's syndrome, diagnosed as a normotensive, hyperreninaemic, hypokalaemic metabolic alkalosis with normal urine chloride excretion, low CH2O/(CH2O+CCl) ratio during maximal water diuresis and negative urine screen for diuretics", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1328936", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 76, 
          "text": "Bartter's syndrome belongs to a group of hypokalemic renal channel diseases.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16953151", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 12, 
          "offsetInEndSection": 197, 
          "text": "Hypokalemia due to renal potassium wasting in the absence of hypertension, moderate metabolic alkalosis, hyperreninism and hyperaldosteronism suggest the presence of Bartter's syndrome.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7869998", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 10, 
          "offsetInEndSection": 294, 
          "text": " Inherited hypokalemic renal tubulopathies are differentiated into at least three clinical subtypes: (1) the Gitelman variant of Bartter syndrome (GS); (2) hyperprostaglandin E syndrome, the antenatal variant of Bartter syndrome (HPS/aBS); and (3) the classic Bartter syndrome (cBS). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10906158", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 141, 
          "offsetInEndSection": 306, 
          "text": "Bartter syndrome, a group of autosomal recessive disorders that are characterized by markedly reduced or absent salt transport by the thick ascending limb of Henle. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12920401", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 136, 
          "text": "Bartter's and Gitelman's syndromes are characterized by hypokalemia, normal to low blood pressure and hypochloremic metabolic alkalosis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15056980", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 21, 
          "offsetInEndSection": 217, 
          "text": "Bartter's syndrome has been used to describe a spectrum of inherited renal tubular disorders with hypokalemic metabolic alkalosis and overlapping and additional clinical and biochemical features. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8897553", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 12, 
          "offsetInEndSection": 168, 
          "text": "antenatal variant of Bartter syndrome is characterized by a history of polyhydramnios, premature birth, metabolic alkalosis, hypokalemia, polyuria and renal", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20127218", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 150, 
          "offsetInEndSection": 354, 
          "text": "Most patients with Bartter syndrome have defects in transporters in the thick ascending limb of the loop of Henle, such as the Na-K-2Cl cotransporter, NKCC2, or the ATP-sensitive potassium channel, ROMK. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9502562", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 12, 
          "offsetInEndSection": 158, 
          "text": "Gitelman's syndrome or familial hypokalemia-hypomagnesemia and Bartter syndrome share some common features but their prognosis is quite different.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7842074", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 169, 
          "text": "Bartter syndrome is a group of inherited, salt-losing tubulopathies presenting as hypokalemic metabolic alkalosis with normotensive hyperreninemia and hyperaldosteronism", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24696311", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 447, 
          "text": "Bartter's and Gitelman's syndromes are two different genetic renal diseases, but are both characterised by hypokalaemia and metabolic alkalosis. Bartter's syndrome is characterised by multiple gene mutations (Na-K-2Cl cotransporter; K(+) channels renal outer medullary potassium channel (ROMK); Cl channels, chloride channel Kb (ClCNKb); regulatory protein Barttin; and Ca(2+) -sensing receptor, CaSR) at the thick ascending limb of Henle's loop, ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22142744", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Is there any tool that facilitates the functional analysis of cis-regulatory regions in zebrafish?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/19653328"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Yes. The zebrafish enhancer detection (ZED) vector is a tool that facilitates transgenesis and the functional analysis of cis-regulatory regions in zebrafish."
      ], 
      "exact_answer": "yes", 
      "concepts": [
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D015027", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012045", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004742", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011401"
      ], 
      "type": "yesno", 
      "id": "588f5e9994c1512c50000004", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 148, 
          "text": "Zebrafish enhancer detection (ZED) vector: a new tool to facilitate transgenesis and the functional analysis of cis-regulatory regions in zebrafish.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19653328", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 197, 
          "offsetInEndSection": 1144, 
          "text": "he cis-regulatory sequences control when, where, and how much genes are transcribed and can activate (enhancers) or repress (silencers) gene expression. Here, we describe a novel Tol2 transposon-based vector for assessing enhancer activity in the zebrafish (Danio rerio). This Zebrafish Enhancer Detector (ZED) vector harbors several key improvements, among them a sensitive and specific minimal promoter chosen for optimal enhancer activity detection, insulator sequences to shield the minimal promoter from position effects, and a positive control for transgenesis. Additionally, we demonstrate that highly conserved noncoding sequences homologous between humans and zebrafish largely with enhancer activity largely retain their tissue-specific enhancer activity during vertebrate evolution. More strikingly, insulator sequences from mouse and chicken, but not conserved in zebrafish, maintain their insulator capacity when tested in this model.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19653328", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 147, 
          "text": "Zebrafish enhancer detection (ZED) vector: a new tool to facilitate transgenesis and the functional analysis of cis-regulatory regions in zebrafish", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19653328", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 149, 
          "text": "Zebrafish enhancer detection (ZED) vector: a new tool to facilitate transgenesis and the functional analysis of cis-regulatory regions in zebrafish.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19653328", 
          "endSection": "title"
        }
      ]
    }, 
    {
      "body": "List RNA modifications databases", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26464443", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27016142", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23118484"
      ], 
      "triples": [], 
      "ideal_answer": [
        "RMBase\nMODOMICS"
      ], 
      "exact_answer": [
        [
          "RMBase", 
          "RNA Modification Base"
        ], 
        [
          "MODOMICS"
        ]
      ], 
      "concepts": [], 
      "type": "list", 
      "id": "58bbb71f22d3005309000016", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 104, 
          "text": "RMBase: a resource for decoding the landscape of RNA modifications from high-throughput sequencing data.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26464443", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 366, 
          "offsetInEndSection": 608, 
          "text": "we developed a novel resource, RMBase (RNA Modification Base, http://mirlab.sysu.edu.cn/rmbase/), to decode the genome-wide landscape of RNA modifications identified from high-throughput modification data generated by 18 independent studies. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26464443", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 859, 
          "offsetInEndSection": 921, 
          "text": " known pathways of RNA modification from the MODOMICS database", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27016142", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 251, 
          "text": "MODOMICS is a database of RNA modifications that provides comprehensive information concerning the chemical structures of modified ribonucleosides, their biosynthetic pathways, RNA-modifying enzymes and location of modified residues in RNA sequences. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23118484", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Please list the 3 findings in HELLP syndrome.", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26446688", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26953551", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11720149", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8678146", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26016316", 
        "http://www.ncbi.nlm.nih.gov/pubmed/1471661", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8765269", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23871223", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10847654", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8059835", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19703145", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23040928", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23697398", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9914607", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11854637"
      ], 
      "triples": [], 
      "ideal_answer": [
        "HELLP syndrome (hemolysis, elevated liver enzymes, low platelets) is an obstetric complication and is characterized by microangiopathic hemolytic anemia, elevated liver enzymes by intravascular breakdown of fibrin in hepatic sinusoids and reduction of platelet circulation by its increased consumption", 
        "hemolysis, elevated liver enzymes and low platelets constitute the hellp syndrome."
      ], 
      "exact_answer": [
        [
          "hemolytic anemia"
        ], 
        [
          "elevated liver enzymes"
        ], 
        [
          "low platlets"
        ]
      ], 
      "concepts": [
        "http://www.disease-ontology.org/api/metadata/DOID:13133", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D017359"
      ], 
      "type": "list", 
      "id": "58bc9a5002b8c60953000008", 
      "snippets": [
        {
          "offsetInBeginSection": 12, 
          "offsetInEndSection": 374, 
          "text": "HELLP syndrome (hemolysis, elevated liver enzymes, low platelets) is an obstetric complication with heterogonous presentation and multisystemic involvement. It is characterized by microangiopathic hemolytic anemia, elevated liver enzymes by intravascular breakdown of fibrin in hepatic sinusoids and reduction of platelet circulation by its increased consumption", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26446688", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 349, 
          "offsetInEndSection": 431, 
          "text": "Hemolysis, elevated liver enzymes and low platelets constitute the HELLP syndrome.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26953551", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 262, 
          "text": "Our objective was to describe the hepatic imaging findings in selected patients with HELLP syndrome (hemolysis, elevated liver enzymes, and low platelet count) and to correlate these findings with the severity of concurrent clinical and laboratory abnormalities.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8678146", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 248, 
          "text": "Our objective was to categorize the histologic findings in the liver in patients with HELLP syndrome (hemolysis, elevated liver enzymes, and low platelet count) and to correlate these findings with the severity of clinical laboratory abnormalities.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1471661", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 451, 
          "text": "OBJECTIVE: Our purpose was to test the hypothesis that the HELLP (hemolysis, elevated liver enzymes, and low platelets) syndrome is the result of excessive vasoconstriction of the hepatic arterial circulation.STUDY DESIGN: Doppler ultrasonography was used to measure the pulsatility index of the common hepatic artery in 14 women with preeclampsia, 15 with preeclampsia complicated by HELLP syndrome, and 8 with HELLP syndrome but without proteinuria.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8059835", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 217, 
          "text": "Extensive hepatic infarction in severe preeclampsia as part of the HELLP syndrome (hemolysis, elevated liver enzymes, and low platelets): evolution of CT findings and successful treatment with plasma exchange therapy.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23040928", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 260, 
          "text": "OBJECTIVE: Our objective was to categorize the histologic findings in the liver in patients with HELLP syndrome (hemolysis, elevated liver enzymes, and low platelet count) and to correlate these findings with the severity of clinical laboratory abnormalities. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1471661", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 179, 
          "text": "The syndrome of haemolysis, elevated liver enzymes and low platelets (HELLP syndrome) is a life threatening, severe complication of pre-eclampsia with typical laboratory findings.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10847654", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 75, 
          "text": "Hemolysis, elevated liver enzymes, and low platelet count (HELLP) syndrome ", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11720149", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 19, 
          "offsetInEndSection": 93, 
          "text": "hemolysis, elevated liver enzymes, and low platelet count (HELLP) syndrome", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11720149", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 81, 
          "text": "HELLP syndrome, a syndrome of hemolysis, elevated liver enzymes and low platelets", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10843242", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 107, 
          "text": "HELLP syndrome is a collection of symptoms described as hemolysis, elevated liver enzymes and low platelets", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25806101", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 168, 
          "offsetInEndSection": 333, 
          "text": "The HELLP syndrome is characterized by the presence of hypertension disorder more a triad: microangiopathic hemolysis, elevated liver enzymes and low platelet count.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26016316", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 55, 
          "offsetInEndSection": 115, 
          "text": "HELLP (hemolysis, elevated liver enzymes, and low platelets)", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8765269", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 88, 
          "offsetInEndSection": 160, 
          "text": " HELLP (hemolysis, elevated liver enzymes, and low platelets) syndrome, ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8765269", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 12, 
          "offsetInEndSection": 136, 
          "text": "Hepatic hemorrhage occurs in less than 5% of patients with hemolysis, elevated liver enzymes, low platelets (HELLP) syndrome", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23871223", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 39, 
          "offsetInEndSection": 100, 
          "text": " HELLP (haemolysis, elevated liver enzymes and low platelets)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15027924", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 9, 
          "offsetInEndSection": 93, 
          "text": "Hemolysis, elevated liver enzymes, and low platelet count syndrome (HELLP syndrome) ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19703145", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 108, 
          "offsetInEndSection": 174, 
          "text": " hemolysis, elevated liver enzymes, low platelets (HELLP) syndrome", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21501125", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 19, 
          "offsetInEndSection": 90, 
          "text": " hemolysis, elevated liver enzymes and low platelet (HELLP) syndrome, i", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19663680", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 12, 
          "offsetInEndSection": 81, 
          "text": "Hemolysis, elevated liver enzymes, and low platelets (HELLP) syndrome", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23697398", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 79, 
          "offsetInEndSection": 144, 
          "text": "HELLP (hemolysis, elevated liver enzymes, and low platelet count)", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9914607", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 373, 
          "offsetInEndSection": 438, 
          "text": "HELLP (hemolysis, elevated liver enzymes, low platelets) syndrome", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11854637", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 30, 
          "offsetInEndSection": 95, 
          "text": "hemolysis, elevated liver enzymes, low platelets (HELLP) syndrome", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17666652", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 166, 
          "offsetInEndSection": 227, 
          "text": "hemolysis, elevated liver enzymes, and low platelets (HELLP),", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15572962", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which mutated gene is associated with Waardenburg and Tietz syndromes?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/27604145", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24379252", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23787126", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23512835", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22258527", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20485200", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10952390", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10851256", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10790403", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9546825", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22371403", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23020089", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10536986", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19938076", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22196401", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23098757", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26252099"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Mutations in microphthalmia-associated transcription factor (MITF) gene cause Waardenburg and Tietz syndromes."
      ], 
      "exact_answer": [
        [
          "microphthalmia-associated transcription factor gene", 
          "MITF"
        ]
      ], 
      "concepts": [
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005796", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013577", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D014849", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D051739", 
        "http://www.uniprot.org/uniprot/MITF_HUMAN"
      ], 
      "type": "factoid", 
      "id": "58a57f9460087bc10a00001f", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 133, 
          "text": "Tietz/Waardenburg type 2A syndrome associated with posterior microphthalmos in two unrelated patients with novel MITF gene mutations.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27604145", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 97, 
          "text": "Tietz syndrome and Waardenburg syndrome type 2A are allelic conditions caused by MITF mutations. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27604145", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 953, 
          "offsetInEndSection": 1054, 
          "text": "For example, mutations of the MITF gene cause Waardenburg syndrome type 2A as well as Tietz syndrome.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24379252", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1152, 
          "offsetInEndSection": 1346, 
          "text": "For example, mutations of MITF, SNAI2 and SOX10 genes are observed in Waardenburg syndrome type II and mutations of EDNRB, EDN3 and SOX10 genes are responsible for Waardenburg syndrome type IV. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24379252", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 480, 
          "offsetInEndSection": 636, 
          "text": "These disorders are represented by Waardenburg syndrome, piebaldism and Tietz syndrome, and are caused by different mutations of various or the same genes. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24379252", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 163, 
          "offsetInEndSection": 344, 
          "text": "Mutations in the MITF have been found in patients with the dominantly inherited hypopigmentation and deafness syndromes Waardenburg syndrome type 2A (WS2A) and Tietz syndrome (TS). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23787126", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1164, 
          "offsetInEndSection": 1342, 
          "text": "All patients with PAX3 mutations had typical phenotype of WS with dystopia canthorum (WS1), whereas patients with MITF gene mutations presented without dystopia canthorum (WS2). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23512835", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1491, 
          "offsetInEndSection": 1676, 
          "text": "MITF 3-bp deletions at amino acid position 217 have previously been described in patients with Tietz syndrome (TS), a clinical entity with hearing loss and generalised hypopigmentation.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23512835", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1689, 
          "offsetInEndSection": 2048, 
          "text": "On the basis of these findings, we conclude that sequencing and copy number analysis of both PAX3 and MITF have to be recommended in the routine molecular diagnostic setting for patients, WS1 and WS2. Furthermore, our genotype-phenotype analyses indicate that WS2 and TS correspond to a clinical spectrum that is influenced by MITF mutation type and position.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23512835", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 142, 
          "text": "Novel and recurrent non-truncating mutations of the MITF basic domain: genotypic and phenotypic variations in Waardenburg and Tietz syndromes.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22258527", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 200, 
          "offsetInEndSection": 487, 
          "text": "A notable relationship has been described between non-truncating mutations of its basic domain and Tietz syndrome, which is characterized by albinoid-like hypopigmentation of the skin and hair, rather than the patchy depigmentation seen in Waardenburg syndrome, and severe hearing loss. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22258527", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 9, 
          "offsetInEndSection": 348, 
          "text": "Mutations in microphthalmia-associated transcription factor (MITF) lead to Waardenburg syndrome type 2 (WS2), a dominantly inherited disorder involving hearing loss and pigment disturbances caused by a lack of melanocytes. On rare occasions, mutations in MITF lead to Tietz syndrome (TS), which is characterized by a severe WS2 phenotype. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20485200", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 257, 
          "offsetInEndSection": 389, 
          "text": "In humans, haploinsufficiency of MITF causes Waardenburg syndrome type 2, while a dominant-negative mutation causes Tietz syndrome. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10952390", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 70, 
          "text": "Tietz syndrome (hypopigmentation/deafness) caused by mutation of MITF.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10851256", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 474, 
          "offsetInEndSection": 869, 
          "text": "This family was reascertained and a missense mutation was found in the basic region of the MITF gene in family members with Tietz syndrome. Mutations in other regions of this gene have been found to produce Waardenburg syndrome type 2 (WS2), which also includes pigmentary changes and hearing loss, but in contrast to Tietz syndrome, depigmentation is patchy and hearing loss is variable in WS2.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10851256", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 266, 
          "offsetInEndSection": 427, 
          "text": "In humans, MITF mutations cause Waardenburg syndrome type 2A (WS2A) and Tietz syndrome, autosomal dominant disorders resulting in deafness and hypopigmentation. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10790403", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 73, 
          "text": "Mutation of the MITF gene in albinism-deafness syndrome (Tietz syndrome).", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9546825", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 260, 
          "offsetInEndSection": 334, 
          "text": "MITF gene mutations account for 20% of Waardenburg syndrome (WS) type II. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9546825", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 163, 
          "offsetInEndSection": 343, 
          "text": "Mutations in the MITF have been found in patients with the dominantly inherited hypopigmentation and deafness syndromes Waardenburg syndrome type 2A (WS2A) and Tietz syndrome (TS).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23787126", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 485, 
          "text": "The microphthalmia-associated transcription factor (MITF) is a basic helix-loop-helix leucine zipper transcription factor, which regulates melanocyte development and the biosynthetic melanin pathway. A notable relationship has been described between non-truncating mutations of its basic domain and Tietz syndrome, which is characterized by albinoid-like hypopigmentation of the skin and hair, rather than the patchy depigmentation seen in Waardenburg syndrome, and severe hearing loss", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22258527", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1650, 
          "offsetInEndSection": 1750, 
          "text": "Mutations of the MITF gene may lead to hereditary diseases: Waardenburg type II and Tietz syndromes.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22371403", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 236, 
          "text": "The human deafness-pigmentation syndromes, Waardenburg syndrome (WS) type 2a, and Tietz syndrome are characterized by profound deafness but only partial cutaneous pigmentary abnormalities. Both syndromes are caused by mutations in MITF.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23020089", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 265, 
          "text": "On some occasions, mutations of a gene cause different syndromes that may have similar phenotypes. For example, mutations of the MITF gene cause Waardenburg syndrome type 2 (Tassabehji et al, 1994; Nobukuni et al, 1996) as well as Tietz syndrome (Smith et al, 1997)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10536986", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1638, 
          "offsetInEndSection": 1738, 
          "text": "Mutations of the MITF gene may lead to hereditary diseases: Waardenburg type II and Tietz syndromes.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22371403", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 162, 
          "offsetInEndSection": 342, 
          "text": "Mutations in the MITF have been found in patients with the dominantly inherited hypopigmentation and deafness syndromes Waardenburg syndrome type 2A (WS2A) and Tietz syndrome (TS).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23787126", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 947, 
          "offsetInEndSection": 1048, 
          "text": "For example, mutations of the MITF gene cause Waardenburg syndrome type 2A as well as Tietz syndrome.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24379252", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 98, 
          "offsetInEndSection": 265, 
          "text": "For example, mutations of the MITF gene cause Waardenburg syndrome type 2 (Tassabehji et al, 1994; Nobukuni et al, 1996) as well as Tietz syndrome (Smith et al, 1997).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10536986", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 116, 
          "text": "Hearing dysfunction in heterozygous Mitf(Mi-wh) /+ mice, a model for Waardenburg syndrome type 2 and Tietz syndrome.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23020089", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 527, 
          "offsetInEndSection": 720, 
          "text": "By analyzing the genes for Waardenburg syndrome, we showed that PAX3, the gene responsible for Waardenburg syndrome type 1, regulates MITF, the gene responsible for Waardenburg syndrome type 2.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10536986", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 260, 
          "offsetInEndSection": 333, 
          "text": "MITF gene mutations account for 20% of Waardenburg syndrome (WS) type II.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9546825", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 163, 
          "offsetInEndSection": 342, 
          "text": "Mutations in the MITF have been found in patients with the dominantly inherited hypopigmentation and deafness syndromes Waardenburg syndrome type 2A (WS2A) and Tietz syndrome (TS)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23787126", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 141, 
          "text": "Novel and recurrent non-truncating mutations of the MITF basic domain: genotypic and phenotypic variations in Waardenburg and Tietz syndromes", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22258527", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 953, 
          "offsetInEndSection": 1053, 
          "text": "For example, mutations of the MITF gene cause Waardenburg syndrome type 2A as well as Tietz syndrome", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24379252", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 474, 
          "offsetInEndSection": 614, 
          "text": "This family was reascertained and a missense mutation was found in the basic region of the MITF gene in family members with Tietz syndrome. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10851256", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 232, 
          "offsetInEndSection": 348, 
          "text": "On rare occasions, mutations in MITF lead to Tietz syndrome (TS), which is characterized by a severe WS2 phenotype. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20485200", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 99, 
          "offsetInEndSection": 267, 
          "text": "For example, mutations of the MITF gene cause Waardenburg syndrome type 2 (Tassabehji et al, 1994; Nobukuni et al, 1996) as well as Tietz syndrome (Smith et al, 1997). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10536986", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 99, 
          "offsetInEndSection": 266, 
          "text": "For example, mutations of the MITF gene cause Waardenburg syndrome type 2 (Tassabehji et al, 1994; Nobukuni et al, 1996) as well as Tietz syndrome (Smith et al, 1997).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10536986", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 266, 
          "offsetInEndSection": 426, 
          "text": "In humans, MITF mutations cause Waardenburg syndrome type 2A (WS2A) and Tietz syndrome, autosomal dominant disorders resulting in deafness and hypopigmentation.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10790403", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 257, 
          "offsetInEndSection": 388, 
          "text": "In humans, haploinsufficiency of MITF causes Waardenburg syndrome type 2, while a dominant-negative mutation causes Tietz syndrome.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10952390", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 134, 
          "text": "Tietz/Waardenburg type 2A syndrome associated with posterior microphthalmos in two unrelated patients with novel MITF gene mutations.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27604145", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 96, 
          "text": "Tietz syndrome and Waardenburg syndrome type 2A are allelic conditions caused by MITF mutations.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27604145", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 117, 
          "text": "Hearing dysfunction in heterozygous Mitf(Mi-wh) /+ mice, a model for Waardenburg syndrome type 2 and Tietz syndrome.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23020089", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 1152, 
          "offsetInEndSection": 1345, 
          "text": "For example, mutations of MITF, SNAI2 and SOX10 genes are observed in Waardenburg syndrome type II and mutations of EDNRB, EDN3 and SOX10 genes are responsible for Waardenburg syndrome type IV.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24379252", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 74, 
          "text": "Mutation of the MITF gene in albinism-deafness syndrome (Tietz syndrome).", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9546825", 
          "endSection": "title"
        }
      ]
    }, 
    {
      "body": "List the three most abundant bacterial phyla present in mouse feces.", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25537565", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23457582", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20926643", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19159975"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Firmicutes\nProteobacteria \nBacteroidetes"
      ], 
      "exact_answer": [
        [
          "Firmicutes"
        ], 
        [
          "Proteobacteria"
        ], 
        [
          "Bacteroidetes"
        ]
      ], 
      "concepts": [], 
      "type": "list", 
      "id": "58bbbe6822d300530900001a", 
      "snippets": [
        {
          "offsetInBeginSection": 862, 
          "offsetInEndSection": 1047, 
          "text": "Amplicons representing the major phyla encountered in the rumen (Firmicutes, 43.7%; Proteobacteria, 28.7%; Bacteroidetes, 25.3%; Spirochea, 1.1%, and Synergistes, 1.1%) were recovered, ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19159975", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 68, 
          "offsetInEndSection": 152, 
          "text": "alterations in the gut microbiota (increased Firmicutes and decreased Bacteroidetes)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20926643", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 385, 
          "offsetInEndSection": 536, 
          "text": "The taxonomic analysis of the metagenomic reads indicated that pygmy loris fecal microbiomes were dominated by Bacteroidetes and Proteobacteria phyla. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23457582", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1025, 
          "offsetInEndSection": 1193, 
          "text": "Specifically, intermittent hypoxia-exposed mice showed a higher abundance of Firmicutes and a smaller abundance of Bacteroidetes and Proteobacteria phyla than controls.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25537565", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What gene is mutated in Sickle Cell Anemia?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/27802215", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27814292", 
        "http://www.ncbi.nlm.nih.gov/pubmed/6310991", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11172667", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17662889", 
        "http://www.ncbi.nlm.nih.gov/pubmed/1301951", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8745433", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20886046", 
        "http://www.ncbi.nlm.nih.gov/pubmed/7624311"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Sickle cell anemia (SCA) is an autosomal recessive disease caused by by the HBB:c.20A>T mutation that leads to hemoglobin S synthesis.", 
        " sca patients present clinical and hematologic variability that cannot be only explained by the single mutation in the beta-globin gene."
      ], 
      "exact_answer": [
        [
          "HBB"
        ]
      ], 
      "concepts": [
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000755", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012805", 
        "http://www.disease-ontology.org/api/metadata/DOID:10923", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D006451"
      ], 
      "type": "factoid", 
      "id": "58bcabc702b8c6095300000e", 
      "snippets": [
        {
          "offsetInBeginSection": 12, 
          "offsetInEndSection": 204, 
          "text": "Sickle cell anemia (SCA) is an inherited blood disorder. SCA patients present clinical and hematologic variability that cannot be only explained by the single mutation in the beta-globin gene.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27802215", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 131, 
          "text": "Sickle cell anemia (SCA) is an autosomal recessive disease caused by the HBB:c.20A>T mutation that leads to hemoglobin S synthesis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27814292", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 110, 
          "text": "Sickle cell anemia is caused by a single type of mutation, a homozygous A\u2192T substitution in the \u00df globin gene.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20886046", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 159, 
          "offsetInEndSection": 486, 
          "text": "Implementation of this approach for disorders resulting from mutations affecting the beta-globin gene (e.g., beta-thalassemia and sickle cell anemia), however, has been hampered by the inability to generate recombinant viruses able to efficiently and faithfully transmit the necessary sequences for appropriate gene expression.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7624311", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 398, 
          "text": "The allele-specific PCR approach has been modified by introducing a second mismatch at the 3'-penultimate link of the primer and used to identify the sickle cell anemia mutation (A-->T transversion in the sixth codon of the human beta-globin gene causing Glu-->Val substitution in the protein), thus obviating the problem of an interpretationally ambiguous 3'-terminal mismatch including T residue.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1301951", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 121, 
          "text": "Sickle-cell anemia results from an A leads to T transversion in the second nucleotide of codon 6 of the beta-globin gene.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6310991", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 221, 
          "text": "Sickle cell anemia is a genetic blood disorder arising from a point mutation in the beta-globin gene that leads to the replacement of glutamic acid residue by valine at the sixth position of the beta--chain of hemoglobin.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11172667", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 11, 
          "offsetInEndSection": 153, 
          "text": "Sickle cell anemia is a genetic blood disease resulting from production of mutant beta-globin (beta(S)) and has severe clinical consequences. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17662889", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is the function of the Indian hedgehog protein in chondrocytes?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25808752", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25479004", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25028519", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23928032", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22190639", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10615989", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9486541", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10631175", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11466306", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21566205", 
        "http://www.ncbi.nlm.nih.gov/pubmed/14991716", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19035497", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24821091", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10491221", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15355563", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19906842", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11714677", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11517192", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10742444", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8662546", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10328918", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11850620", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12745383", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18059015", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12213208", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17328886", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10465785", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11332615", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17907424", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11748145", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12968668", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21411723", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18434416", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21795282", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10208865", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22507129", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24844414"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Indian hedgehog is a protein that regulates endochondral differentiation and ossification in both a parathyroid hormone-related protein (PTHrP)-dependent and -independent manner by activating transcriptional mediator Gli2 and is an essential factor for proper skeletal development."
      ], 
      "concepts": [
        "http://www.uniprot.org/uniprot/IHH_PUNTE", 
        "http://www.uniprot.org/uniprot/IHH_HUMAN", 
        "http://www.uniprot.org/uniprot/IHH_DEVPA", 
        "http://www.uniprot.org/uniprot/IHH_DEVMA", 
        "http://www.uniprot.org/uniprot/IHH_DEVDE", 
        "http://www.uniprot.org/uniprot/IHH_DANKE", 
        "http://www.uniprot.org/uniprot/IHH_DANAT", 
        "http://www.uniprot.org/uniprot/IHH_DANAP", 
        "http://www.uniprot.org/uniprot/IHH_CHICK", 
        "http://www.uniprot.org/uniprot/IHH_CARAU", 
        "http://www.uniprot.org/uniprot/IHH_XENLA", 
        "http://www.uniprot.org/uniprot/IHH_RASPA", 
        "http://www.uniprot.org/uniprot/IHH_RASEL", 
        "http://www.uniprot.org/uniprot/IHH_TRIHE", 
        "http://www.uniprot.org/uniprot/IHH_MOUSE", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D053823", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D019902", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D019485"
      ], 
      "type": "summary", 
      "id": "58b95ea222d3005309000011", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 191, 
          "text": "Indian hedgehog (Ihh) regulates endochondral ossification in both a parathyroid hormone-related protein (PTHrP)-dependent and -independent manner by activating transcriptional mediator Gli2. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25808752", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 230, 
          "text": "Wnt/\u03b2-catenin, Indian hedgehog (Ihh)/Parathyroid-related peptide (PTHrP) and retinoid signaling pathways regulate cartilage differentiation, growth, and function during development and play a key role in endochondral ossification.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25479004", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 434, 
          "text": "Indian hedgehog (Ihh) is essential for chondrocyte differentiation and endochondral ossification and acts with parathyroid hormone-related peptide in a negative feedback loop to regulate early chondrocyte differentiation and entry to hypertrophic differentiation. Independent of this function, we and others recently reported independent Ihh functions to promote chondrocyte hypertrophy and matrix mineralization in vivo and in vitro.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25028519", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 540, 
          "offsetInEndSection": 708, 
          "text": "We recently discovered that Ihh overexpression in chondrocytes stimulated the expression of late chondrocyte differentiation markers and induced matrix mineralization. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25028519", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 985, 
          "offsetInEndSection": 1155, 
          "text": "In addition, we found that Ihh induced Runx2 expression in chondrocytes without up-regulating other modulators of chondrocyte maturation such as Mef2c, Foxa2, and Foxa3. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25028519", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1611, 
          "offsetInEndSection": 1756, 
          "text": "Thus, Ihh signaling could be an important player for not only early chondrocyte differentiation but maturation and calcification of chondrocytes.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25028519", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 106, 
          "text": "The Ihh signal is essential for regulating proliferation and hypertrophy of cultured chicken chondrocytes.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23928032", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 113, 
          "text": "The Indian hedgehog (Ihh) signal plays a vital role in regulating proliferation and hypertrophy of chondrocytes. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23928032", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 912, 
          "offsetInEndSection": 1246, 
          "text": "Based on these results, the Ihh signal is essential for balancing chicken chondrocyte proliferation and hypertrophy, and the regulatory function of PTHrP acts in an Ihh-dependent manner. Furthermore, BMP-6 and Bcl-2 played roles in maintaining the development of chondrocytes and may be downstream regulatory factors of Ihh signaling.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23928032", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 148, 
          "text": "Atf4 is a leucine zipper-containing transcription factor that activates osteocalcin (Ocn) in osteoblasts and indian hedgehog (Ihh) in chondrocytes. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22190639", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 118, 
          "offsetInEndSection": 327, 
          "text": "Indian hedgehog (Ihh) is produced by prehypertrophic chondrocytes in developing long bones and regulates chondrocyte proliferation and other events, but it is not known whether it requires HS-PGs for function.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14991716", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 330, 
          "offsetInEndSection": 459, 
          "text": "We have shown that Indian hedgehog gene (Ihh) is expressed in cartilage anlage and later in mature and hypertrophic chondrocytes.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10615989", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 91, 
          "text": "Regulation of rate of cartilage differentiation by Indian hedgehog and PTH-related protein.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8662546", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 798, 
          "offsetInEndSection": 1049, 
          "text": "In normal growth plates, differentiation of proliferative chondrocytes to post-mitotic hypertrophic chondrocytes is regulated in part by a tightly coupled signaling relay involving parathyroid hormone related protein (PTHrP) and Indian hedgehog (IHH).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11850620", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 112, 
          "text": "The Indian hedgehog (Ihh) signal plays a vital role in regulating proliferation and hypertrophy of chondrocytes.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23928032", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 115, 
          "text": "Indian hedgehog and syndecans-3 coregulate chondrocyte proliferation and function during chick limb skeletogenesis.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14991716", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 714, 
          "offsetInEndSection": 902, 
          "text": "We further demonstrate that misexpression of Indian hedgehog appears to directly upregulate BMP2 and BMP4 expression, independent of the differentiation state of the flanking chondrocytes.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10328918", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 119, 
          "offsetInEndSection": 328, 
          "text": "Indian hedgehog (Ihh) is produced by prehypertrophic chondrocytes in developing long bones and regulates chondrocyte proliferation and other events, but it is not known whether it requires HS-PGs for function.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14991716", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1155, 
          "offsetInEndSection": 1409, 
          "text": "The cellular expression of two markers of chondrocyte differentiation, Indian hedgehog, expressed in pre-hypertrophic cells and collagen type X, expressed in hypertrophic chondrocytes, were both significantly inhibited after incubation with isoproterenol", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18059015", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 119, 
          "offsetInEndSection": 327, 
          "text": "Indian hedgehog (Ihh) is produced by prehypertrophic chondrocytes in developing long bones and regulates chondrocyte proliferation and other events, but it is not known whether it requires HS-PGs for function", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14991716", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 230, 
          "text": "Four distinct chondrocyte populations in the fetal bovine growth plate: highest expression levels of PTH/PTHrP receptor, Indian hedgehog, and MMP-13 in hypertrophic chondrocytes and their suppression by PTH (1-34) and PTHrP (1-40)", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12213208", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 129, 
          "offsetInEndSection": 365, 
          "text": "Although it is known that parathyroid hormone related protein (PTHrP) and Indian hedgehog regulate the differentiation of growth plate chondrocytes, how these pathways interact to regulate chondrocyte development is not fully elucidated", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17328886", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 160, 
          "offsetInEndSection": 411, 
          "text": "Indian hedgehog (Ihh) signaling from prehypertrophic chondrocytes has been implicated in the control of chondrocyte maturation by way of feedback control of a second secreted factor parathyroid hormone-related peptide (PTHrP) at the articular surfaces", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10465785", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 254, 
          "text": "Mutant BMP receptors were transfected into cultured embryonic upper sternal chrondrocytes using retroviral vectors to determine if BMP signaling is required for chondrocyte maturation and the expression of a key regulatory molecule, Indian hedgehog (Ihh)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11332615", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 134, 
          "text": "Chondrocytes of the epiphyseal growth zone are regulated by the Indian hedgehog (IHH)-parathyroid hormone-related protein (PTHrP) axis", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19035497", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 738, 
          "offsetInEndSection": 1008, 
          "text": "The polymorphic layer in P15 mutants contained fewer Sox9-expressing chondroprogenitor cells because of reduced mitotic activity, and newly differentiated chondrocytes underwent precocious hypertrophic enlargement accompanied by early activation of Indian hedgehog (Ihh)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21566205", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 849, 
          "offsetInEndSection": 1116, 
          "text": "In an effort to lessen the severity of bone defects caused by HhAntag, we treated young mice simultaneously with HhAntag and parathyroid hormone-related protein (PTHrP), which functions downstream of Indian Hedgehog to maintain chondrocytes in a proliferative state. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21411723", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 121, 
          "text": "Chondrocyte differentiation during embryonic bone growth is controlled by interactions between PTHrP and Indian hedgehog.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11517192", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 225, 
          "offsetInEndSection": 329, 
          "text": "Hedgehog genes encode secreted proteins which mediate patterning and growth during skeletal development.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10615989", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 230, 
          "text": "Indian hedgehog (Ihh) has recently been shown to be expressed in prehypertrophic and hypertrophic chondrocytes during embryonic development, and it has been implicated in the regulation of terminal differentiation of chondrocytes.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10742444", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 116, 
          "text": "Indian hedgehog and syndecans-3 coregulate chondrocyte proliferation and function during chick limb skeletogenesis.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14991716", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 94, 
          "text": "Indian Hedgehog signalling triggers Nkx3.2 protein degradation during chondrocyte maturation.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22507129", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 138, 
          "text": "Regulation of articular chondrocyte proliferation and differentiation by indian hedgehog and parathyroid hormone-related protein in mice.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19035497", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 135, 
          "text": "Chondrocytes of the epiphyseal growth zone are regulated by the Indian hedgehog (IHH)-parathyroid hormone-related protein (PTHrP) axis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19035497", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 655, 
          "offsetInEndSection": 746, 
          "text": "Regulation of rate of cartilage differentiation by Indian hedgehog and PTH-related protein.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9486541", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 99, 
          "text": "Expression of indian hedgehog, bone morphogenetic protein 6 and gli during skeletal morphogenesis.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9486541", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 83, 
          "text": "Indian hedgehog signals independently of PTHrP to promote chondrocyte hypertrophy.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18434416", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 59, 
          "text": "Age-dependent effects of hedgehog protein on chondrocytes.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10615989", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 367, 
          "offsetInEndSection": 568, 
          "text": "Indian hedgehog (Ihh), a secreted protein expressed in early hypertrophic chondrocytes, is thought to be involved in regulation of hypertrophic conversion via a feedback loop through the perichondrium.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10208865", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 92, 
          "text": "Regulation of rate of cartilage differentiation by Indian hedgehog and PTH-related protein.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8662546", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 1949, 
          "offsetInEndSection": 2127, 
          "text": "These observations are in keeping with the proposed function of gli as a negative regulator of Ihh signaling and the induction of Bmps by Hedgehog proteins (Roberts et al., 1995.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9486541", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is the function of R-spondin 1 and noggin in non-damaged gallbladders?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26993089"
      ], 
      "triples": [], 
      "ideal_answer": [
        "R-spondin 1 and noggin facilitate expansion of resident stem cells from non-damaged gallbladders."
      ], 
      "exact_answer": [
        [
          "The expansion of resident stem cells."
        ]
      ], 
      "concepts": [
        "http://www.uniprot.org/uniprot/NOGG_XENLA", 
        "http://www.uniprot.org/uniprot/NOGG_HUMAN", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005704", 
        "http://www.biosemantics.org/jochem#4264633", 
        "http://www.uniprot.org/uniprot/RSPO1_DANRE", 
        "http://www.uniprot.org/uniprot/RSPO1_HUMAN", 
        "http://www.uniprot.org/uniprot/RSPO1_MOUSE", 
        "http://www.uniprot.org/uniprot/SPON1_CHICK", 
        "http://www.uniprot.org/uniprot/SPON1_XENLA", 
        "http://www.uniprot.org/uniprot/SPON1_MOUSE", 
        "http://www.uniprot.org/uniprot/SPON1_RAT"
      ], 
      "type": "factoid", 
      "id": "5883a727e56acf5176000001", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 97, 
          "text": "R-spondin 1 and noggin facilitate expansion of resident stem cells from non-damaged gallbladders.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26993089", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 98, 
          "text": "R-spondin 1 and noggin facilitate expansion of resident stem cells from non-damaged gallbladders.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26993089", 
          "endSection": "title"
        }
      ]
    }, 
    {
      "body": "List the classical triad of symptoms of the Melkersson\u2013Rosenthal syndrome.", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26635986", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26698837", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24656464", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24827666", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24874612", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24225172", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22836908", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8302226", 
        "http://www.ncbi.nlm.nih.gov/pubmed/14980194", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16856704", 
        "http://www.ncbi.nlm.nih.gov/pubmed/7856459", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12081001", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16989500", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8725591", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10332378", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17103360", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12783021", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9224474", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10938204", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10534638", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15865255", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10481507", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11995671", 
        "http://www.ncbi.nlm.nih.gov/pubmed/1597367", 
        "http://www.ncbi.nlm.nih.gov/pubmed/1923442", 
        "http://www.ncbi.nlm.nih.gov/pubmed/3228056", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15068454", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16096940", 
        "http://www.ncbi.nlm.nih.gov/pubmed/7640193", 
        "http://www.ncbi.nlm.nih.gov/pubmed/2584463"
      ], 
      "triples": [], 
      "ideal_answer": [
        "The Melkersson-Rosenthal syndrome consists of the classical triad of symptoms:\n1) orofacial oedema \n2) fissured tongue (lingua plicata) and\n3) facial paralysis."
      ], 
      "exact_answer": [
        [
          "orofacial oedema", 
          "lip and face swelling"
        ], 
        [
          "fissured tongue", 
          "lingua plicata"
        ], 
        [
          "facial paralysis", 
          "facial palsy"
        ]
      ], 
      "concepts": [
        "http://www.disease-ontology.org/api/metadata/DOID:225", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013577", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008556", 
        "http://www.disease-ontology.org/api/metadata/DOID:1761"
      ], 
      "type": "list", 
      "id": "58b53bf722d3005309000004", 
      "snippets": [
        {
          "offsetInBeginSection": 310, 
          "offsetInEndSection": 451, 
          "text": "The Melkersson-Rosenthal syndrome consists of a triad of recurrent lip and/or face swelling, fissured tongue, and intermittent facial palsy. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26698837", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1007, 
          "offsetInEndSection": 1150, 
          "text": "The patient has a typical for Melkersson-Rosenthal syndrome triad of symptoms: bilateral facial nerve palsy, lingua plicata and facial oedema. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26698837", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 12, 
          "offsetInEndSection": 182, 
          "text": "Melkersson-Rosenthal syndrome (MRS) is a rare disorder of unknown cause. The classical triad of MRS is orofacial edema, recurrent facial paralysis, and a fissured tongue.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24656464", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 168, 
          "text": "Melkersson-Rosenthal syndrome (MRS) is a rare granulomatous inflammatory disease characterised by the triad of orofacial oedema, facial nerve palsy and furrowed tongue.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24827666", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 12, 
          "offsetInEndSection": 221, 
          "text": "Melkersson-Rosenthal syndrome (MRS) is a rare neuro-mucocutaneous granulomatous disorder of unknown etiology, characterized by the triad of facial palsy, lingua plicata (fissured tongue), and orofacial edema. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24874612", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 12, 
          "offsetInEndSection": 352, 
          "text": "Melkerrson-Rosenthal syndrome is a rare disorder of unknown etiology. The classical triad of recurrent facial paralysis, swelling of the face, lips and deep furrowed tongue (Lingua Plicata) is seen in very few cases, majority of the patients often present with one or two symptoms only, which often leads to misdiagnosis and mismanagement. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24225172", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 214, 
          "text": "Melkersson-Rosenthal syndrome (MRS) is a rare neuromucocutaneous syndrome marked by the triad of recurrent nonpitting orofacial edema, fissured dorsal tongue (lingua plicata), and lower motoneuron facial paralysis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22836908", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 236, 
          "offsetInEndSection": 510, 
          "text": "Recurrent facial nerve palsy, facial swelling, and fissured tongue are the symptoms and signs of this condition. However, this triad is not typical in all patients as patients may present with one or more of the symptoms, which makes management of this condition difficult. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26635986", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 220, 
          "text": "Melkersson-Rosenthal syndrome may manifest as the classical triad (orofacial edema, facial nerve palsy and stable lingua plicata) but monosymptomatic manifestations or combinations of typical symptoms are not infrequent.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14980194", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 217, 
          "text": "Melkersson-Rosenthal Syndrome (MRS) is a systemic neuro-mucocutaneous granulomatous disease, characterized in its classical form by a triad of recurrent facial nerve paralysis, swelling of the lips and lingua plicata.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16856704", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 123, 
          "text": "Melkersson-Rosenthal syndrome is classically described as a triad of orofacial swelling, facial palsy, and fissured tongue.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10332378", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 164, 
          "text": "Melkersson-Rosenthal syndrome is a rare disorder consisting of the triad of persistent or recurrent orofacial edema, relapsing facial paralysis and fissured tongue.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10938204", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 140, 
          "text": "The Melkersson-Rosenthal syndrome consists of a triad of recurrent lip and/or face swelling, fissured tongue, and intermittent facial palsy.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10534638", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 164, 
          "text": "The Melkersson-Rosenthal syndrome consists of a triad of symptoms: peripheral facial nerve paralysis, congenital \"lingua plicata\" and noninflammatory facial oedema.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10481507", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 143, 
          "text": "The Melkersson-Rosenthal syndrome consists of triad of symptoms: recurrent oedema of lips, recurrent facial nerve paralysis and lingua plicata.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15865255", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 115, 
          "offsetInEndSection": 254, 
          "text": "Melkersson-Rosenthal syndrome is characterised by a triad of recurrent orofacial swelling, relapsing facial paralysis, and fissured tongue.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17103360", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 142, 
          "text": "The Melkersson-Rosenthal syndrome consists of triad of symptoms: recurrent oedema of lips, recurrent facial nerve paralysis and lingua plicata", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15865255", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 219, 
          "text": "Melkersson-Rosenthal syndrome may manifest as the classical triad (orofacial edema, facial nerve palsy and stable lingua plicata) but monosymptomatic manifestations or combinations of typical symptoms are not infrequent", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14980194", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 188, 
          "text": "Melkersson-Rosenthal syndrome (MRS) is a rare disorder of unknown etiology characterized by a triad of symptoms: recurrent orofacial swelling, relapsing facial palsy. and a fissured tongue", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11995671", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 163, 
          "text": "The Melkersson-Rosenthal syndrome consists of a triad of symptoms: peripheral facial nerve paralysis, congenital \"lingua plicata\" and noninflammatory facial oedema", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10481507", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 192, 
          "text": "Melkersson-Rosenthal syndrome (MRS) is characterized by the triad of facial paralysis, facial oedema, and lingua plicata in association with other symptoms, such as headache and mental changes", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1597367", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 169, 
          "text": "Peripheral facial nerve palsy, recurrent or persistent oral or facial swelling, and fissured tongue constitute a triad of symptoms known as Melkersson-Rosenthal syndrome", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1923442", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 175, 
          "text": "Melkersson-Rosenthal (MRS) syndrome is characterized by a classical triad of recurrent or persistent orofacial swelling, peripheral facial nerve paralysis and lingua plicata. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15068454", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 233, 
          "text": "BACKGROUND: Melkersson-Rosenthal syndrome may manifest as the classical triad (orofacial edema, facial nerve palsy and stable lingua plicata) but monosymptomatic manifestations or combinations of typical symptoms are not infrequent. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14980194", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 79, 
          "offsetInEndSection": 312, 
          "text": "The syndrome is classically characterized by a triad of signs consisting of facial edema, recurrent peripheral facial nerve paralysis, and congenital fissured tongue, although it may also present in a mono- or oligosymptomatic form. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16096940", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 96, 
          "offsetInEndSection": 209, 
          "text": "The classic triad of signs includes recurrent orofacial edema, recurrent facial nerve palsy, and lingua plicata. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2584463", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 193, 
          "text": "Melkersson-Rosenthal syndrome (MRS) is characterized by the triad of facial paralysis, facial oedema, and lingua plicata in association with other symptoms, such as headache and mental changes.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1597367", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 971, 
          "offsetInEndSection": 1113, 
          "text": "The patient has a typical for Melkersson-Rosenthal syndrome triad of symptoms: bilateral facial nerve palsy, lingua plicata and facial oedema.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26698837", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 170, 
          "text": "Peripheral facial nerve palsy, recurrent or persistent oral or facial swelling, and fissured tongue constitute a triad of symptoms known as Melkersson-Rosenthal syndrome.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1923442", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 77, 
          "offsetInEndSection": 160, 
          "text": "Classical signs include recurrent facial palsy, lingua plicata and orofacial edema.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8302226", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 73, 
          "offsetInEndSection": 236, 
          "text": "The classical triad includes recurrent orofacial oedema involving predominantly the lips (macrocheilitis), intermittent peripheral facial palsy and scrotal tongue.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7856459", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 972, 
          "offsetInEndSection": 1114, 
          "text": "The patient has a typical for Melkersson-Rosenthal syndrome triad of symptoms: bilateral facial nerve palsy, lingua plicata and facial oedema.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26698837", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which disease is treated with taliglucerase alfa?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/27102949", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27174694", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27499018", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26053270", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23199589", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25453586", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21900191", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24950666", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22654679", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27839981", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21235447", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23980545", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22916340", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24630271", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25812601", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23046562", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27559188"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Taliglucerase alfa, the first available plant cell-expressed recombinant therapeutic protein, is an enzyme replacement therapy approved for Gaucher disease."
      ], 
      "exact_answer": [
        [
          "Gaucher disease"
        ]
      ], 
      "concepts": [
        "http://www.disease-ontology.org/api/metadata/DOID:4", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=diseases_category"
      ], 
      "type": "factoid", 
      "id": "5891b125621ea6ff7e00000e", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 165, 
          "text": "Enzyme replacement therapy with taliglucerase alfa: 36-month safety and efficacy results in adult patients with Gaucher disease previously treated with imiglucerase.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27102949", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 231, 
          "text": "Taliglucerase alfa is the first available plant cell-expressed human recombinant therapeutic protein. It is indicated for treatment of patients with type 1 Gaucher disease (GD) in adult and pediatric patients in several countries. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27102949", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1425, 
          "offsetInEndSection": 1656, 
          "text": "The 36-month results of switching from imiglucerase to taliglucerase alfa treatment in adults with GD provide further data on the clinical safety and efficacy of taliglucerase alfa beyond the initial 9 months of the original study.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27102949", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 131, 
          "text": "Long-term efficacy and safety results of taliglucerase alfa up to 36 months in adult treatment-na\u00efve patients with Gaucher disease.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27174694", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 320, 
          "text": "Taliglucerase alfa is an intravenous enzyme replacement therapy approved for treatment of type 1 Gaucher disease (GD), and is the first available plant cell-expressed recombinant therapeutic protein. Herein, we report long-term safety and efficacy results of taliglucerase alfa in treatment-na\u00efve adult patients with GD.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27174694", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 996, 
          "offsetInEndSection": 1168, 
          "text": " These 36-month results of taliglucerase alfa in treatment-na\u00efve adult patients with GD demonstrate continued improvement in disease parameters with no new safety concerns.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27174694", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 130, 
          "text": "Long-term efficacy and safety results of taliglucerase alfa through 5years in adult treatment-na\u00efve patients with Gaucher disease.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27499018", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 161, 
          "text": "Taliglucerase alfa, the first available plant cell-expressed recombinant therapeutic protein, is an enzyme replacement therapy approved for Gaucher disease (GD).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27499018", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 155, 
          "text": "Long-term safety and efficacy of taliglucerase alfa in pediatric Gaucher disease patients who were treatment-na\u00efve or previously treated with imiglucerase.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27839981", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 261, 
          "text": "A Phase 3, multicenter, open-label, switchover trial to assess the safety and efficacy of taliglucerase alfa, a plant cell-expressed recombinant human glucocerebrosidase, in adult and pediatric patients with Gaucher disease previously treated with imiglucerase.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24950666", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 1412, 
          "offsetInEndSection": 1496, 
          "text": "These results support safety and efficacy of taliglucerase alfa for Gaucher disease.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21900191", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 100, 
          "text": "Taliglucerase alfa leads to favorable bone marrow responses in patients with type I Gaucher disease.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23199589", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 58, 
          "text": "Taliglucerase alfa for the treatment of Gaucher's disease.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22916340", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 104, 
          "text": "Safety and efficacy of two dose levels of taliglucerase alfa in pediatric patients with Gaucher disease.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25453586", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 1422, 
          "offsetInEndSection": 1506, 
          "text": "These results support safety and efficacy of taliglucerase alfa for Gaucher disease.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21900191", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1217, 
          "offsetInEndSection": 1372, 
          "text": "These findings provide evidence of the efficacy and safety profile of taliglucerase alfa as an ERT for GD in patients previously treated with imiglucerase.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24950666", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 388, 
          "offsetInEndSection": 543, 
          "text": "This multicenter, randomized, double-blind, parallel-dose, 12-month study assessed efficacy and safety of taliglucerase alfa in pediatric patients with GD.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25453586", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 260, 
          "text": "A Phase 3, multicenter, open-label, switchover trial to assess the safety and efficacy of taliglucerase alfa, a plant cell-expressed recombinant human glucocerebrosidase, in adult and pediatric patients with Gaucher disease previously treated with imiglucerase", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24950666", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 308, 
          "offsetInEndSection": 520, 
          "text": "A Phase 3, multicenter, open-label, 9-month study assessed safety and efficacy of switching to taliglucerase alfa in adult and pediatric patients with GD treated with imiglucerase for at least the previous 2years", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24950666", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1217, 
          "offsetInEndSection": 1371, 
          "text": "These findings provide evidence of the efficacy and safety profile of taliglucerase alfa as an ERT for GD in patients previously treated with imiglucerase", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24950666", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1174, 
          "offsetInEndSection": 1396, 
          "text": "Clinical trials have demonstrated that taliglucerase alfa is efficacious, with a well-established safety profile in adult, ERT-na\u00efve patients with symptomatic GD1, and for such patients previously treated with imiglucerase", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24630271", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 2407, 
          "offsetInEndSection": 3070, 
          "text": "One study examined substrate reduction therapy in people with chronic neuronopathic (type 3) Gaucher disease who continued to receive enzyme replacement therapy.Treatment-na\u00efve participants had similar increases in haemoglobin when comparing those receiving imiglucerase or alglucerase at 60 units/kg, imiglucerase or velaglucerase alfa at 60 U/kg, taliglucerase alfa at 30 units/kg or 60 units/kg, and velaglucerase alfa at 45 units/g or 60 units/kg. For platelet count response in participants with intact spleens, a benefit for imiglucerase over velaglucerase alfa at 60 units/kg was observed, mean difference -79.87 (95% confidence interval -137.57 to -22.17)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25812601", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1217, 
          "offsetInEndSection": 1373, 
          "text": "These findings provide evidence of the efficacy and safety profile of taliglucerase alfa as an ERT for GD in patients previously treated with imiglucerase. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24950666", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 212, 
          "text": "Taliglucerase alfa (Protalix Biotherapeutics, Israel) is a carrot-cell-expressed recombinant human beta-glucocerebrosidase recently approved in the United States for the treatment of type 1 Gaucher disease (GD). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23199589", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 997, 
          "offsetInEndSection": 1168, 
          "text": "These 36-month results of taliglucerase alfa in treatment-na\u00efve adult patients with GD demonstrate continued improvement in disease parameters with no new safety concerns.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27174694", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 308, 
          "offsetInEndSection": 521, 
          "text": "A Phase 3, multicenter, open-label, 9-month study assessed safety and efficacy of switching to taliglucerase alfa in adult and pediatric patients with GD treated with imiglucerase for at least the previous 2years.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24950666", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1174, 
          "offsetInEndSection": 1397, 
          "text": "Clinical trials have demonstrated that taliglucerase alfa is efficacious, with a well-established safety profile in adult, ERT-na\u00efve patients with symptomatic GD1, and for such patients previously treated with imiglucerase.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24630271", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1509, 
          "offsetInEndSection": 1628, 
          "text": "These data suggest that taliglucerase alfa has the potential to be a therapeutic treatment option for children with GD.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25453586", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 166, 
          "text": "Enzyme replacement therapy with taliglucerase alfa: 36-month safety and efficacy results in adult patients with Gaucher disease previously treated with imiglucerase.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27102949", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 156, 
          "text": "Long-term safety and efficacy of taliglucerase alfa in pediatric Gaucher disease patients who were treatment-na\u00efve or previously treated with imiglucerase.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27839981", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 262, 
          "text": "A Phase 3, multicenter, open-label, switchover trial to assess the safety and efficacy of taliglucerase alfa, a plant cell-expressed recombinant human glucocerebrosidase, in adult and pediatric patients with Gaucher disease previously treated with imiglucerase.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24950666", 
          "endSection": "title"
        }
      ]
    }, 
    {
      "body": "What is formin associated with in the snail?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26923788"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Formin is associated with Left-Right asymmetry in the pond snail and the frog.", 
        "Formin Is Associated with Left-Right Asymmetry in the Pond Snail and the Frog"
      ], 
      "exact_answer": [
        [
          "Left-Right Asymmetry"
        ]
      ], 
      "concepts": [
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012908", 
        "http://www.biosemantics.org/jochem#4263720", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D052078", 
        "http://www.uniprot.org/uniprot/FMNL1_HUMAN"
      ], 
      "type": "factoid", 
      "id": "587f795d92a5b8ad44000007", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 77, 
          "text": "Formin Is Associated with Left-Right Asymmetry in the Pond Snail and the Frog", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26923788", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 467, 
          "offsetInEndSection": 1355, 
          "text": " Here, we report that a disabling mutation in one copy of a tandemly duplicated, diaphanous-related formin is perfectly associated with symmetry breaking in the pond snail. This is supported by the observation that an anti-formin drug treatment converts dextral snail embryos to a sinistral phenocopy, and in frogs, drug inhibition or overexpression by microinjection of formin has a chirality-randomizing effect in early (pre-cilia) embryos. Contrary to expectations based on existing models [3, 4 and 5], we discovered asymmetric gene expression in 2- and 4-cell snail embryos, preceding morphological asymmetry. As the formin-actin filament has been shown to be part of an asymmetry-breaking switch in vitro [6 and 7], together these results are consistent with the view that animals with diverse body plans may derive their asymmetries from the same intracellular chiral elements [8].", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26923788", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 465, 
          "offsetInEndSection": 636, 
          "text": "Here, we report that a disabling mutation in one copy of a tandemly duplicated, diaphanous-related formin is perfectly associated with symmetry breaking in the pond snail.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26923788", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 637, 
          "offsetInEndSection": 906, 
          "text": "This is supported by the observation that an anti-formin drug treatment converts dextral snail embryos to a sinistral phenocopy, and in frogs, drug inhibition or overexpression by microinjection of formin has a chirality-randomizing effect in early (pre-cilia) embryos.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26923788", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 468, 
          "offsetInEndSection": 639, 
          "text": "Here, we report that a disabling mutation in one copy of a tandemly duplicated, diaphanous-related formin is perfectly associated with symmetry breaking in the pond snail.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26923788", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 640, 
          "offsetInEndSection": 909, 
          "text": "This is supported by the observation that an anti-formin drug treatment converts dextral snail embryos to a sinistral phenocopy, and in frogs, drug inhibition or overexpression by microinjection of formin has a chirality-randomizing effect in early (pre-cilia) embryos.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26923788", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is the major difference between eucaryotes and procaryotes?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/16775624", 
        "http://www.ncbi.nlm.nih.gov/pubmed/98518", 
        "http://www.ncbi.nlm.nih.gov/pubmed/3023854", 
        "http://www.ncbi.nlm.nih.gov/pubmed/3271526", 
        "http://www.ncbi.nlm.nih.gov/pubmed/2345155", 
        "http://www.ncbi.nlm.nih.gov/pubmed/7786016", 
        "http://www.ncbi.nlm.nih.gov/pubmed/7533711"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Eucaryotes have a nucleolus, Procaryotes do not. Eucrayotes have a nuclear membrane, organelles and differ in transcription and translation. Procaryotes have polycistronic RNA and the initiation of protein synthesis proceeds with an initiator tRNA which is found to be modified (formylated) in procaryotes and not in eucaryotes. ", 
        "The nucleolus is the most prominent compartment in the nucleus and known as the site for ribosome biogenesis in eucaryotes. In contrast, there is no such equivalent structure for ribosome synthesis in procaryotes Eucaryotic and procaryotic organisms differ in two aspects of their translation machinery: polycistronic messengers are expressed as a sequence of individual proteins only in procaryotes, and the initiation of protein synthesis proceeds with an initiator tRNA which is found to be modified (formylated) in procaryotes and not in eucaryotes.", 
        "The nucleolus is the most prominent compartment in the nucleus and known as the site for ribosome biogenesis in eucaryotes. In contrast, there is no such equivalent structure for ribosome synthesis in procaryotes Eucaryotic and procaryotic organisms differ in two aspects of their translation machinery: polycistronic messengers are expressed as a sequence of individual proteins only in procaryotes, and the initiation of protein synthesis proceeds with an initiator tRNA which is found to be modified (formylated) in procaryotes and not in eucaryotes. extra guanylate at the 5' end of mature E. coli tRNAHis is encoded in the gene and is found in tRNA as the result of an unusual cleavage by RNase P  There are considerable differences of run distributions in DNA sequences of procaryotes, invertebrates and vertebrates. However, some interesting exceptions from this rule exist for the run distribution of adenine in procaryotes and for the arrangement of purine-pyrimidine runs in eucaryotes"
      ], 
      "concepts": [], 
      "type": "summary", 
      "id": "58a1c6b678275d0c4a000057", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 212, 
          "text": "The nucleolus is the most prominent compartment in the nucleus and known as the site for ribosome biogenesis in eucaryotes. In contrast, there is no such equivalent structure for ribosome synthesis in procaryotes", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16775624", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 340, 
          "text": "Eucaryotic and procaryotic organisms differ in two aspects of their translation machinery: polycistronic messengers are expressed as a sequence of individual proteins only in procaryotes, and the initiation of protein synthesis proceeds with an initiator tRNA which is found to be modified (formylated) in procaryotes and not in eucaryotes.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/98518", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 356, 
          "offsetInEndSection": 503, 
          "text": "extra guanylate at the 5' end of mature E. coli tRNAHis is encoded in the gene and is found in tRNA as the result of an unusual cleavage by RNase P", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3023854", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 130, 
          "offsetInEndSection": 250, 
          "text": " There are considerable differences of run distributions in DNA sequences of procaryotes, invertebrates and vertebrates.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3271526", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 399, 
          "offsetInEndSection": 571, 
          "text": "However, some interesting exceptions from this rule exist for the run distribution of adenine in procaryotes and for the arrangement of purine-pyrimidine runs in eucaryotes", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3271526", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1320, 
          "offsetInEndSection": 1447, 
          "text": "This was thought to be explained by the lack of mitochondria in procaryotes, the target site of uncoupling agents in eucaryotes", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7533711", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 341, 
          "text": "Eucaryotic and procaryotic organisms differ in two aspects of their translation machinery: polycistronic messengers are expressed as a sequence of individual proteins only in procaryotes, and the initiation of protein synthesis proceeds with an initiator tRNA which is found to be modified (formylated) in procaryotes and not in eucaryotes. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/98518", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is the HSP70-HSP110 disaggregase machinery?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/27477512"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Clearance of misfolded and aggregated proteins is central to cell survival. UBQLN2 acts with the HSP70-HSP110 disaggregase machinery to clear protein aggregates via the 26S proteasome. UBQLN2 recognizes client-bound HSP70 and links it to the proteasome to allow for the degradation of aggregated and misfolded proteins. We further show that this process is active in the cell nucleus, where another system for aggregate clearance, autophagy, does not act."
      ], 
      "concepts": [], 
      "type": "summary", 
      "id": "58bc640002b8c60953000003", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 75, 
          "text": "Clearance of misfolded and aggregated proteins is central to cell survival.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27477512", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 471, 
          "offsetInEndSection": 851, 
          "text": "UBQLN2 acts with the HSP70-HSP110 disaggregase machinery to clear protein aggregates via the 26S proteasome. UBQLN2 recognizes client-bound HSP70 and links it to the proteasome to allow for the degradation of aggregated and misfolded proteins. We further show that this process is active in the cell nucleus, where another system for aggregate clearance, autophagy, does not act. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27477512", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Has whole exome sequencing been performed in Alzheimer patients?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26522186", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27822510", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24958194", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23237904", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22153900", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22472873"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Yes, numerous whole exome sequencing studies of ALzheimer patients have been conducted."
      ], 
      "exact_answer": "yes", 
      "concepts": [], 
      "type": "yesno", 
      "id": "58bbb8ae22d3005309000018", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 130, 
          "text": "Pilot whole-exome sequencing of a German early-onset Alzheimer's disease cohort reveals a substantial frequency of PSEN2 variants.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26522186", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 129, 
          "offsetInEndSection": 304, 
          "text": "We performed whole-exome sequencing in early-onset Alzheimer disease (EOAD) and late-onset Alzheimer disease (LOAD) families followed by functional studies of select variants.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27822510", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 202, 
          "offsetInEndSection": 480, 
          "text": "Whole-exome sequencing revealed a nonsense mutation in PRNP (NM_000311, c.C478T; p.Q160*; rs80356711) associated with homozygosity for the V allele at position 129 of the protein, further highlighting how very similar genotypes in PRNP result in strikingly different phenotypes.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24958194", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 293, 
          "text": "In the search for new genes in Alzheimer's disease, classic linkage-based and candidate-gene-based association studies have been supplanted by exome sequencing, genome-wide sequencing (for mendelian forms of Alzheimer's disease), and genome-wide association studies (for non-mendelian forms). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23237904", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 361, 
          "offsetInEndSection": 493, 
          "text": "We performed whole exome sequencing in a Turkish patient clinically diagnosed with Alzheimer's disease from a consanguineous family ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22153900", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 322, 
          "text": "Performing exome sequencing in 14 autosomal dominant early-onset Alzheimer disease (ADEOAD) index cases without mutation on known genes (amyloid precursor protein (APP), presenilin1 (PSEN1) and presenilin2 (PSEN2)), we found that in five patients, the SORL1 gene harbored unknown nonsense (n=1) or missense (n=4) mutations", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22472873", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which is the genome browser database for DNA shape annotations?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25326329"
      ], 
      "triples": [], 
      "ideal_answer": [
        "GBshape provides minor groove width, propeller twist, roll, helix twist and hydroxyl radical cleavage predictions for the entire genomes of 94 organisms. Additional genomes can easily be added using the GBshape framework. GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as a function of genomic position at nucleotide resolution."
      ], 
      "exact_answer": [
        [
          "GBshape"
        ]
      ], 
      "concepts": [
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016678", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D019991"
      ], 
      "type": "factoid", 
      "id": "587e1bfdfc7e8dd84f000002", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 60, 
          "text": "GBshape: a genome browser database for DNA shape annotations", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25326329", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 531, 
          "offsetInEndSection": 1352, 
          "text": "Our Genome Browser for DNA shape annotations (GBshape; freely available at http://rohslab.cmb.usc.edu/GBshape/) provides minor groove width, propeller twist, roll, helix twist and hydroxyl radical cleavage predictions for the entire genomes of 94 organisms. Additional genomes can easily be added using the GBshape framework. GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as a function of genomic position at nucleotide resolution. As biological applications, we illustrate the periodicity of DNA shape features that are present in nucleosome-occupied sequences from human, fly and worm, and we demonstrate structural similarities between transcription start sites in the genomes of four Drosophila species", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25326329", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 61, 
          "text": "GBshape: a genome browser database for DNA shape annotations.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25326329", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 852, 
          "offsetInEndSection": 1072, 
          "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as a function of genomic position at nucleotide resolution.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25326329", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 528, 
          "offsetInEndSection": 785, 
          "text": "Our Genome Browser for DNA shape annotations (GBshape; freely available at http://rohslab.cmb.usc.edu/GBshape/) provides minor groove width, propeller twist, roll, helix twist and hydroxyl radical cleavage predictions for the entire genomes of 94 organisms.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25326329", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 857, 
          "offsetInEndSection": 1078, 
          "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as a function of genomic position at nucleotide resolution. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25326329", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 857, 
          "offsetInEndSection": 1077, 
          "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as a function of genomic position at nucleotide resolution.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25326329", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 62, 
          "text": "GBshape: a genome browser database for DNA shape annotations.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25326329", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 531, 
          "offsetInEndSection": 788, 
          "text": "Our Genome Browser for DNA shape annotations (GBshape; freely available at http://rohslab.cmb.usc.edu/GBshape/) provides minor groove width, propeller twist, roll, helix twist and hydroxyl radical cleavage predictions for the entire genomes of 94 organisms.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25326329", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Is Stat4 a transcription factor?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25829541", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25798064", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25178516", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25852285"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Yes, Stat4 is a transcription factor.\nStat4 is a member of the signal transducer and activator of transcription (STAT) family of molecules that localizes to the cytoplasm. STAT4 regulates various genes expression as a transcription factor after it is phosphorylated, dimerizes and translocates to the nucleus."
      ], 
      "exact_answer": "yes", 
      "concepts": [], 
      "type": "yesno", 
      "id": "58bc58c302b8c60953000001", 
      "snippets": [
        {
          "offsetInBeginSection": 713, 
          "offsetInEndSection": 750, 
          "text": "transcription factors T-bet and STAT4", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25829541", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 272, 
          "text": "STAT4 is a member of the signal transducer and activator of transcription (STAT) family of molecules that localizes to the cytoplasm. STAT4 regulates various genes expression as a transcription factor after it is phosphorylated, dimerizes and translocates to the nucleus. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25798064", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 117, 
          "text": "STAT4 is a latent cytosolic factor that encodes a transcription factor transmitting signals stimulated by cytokines. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25178516", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 4, 
          "offsetInEndSection": 168, 
          "text": " To investigate the role of signal transduction and activation of transcription 4 (STAT4) in the development and progression of human hepatocellular carcinoma (HCC)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25852285", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Have the promoter regions of the genes implicated in Rett Syndrome been characterized with CAGE?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25539566"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Yes. Promoter regions of the genes implicated in Rett Syndrome have been characterized using CAGE."
      ], 
      "exact_answer": "yes", 
      "concepts": [
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011401", 
        "http://www.disease-ontology.org/api/metadata/DOID:1206", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D015518"
      ], 
      "type": "yesno", 
      "id": "589644c478275d0c4a00000d", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 71, 
          "text": "CAGE-defined promoter regions of the genes implicated in Rett Syndrome.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25539566", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 12, 
          "offsetInEndSection": 1212, 
          "text": "Mutations in three functionally diverse genes cause Rett Syndrome. Although the functions of Forkhead box G1 (FOXG1), Methyl CpG binding protein 2 (MECP2) and Cyclin-dependent kinase-like 5 (CDKL5) have been studied individually, not much is known about their relation to each other with respect to expression levels and regulatory regions. Here we analyzed data from hundreds of mouse and human samples included in the FANTOM5 project, to identify transcript initiation sites, expression levels, expression correlations and regulatory regions of the three genes.RESULTS: Our investigations reveal the predominantly used transcription start sites (TSSs) for each gene including novel transcription start sites for FOXG1. We show that FOXG1 expression is poorly correlated with the expression of MECP2 and CDKL5. We identify promoter shapes for each TSS, the predicted location of enhancers for each gene and the common transcription factors likely to regulate the three genes. Our data imply Polycomb Repressive Complex 2 (PRC2) mediated silencing of Foxg1 in cerebellum.CONCLUSIONS: Our analyses provide a comprehensive picture of the regulatory regions of the three genes involved in Rett Syndrome.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25539566", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 70, 
          "text": "CAGE-defined promoter regions of the genes implicated in Rett Syndrome", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25539566", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 72, 
          "text": "CAGE-defined promoter regions of the genes implicated in Rett Syndrome.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25539566", 
          "endSection": "title"
        }
      ]
    }, 
    {
      "body": "Has \"RNA interference\" been awarded Nobel prize?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/20717561", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25048083", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24235106", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26648823"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Since the first unequivocal description of RNA interference (RNAi) in 1998, it has remained one of the hottest topics under investigation, culminating in the award of a Nobel Prize to its discoverers in 2006."
      ], 
      "exact_answer": "yes", 
      "concepts": [], 
      "type": "yesno", 
      "id": "58bbb68b22d3005309000015", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 208, 
          "text": "Since the first unequivocal description of RNA interference (RNAi) in 1998, it has remained one of the hottest topics under investigation, culminating in the award of a Nobel Prize to its discoverers in 2006.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20717561", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 341, 
          "text": "RNA interference (RNAi) is considered one of the most powerful genomic tools which allows the study of drug discovery and understanding of the complex cellular processes by high-content screens. This field of study, which was the subject of 2006 Nobel Prize of medicine, has drastically changed the conventional methods of analysis of genes.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24235106", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 187, 
          "offsetInEndSection": 373, 
          "text": " Almost 10 years after Fire and Mello received the Nobel Prize for the discovery of this mechanism in flat worms, RNA interference is on the edge of becoming a new class of therapeutics.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26648823", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Is there any role for Pds5b in cohesion establishment?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24141881"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Yes. Pds5 proteins are essential for cohesion establishment by allowing Smc3 acetylation by the cohesin acetyl transferases (CoATs) Esco1/2 and binding of Sororin."
      ], 
      "exact_answer": "yes", 
      "concepts": [
        "http://www.uniprot.org/uniprot/PDS5B_MOUSE", 
        "http://www.uniprot.org/uniprot/PDS5B_RAT", 
        "http://amigo.geneontology.org/amigo/term/GO:0034085", 
        "http://amigo.geneontology.org/amigo/term/GO:0034087", 
        "http://amigo.geneontology.org/amigo/term/GO:0034089", 
        "http://www.uniprot.org/uniprot/PD5BA_XENLA", 
        "http://www.uniprot.org/uniprot/PDS5A_RAT", 
        "http://www.uniprot.org/uniprot/PD5AA_XENLA"
      ], 
      "type": "yesno", 
      "id": "5889e2c83b87a8a73800000a", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 86, 
          "text": "Pds5B is required for cohesion establishment and Aurora B accumulation at centromeres.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24141881", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 444, 
          "offsetInEndSection": 1070, 
          "text": "Here, we demonstrate that Pds5 proteins are essential for cohesion establishment by allowing Smc3 acetylation by the cohesin acetyl transferases (CoATs) Esco1/2 and binding of Sororin. While both proteins contribute to telomere and arm cohesion, Pds5B is specifically required for centromeric cohesion. Furthermore, reduced accumulation of Aurora B at the inner centromere region in cells lacking Pds5B impairs its error correction function, promoting chromosome mis-segregation and aneuploidy. Our work supports a model in which the composition and function of cohesin complexes differs between different chromosomal regions.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24141881", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 87, 
          "text": "Pds5B is required for cohesion establishment and Aurora B accumulation at centromeres.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24141881", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 444, 
          "offsetInEndSection": 628, 
          "text": "Here, we demonstrate that Pds5 proteins are essential for cohesion establishment by allowing Smc3 acetylation by the cohesin acetyl transferases (CoATs) Esco1/2 and binding of Sororin.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24141881", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which factors are considered in the FUNC score for intracerebral hemorrhage?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/18556582"
      ], 
      "triples": [], 
      "ideal_answer": [
        "FUNC score includes Age, Glasgow Coma Scale, ICH location, volume and pre-ICH cognitive impairment."
      ], 
      "exact_answer": [
        [
          "Age"
        ], 
        [
          "Glasgow Coma Scale"
        ], 
        [
          "ICH location"
        ], 
        [
          "ICH volume"
        ], 
        [
          "pre-ICH cognitive impairment"
        ]
      ], 
      "concepts": [
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D020299"
      ], 
      "type": "list", 
      "id": "58850e50e56acf5176000013", 
      "snippets": [
        {
          "offsetInBeginSection": 782, 
          "offsetInEndSection": 1065, 
          "text": "Age, Glasgow Coma Scale, ICH location, volume (all P<0.0001), and pre-ICH cognitive impairment (P=0.005) were independently associated with Glasgow Outcome Score>or = 4. The FUNC score was developed as a sum of individual points (0-11) based on strength of association with outcome. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18556582", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 782, 
          "offsetInEndSection": 951, 
          "text": "Age, Glasgow Coma Scale, ICH location, volume (all P<0.0001), and pre-ICH cognitive impairment (P=0.005) were independently associated with Glasgow Outcome Score>or = 4.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18556582", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Where is the respirasome located?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/27912054", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27830641"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Respirasomes are macromolecular assemblies of the respiratory chain complexes I, III and IV in the inner mitochondrial membrane. The 4.0 \u00c5 cryo-EM structure of one of the most intricate enzyme systems, the respirasome, in the mitochondrial inner membrane is now available."
      ], 
      "exact_answer": [
        [
          "In the inner mitochondrial membrane"
        ]
      ], 
      "concepts": [], 
      "type": "factoid", 
      "id": "58a9d8a1396a458e50000005", 
      "snippets": [
        {
          "offsetInBeginSection": 181, 
          "offsetInEndSection": 305, 
          "text": "he 4.0\u00a0\u00c5 cryo-EM structure of one of the most intricate enzyme systems, the respirasome, in the mitochondrial inner membrane", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27912054", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 128, 
          "text": "Respirasomes are macromolecular assemblies of the respiratory chain complexes I, III and IV in the inner mitochondrial membrane.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27830641", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Describe the usefulness of MiRduplexSVM.", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25961860"
      ], 
      "triples": [], 
      "ideal_answer": [
        "MiRduplexSVM is a high-performing miRNA-duplex prediction and evaluation methodology. It's a method that combines a unique problem representation and an unbiased optimization protocol to learn from mirBase19.0 an accurate predictive model. It is the first model that provides precise information about all four ends of the miRNA duplex."
      ], 
      "concepts": [
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D035683"
      ], 
      "type": "summary", 
      "id": "5895ee638707e6ea39000001", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 83, 
          "text": "MiRduplexSVM: A High-Performing MiRNA-Duplex Prediction and Evaluation Methodology.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25961860", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 160, 
          "offsetInEndSection": 426, 
          "text": "Our method combines a unique problem representation and an unbiased optimization protocol to learn from mirBase19.0 an accurate predictive model, termed MiRduplexSVM. This is the first model that provides precise information about all four ends of the miRNA duplex. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25961860", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1418, 
          "offsetInEndSection": 1565, 
          "text": "In relation with recent confidence evaluation methods used in miRBase, MiRduplexSVM was successful in identifying high confidence potential miRNAs.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25961860", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 159, 
          "offsetInEndSection": 325, 
          "text": "Our method combines a unique problem representation and an unbiased optimization protocol to learn from mirBase19.0 an accurate predictive model, termed MiRduplexSVM.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25961860", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 685, 
          "offsetInEndSection": 908, 
          "text": "(b) In all comparisons, MiRduplexSVM shows superior performance, achieving up to a 60% increase in prediction accuracy for mammalian hairpins and can generalize very well on plant hairpins, without any special optimization.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25961860", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 84, 
          "text": "MiRduplexSVM: A High-Performing MiRNA-Duplex Prediction and Evaluation Methodology.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25961860", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 1426, 
          "offsetInEndSection": 1573, 
          "text": "In relation with recent confidence evaluation methods used in miRBase, MiRduplexSVM was successful in identifying high confidence potential miRNAs.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25961860", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 160, 
          "offsetInEndSection": 326, 
          "text": "Our method combines a unique problem representation and an unbiased optimization protocol to learn from mirBase19.0 an accurate predictive model, termed MiRduplexSVM.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25961860", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 689, 
          "offsetInEndSection": 912, 
          "text": "(b) In all comparisons, MiRduplexSVM shows superior performance, achieving up to a 60% increase in prediction accuracy for mammalian hairpins and can generalize very well on plant hairpins, without any special optimization.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25961860", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What genes are drug targets for Fibrodysplasia Ossificans Progressiva (FOP)?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/18830232", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23646137", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15288357", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16753021", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23229308", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19400542", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16831905", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16080294", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17967130", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9042799", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26626181", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17477807", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23599718", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18328989", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22977237", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22408438", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22011642", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11140409", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15940369", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26621707", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19929436", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26333933", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26695699", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19795179", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24047559", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11076054", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25413979", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22408652", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26896819", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26058333", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25136070"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Inhibitors of ALK2(ACVR1) are used for the treatment of FOP. Current therapies for FOP are Dorsomorphin analogues which function as BMP inhibitor.  if B cells control excess BMP-4 production in FOP, use of Rituximab, a monoclonal which targets B cells, could be a treatment alternative for FOP.", 
        "here, it is noted that if b cells are found to be the lymphocytes responsible for excess bmp-4 production in fop, use of rituximab, a monoclonal anti-cd20 antibody which effectively targets b cells, could be a less permanent and less risky treatment alternative for fop.", 
        " Recently, FOP has been associated with a specific mutation of ACVR1, the gene coding for a bone morphogenetic protein type I receptor. "
      ], 
      "exact_answer": [
        [
          "ALK2"
        ], 
        [
          "BMP"
        ]
      ], 
      "concepts": [
        "http://www.disease-ontology.org/api/metadata/DOID:13374", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D055415", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D052005"
      ], 
      "type": "list", 
      "id": "589dee3778275d0c4a000050", 
      "snippets": [
        {
          "offsetInBeginSection": 294, 
          "offsetInEndSection": 430, 
          "text": " Recently, FOP has been associated with a specific mutation of ACVR1, the gene coding for a bone morphogenetic protein type I receptor. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18830232", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 148, 
          "offsetInEndSection": 371, 
          "text": "Small molecule inhibitors of the bone morphogenetic protein (BMP) receptor kinase ALK2 (ACVR1) are needed urgently to treat the progressively debilitating musculoskeletal disease fibrodysplasia ossificans progressiva (FOP).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23646137", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 372, 
          "offsetInEndSection": 484, 
          "text": "Dorsomorphin analogues, first identified in zebrafish, remain the only BMP inhibitor chemotype reported to date.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23646137", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 485, 
          "offsetInEndSection": 733, 
          "text": "By screening an assay panel of 250 recombinant human kinases we identified a highly selective 2-aminopyridine-based inhibitor K02288 with in vitro activity against ALK2 at low nanomolar concentrations similar to the current lead compound LDN-193189", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23646137", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 780, 
          "offsetInEndSection": 1050, 
          "text": "Here, it is noted that if B cells are found to be the lymphocytes responsible for excess BMP-4 production in FOP, use of Rituximab, a monoclonal anti-CD20 antibody which effectively targets B cells, could be a less permanent and less risky treatment alternative for FOP.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15288357", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 280, 
          "text": "A new mutation of the Noggin gene in a French Fybrodysplasia ossificans progressiva (FOP) family: Fibrodysplasia ossificans progressiva (FOP) is a very rare disease characterized by congenital malformation of the great toes and progressive heterotopic ossification of the muscles.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16080294", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 96, 
          "text": "Localization of the gene for fibrodysplasia ossificans progressiva (FOP) to chromosome 17q21-22.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11140409", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 97, 
          "text": "A new mutation of the noggin gene in a French Fibrodysplasia ossificans progressiva (FOP) family.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16080294", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 103, 
          "text": "Rarely occurring mutation of ACVR1 gene in Moroccan patient with fibrodysplasia ossificans progressiva.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19795179", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 279, 
          "text": "A new mutation of the Noggin gene in a French Fybrodysplasia ossificans progressiva (FOP) family: Fibrodysplasia ossificans progressiva (FOP) is a very rare disease characterized by congenital malformation of the great toes and progressive heterotopic ossification of the muscles", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16080294", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 81, 
          "offsetInEndSection": 368, 
          "text": "Mutations in the ACVR1 gene are associated with Fibrodysplasia Ossificans Progressiva (FOP), a rare and extremely disabling disorder characterized by congenital malformation of the great toes and progressive heterotopic endochondral ossification in muscles and other non-skeletal tissues", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24047559", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 168, 
          "text": "Mutations of the noggin (NOG) and of the activin A type I receptor (ACVR1) genes in a series of twenty-seven French fibrodysplasia ossificans progressiva (FOP) patients", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19400542", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 106, 
          "text": "ACVR1, a therapeutic target of fibrodysplasia ossificans progressiva, is negatively regulated by miR-148a.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22408438", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 1037, 
          "offsetInEndSection": 1140, 
          "text": "These mutations represent new targets for therapeutic intervention in this otherwise incurable disease.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24705252", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 894, 
          "offsetInEndSection": 1041, 
          "text": "In this study, we examined downstream signaling targets to study the BMP-Smad and BMP-p38 mitogen-activated protein kinase (MAPK) pathways in FOP. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16753021", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 93, 
          "offsetInEndSection": 382, 
          "text": "Mutations in the ACVR1 gene are associated with Fibrodysplasia Ossificans Progressiva (FOP), a rare and extremely disabling disorder characterized by congenital malformation of the great toes and progressive heterotopic endochondral ossification in muscles and other non-skeletal tissues. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24047559", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 122, 
          "text": "Linkage exclusion and mutational analysis of the noggin gene in patients with fibrodysplasia ossificans progressiva (FOP).", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11076054", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 170, 
          "offsetInEndSection": 375, 
          "text": "Fibrodysplasia ossificans progressiva (FOP), a rare disorder characterized by progressive ossification of connective tissue, is caused by an activating mutation in Acvr1 (the gene that encodes ACVR1/ALK2).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25413979", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 185, 
          "offsetInEndSection": 488, 
          "text": "This gene encodes the type I bone morphogenic protein receptor ALK2, with the residues affected identical to those that, when mutated in the germline, give rise to the congenital malformation syndrome fibrodysplasia ossificans progressiva (FOP), resulting in the transformation of soft tissue into bone.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25136070", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 107, 
          "text": "ACVR1, a therapeutic target of fibrodysplasia ossificans progressiva, is negatively regulated by miR-148a.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22408438", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 98, 
          "text": "A new mutation of the noggin gene in a French Fibrodysplasia ossificans progressiva (FOP) family.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16080294", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 63, 
          "text": "Neofunction of ACVR1 in fibrodysplasia ossificans progressiva.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26621707", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 276, 
          "offsetInEndSection": 554, 
          "text": "The discovery of the FOP gene establishes a crucial milestone in understanding FOP, reveals a highly conserved target in the BMP signaling pathway for drug development and specifically stimulates therapeutic approaches for the development of inhibitors for ACVR1/ALK2 signaling.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23599718", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 749, 
          "offsetInEndSection": 1069, 
          "text": "The discovery of the FOP gene establishes a critical milestone in understanding FOP, reveals a highly conserved druggable target in the TGF-beta/bone morphogenetic protein signaling pathway and compels therapeutic approaches for the development of small molecule signal transduction inhibitors for activin-like kinase-2.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17477807", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What kind of analyses are performed with the software tool \"unipept\"", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26819472", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27380722", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25477242", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26058579", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23153116"
      ], 
      "triples": [], 
      "ideal_answer": [
        "The Unipept web application (http://unipept.ugent.be) supports biodiversity analysis of large and complex metaproteome samples using tryptic peptide information obtained from shotgun MS/MS experiments. The application designed for metaproteomics analysis with a focus on interactive datavisualization."
      ], 
      "concepts": [], 
      "type": "summary", 
      "id": "58bbbf3722d300530900001b", 
      "snippets": [
        {
          "offsetInBeginSection": 12, 
          "offsetInEndSection": 146, 
          "text": "Unipept is an open source web application that is designed for metaproteomics analysis with a focus on interactive datavisualization. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26819472", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 204, 
          "text": "The Unique Peptide Finder (http://unipept.ugent.be/peptidefinder) is an interactive web application to quickly hunt for tryptic peptides that are unique to a particular species, genus, or any other taxon.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27380722", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 928, 
          "offsetInEndSection": 1164, 
          "text": "Computations are extremely fast since they are underpinned by the Unipept database, the lowest common ancestor algorithm implemented in Unipept and modern web technologies that facilitate in-browser data storage and parallel processing.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27380722", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 187, 
          "text": "Unipept (http://unipept.ugent.be) is a web application that offers a user-friendly way to explore the biodiversity of complex metaproteome samples by providing interactive visualizations.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25477242", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1169, 
          "offsetInEndSection": 1281, 
          "text": "Outputted results are compatible with tools for taxonomic and functional characterization (e.g. Unipept, MEGAN5)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26058579", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 201, 
          "text": "The Unipept web application (http://unipept.ugent.be) supports biodiversity analysis of large and complex metaproteome samples using tryptic peptide information obtained from shotgun MS/MS experiments.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23153116", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is the role of gamma-secreatase complex in Alzheimer's Disease?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/19958468", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20035833", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20129170", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20600609", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20445084", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19625750", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18063223", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19376115", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19181896", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19299585", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18320103", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26559975", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24900409", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17560791", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15766275", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16675392", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15992373", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17298085", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23379308", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23316412", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21487536", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18393798", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18038124", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16804564", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16944319"
      ], 
      "triples": [], 
      "ideal_answer": [
        "The gamma-secretase complex has a decisive role in the development of Alzheimer's disease, as it cleaves a precursor protein to create the amyloid beta peptide whose aggregates form the senile plaques encountered in the brains of patients. Gamma-secretase is a member of the intramembrane-cleaving proteases which process their transmembrane substrates within the bilayer."
      ], 
      "exact_answer": [
        [
          "cleaves a precursor protein to create the amyloid beta peptide"
        ]
      ], 
      "concepts": [
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012380", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000544", 
        "http://www.disease-ontology.org/api/metadata/DOID:10652", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D053829"
      ], 
      "type": "factoid", 
      "id": "58a2c77a60087bc10a000002", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 88, 
          "text": "gamma-Secretase is critically involved in the Notch pathway and in Alzheimer's disease. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19958468", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 374, 
          "text": "Presenilins are the catalytic subunit of the large gamma-secretase complex, that promotes intramembranous proteolysis of the beta-amyloid precursor protein (APP), resulting in the production of beta-amyloid (A beta). Mutant presenilin causes early-onset familial Alzheimer's disease (FAD), is related to abnormal Ca(2+) signaling, and render cells vulnerable to cell death. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20035833", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 406, 
          "text": "Presenilins form the catalytic part of the gamma-secretases, protein complexes that are responsible for the intramembranous cleavage of transmembrane proteins. The presenilins are involved in several biological functions, but are best known for their role in the generation of the beta-amyloid (Abeta) peptide in Alzheimer's disease and are therefore thought to be important drug targets for this disorder.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20129170", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 201, 
          "text": "Amyloid-beta peptides (Abeta) generated by proteolysis of the beta-amyloid precursor protein (APP) by beta- and gamma-secretases play an important role in the pathogenesis of Alzheimer's disease (AD). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20600609", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 369, 
          "text": "The gamma-secretase complex has a decisive role in the development of Alzheimer's disease, in that it cleaves a precursor to create the amyloid beta peptide whose aggregates form the senile plaques encountered in the brains of patients. Gamma-secretase is a member of the intramembrane-cleaving proteases which process their transmembrane substrates within the bilayer.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20445084", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 177, 
          "text": "The GxxxG motif in the transmembrane domain of AbetaPP plays an essential role in the interaction of CTF beta with the gamma-secretase complex and the formation of amyloid-beta.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19625750", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 252, 
          "text": "Gamma-secretase-mediated processing of the amyloid-beta protein precursor (AbetaPP) is a crucial step in the formation of the amyloid-beta peptide (Abeta), but little is known about how the substrate AbetaPP interacts with the gamma-secretase complex. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19625750", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 816, 
          "offsetInEndSection": 977, 
          "text": "Thus, the present study revealed an essential role for the GxxxG motif in the interaction of AbetaPP with the gamma-secretase complex and the formation of Abeta.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19625750", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1111, 
          "offsetInEndSection": 1318, 
          "text": "Taken together, our results suggest an important role of hypoxia in modulating the APP processing by facilitating both beta- and gamma-cleavage which may result in a significant increase of Abeta generation.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18063223", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 212, 
          "text": "The gamma-secretase, composed of presenilin-1 (PS1) or presenilin-2 (PS2), nicastrin (NCT), anterior pharynx-defective phenotype 1 (APH-1), and PEN-2, is critical for the development of Alzheimer's disease (AD). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19376115", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 177, 
          "offsetInEndSection": 741, 
          "text": "APP is a ubiquitous membrane protein that is physiologically processed by site-specific proteolysis firstly by alpha- or beta-secretases, releasing a large fragment called APP(S) that contains most of the extracellular sequences of APP, a small extracellular stub, the transmembrane region and the cytoplasmic tail of APP (;AICD'-APP intracellular domain). These are subsequently cleaved by gamma-secretase at multiple sites in the transmembrane region, releasing small peptides, Abeta(1-40) and Abeta(1-42), the major components of AD-associated amyloid fibrils. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19181896", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 850, 
          "offsetInEndSection": 1108, 
          "text": "As PS1 has been shown to play a critical role in facilitating gamma-secretase activity, and mutations in this protein are associated with familial AD (FAD), we have cloned it from SAMP8 mouse hippocampus and compared its sequence with those of other species.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19181896", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1475, 
          "offsetInEndSection": 1709, 
          "text": "An increased amount or mutation(s) in PS1, which alters the stoichiometric balance of the gamma-secretase complex, may be the cause of aberrant or increased processing of APP, resulting in Abeta accumulation leading to loss of memory.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19181896", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 88, 
          "text": "The gamma-secretase complex plays a role in Alzheimer's disease and cancer progression. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19299585", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 87, 
          "text": "The gamma-secretase complex plays a role in Alzheimer's disease and cancer progression.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19299585", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 104, 
          "text": "Suppressor Mutations for Presenilin 1 Familial Alzheimer Disease Mutants Modulate \u03b3-Secretase Activities", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26559975", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 108, 
          "text": "Synthesis and SAR Studies of Fused Oxadiazines as \u03b3-Secretase Modulators for Treatment of Alzheimers Disease", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24900409", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 142, 
          "text": "Pathological activity of familial Alzheimer's disease-associated mutant presenilin can be executed by six different gamma-secretase complexes.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17560791", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 500, 
          "offsetInEndSection": 851, 
          "text": "The reconstituted enzyme processes C99 and the Notch-like substrate N160 and displays the characteristic features of gamma-secretase in terms of sensitivity to a gamma-secretase inhibitor, upregulation of Abeta42 production by a familial Alzheimer's disease (FAD) mutation in the APP gene, and downregulation of Notch processing by PS1 FAD mutations. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15766275", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 702, 
          "offsetInEndSection": 923, 
          "text": "The Aph1B complex contributes to total gamma-secretase activity in the human brain, and thus specific targeting of Aph1B-containing gamma-secretase complexes may help generate less toxic therapies for Alzheimer's disease.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19299585", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 295, 
          "text": "Genetic analysis of familial Alzheimer's disease has revealed that mutations in the gamma-secretase enzyme presenilin promote toxic Abeta secretion; however, presenilin mutations might also influence tau hyperphosphorylation and neurodegeneration through gamma-secretase-independent mechanisms. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16675392", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 517, 
          "offsetInEndSection": 728, 
          "text": "Here, we show that familial Alzheimer's disease mutations clustered near the sites of gamma-secretase cleavage actually decrease gamma-secretase-mediated release of the intracellular fragment of APP (CTFgamma). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15992373", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 120, 
          "offsetInEndSection": 350, 
          "text": "Beside the well investigated role of presenilins as the catalytic unit in \u03b3-secretase complex, their involvement in regulation of intracellular calcium homeostasis has recently come into more focus of Alzheimer's disease research.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23379308", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 152, 
          "text": "The \u03b3-secretase complex is a promising target in Alzheimer's disease because of its role in the amyloidogenic processing of \u03b2-amyloid precursor protein.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23316412", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 344, 
          "offsetInEndSection": 644, 
          "text": "Genetic studies of early-onset familial Alzheimer's disease cases revealed causative mutations in the genes encoding \u03b2-amyloid precursor protein and the \u03b3-secretase-complex components presenilin-1 and presenilin-2, supporting an important role of \u03b2-amyloid in the pathogenesis of Alzheimer's disease.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21487536", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 93, 
          "text": "Assembly, maturation, and trafficking of the gamma-secretase complex in Alzheimer's disease.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18393798", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 216, 
          "offsetInEndSection": 352, 
          "text": "Gamma-secretase was first recognized because of its role in the production of Abeta peptides that are pathogenic in Alzheimer's disease.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16804564", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 63, 
          "text": "Regulation of gamma-secretase activity in Alzheimer's disease.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17298085", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 560, 
          "offsetInEndSection": 835, 
          "text": "Drugs that regulate the production of Abeta by inhibiting or modulating gamma-secretase activity could provide a disease-modifying effect on Alzheimer's disease, although recent studies suggest that gamma-secretase plays important roles in cellular signaling including Notch.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18038124", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 702, 
          "offsetInEndSection": 924, 
          "text": "The Aph1B complex contributes to total gamma-secretase activity in the human brain, and thus specific targeting of Aph1B-containing gamma-secretase complexes may help generate less toxic therapies for Alzheimer's disease..", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19299585", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 350, 
          "offsetInEndSection": 458, 
          "text": "The gamma-secretase complex is therefore believed to be critical in the pathogenesis of Alzheimer's disease.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17298085", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 86, 
          "text": "gamma-Secretase heterogeneity in the Aph1 subunit: relevance for Alzheimer's disease.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19299585", 
          "endSection": "title"
        }
      ]
    }, 
    {
      "body": "Which syndromes are associated with heterochromia iridum?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25971175", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24194866", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21339912", 
        "http://www.ncbi.nlm.nih.gov/pubmed/7702105", 
        "http://www.ncbi.nlm.nih.gov/pubmed/14166458", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23840513", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12825064", 
        "http://www.ncbi.nlm.nih.gov/pubmed/1480396", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8092450", 
        "http://www.ncbi.nlm.nih.gov/pubmed/3792843", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20199465", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16826074", 
        "http://www.ncbi.nlm.nih.gov/pubmed/6823113", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17878817", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22174915", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8981698", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16814183"
      ], 
      "triples": [], 
      "ideal_answer": [
        "The syndromes that are associated with heterochromia iridum are:\n1) Ascher's syndrome\n2) Waardenburg Syndrome type II (WS2)\n3) Horner's syndrome."
      ], 
      "exact_answer": [
        [
          "Ascher's syndrome"
        ], 
        [
          "Waardenburg Syndrome type II", 
          "WS2", 
          "WS Type II"
        ], 
        [
          "Horner's syndrome"
        ]
      ], 
      "concepts": [
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013577"
      ], 
      "type": "list", 
      "id": "58b52c8822d3005309000001", 
      "snippets": [
        {
          "offsetInBeginSection": 532, 
          "offsetInEndSection": 797, 
          "text": "To our knowledge, this is the first reported case of Ascher's syndrome associated with iris coloboma, heterochromia iridum, and narrowing of horizontal palpebral fissure and decreased outer intercanthal distance secondary to lengthening of lateral canthal ligament.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25971175", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 604, 
          "offsetInEndSection": 763, 
          "text": " Sensorineural hearing loss (17/20, 85.0%) and heterochromia iridum (20/20, 100.0%) were the most commonly observed clinical features in Chinese WS2 patients. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24194866", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 280, 
          "text": "Waardenburg Syndrome (WS) is an autosomal-dominant disorder characterized by sensorineural hearing loss and pigmentary abnormalities of the eyes, hair, and skin. Microphthalmia-associated transcription factor (MITF) gene mutations account for about 15% of WS type II (WS2) cases. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24194866", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 659, 
          "offsetInEndSection": 815, 
          "text": "The association of congenital Horner's syndrome and hypochromia iridum without anhidrosis is highly suggestive of sympathetic pathway injury early in life. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21339912", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 246, 
          "text": "The Waardenburg syndrome (WS) consists of at least two distinct autosomal dominant hereditary disorders. WS Type I has been mapped to the distal part of chromosome 2q and the gene identified as PAX3. Other gene(s) are responsible for WS Type II. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7702105", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 574, 
          "offsetInEndSection": 704, 
          "text": "Sensorineural hearing loss (77%) and heterochromia iridum (47%) were the two most important diagnostic indicators for WS Type II. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7702105", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 76, 
          "text": "WAARDENBURG'S SYNDROME AND HETEROCHROMIA IRIDUM IN A DEAF SCHOOL POPULATION.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14166458", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 216, 
          "text": "Waardenburg's syndrome consists of lateral displacement of the inner canthi of the eyes (dystopia canthorum), a broad nasal root and confluent eyebrows, heterochromia iridum, a white forelock and congenital deafness.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14166458", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 528, 
          "offsetInEndSection": 793, 
          "text": "To our knowledge, this is the first reported case of Ascher's syndrome associated with iris coloboma, heterochromia iridum, and narrowing of horizontal palpebral fissure and decreased outer intercanthal distance secondary to lengthening of lateral canthal ligament.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25971175", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 569, 
          "offsetInEndSection": 698, 
          "text": "Sensorineural hearing loss (77%) and heterochromia iridum (47%) were the two most important diagnostic indicators for WS Type II.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7702105", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 600, 
          "offsetInEndSection": 757, 
          "text": "Sensorineural hearing loss (17/20, 85.0%) and heterochromia iridum (20/20, 100.0%) were the most commonly observed clinical features in Chinese WS2 patients.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24194866", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 278, 
          "text": "We present the genetic analyses conducted on a three-generation family (14 individuals) with three members affected with isolated-Hirschsprung disease (HSCR) and one with HSCR and heterochromia iridum (syndromic-HSCR), a phenotype reminiscent of Waardenburg-Shah syndrome (WS4).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23840513", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 77, 
          "text": "Heterochromia iridis and Horner's syndrome due to paravertebral neurilemmoma.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6823113", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 51, 
          "text": "[Iris heterochromia in acquired Horner's syndrome].", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17878817", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 122, 
          "text": "BACKGROUND: Heterochromia iridis, asymmetry of iris pigmentation, has been well described with congenital Horner syndrome.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1480396", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 118, 
          "text": "A case of heterochromia iridis and Horner's syndrome is reported in a 7-year old girl with paravertebral neurilemmoma.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6823113", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 277, 
          "text": "We present the genetic analyses conducted on a three-generation family (14 individuals) with three members affected with isolated-Hirschsprung disease (HSCR) and one with HSCR and heterochromia iridum (syndromic-HSCR), a phenotype reminiscent of Waardenburg-Shah syndrome (WS4)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23840513", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 531, 
          "offsetInEndSection": 794, 
          "text": "To our knowledge, this is the first reported case of Aschers syndrome associated with iris coloboma, heterochromia iridum, and narrowing of horizontal palpebral fissure and decreased outer intercanthal distance secondary to lengthening of lateral canthal ligament", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25971175", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 74, 
          "text": "WAARDENBURGS SYNDROME AND HETEROCHROMIA IRIDUM IN A DEAF SCHOOL POPULATION", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14166458", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 214, 
          "text": "Waardenburgs syndrome consists of lateral displacement of the inner canthi of the eyes (dystopia canthorum), a broad nasal root and confluent eyebrows, heterochromia iridum, a white forelock and congenital deafness", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14166458", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 605, 
          "offsetInEndSection": 761, 
          "text": "Sensorineural hearing loss (17/20, 85.0%) and heterochromia iridum (20/20, 100.0%) were the most commonly observed clinical features in Chinese WS2 patients", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24194866", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 605, 
          "offsetInEndSection": 763, 
          "text": "Sensorineural hearing loss (17/20, 85.0%) and heterochromia iridum (20/20, 100.0%) were the most commonly observed clinical features in Chinese WS2 patients. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24194866", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 209, 
          "text": "A dominantly inherited syndrome associated with hypopigmentation, heterochromia irides, colobomatous eyes and bilateral hearing loss has been ascertained in Fleckvieh cattle (German White Fleckvieh syndrome). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22174915", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 574, 
          "offsetInEndSection": 703, 
          "text": "Sensorineural hearing loss (77%) and heterochromia iridum (47%) were the two most important diagnostic indicators for WS Type II.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7702105", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 605, 
          "offsetInEndSection": 762, 
          "text": "Sensorineural hearing loss (17/20, 85.0%) and heterochromia iridum (20/20, 100.0%) were the most commonly observed clinical features in Chinese WS2 patients.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24194866", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 77, 
          "text": "WAARDENBURG'S SYNDROME AND HETEROCHROMIA IRIDUM IN A DEAF SCHOOL POPULATION.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14166458", 
          "endSection": "title"
        }
      ]
    }, 
    {
      "body": "What is the target of tanezumab?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/27381034", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26962464", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27936977", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25594611", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21130822", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23028238", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26940379", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23628600", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23707270", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21420111", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20140821", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24830649", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24691709", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24809946", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24452657", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18505735", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25527221", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21802499", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25326242", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23852695", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25073573", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22004765", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23010344", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20942668", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21696889"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Tanezumab is a humanized monoclonal antibody against nerve growth factor."
      ], 
      "exact_answer": [
        [
          "nerve growth factor", 
          "NGF"
        ]
      ], 
      "concepts": [], 
      "type": "factoid", 
      "id": "5890e163621ea6ff7e000004", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 142, 
          "text": "Nerve growth factor inhibition with tanezumab influences weight-bearing and subsequent cartilage damage in the rat medial meniscal tear model.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27381034", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 229, 
          "text": "OBJECTIVE: To investigate whether the effects of nerve growth factor (NGF) inhibition with tanezumab on rats with medial meniscal tear (MMT) effectively model rapidly progressive osteoarthritis (RPOA) observed in clinical trials.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27381034", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 559, 
          "offsetInEndSection": 847, 
          "text": " Current research focuses on the development of new OA drugs (such as sprifermin/recombinant human fibroblast growth factor-18, tanezumab/monoclonal antibody against \u03b2-nerve growth factor), which aims for more effectiveness and less incidence of adverse effects than the traditional ones.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26962464", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 549, 
          "offsetInEndSection": 775, 
          "text": "Areas covered: This manuscript is a review that examines both the pharmacological properties and clinical studies of tanezumab, the most widely studied antibody to NGF, for management of osteoarthritis (OA) and low back pain. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27936977", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 135, 
          "text": "OBJECTIVE: Evaluate efficacy and safety of tanezumab, a humanized monoclonal antibody against nerve growth factor, in neuropathic pain.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25594611", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 696, 
          "offsetInEndSection": 852, 
          "text": "In preclinical studies, tanezumab, and its murine precursor muMab-911, effectively targeted the NGF pathway in various chronic and inflammatory pain models.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20140821", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 514, 
          "offsetInEndSection": 696, 
          "text": "Tanezumab (RN-624), a first-in-class recombinant humanized mAb targeting NGF, is being developed by Pfizer Inc for the potential treatment of pain associated with several conditions.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20140821", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1029, 
          "offsetInEndSection": 1343, 
          "text": "Given that tanezumab is an antibody, the drug demonstrates the general advantages of this class of products (including good specificity and favorable pharmacokinetics), and also appears to be particularly well suited for targeting the chronic and inflammatory-mediating pain actions of NGF and its receptor system.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20140821", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 323, 
          "text": "In this randomized, double-blind, placebo controlled phase 2 study we investigated tanezumab, a humanized monoclonal antibody that specifically inhibits nerve growth factor as a treatment for interstitial cystitis pain.Patients with interstitial cystitis received a single intravenous dose of 200 \u03bcg/kg tanezumab or placebo", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21420111", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 78, 
          "text": "Nerve safety of tanezumab, a nerve growth factor inhibitor for pain treatment.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25073573", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 700, 
          "offsetInEndSection": 856, 
          "text": "In preclinical studies, tanezumab, and its murine precursor muMab-911, effectively targeted the NGF pathway in various chronic and inflammatory pain models.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20140821", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 517, 
          "offsetInEndSection": 699, 
          "text": "Tanezumab (RN-624), a first-in-class recombinant humanized mAb targeting NGF, is being developed by Pfizer Inc for the potential treatment of pain associated with several conditions.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20140821", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1035, 
          "offsetInEndSection": 1350, 
          "text": "Given that tanezumab is an antibody, the drug demonstrates the general advantages of this class of products (including good specificity and favorable pharmacokinetics), and also appears to be particularly well suited for targeting the chronic and inflammatory-mediating pain actions of NGF and its receptor system..", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20140821", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Could plasmepsins be used as targets for developing anti-malaria drugs?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25827401", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26214367", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26566224", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24975562", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24983235", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25719272", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27718413", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23466235", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9561244", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22242846", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17727268", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19437467", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11841219", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15181345", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21382523", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21334328", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19472268", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8816746", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18442137", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12767832", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16138859", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21760810", 
        "http://www.ncbi.nlm.nih.gov/pubmed/14636976", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21136953", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16054370", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17585371", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21428877", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24468190", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15011947", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20056606", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16838300", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12435452"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Yes, plasmepsins, which are essential Plasmodium proteases, could be highly promising anti-malarial drug targets."
      ], 
      "exact_answer": "yes", 
      "concepts": [
        "http://www.disease-ontology.org/api/metadata/DOID:12365", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000962", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016780", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008288", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D015195"
      ], 
      "type": "yesno", 
      "id": "58a6d89660087bc10a00002b", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 88, 
          "text": "Fighting malaria: structure-guided discovery of nonpeptidomimetic plasmepsin inhibitors.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25719272", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 116, 
          "offsetInEndSection": 274, 
          "text": "Given that the parasite needs the resulting amino acid building blocks for its growth and development, plasmepsins are an important antimalarial drug target. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25719272", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 652, 
          "offsetInEndSection": 1056, 
          "text": "Due to early crystallographic evidence, plasmepsin II (Plm II) emerged as well explored target to develop novel antimalarials as well as a starting point to develop inhibitors targeting some other subtypes of plasmepsins i.e. Plm I, II, IV and V. With the advancements in drug discovery, several computational and synthetic approaches were employed in order to develop novel inhibitors targeting Plm II. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25827401", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 106, 
          "text": "Structural basis for plasmepsin V inhibition that blocks export of malaria proteins to human erythrocytes.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26214367", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 295, 
          "text": "Plasmepsin V, an essential aspartyl protease of malaria parasites, has a key role in the export of effector proteins to parasite-infected erythrocytes. Consequently, it is an important drug target for the two most virulent malaria parasites of humans, Plasmodium falciparum and Plasmodium vivax.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26214367", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 219, 
          "offsetInEndSection": 388, 
          "text": "Plasmepsin V (PmV) is an essential Plasmodium protease and a highly promising antimalarial target, which still lacks molecular characterization and drug-like inhibitors.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26566224", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1375, 
          "offsetInEndSection": 1503, 
          "text": "Our inhibitors act 'on-target', confirmed by cellular interference of PmV function and biochemical interaction with inhibitors. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26566224", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1826, 
          "offsetInEndSection": 2191, 
          "text": "Our work disclosed novel pursuable drug design strategies for highly efficient PmV inhibition highlighting novel molecular elements necessary for picomolar activity against PmV. All the presented data are discussed in respect to human aspartic proteases and previously reported inhibitors, highlighting differences and proposing new strategies for drug development.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26566224", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 362, 
          "offsetInEndSection": 458, 
          "text": "High binding likeness on antimalarial target plasmepsin was detected through molecular docking. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24975562", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1097, 
          "offsetInEndSection": 1303, 
          "text": "This provides the first direct evidence that PMV activity is essential for protein export in Plasmodium spp. and for parasite survival in human erythrocytes and validates PMV as an antimalarial drug target.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24983235", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 169, 
          "offsetInEndSection": 310, 
          "text": "The export mechanism involves the Plasmodium export element (PEXEL), which is a cleavage site for the parasite protease, Plasmepsin V (PMV). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24983235", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 152, 
          "text": "Plasmepsin II (PM II) is an attractive target for anti-malaria drug discovery, which involves in host hemoglobin degradation in the acidic food vacuole.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23466235", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 202, 
          "offsetInEndSection": 480, 
          "text": "These methods are utilized to search for inhibitors of the aspartyl proteases, plasmepsin II and cathepsin D. Plasmepsin II, a protease found in the malaria parasite, hydrolyzes human hemoglobin, the nutrient source for the parasite and is a new target for anti-malaria therapy.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9561244", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 836, 
          "offsetInEndSection": 1040, 
          "text": "Given recent advances in understanding the fundamental roles of the various plasmepsins, it is likely that the most effective antimalarial plasmepsin targets will be the non-digestive vacuole plasmepsins.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22242846", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 142, 
          "text": "Plasmepsins (PMs) are essential proteases of the plasmodia parasites and are therefore promising targets for developing drugs against malaria.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19472268", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 165, 
          "offsetInEndSection": 274, 
          "text": "Therefore, the plasmepsins of malaria parasites have been recognized as attractive antimalarial drug targets.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21334328", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 85, 
          "offsetInEndSection": 201, 
          "text": "As inhibition of plasmepsins leads to the parasite's death, these enzymes can be utilized as potential drug targets.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16138859", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 377, 
          "offsetInEndSection": 515, 
          "text": "falciparum plasmepsins II and IV make structure-based drug design of antimalarial compounds that focus on inhibiting plasmepsins possible.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18442137", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 250, 
          "offsetInEndSection": 462, 
          "text": "The malarial parasite encodes two homologous aspartic proteases, plasmepsins I and II, which are essential components of its hemoglobin-degradation pathway and are novel targets for antimalarial drug development.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8816746", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1906, 
          "offsetInEndSection": 2052, 
          "text": "vivax plasmepsins (PvPMs) from different geographical regions are of utmost importance for drugs and vaccine designs for anti-malarial strategies.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21382523", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 155, 
          "offsetInEndSection": 345, 
          "text": "In P.falciparum, plasmepsins I, II, IV and HAP have been directly implicated in hemoglobin degradation during malaria infection, and are now considered targets for anti-malarial drug design.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12767832", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1531, 
          "offsetInEndSection": 1743, 
          "text": "These results shed light on the role of V105 and T108 residues in plasmepsin specificities, and they should be useful in structure-based design of novel, selective inhibitors that may serve as antimalarial drugs.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18442137", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 110, 
          "offsetInEndSection": 245, 
          "text": "The aspartic proteases plasmepsins, whose inhibition leads to parasite death, are classified as targets for the design of potent drugs.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21760810", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 818, 
          "offsetInEndSection": 994, 
          "text": "A large compound library of about 1 million chemical compounds was docked on 5 different targets of plasmepsins using two different docking software, namely FlexX and AutoDock.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17727268", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 114, 
          "offsetInEndSection": 281, 
          "text": "Plasmodium aspartic proteases known as plasmepsins play an important role on haemoglobin degradation and are being studied as drug targets for chemotherapy of malaria.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14636976", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 615, 
          "offsetInEndSection": 815, 
          "text": "Our study revealed about 100 parasite-coded gene products that included many known drug targets such as Pf hypoxanthine guanine phosphoribosyl transferase, Pf L-lactate dehydrogenase, and Plasmepsins.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21136953", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 175, 
          "offsetInEndSection": 295, 
          "text": "The two aspartic proteases, plasmepsins I and II, from Plasmodium falciparum have recently emerged as potential targets.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16054370", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 146, 
          "offsetInEndSection": 303, 
          "text": "Plasmepsins are highly promising as drug targets, especially when combined with the inhibition of falcipains that are also involved in hemoglobin catabolism.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17585371", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 984, 
          "offsetInEndSection": 1133, 
          "text": "Among such enzymes, Plasmepsins (aspartic proteases) and, especially, Falcipains (cysteine proteases) are highly promising antimalarial drug targets.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21428877", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 703, 
          "offsetInEndSection": 878, 
          "text": "The high sequence conservations between the plasmepsins from the isolates support the notion that the enzymes could be reliable targets for new antimalarial chemotherapeutics.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15181345", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 652, 
          "offsetInEndSection": 877, 
          "text": "Due to early crystallographic evidence, plasmepsin II (Plm II) emerged as well explored target to develop novel antimalarials as well as a starting point to develop inhibitors targeting some other subtypes of plasmepsins i.e.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25827401", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 469, 
          "offsetInEndSection": 651, 
          "text": "Plasmepsin, an aspartic protease, which is involved in the hemoglobin breakdown into smaller peptides emerged as a crucial target to develop new chemical entities to counter malaria.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25827401", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1160, 
          "offsetInEndSection": 1233, 
          "text": "were employed in order to develop new chemical entities targeting Plm II.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25827401", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 899, 
          "offsetInEndSection": 1055, 
          "text": "With the advancements in drug discovery, several computational and synthetic approaches were employed in order to develop novel inhibitors targeting Plm II.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25827401", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1906, 
          "offsetInEndSection": 2053, 
          "text": "vivax plasmepsins (PvPMs) from different geographical regions are of utmost importance for drugs and vaccine designs for anti-malarial strategies..", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21382523", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 296, 
          "offsetInEndSection": 422, 
          "text": "We developed a potent inhibitor of plasmepsin V, called WEHI-842, which directly mimics the Plasmodium export element (PEXEL).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26214367", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1768, 
          "offsetInEndSection": 1905, 
          "text": "In order to validate appropriate use of PM4 as potential anti-malarial drug target, studies on genetic and structural variations among P.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21382523", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 482, 
          "offsetInEndSection": 642, 
          "text": "Over the past decade, much effort has been placed towards developing plasmepsin inhibitors as antimalarial agents, particularly targeting the digestive vacuole.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22242846", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is MRSA?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/27736763", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27721155", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17537949", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19732087", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15060266", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19130105", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23824338", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21075466", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25113379", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27450316", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26812054", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17385151", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24267132", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17581935", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18347206", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22176801", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22291965", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15884297", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20071548", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19777772", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21571749", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8851953", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24322533", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19162372", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23405883", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26047024", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25108628", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25865979", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20861339", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23756924", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19710260", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22814471", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19828738", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20071545", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19129414", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19506056", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20524852", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24850346", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19252301", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12723397", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24045390", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26684366", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27025639", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15472807", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27112442"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Methicillin resistant Staphylococcus aureus (MRSA) has become a severe health concern because of its treatment difficulties.", 
        "community-associated methicillin resistant staphylococcus aureus (ca-mrsa) has become a severe health concern because of its treatment difficulties.", 
        "(MRSA, methicillin-resistant S. aureus)"
      ], 
      "exact_answer": [
        [
          "methicillin-resistant S. aureus", 
          "MRSA"
        ]
      ], 
      "concepts": [], 
      "type": "factoid", 
      "id": "58a32efe60087bc10a000013", 
      "snippets": [
        {
          "offsetInBeginSection": 137, 
          "offsetInEndSection": 176, 
          "text": "(MRSA, methicillin-resistant S. aureus)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27736763", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 148, 
          "text": "Community-associated methicillin resistant Staphylococcus aureus (CA-MRSA) has become a severe health concern because of its treatment difficulties.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27721155", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 160, 
          "text": "We investigated the distribution of MRSA (methicillin-resistant Staphylococcus aureus) on and around six patients with MRSA infection in our neurosurgical ward.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8851953", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 184, 
          "text": "The aim of this study was to assess to what extent patients with meticillin-resistant Staphylococcus aureus (MRSA) at respiratory sites shed viable MRSA into the air of hospital rooms.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19162372", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 187, 
          "text": "Community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) is increasing in prevalence among asymptomatic carriers and in cases of paediatric soft-tissue infections alike.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24322533", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 665, 
          "offsetInEndSection": 875, 
          "text": "Most of MRSA strains and a part of methicillin-susceptible S. aureus (MSSA) strains harbored unique combinations of non-\u00df-lactamase genes aac(6)/aph(2\u2033), aph(3)-III, ant (4,4\u2033), ermA, ermC, mrsA, tetM, and tetK", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23405883", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 234, 
          "text": "Healthcare- and Community-Associated Methicillin-Resistant Staphylococcus aureus (MRSA) and Fatal Pneumonia with Pediatric Deaths in Krasnoyarsk, Siberian Russia: Unique MRSAs Multiple Virulence Factors, Genome, and Stepwise Evolution", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26047024", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 309, 
          "text": "It was found in the present study that combined use of fusidic acid (FA) and berberine chloride (BBR) offered an in vitro synergistic action against 7 of the 30 clinical methicillin-resistant Staphylococcus aureus (MRSA) strains, with a fractional inhibitory concentration (FIC) index ranging from 0.5 to 0.19", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25108628", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 124, 
          "text": "Vancomycin MIC creep in methicillin-resistant Staphylococcus aureus (MRSA) isolates from 2006 to 2010 in a hospital in China", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25865979", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 184, 
          "text": "To assess whether vancomycin minimum inhibitory concentration (MIC) creeps among clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA) in a regional hospital in China", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25865979", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 261, 
          "text": "Detection of methicillin-resistant Staphylococcus aureus (MRSA) in specimens from various body sites: performance characteristics of the BD GeneOhm MRSA assay, the Xpert MRSA assay, and broth-enriched culture in an area with a low prevalence of MRSA infections.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20861339", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 175, 
          "text": "Rapid detection of Methicillin-Resistant Staphylococcus aureus MRSA in nose, groin, and axilla swabs by the BD GeneOhm MRSA achromopeptidase assay and comparison with culture.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23756924", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 265, 
          "text": "Methicillin-resistant Staphylococcus aureus (MRSA) detection: comparison of two molecular methods (IDI-MRSA PCR assay and GenoType MRSA Direct PCR assay) with three selective MRSA agars (MRSA ID, MRSASelect, and CHROMagar MRSA) for use with infection-control swabs.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17537949", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 181, 
          "text": "Comparison of the Xpert methicillin-resistant Staphylococcus aureus (MRSA) assay, BD GeneOhm MRSA assay, and culture for detection of nasal and cutaneous groin colonization by MRSA.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19710260", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 221, 
          "text": "Comparison of the BD Max methicillin-resistant Staphylococcus aureus (MRSA) assay and the BD GeneOhm MRSA achromopeptidase assay with direct- and enriched-culture techniques using clinical specimens for detection of MRSA.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22814471", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 229, 
          "text": "Comparison of MRSASelect Agar, CHROMagar Methicillin-Resistant Staphylococcus aureus (MRSA) Medium, and Xpert MRSA PCR for detection of MRSA in Nares: diagnostic accuracy for surveillance samples with various bacterial densities.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19828738", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 157, 
          "text": "Rapid detection of methicillin-resistant Staphylococcus aureus (MRSA) in diverse clinical specimens by the BD GeneOhm MRSA assay and comparison with culture.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20071545", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 159, 
          "text": "Multicenter evaluation of the Cepheid Xpert methicillin-resistant Staphylococcus aureus (MRSA) test as a rapid screening method for detection of MRSA in nares.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19129414", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 171, 
          "text": "Prospective comparison of the clinical impacts of heterogeneous vancomycin-intermediate methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-susceptible MRSA.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19506056", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 182, 
          "text": "Long-term control of endemic hospital-wide methicillin-resistant Staphylococcus aureus (MRSA): the impact of targeted active surveillance for MRSA in patients and healthcare workers.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20524852", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 203, 
          "text": "Methicillin-resistant Staphylococcus aureus (MRSA) infections pose a major challenge in health care, yet the limited heterogeneity within this group hinders molecular investigations of related outbreaks.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24850346", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 380, 
          "text": "In a previous study, we reported that two kaempferol glycosides isolated from Laurus nobilis L., kaempferol-3-O-alpha-L-(2'',4''-di-E-p-coumaroyl)-rhamnoside (C2) and kaempferol-3-O-alpha-L-(2''-E-p-coumaroyl-4''-Z-p-coumaroyl)-rhamnoside (C3), showed strong antibacterial activities against methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19252301", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 165, 
          "text": "This article explains what methicillin-resistant Staphylococcus aureus (MRSA) is, how it is spread and what the real challenges are in healthcare settings in the UK.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15884297", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 127, 
          "text": "Methicillin-resistant Staphylococcus aureus (MRSA) is an emerging threat to public health, especially in correctional settings.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21571749", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 328, 
          "text": "There are few more compelling questions in clinical microbiology today than the issue of whether or not to screen for the presence of methicillin-resistant Staphylococcus aureus (MRSA), with the results being used to institute infection control interventions aimed at preventing transmission of MRSA in health care environments.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20071548", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 266, 
          "text": "Methicillin-resistant Staphylococcus aureus (MRSA) detection: comparison of two molecular methods (IDI-MRSA PCR assay and GenoType MRSA Direct PCR assay) with three selective MRSA agars (MRSA ID, MRSASelect, and CHROMagar MRSA) for use with infection-control swabs.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17537949", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 154, 
          "text": "Do methicillin resistant staphylococcus (MRSA) carrier patients influence MRSA infection more than MRSA-carrier medical officers and MRSA-carrier family?", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24045390", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 126, 
          "offsetInEndSection": 176, 
          "text": "methicillin-resistant Staphylococcus aureus (MRSA)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19732087", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 88, 
          "offsetInEndSection": 142, 
          "text": " methicillin-resistant Staphylococcus aureus (CA-MRSA)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15060266", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 45, 
          "offsetInEndSection": 96, 
          "text": "methicillin-resistant Staphylococcus aureus (MRSA) ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19130105", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 23, 
          "offsetInEndSection": 84, 
          "text": "methicillin-resistant Staphylococcus aureus (MRSA) infections", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23824338", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 29, 
          "offsetInEndSection": 86, 
          "text": "methicillin resistant Staphylococcus aureus (MRSA CC398) ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21075466", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 138, 
          "offsetInEndSection": 190, 
          "text": " (methicillin-resistant Staphylococcus aureus) MRSA ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25113379", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 12, 
          "offsetInEndSection": 62, 
          "text": "Methicillin-resistant Staphylococcus aureus (MRSA)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27450316", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 349, 
          "offsetInEndSection": 399, 
          "text": "methicillin-resistant Staphylococcus aureus (MRSA)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26812054", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 72, 
          "offsetInEndSection": 122, 
          "text": "methicillin-resistant Staphylococcus aureus (MRSA)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17385151", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 66, 
          "offsetInEndSection": 116, 
          "text": "methicillin-resistant Staphylococcus aureus (MRSA)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24267132", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 54, 
          "offsetInEndSection": 105, 
          "text": "methicillin-resistant Staphylococcus aureus (MRSA) ", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17581935", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 60, 
          "offsetInEndSection": 110, 
          "text": "methicillin-resistant Staphylococcus aureus (MRSA)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18347206", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 43, 
          "text": "Methicillin-resistant Staphylococcus aureus", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22176801", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 65, 
          "offsetInEndSection": 116, 
          "text": " methicillin-resistant Staphylococcus aureus (MRSA)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25648247", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 33, 
          "offsetInEndSection": 86, 
          "text": "methicillin-resistant Staphylococcus aureus-(CA-MRSA)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22291965", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 396, 
          "offsetInEndSection": 446, 
          "text": "methicillin-resistant Staphylococcus aureus (MRSA)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19777772", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 50, 
          "text": "Methicillin-resistant Staphylococcus aureus (MRSA)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25240872", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 84, 
          "offsetInEndSection": 134, 
          "text": "methicillin-resistant Staphylococcus aureus (MRSA)", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12723397", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 45, 
          "offsetInEndSection": 95, 
          "text": "methicillin-resistant Staphylococcus aureus (MRSA)", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26684366", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 73, 
          "offsetInEndSection": 123, 
          "text": "methicillin-resistant Staphylococcus aureus (MRSA)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26684366", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 58, 
          "offsetInEndSection": 111, 
          "text": "methicillin-resistant Staphylococcus aureus (HA-MRSA)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27025639", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 43, 
          "offsetInEndSection": 94, 
          "text": "methicillin-resistant Staphylococcus aureus (MRSA) ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15472807", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 229, 
          "offsetInEndSection": 280, 
          "text": "methicillin-resistant Staphylococcus aureus (MRSA).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17121622", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 52, 
          "offsetInEndSection": 102, 
          "text": "methicillin-resistant Staphylococcus aureus (MRSA)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27112442", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "List peptide fragmentations methods in mass spectrometry", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26780731", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27139140", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27098412", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27613306", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27520322", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27914015"
      ], 
      "triples": [], 
      "ideal_answer": [
        "CID, HCD, ECD, ETD and PSD are different peptide fragmentation technologies used in mass spectrometry."
      ], 
      "exact_answer": [
        [
          "CID", 
          "collision-induced dissociation"
        ], 
        [
          "HCD", 
          "Higher-energy collisional dissociation"
        ], 
        [
          "ECD", 
          "electron capture dissociation"
        ], 
        [
          "ETD", 
          "electron transfer dissociation"
        ], 
        [
          "PSD", 
          "post-source decay"
        ]
      ], 
      "concepts": [], 
      "type": "list", 
      "id": "58a8071760087bc10a000037", 
      "snippets": [
        {
          "offsetInBeginSection": 585, 
          "offsetInEndSection": 632, 
          "text": " using the CID and HCD fragmentation techniques", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26780731", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 947, 
          "offsetInEndSection": 982, 
          "text": "By integrating HCD-MS/MS, CID-MS/MS", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27139140", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 787, 
          "offsetInEndSection": 840, 
          "text": "ECD and ETD induced different fragmentation processes", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27098412", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 118, 
          "offsetInEndSection": 496, 
          "text": "MALDI post-source decay (PSD), MALDI 157 nm photodissociation, tris(2,4,6-trimethoxyphenyl)phosphonium bromide (TMPP) charge tagging in PSD and photodissociation, ESI collision-induced dissociation (CID), electron transfer dissociation (ETD), and free-radical initiated peptide sequencing (FRIPS) with CID were applied to peptides containing either aspartic or isoaspartic acid.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27613306", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 650, 
          "offsetInEndSection": 705, 
          "text": "automated analysis of HCD and ETD fragmentation spectra", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27520322", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1064, 
          "offsetInEndSection": 1147, 
          "text": "The combination of DIA analysis and ETD fragmentation with supplemental CID energy ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27914015", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Is avanafil indicated for treatment of erectile dysfunction?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26784833", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27121186", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27377089", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25591992", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25801159", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26316720", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22857780", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23955441", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22759639", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24259695", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25684196", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23219537", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25582903", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24331245", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22248153", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22448738", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24589460", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24701971", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23521325", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22704456", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23321580", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22788525", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25455484", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23590161"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Yes, avanafil is indicated for treatment of erectile dysfunction."
      ], 
      "exact_answer": "yes", 
      "concepts": [
        "http://www.biosemantics.org/jochem#4243720", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013812", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D007172"
      ], 
      "type": "yesno", 
      "id": "5895d0457d9090f35300000d", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 123, 
          "text": "CONTEXT: Avanafil (AVA) is used in the treatment of erectile dysfunction, but is reported for its poor aqueous solubility. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26784833", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 225, 
          "text": "BACKGROUND: Phosphodiesterase 5 inhibitors (PDE5-Is) sildenafil, vardenafil, tadalafil and the recently approved avanafil represent the first-line choice for both on-demand and chronic treatment of erectile dysfunction (ED). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27121186", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 184, 
          "text": "A survey on the experience of 136 Italian urologists in the treatment of erectile dysfunction with PDE5 inhibitors and recommendations for the use of Avanafil in the clinical practice.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27377089", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 132, 
          "text": "Efficacy of Avanafil 15 Minutes after Dosing in Men with Erectile Dysfunction: A Randomized, Double-Blind, Placebo Controlled Study.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25591992", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 129, 
          "text": "PURPOSE: We examined the therapeutic effects of avanafil 15 minutes after dosing in men with mild to severe erectile dysfunction.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25591992", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 307, 
          "offsetInEndSection": 440, 
          "text": "Sildenafil, vardenafil, tadalafil and avanafil are FDA approved drugs in market as PDE5 inhibitors for treating erectile dysfunction.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25801159", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1428, 
          "offsetInEndSection": 1711, 
          "text": "CONCLUSION: Avanafil along with the other PDE5Is has shown to be a safe and effective oral treatment for ED, with avanafil's possible place in therapy for patients who want an on-demand option or as an alternative in patients who experience visual disturbances with the other agents.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26316720", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 137, 
          "text": "Avanafil (STENDRA\u2122, SPEDRA\u2122, Zepeeed\u2122) is an oral phosphodiesterase type 5 inhibitor indicated for the treatment of erectile dysfunction.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23955441", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 260, 
          "offsetInEndSection": 669, 
          "text": "In a 12-week, randomized, double-blind, placebo-controlled, multicentre trial in patients with erectile dysfunction, avanafil 50, 100 and 200 mg recipients had significantly greater improvements from baseline than placebo recipients in mean international index of erectile dysfunction-erectile function domain scores and in successful vaginal penetration and sexual intercourse attempts (coprimary endpoints).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23955441", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 70, 
          "text": "Avanafil for the treatment of erectile dysfunction. An updated review.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25582903", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 144, 
          "text": "Selectivity of avanafil, a PDE5 inhibitor for the treatment of erectile dysfunction: implications for clinical safety and improved tolerability.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22759639", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 135, 
          "text": "A randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of avanafil in subjects with erectile dysfunction.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22248153", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 95, 
          "text": "Avanafil, a potent and highly selective phosphodiesterase-5 inhibitor for erectile dysfunction.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22704456", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 176, 
          "text": "Avanafil, a highly selective phosphodiesterase type 5 inhibitor for erectile dysfunction, shows good safety profiles for retinal function and hemodynamics in anesthetized dogs.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23321580", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 1809, 
          "offsetInEndSection": 1912, 
          "text": "Cumulative data suggest that avanafil has a promising pharmacological profile for erectile dysfunction.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22704456", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1475, 
          "offsetInEndSection": 1630, 
          "text": "These findings suggest that intracavernosal administration of avanafil might be beneficial for the treatment of erectile dysfunction in patients with T2DM.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24331245", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 147, 
          "text": "An open-label, long-term evaluation of the safety, efficacy and tolerability of avanafil in male patients with mild to severe erectile dysfunction.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23521325", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 138, 
          "text": "The effect of intracavernosal avanafil, a newer phosphodiesterase-5 inhibitor, on neonatal type 2 diabetic rats with erectile dysfunction.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24331245", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 159, 
          "text": "A phase 3, placebo controlled study of the safety and efficacy of avanafil for the treatment of erectile dysfunction after nerve sparing radical prostatectomy.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23219537", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 118, 
          "offsetInEndSection": 246, 
          "text": "Avanafil is a potent selective phosphodiesterase type 5 (PDE5) inhibitor newly developed for treating erectile dysfunction (ED).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22448738", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1259, 
          "offsetInEndSection": 1546, 
          "text": "Adverse events most commonly reported with avanafil treatment were headache, nasopharyngitis, flushing, and sinus congestion.Avanafil was safe and effective for treating erectile dysfunction in men with diabetes and was effective as early as 15 minutes and more than 6 hours after dosing", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22857780", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 136, 
          "text": "Avanafil (STENDRA\u2122, SPEDRA\u2122, Zepeeed\u2122) is an oral phosphodiesterase type 5 inhibitor indicated for the treatment of erectile dysfunction", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23955441", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 138, 
          "offsetInEndSection": 670, 
          "text": "Avanafil is rapidly absorbed after oral administration, with a median time to maximum plasma concentration of 30 to 45 min. In a 12-week, randomized, double-blind, placebo-controlled, multicentre trial in patients with erectile dysfunction, avanafil 50, 100 and 200 mg recipients had significantly greater improvements from baseline than placebo recipients in mean international index of erectile dysfunction-erectile function domain scores and in successful vaginal penetration and sexual intercourse attempts (coprimary endpoints)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23955441", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 184, 
          "text": "A phase II, single-blind, randomized, crossover evaluation of the safety and efficacy of avanafil using visual sexual stimulation in patients with mild to moderate erectile dysfunction", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22788525", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 375, 
          "text": "To evaluate the safety, efficacy and time course of three doses of avanafil (50 mg, 100 mg and 200 mg) compared with sildenafil 50 mg or placebo, given in conjunction with visual sexual stimulation (VSS) videos in men with mild to moderate erectile dysfunction (ED).Male patients, 35-70 years of age, with mild to moderate ED of \u22656 months duration, were included in the study", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22788525", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 33, 
          "text": "Avanafil for erectile dysfunction", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24259695", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 472, 
          "text": "To review the pharmacology, pharmacokinetics, safety, and efficacy of avanafil and evaluate relevant clinical trial data.A MEDLINE, International Pharmaceutical Abstracts, ClinicalTrials.gov, and Google Scholar searches (1966 to July 2013) were conducted using the key words: avanafil, erectile dysfunction, and phosphodiesterase type 5 (PDE5) inhibitor.Articles evaluating avanafil for erectile dysfunction (ED) published in English and using human subjects were selected", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24259695", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1060, 
          "offsetInEndSection": 1305, 
          "text": "In trials in patients with erectile dysfunction in association with diabetes mellitus, and after nerve-sparing radical prostatectomy, avanafil 100 or 200 mg was significantly more efficacious than placebo for primary and most secondary endpoints", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23955441", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1321, 
          "offsetInEndSection": 1864, 
          "text": "However, the potentiating effect of avanafil at 1 mg/kg was significantly weaker than that of sildenafil (p &lt;0.05).Data suggest that avanafil has a favorable safety profile for erectile dysfunction, which is attributable to its high inhibitory selectivity for phosphodiesterase type 5 against type 6 (retina) and 1 (vessels, etc), respectively, and its short acting pharmacodynamic property.<CopyrightInformation>Copyright \u00a9 2013 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.</", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23321580", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 128, 
          "text": "Avanafil for the treatment of erectile dysfunction: a multicenter, randomized, double-blind study in men with diabetes mellitus.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22857780", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 176, 
          "text": "The discovery of avanafil for the treatment of erectile dysfunction: a novel pyrimidine-5-carboxamide derivative as a potent and highly selective phosphodiesterase 5 inhibitor.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25455484", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 144, 
          "text": "Efficacy and safety of avanafil for treating erectile dysfunction: results of a multicentre, randomized, double-blind, placebo-controlled trial.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22448738", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 212, 
          "text": "Phosphodiesterase 5 inhibitors (PDE5-Is) sildenafil, vardenafil, tadalafil and the recently approved avanafil represent the first-line choice for both on-demand and chronic treatment of erectile dysfunction (ED).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27121186", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 204, 
          "text": "The phosphodiesterese-5 (PDE5) inhibitors, including sildenafil (Viagra\u2122), vardenafil (Levitra\u2122), tadalafil (Cialis\u2122) and avanafil (Stendra\u2122) have been developed for the treatment of erectile dysfunction.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23590161", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 299, 
          "text": "To compare the efficacy and safety between different dosages of avanafil for the treatment of erectile dysfunction (ED).PubMed, Cochrane Library, and Embase were searched to identify randomized controlled trials which compared avanafil with placebo, or compared different dosages of avanafil for ED.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24701971", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 389, 
          "text": "We evaluated the safety and efficacy of 100 and 200 mg avanafil for the treatment of adult males with erectile dysfunction after bilateral nerve sparing radical prostatectomy.This was a double-blind, placebo controlled, parallel group, phase 3 study in males age 18 to 70 years with a history of erectile dysfunction of 6 months or more after bilateral nerve sparing radical prostatectomy.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23219537", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 279, 
          "text": "To determine the effect of avanafil, a novel phosphodiesterase-5 inhibitor, on the treatment of erectile dysfunction associated with type 2 diabetes mellitus (T2DM).In 2-day-old rats, T2DM was induced by single intraperitoneal injection of 90 mg/kg of streptozotocin (STZ; i.p.).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24331245", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1434, 
          "offsetInEndSection": 1665, 
          "text": "These findings suggest that intracavernosal administration of avanafil might be beneficial for the treatment of erectile dysfunction in patients with T2DM.<CopyrightInformation>Copyright \u00a9 2014 Elsevier Inc. All rights reserved.</C", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24331245", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 142, 
          "text": "Avanafil, a potent new selective phosphodiesterase type 5 (PDE5) inhibitor, has been developed for the treatment of erectile dysfunction (ED).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24589460", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1260, 
          "offsetInEndSection": 1548, 
          "text": "Adverse events most commonly reported with avanafil treatment were headache, nasopharyngitis, flushing, and sinus congestion.Avanafil was safe and effective for treating erectile dysfunction in men with diabetes and was effective as early as 15 minutes and more than 6 hours after dosing.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22857780", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 481, 
          "offsetInEndSection": 1150, 
          "text": "Coprimary end points assessed changes in the percentage of sexual attempts in which men were able to maintain an erection of sufficient duration to have successful intercourse (Sexual Encounter Profile [SEP] 3), percentage of sexual attempts in which men were able to insert the penis into the partner's vagina (SEP 2), and International Index of Erectile Function erectile function domain score.RESULTS: Compared with placebo, least-squares mean change from baseline to study end in SEP 3, SEP 2, and International Index of Erectile Function erectile function domain score were significantly improved with both avanafil, 100 mg (P?.002), and avanafil, 200 mg (P<.001).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22857780", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1299, 
          "offsetInEndSection": 1599, 
          "text": "Adverse events most commonly reported with avanafil treatment were headache, nasopharyngitis, flushing, and sinus congestion.CONCLUSION: Avanafil was safe and effective for treating erectile dysfunction in men with diabetes and was effective as early as 15 minutes and more than 6 hours after dosing.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22857780", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 71, 
          "text": "Avanafil for the treatment of erectile dysfunction. An updated review.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25582903", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 35, 
          "text": "Avanafil for erectile dysfunction.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24259695", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 129, 
          "text": "Avanafil for the treatment of erectile dysfunction: a multicenter, randomized, double-blind study in men with diabetes mellitus.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22857780", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 120, 
          "text": "To compare the efficacy and safety between different dosages of avanafil for the treatment of erectile dysfunction (ED).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24701971", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 145, 
          "text": "Selectivity of avanafil, a PDE5 inhibitor for the treatment of erectile dysfunction: implications for clinical safety and improved tolerability.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22759639", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 160, 
          "text": "A phase 3, placebo controlled study of the safety and efficacy of avanafil for the treatment of erectile dysfunction after nerve sparing radical prostatectomy.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23219537", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 175, 
          "text": "We evaluated the safety and efficacy of 100 and 200 mg avanafil for the treatment of adult males with erectile dysfunction after bilateral nerve sparing radical prostatectomy.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23219537", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is \"Epitranscriptome analysis\"?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26501195", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26733207", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27172004", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27808276", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26176336", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25370990", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27911721"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Modified nucleotides in messenger RNA (mRNA) have been discovered over 40 years ago, but until recently little was known about which transcripts contain them and what their function is. High-throughput sequencing approaches revealed a dynamic landscape of the 'Epitranscriptome' for many mRNA modifications in various organisms from yeast to humans.\t\t\nThe detection methods of RNA modifications has enabled investigation of a new layer of gene regulation - the epitranscriptome."
      ], 
      "concepts": [], 
      "type": "summary", 
      "id": "58bbb64422d3005309000014", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 229, 
          "text": "The simultaneous detection of all the post-transcriptional modifications (PTMs) that decorate cellular RNA can provide comprehensive information on the effects of changing environmental conditions on the entire epitranscriptome. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26733207", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 193, 
          "text": "The advent of high-throughput sequencing technologies coupled with new detection methods of RNA modifications has enabled investigation of a new layer of gene regulation - the epitranscriptome.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27172004", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 557, 
          "offsetInEndSection": 787, 
          "text": " Other mRNA modifications, including N1-methyladenosine (m1A), 5-methylcytosine (m5C) and pseudouridine, together with m6A form the epitranscriptome and collectively code a new layer of information that controls protein synthesis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27808276", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1589, 
          "offsetInEndSection": 1742, 
          "text": " the utility of mass spectrometry approaches for discovery-based analyses of RNA modifications, such as are required for studies of the epitranscriptome.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26176336", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 176, 
          "offsetInEndSection": 429, 
          "text": "Despite the intriguing advancements, little is known so far about the dynamic landscape of RNA methylome across different cell types and how the epitranscriptome is regulated at the system level by enzymes, i.e., RNA methyltransferases and demethylases.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25370990", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 350, 
          "text": "Modified nucleotides in messenger RNA (mRNA) have been discovered over 40 years ago, but until recently little was known about which transcripts contain them and what their function is. High-throughput sequencing approaches revealed a dynamic landscape of the 'Epitranscriptome' for many mRNA modifications in various organisms from yeast to humans. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27911721", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which infection can be prevented with Dapivirine?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26514157", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26837628", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26900902", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26963505", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25079391", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25880636", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19029331", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24901365", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19623693", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22708075", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26061040", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25845860", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18086845", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20574411", 
        "http://www.ncbi.nlm.nih.gov/pubmed/14693562", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23360246", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20854207", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19388819", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24449442", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24693866", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23177261", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21109069", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27398859", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23965226", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25089538", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26732684", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19958831", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24862093"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Vaginal ring containing Dapivirine is used for HIV prevention in women."
      ], 
      "exact_answer": [
        [
          "HIV"
        ]
      ], 
      "concepts": [
        "http://www.biosemantics.org/jochem#http://www.biosemantics.org/jochem#:4243195", 
        "http://www.biosemantics.org/jochem#4243195", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D007239", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D017053"
      ], 
      "type": "factoid", 
      "id": "5880b812c872c95565000006", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 519, 
          "text": "OBJECTIVES: The objectives of this study were to comprehensively assess mRNA expression of 84 drug transporters in human colorectal biopsies and six representative cell lines, and to investigate the alteration of drug transporter gene expression after exposure to three candidate microbicidal antiretroviral (ARV) drugs (tenofovir, darunavir and dapivirine) in the colorectal epithelium. The outcome of the objectives informs development of optimal ARV-based microbicidal formulations for prevention of HIV-1 infection.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26514157", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 225, 
          "text": "We evaluated the adherence and acceptability of a vaginal ring containing dapivirine, maraviroc, or both drugs for 28\u00a0days during a Phase I placebo-controlled trial in 48 HIV-negative sexually abstinent U.S. women aged 18-40.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26837628", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 74, 
          "text": "Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26900902", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 423, 
          "offsetInEndSection": 1292, 
          "text": "Methods We conducted a phase 3, randomized, double-blind, placebo-controlled trial of a monthly vaginal ring containing dapivirine, a non-nucleoside HIV-1 reverse-transcriptase inhibitor, involving women between the ages of 18 and 45 years in Malawi, South Africa, Uganda, and Zimbabwe. Results Among the 2629 women who were enrolled, 168 HIV-1 infections occurred: 71 in the dapivirine group and 97 in the placebo group (incidence, 3.3 and 4.5 per 100 person-years, respectively). The incidence of HIV-1 infection in the dapivirine group was lower by 27% (95% confidence interval [CI], 1 to 46; P=0.05) than that in the placebo group. In an analysis that excluded data from two sites that had reduced rates of retention and adherence, the incidence of HIV-1 infection in the dapivirine group was lower by 37% (95% CI, 12 to 56; P=0.007) than that in the placebo group.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26900902", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1713, 
          "offsetInEndSection": 1902, 
          "text": "Conclusions A monthly vaginal ring containing dapivirine reduced the risk of HIV-1 infection among African women, with increased efficacy in subgroups with evidence of increased adherence. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26900902", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 442, 
          "text": "BACKGROUND: This was the first microbicide trial conducted in Africa to evaluate an antiretroviral-containing vaginal ring as an HIV prevention technology for women.OBJECTIVES: The trial assessed and compared the safety, acceptability and adherence to product use of a 4-weekly administered vaginal ring containing the antiretroviral microbicide, dapivirine, with a matching placebo ring among women from four countries in sub-Saharan Africa.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26963505", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1817, 
          "offsetInEndSection": 2046, 
          "text": "CONCLUSIONS: The dapivirine vaginal ring has a favourable safety and acceptability profile. If proven safe and effective in large-scale trials, it will be an important component of combination HIV prevention approaches for women.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26963505", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 176, 
          "text": "PURPOSE: To develop polymeric films containing dual combinations of anti-HIV drug candidate tenofovir, maraviroc and dapivirine for vaginal application as topical microbicides.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25079391", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 332, 
          "offsetInEndSection": 532, 
          "text": "Efficacy trials with a dapivirine-containing vaginal ring for HIV prevention are ongoing and plans to develop multi-purpose vaginal rings for prevention of both HIV and pregnancy have been elaborated.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25880636", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 149, 
          "text": "Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19029331", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 900, 
          "offsetInEndSection": 1054, 
          "text": "The incidence of HIV-1 infection in the dapivirine group was lower by 27% (95% confidence interval [CI], 1 to 46; P=0.046) than that in the placebo group.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26900902", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1054, 
          "offsetInEndSection": 1287, 
          "text": "In an analysis that excluded data from two sites that had reduced rates of retention and adherence, the incidence of HIV-1 infection in the dapivirine group was lower by 37% (95% CI, 12 to 56; P=0.007) than that in the placebo group.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26900902", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 608, 
          "offsetInEndSection": 830, 
          "text": "Within this study the in vitro bioactivity of dapivirine as compared to the NNRTI UC781 was further established and a quick dissolve film was developed for vaginal application of dapivirine for prevention of HIV infection.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22708075", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 146, 
          "text": "Dapivirine, a nonnucleoside reverse transcriptase inhibitor, is in development as a microbicide for the protection of women against HIV infection.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20574411", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 164, 
          "text": "Dapivirine is a nonnucleoside reverse transcriptase inhibitor being developed as a topical microbicide for the prevention of human immunodeficiency virus infection.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18086845", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 705, 
          "offsetInEndSection": 960, 
          "text": "Dapivirine from both IVRs was successfully distributed throughout the lower genital tract at concentrations>1000x the EC(50) against wild-type HIV-1 (LAI) in MT4 cells suggesting that IVR delivery of microbicides is a viable option meriting further study.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19388819", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 272, 
          "text": "The nonnucleoside reverse transcriptase inhibitors UC-781 and TMC120-R147681 (Dapivirine) effectively prevented human immunodeficiency virus (HIV) infection in cocultures of monocyte-derived dendritic cells and T cells, representing primary targets in sexual transmission.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14693562", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 345, 
          "text": "To assess the potential of polymeric nanoparticles (NPs) to affect the genital distribution and local and systemic pharmacokinetics (PK) of the anti-HIV microbicide drug candidate dapivirine after vaginal delivery.Dapivirine-loaded, poly(ethylene oxide)-coated poly(epsilon-caprolactone) (PEO-PCL) NPs were prepared by a nanoprecipitation method", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24449442", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 271, 
          "text": "The nonnucleoside reverse transcriptase inhibitors UC-781 and TMC120-R147681 (Dapivirine) effectively prevented human immunodeficiency virus (HIV) infection in cocultures of monocyte-derived dendritic cells and T cells, representing primary targets in sexual transmission", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14693562", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 165, 
          "text": "Dapivirine is a nonnucleoside reverse transcriptase inhibitor being developed as a topical microbicide for the prevention of human immunodeficiency virus infection. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18086845", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 972, 
          "offsetInEndSection": 1144, 
          "text": "CONCLUSIONS: The study demonstrates proof of concept for a dapivirine-releasing diaphragm with daily release quantities potentially capable of preventing HIV transmission. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23177261", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 304, 
          "offsetInEndSection": 740, 
          "text": "Antiretroviral-containing vaginal microbicide rings, which release medication over a month or longer, may reduce these adherence challenges.ASPIRE (A Study to Prevent Infection with a Ring for Extended Use) is a phase III, randomized, double-blind, placebo-controlled trial testing the safety and effectiveness of a vaginal ring containing the non-nucleoside reverse transcriptase inhibitor dapivirine for prevention of HIV-1 infection.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26061040", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 642, 
          "offsetInEndSection": 774, 
          "text": "Dapivirine demonstrated potent dose-dependent inhibitory effects against a broad panel of HIV type 1 isolates from different clades.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19029331", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 657, 
          "offsetInEndSection": 829, 
          "text": "Two large efficacy trials of a vaginal ring containing the investigational drug dapivirine demonstrated efficacy and safety in preventing HIV infections in women in Africa.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27398859", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 575, 
          "offsetInEndSection": 831, 
          "text": "In doing so, we discovered that dapivirine and maraviroc, a non-nucleoside reverse transcriptase inhibitor and an entry inhibitor currently in development as microbicides for HIV PrEP, are differentially metabolized in colorectal tissue and vaginal tissue.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23965226", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1267, 
          "offsetInEndSection": 1611, 
          "text": "Plasma dapivirine concentrations were low (<1 ng/ml) and remained well below those observed at the maximum tolerated dose for oral treatment (mean Cmax of 2286 \u200ang/ml).CONCLUSION: The dapivirine vaginal ring has a safety and pharmacokinetic profile that supports its use as a sustained-release topical microbicide for HIV-1 prevention in women.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24901365", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 445, 
          "offsetInEndSection": 741, 
          "text": "ASPIRE (A Study to Prevent Infection with a Ring for Extended Use) is a phase III, randomized, double-blind, placebo-controlled trial testing the safety and effectiveness of a vaginal ring containing the non-nucleoside reverse transcriptase inhibitor dapivirine for prevention of HIV-1 infection.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26061040", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 232, 
          "text": "Dual segment polyurethane intravaginal rings (IVRs) were fabricated to enable sustained release of antiretroviral agents dapivirine and tenofovir to prevent the male to female sexual transmission of the human immunodeficiency virus.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19958831", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 937, 
          "offsetInEndSection": 1095, 
          "text": "The study demonstrates proof of concept for a dapivirine-releasing diaphragm with daily release quantities potentially capable of preventing HIV transmission.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23177261", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is Bexsero?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26126001", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26379162", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26603630", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26853725", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27163398", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26304221", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27808594", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26686570", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25043395", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27109566", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27521232", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21615224", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26788735", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24284038", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26788734", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26487381", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26433141", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24141209", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25713028", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24631075", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24462403", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23472347", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25368410", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26068564", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23954380", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23575646", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25986879", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25161192", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25301037", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22426368", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25325113", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23811804", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24807056", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27573083", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27302338", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25882169", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24815780", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27923519", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27002504"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Bexsero is a 4-component vaccine against capsular Meningococcus serogroup B (4CMenB), which has recently been licensed in Europe, Canada and Australia.", 
        "Bexsero is amulticomponent vaccine against serogroup B Neisseria meningitidis (MenB)."
      ], 
      "concepts": [
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D038541", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008585", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008589", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D022401", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D065288", 
        "http://www.disease-ontology.org/api/metadata/DOID:13668"
      ], 
      "type": "summary", 
      "id": "589af57a78275d0c4a000038", 
      "snippets": [
        {
          "offsetInBeginSection": 529, 
          "offsetInEndSection": 662, 
          "text": "A capsular group B meningococcal vaccine - 4CMenB (Bexsero) - has recently been licensed in the European Union, Canada and Australia.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26126001", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 191, 
          "text": "The 4-component meningococcal serogroup B vaccine 4CMenB (Bexsero) is the first vaccine against this serogroup and has been approved by licensing authorities in Europe, Canada and Australia. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26379162", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1, 
          "offsetInEndSection": 149, 
          "text": "Implementation of meningococcal B vaccination (Bexsero\u00ae) in France: Physicians' perceptions and experiences of a few months after marketing approval", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26603630", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 12, 
          "offsetInEndSection": 215, 
          "text": "In December 2013, the French public health authorities recommended the use of Bexsero\u00ae (meningococcus B vaccine) in areas with endemic risk and for patients at risk for invasive meningococcal B disease. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26603630", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1, 
          "offsetInEndSection": 47, 
          "text": "Bexsero, a novel vaccine against meningococcus", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26853725", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 207, 
          "text": "Meningococcus B is the most prevalent Neisseria meningitidis serogroup isolated in Hungary. Bexsero is one of the vaccines developed against it, which has been available in Hungary since the summer of 2014. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26853725", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 136, 
          "text": "Vaccinating Italian infants with a new multicomponent vaccine (Bexsero\u00ae) against meningococcal B disease: A cost-effectiveness analysis.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27163398", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 157, 
          "text": "The European Medicines Agency has approved a multicomponent serogroup B meningococcal vaccine (Bexsero\u00ae) for use in individuals of 2 months of age and older.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27163398", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1620, 
          "offsetInEndSection": 1856, 
          "text": "Our results suggest that vaccinating infants in Italy with Bexsero\u00ae has the ability to significantly reduce meningococcal disease and, if the probable underestimation of disease incidence is considered, routine vaccination is advisable.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27163398", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 593, 
          "offsetInEndSection": 802, 
          "text": "Since the antigens selected for Bexsero\u00ae are also harbored by meningococci belonging to other serogroups there may be the potential for Bexsero\u00ae to offer a certain level of protection against non-B serogroups.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26788735", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 49, 
          "text": "[Bexsero, a novel vaccine against meningococcus].", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26853725", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 452, 
          "offsetInEndSection": 506, 
          "text": "The new available vaccines are Bexsero\u00ae and Trumenba\u00ae.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26788734", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 359, 
          "text": "Surface-expressed protein antigens such as factor H-binding protein (fHbp), Neisserial adhesin A (NadA), Neisserial heparin-binding antigen (NHBA) and Porin protein A (PorA); all express sequence variability that can affect their function as protective immunogens when used in meningococcal serogroup B vaccines like the recently-approved 4CMenB (Bexsero(\u00ae)).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24631075", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 156, 
          "text": "Proteinaceous meningococcal B vaccines are under development, and the most advanced, Bexsero, is currently being evaluated by the European Medicines Agency.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23472347", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 228, 
          "offsetInEndSection": 468, 
          "text": "Among them, the Reverse Vaccinology approach was successfully applied to the development of an innovative vaccine against Neisseria meningitidis serogroup B, now available on the market with the commercial name BEXSERO\u00ae (Novartis Vaccines).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25368410", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 256, 
          "offsetInEndSection": 516, 
          "text": "Recently, a vaccine, 4CMenB (Bexsero(\u00ae)), containing three recombinant proteins, and outer membrane vesicles (OMV) derived from a serogroup B meningococcal strain (MenB) has been licensed in Europe and Australia and is indicated for persons aged 2 mo or older.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24141209", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 242, 
          "text": "Multicomponent meningococcal serogroup B vaccine (4CMenB; Bexsero(\u00ae)) is a unique vaccine containing four main immunogenic components: three recombinant proteins combined with outer membrane vesicles derived from meningococcal NZ98/254 strain", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23575646", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 253, 
          "offsetInEndSection": 453, 
          "text": "Recently, a universal serogroup B meningococcal vaccine, Bexsero(\u00ae), was licensed in Europe, Australia and United States, following several clinical studies demonstrating its immunogenicity and safety", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25986879", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 807, 
          "offsetInEndSection": 992, 
          "text": "Like any drug, Bexsero(\u00ae) and Trumemba(\u00ae) will require close observation to assess their impact on meningococcal epidemiology. <CopyrightInformation>Copyright \u00a9 2015 Elsevier Masson SAS", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25986879", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 156, 
          "text": "Bexsero, a new vaccine against Neisseria meningitidis serogroup B (MenB), is composed of 3 main recombinant proteins and an outer membrane vesicle component", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25713028", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 173, 
          "text": "The meningococcal 4CMenB vaccine (Bexsero; Novartis) contains four antigens that can elicit serum bactericidal activity, one of which is factor H (FH)-binding protein (FHbp)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25161192", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 109, 
          "text": "In December 2013 Bexsero\u00ae became available in Germany for vaccination against serogroup B meningococci (MenB)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26487381", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 376, 
          "offsetInEndSection": 495, 
          "text": "Bexsero\u00ae is based on surface protein antigens expressed by about 80% of circulating serogroup B meningococci in Germany", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26487381", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 107, 
          "text": "Re-evaluating cost effectiveness of universal meningitis vaccination (Bexsero) in England: modelling study.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25301037", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 74, 
          "text": "Bexsero: a multicomponent vaccine for prevention of meningococcal disease.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22426368", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 502, 
          "text": "OBJECTIVE: To use mathematical and economic models to predict the epidemiological and economic impact of vaccination with Bexsero, designed to protect against group B meningococcal disease, to help inform vaccine policy in the United Kingdom.DESIGN: Modelling study.SETTING: England.POPULATION: People aged 0-99.INTERVENTIONS: Incremental impact of introductory vaccine strategies simulated with a transmission dynamic model of meningococcal infection and vaccination including potential herd effects. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25301037", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 164, 
          "text": "Preventing secondary cases of invasive meningococcal capsular group B (MenB) disease using a recently-licensed, multi-component, protein-based vaccine (Bexsero(\ufffd)).", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25043395", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 162, 
          "text": "Modelled evaluation of multi-component meningococcal vaccine (Bexsero\u00ae) for the prevention of invasive meningococcal disease in infants and adolescents in the UK.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24284038", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 196, 
          "text": "BACKGROUND: 4CMenB (Bexsero), a vaccine developed against invasive meningococcal disease caused by capsular group B strains (MenB), was recently licensed for use by the European Medicines Agency. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23954380", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 133, 
          "offsetInEndSection": 216, 
          "text": "Bexsero is the first meningococcal B vaccine to be approved in the European Union. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25325113", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 86, 
          "text": "Quantification by LC-MS(E) of outer membrane vesicle proteins of the Bexsero\u00ae vaccine.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24462403", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 206, 
          "text": "We previously demonstrated the immunogenicity and tolerability of the serogroup B meningococcal vaccine, 4CMenB (Bexsero), in 11-17 y-olds randomized to receive 1, 2, or 3 doses at 1, 2, or 6 mo intervals. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23811804", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 316, 
          "text": "This policy statement provides recommendations for the prevention of serogroup B meningococcal disease through the use of 2 newly licensed serogroup B meningococcal vaccines: MenB-FHbp (Trumenba; Wyeth Pharmaceuticals, a subsidiary of Pfizer, Philadelphia, PA) and MenB-4C (Bexsero; Novartis Vaccines, Siena, Italy).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27573083", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 283, 
          "text": "An outbreak of Neisseria meningitidis serotype B infection occurred at a small residential university; public health announced an organizational vaccination program with the 4-component Meningococcal B (4CMenB) vaccine (Bexsero(TM), Novartis/GlaxoSmithKline Inc.) several days later.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27302338", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 112, 
          "text": "Bexsero, a new vaccine against serogroup B meningococcal disease (MenB), was licensed in Europe in January 2013.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27109566", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 291, 
          "text": "Recently approved in the EU, US, Australia, and Canada, 4CMenB (Bexsero(\u00ae), GSK Vaccines) is a multi-component meningococcal B (MenB) vaccine containing 3 surface exposed recombinant proteins (fHbp, NadA, and NHBA) and New Zealand strain outer membrane vesicles (NZ OMV) containing PorA 1.4.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25882169", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 113, 
          "offsetInEndSection": 257, 
          "text": "In Germany, Bexsero is recommended for persons at increased risk of invasive meningococcal disease, but not for universal childhood vaccination.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27109566", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 258, 
          "offsetInEndSection": 488, 
          "text": "To support decision making we adapted the independently developed model for England to the German setting to predict the potential health impact and cost-effectiveness of universal vaccination with Bexsero(\u00ae) against MenB disease.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27109566", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 463, 
          "offsetInEndSection": 955, 
          "text": "This has resulted in a multicomponent, recombinant, meningococcal serogroup B vaccine: 4CMenB (Bexsero(\u00ae), Novartis Vaccines & Diagnostics, NC, USA), containing four main immunogenic components: two recombinant fusion proteins (Neisseria heparin-binding antigen-GNA1030 and factor H-binding protein-GNA2091); recombinant Neisserial adhesion A; and detergent-treated outer membrane vesicles derived from the meningococcal NZ98/254 strain, where porin A 1.4 is the major immunodominant antigen.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24815780", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 195, 
          "text": "BACKGROUND: 4CMenB (Bexsero), a vaccine developed against invasive meningococcal disease caused by capsular group B strains (MenB), was recently licensed for use by the European Medicines Agency.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23954380", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 188, 
          "offsetInEndSection": 298, 
          "text": "In January 2015, FDA licensed a second MenB vaccine (MenB-4C [Bexsero, Novartis Vaccines]) as a 2-dose series.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26068564", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 157, 
          "text": "Bexsero, a new vaccine against Neisseria meningitidis serogroup B (MenB), is composed of 3 main recombinant proteins and an outer membrane vesicle component.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25713028", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 164, 
          "text": "Preventing secondary cases of invasive meningococcal capsular group B (MenB) disease using a recently-licensed, multi-component, protein-based vaccine (Bexsero(\u00ae)).", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25043395", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 50, 
          "text": "[Bexsero, a novel vaccine against meningococcus].", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26853725", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 86, 
          "text": "Modelling the cost-effectiveness of catch-up 'MenB' (Bexsero) vaccination in England.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27923519", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 108, 
          "text": "Re-evaluating cost effectiveness of universal meningitis vaccination (Bexsero) in England: modelling study.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25301037", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 476, 
          "offsetInEndSection": 592, 
          "text": "The novel vaccine Bexsero (previously 4CMenB) has been developed and proven safe and immunogenic in clinical trials.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21615224", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 127, 
          "text": "Multicomponent meningococcal serogroup B vaccine (4CMenB; Bexsero(\u00ae)): a review of its use in primary and booster vaccination.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23575646", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 53, 
          "offsetInEndSection": 157, 
          "text": "Bexsero, the recently licensed multicomponent vaccine against serogroup B Neisseria meningitidis (MenB).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26304221", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 197, 
          "offsetInEndSection": 342, 
          "text": "Recommendation for anti-meningococcal vaccination among these workers has been recently updated upon the licensure in Europe of Bexsero\u00ae vaccine.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27808594", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 804, 
          "offsetInEndSection": 894, 
          "text": "Clinical recommendations for the use of Bexsero have been published in several countries. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26686570", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Is there a role for gamma knife in treatment of Obsessive-Compulsive Disorder?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/27903196", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25050687", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25165567", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24099662", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24093580", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23829816", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21150752", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19996247", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18081480", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15554782", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12856488", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18188146", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10099102", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10069581", 
        "http://www.ncbi.nlm.nih.gov/pubmed/7841817", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8517190", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23872618", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25054836", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18835422"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Yes. Gamma knife radiosurgery is being increasingly to treat refractory obsessive- compulsive disorder (OCD). It is reserved for severe, treatment-refractory disease that has not responded to multiple treatments."
      ], 
      "exact_answer": "yes", 
      "concepts": [
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D009771", 
        "http://www.disease-ontology.org/api/metadata/DOID:10933"
      ], 
      "type": "yesno", 
      "id": "5898500478275d0c4a000017", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 199, 
          "text": "OBJECTIVE Functional Gamma Knife radiosurgery (GKRS) procedures have been increasingly used for treating patients with tremor, trigeminal neuralgia (TN), and refractory obsessive-compulsive disorder.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27903196", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 825, 
          "offsetInEndSection": 1165, 
          "text": "METHODS The authors constructed a linear-quadratic model of BED in functional GKRS with a dose-protraction factor to correct for intrafraction DNA-damage repair and used standard single-fraction doses for trigeminal nerve ablation for TN (85 Gy), thalamotomy for tremor (130 Gy), and capsulotomy for obsessive-compulsive disorder (180 Gy). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27903196", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 69, 
          "text": "Gamma knife for obsessive compulsive disorder: can it be detrimental?", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25050687", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 205, 
          "offsetInEndSection": 318, 
          "text": "Gamma knife radiosurgery (GKRS) is also being practised to treat refractory obsessive- compulsive disorder (OCD).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25050687", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1078, 
          "offsetInEndSection": 1344, 
          "text": "Radio and neurosurgical procedures, including gamma knife radiation and deep brain stimulation, are reserved for severe, treatment-refractory disease that has not responded to multiple treatments, and some patients may benefit from transcranial magnetic stimulation.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25165567", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 906, 
          "offsetInEndSection": 1000, 
          "text": " We close with a discussion of gamma knife capsulotomy, a modality with deep historical roots.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24099662", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 101, 
          "text": "Results following gamma knife radiosurgical anterior capsulotomies for obsessive compulsive disorder.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21150752", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 203, 
          "offsetInEndSection": 316, 
          "text": "Gamma knife radiosurgery (GKRS) is also being practised to treat refractory obsessive- compulsive disorder (OCD).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25050687", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 150, 
          "text": "Lesion topography and outcome after thermocapsulotomy or gamma knife capsulotomy for obsessive-compulsive disorder: relevance of the right hemisphere.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10069581", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 141, 
          "text": "Neuropsychological outcome of ventral capsular/ventral striatal gamma capsulotomy for refractory obsessive-compulsive disorder: a pilot study", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19996247", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 124, 
          "text": "Gamma ventral capsulotomy for treatment of resistant obsessive-compulsive disorder: a structural MRI pilot prospective study", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18835422", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 100, 
          "text": "Results following gamma knife radiosurgical anterior capsulotomies for obsessive compulsive disorder", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21150752", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 1334, 
          "offsetInEndSection": 1553, 
          "text": "At 28 months, the third patient is living and working independently, and her YBOCS score is 18.CONCLUSION: Within a strict protocol, gamma knife radiosurgery provided improvement of OCD behavior with no adverse effects.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21150752", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 70, 
          "text": "Gamma knife for obsessive compulsive disorder: can it be detrimental?", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25050687", 
          "endSection": "title"
        }
      ]
    }, 
    {
      "body": "What is the mechanism of action of the biguanide class of diabetes drugs?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/27939359", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26166607", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21147283", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23292513", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8914439", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25793062"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Bioguaides like Metformin, decrease amount of glucose released from liver and increases insulin sensitivity. ", 
        "this biguanide is an oral insulin-sensitizing agent capable of increasing insulin sensitivity and decreasing plasma fasting insulin levels."
      ], 
      "concepts": [
        "http://www.biosemantics.org/jochem#http://www.biosemantics.org/jochem#:4275167", 
        "http://www.disease-ontology.org/api/metadata/DOID:9351", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D003920", 
        "http://www.biosemantics.org/jochem#4275167", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D001645", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D003924", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008687"
      ], 
      "type": "summary", 
      "id": "58a22eb460087bc10a000001", 
      "snippets": [
        {
          "offsetInBeginSection": 753, 
          "offsetInEndSection": 792, 
          "text": "Metformin sensitizes the insulin action", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27939359", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 471, 
          "offsetInEndSection": 611, 
          "text": "This biguanide is an oral insulin-sensitizing agent capable of increasing insulin sensitivity and decreasing plasma fasting insulin levels. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26166607", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 119, 
          "text": "Metformin is an oral anti-diabetic drug of the biguanide class that is commonly used to treat type 2 diabetes mellitus.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21147283", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 160, 
          "text": "Metformin, an oral anti-diabetic agent in the biguanide class is a widely prescribed drug to treat high blood glucose in patients with type 2 diabetes mellitus.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25793062", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 162, 
          "offsetInEndSection": 401, 
          "text": "etformin has three different roles, including blood glucose regulatory effect, protection of kidney tubular cell by acting as an effective antioxidant and finally ameliorative effect on diabetic kidney disease through saving the podocytes.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25793062", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Where is the proteasome located?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26743630", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25413350", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21976669", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18948196", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16371511", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17428875", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20026058", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10502681", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11295498", 
        "http://www.ncbi.nlm.nih.gov/pubmed/7957966", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10657252", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11175258", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22458048", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9050876", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15791592", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9799224", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10995887", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22411744", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11734567", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17977463", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9804081", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9321388", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20491623"
      ], 
      "triples": [], 
      "ideal_answer": [
        "The proteasome can be found in perinuclear and nuclear location, as well as in cytosolic compartments, such as mitochondria and endoplasmic reticulum. Proteasome-mediated degradation of cell cycle regulatory proteins, production and loading of antigenic peptides onto HLA molecules, and transient homing of diverse virion proteins required for entry and/or egress have been also shown to be coordinated at the centrosome."
      ], 
      "concepts": [
        "http://amigo.geneontology.org/amigo/term/GO:0000502", 
        "http://amigo.geneontology.org/amigo/term/GO:0031144"
      ], 
      "type": "summary", 
      "id": "58b558d522d3005309000006", 
      "snippets": [
        {
          "offsetInBeginSection": 409, 
          "offsetInEndSection": 611, 
          "text": "Cellular regulation by UPS- mediated protein degradation is a highly specific and selective process that depends on time (e.g. cell cycle) and location (nucleus, mitochondria or endoplasmic reticulum). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26743630", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 139, 
          "text": "In eukaryotic cells, regulated protein degradation of intracellular proteins is mediated largely by the ubiquitin proteasome system (UPS). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26743630", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 468, 
          "offsetInEndSection": 689, 
          "text": "We followed two key parameters of this process: the distribution of proteasomes in nuclear and cytosolic compartments, and the formation of cytoplasmic aggregate-like structures called proteasome storage granules (PSGs). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25413350", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 736, 
          "offsetInEndSection": 1042, 
          "text": "Subsequently, cellular distribution of the PAI-2\u00b7proteasome complexes was established by immunogold staining and electron microscopy analyses. As judged by confocal microscopy, both proteins appeared in a diffuse cytosolic pattern, but they also could be found in a dense perinuclear and nuclear location. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21976669", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 204, 
          "offsetInEndSection": 302, 
          "text": " Frequently ubiquitinated proteins are targeted to the proteasome for degradation in the cytosol. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18948196", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1354, 
          "offsetInEndSection": 1636, 
          "text": " More recently, proteasome-mediated degradation of cell cycle regulatory proteins, production and loading of antigenic peptides onto HLA molecules, and transient homing of diverse virion proteins required for entry and/or egress have been shown to be coordinated at the centrosome. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17428875", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1127, 
          "offsetInEndSection": 1363, 
          "text": "We conclude that N-terminal sequences of Wld(S) protein influence the intranuclear location of both ubiquitin proteasome and NAD(+) synthesis machinery and that an evolutionary recent sequence mediates binding of mammalian Ube4b to VCP.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16371511", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 298, 
          "text": "Two new forms of proteasomes, designated as the endoplasmic reticulum (ER) membrane-associated proteasome (ERa proteasome) and ER membrane-bound proteasome (ERb proteasome), were purified to homogeneity from 0.0125 and 2.5% sodium cholate extracts, respectively, of a rat liver microsomal fraction.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10502681", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 276, 
          "offsetInEndSection": 396, 
          "text": "The proteasome is a large multicatalytic, proteinase complex located in the cytosol and the nucleus of eukaryotic cells.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22458048", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 135, 
          "text": "Subcellular distribution of proteasomes implicates a major location of protein degradation in the nuclear envelope-ER network in yeast.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9799224", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 1177, 
          "offsetInEndSection": 1500, 
          "text": "JAB1, which is thought to bind p27KIP1 and transport it from the nucleus to the cytoplasm for proteasome/ubiquitin-mediated degradation, was found to be localized both in the cytoplasm and the nucleus in undifferentiated and differentiating tumors whereas located predominantly in the nucleus of differentiated tumor cells.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10995887", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 764, 
          "offsetInEndSection": 896, 
          "text": "20S proteasomes are present in all areas where ATPase subunits are detected, consistent with the presence of intact 26S proteasomes.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11175258", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 979, 
          "offsetInEndSection": 1091, 
          "text": "Inhibition of proteasomes located in axons resulted in an accumulation of ubiquitinated proteins in these axons.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22411744", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1432, 
          "offsetInEndSection": 1639, 
          "text": "All these observations indicate that the mouse sperm proteasome participates in the binding to the zona pellucida and the acrosome reaction and that there is a pool of proteasomes located on the sperm head..", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15791592", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1204, 
          "offsetInEndSection": 1387, 
          "text": "Thus, newly synthesized apoB is localized throughout the entire ER and degraded homogeneously, most likely by neighboring proteasomes located on the cytosolic side of the ER membrane.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11734567", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 212, 
          "text": "While misfolded and short-lived proteins are degraded in proteasomes located in the nucleus and cytoplasm, the degradation of organelles and long-lived proteins in the lysosome occurs by the process of autophagy.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17977463", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 528, 
          "offsetInEndSection": 610, 
          "text": "The GFP-tagged proteasomes were located within both the cytoplasm and the nucleus.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9321388", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 117, 
          "text": "Proteasomes are large multicatalytic proteinase complexes located in the cytosol and the nucleus of eukaryotic cells.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20491623", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 418, 
          "offsetInEndSection": 549, 
          "text": "Immunohistochemically, proteasomes (26S) were located in the cytoplasm in normal human muscle, but the staining intensity was weak.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9804081", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 746, 
          "offsetInEndSection": 867, 
          "text": "In DMRV, proteasomes often were located within or on the rim of rimmed vacuoles, and in the cytoplasm of atrophic fibers.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9804081", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is clinical presentation of the Gardner-Diamond syndrome?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26101006", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26137346", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26078671", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23825859", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21548659", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20204908", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10966177", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23723552", 
        "http://www.ncbi.nlm.nih.gov/pubmed/4059144", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19192020", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23580908", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12838436", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15956886", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18417404", 
        "http://www.ncbi.nlm.nih.gov/pubmed/3627621", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16023271", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11475645", 
        "http://www.ncbi.nlm.nih.gov/pubmed/921453", 
        "http://www.ncbi.nlm.nih.gov/pubmed/2345102", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27011410", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19030312"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Psychogenic purpura, also known as Gardner-Diamond syndrome, is a rare, distinctive, localized cutaneous reaction pattern mostly affecting psychologically disturbed adult women. Repeated crops of tender, ill-defined ecchymotic lesions on the extremities and external bleeding from other sites characterize the condition."
      ], 
      "concepts": [], 
      "type": "summary", 
      "id": "5895e2567d9090f353000011", 
      "snippets": [
        {
          "offsetInBeginSection": 542, 
          "offsetInEndSection": 771, 
          "text": "Antidepressants were prescribed by the psychiatrist that not only cured the depression with time but also the bleeding episodes which were actually related to child's depression (Gardner-Diamond syndrome or psychogenic purpura). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26101006", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 47, 
          "text": "Psychogenic Purpura (Gardner-Diamond Syndrome).", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26137346", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 316, 
          "text": "Psychogenic purpura, also known as Gardner-Diamond syndrome or autoerythrocyte sensitization syndrome, is a rare condition characterized by spontaneous development of painful edematous skin lesions progressing to ecchymosis over the next 24 hours. Severe stress and emotional trauma always precede the skin lesions. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26137346", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 237, 
          "text": "Gardner Diamond syndrome is a rare condition characterized with painful ecchymoses in different parts of the body and cutaneous and mucosal hemorrhages. The etiology is not known fully and psychogenic factors are thought to be involved. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26078671", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 321, 
          "text": "Psychogenic purpura, also known as Gardner-Diamond syndrome, is a rare, distinctive, localized cutaneous reaction pattern mostly affecting psychologically disturbed adult women. Repeated crops of tender, ill-defined ecchymotic lesions on the extremities and external bleeding from other sites characterize the condition. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23825859", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 520, 
          "offsetInEndSection": 766, 
          "text": "PPDDM includes impulse control disorders, obsessive-compulsive disorders, factitious disorder, factitious disorder by proxy, self-mutilation, delusions of parasitosis, psychogenic purpura/Gardner-Diamond syndrome, and cutaneous sensory disorders.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21548659", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 159, 
          "text": "Psychogenic purpura (Gardner-Diamond syndrome) is the occurrence and spontaneous recurrence of painful ecchymosis following emotional stress and minor trauma. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20204908", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 169, 
          "text": "We describe the clinical presentation and course of a patient with autoerythrocyte sensitization (Gardner-Diamond) syndrome, and review the literature for similar cases.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10966177", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 138, 
          "text": "Gardner-Diamond syndrome (GDS) is also known as psychogenic purpura, autoerythrocyte sensitization syndrome and painful bruising syndrome.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23580908", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 88, 
          "text": "Autoerythrocyte sensitization (Gardner-Diamond) syndrome mimicking compartment syndrome.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12838436", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 92, 
          "text": "Autoerythrocyte sensitization syndrome (Gardner-Diamond syndrome): review of the literature.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19192020", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 116, 
          "text": "We report a case with an unusual manifestation of autoerythrocyte sensitization syndrome (Gardner-Diamond syndrome).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12838436", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 150, 
          "text": "The Gardner-Diamond syndrome is a disorder characterized by recurrent spontaneous painful bruising in patients with underlying psychosis and neurosis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15956886", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 156, 
          "text": "A 54-year old anorectic patient with painful bruising syndrome (Gardner-Diamond syndrome) suffered from various gastrointestinal and psychologic complaints.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11475645", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 285, 
          "text": "This paper presents a 26-year-old woman with the characteristic features of Gardner-Diamond syndrome: recurrent painful bruises reproducible by intradermal injection of autologous red blood cells, and a \"hysterical\" personality pattern together with nonspecific multisystem complaints.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2345102", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 144, 
          "text": "Gardner-Diamond's syndrome, or autoerythrocyte sensitization, is a disorder of spontaneous, painful ecchymoses whose pathogenesis is unresolved.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/921453", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 89, 
          "text": "Autoerythrocyte sensitization (Gardner-Diamond) syndrome mimicking compartment syndrome.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12838436", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 58, 
          "text": "Autoerythrocyte sensitization (Gardner-Diamond) syndrome.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10966177", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 104, 
          "text": "Autoerythrocyte sensitization syndrome (Gardner-Diamond syndrome) associated with cutaneous vasculitis.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18417404", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 236, 
          "text": "Gardner-Diamond syndrome (GDS) is an uncommon disease clinically characterized by a wide spectrum of psycho-emotive symptoms associated with painful ecchymoses/purpuric lesions and positivity of auto-erythrocyte sensitization skin test.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27011410", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Where can you find the annulus of Zinn?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24697862", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22336122", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21772799", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16917665", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16955671", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11601571", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22581081", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8827557", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25744329", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17667093", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8604741", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25650797", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9783284", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17080461"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Annulus of Zinn is in the orbit."
      ], 
      "exact_answer": [
        [
          "orbit", 
          "EYE"
        ]
      ], 
      "concepts": [], 
      "type": "factoid", 
      "id": "58917c88621ea6ff7e00000a", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 81, 
          "text": "Should the annular tendon of the eye be named 'annulus of Zinn' or 'of Valsalva'?", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24697862", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 247, 
          "text": "The annular tendon is commonly named 'annulus of Zinn', from the German anatomist and botanist Johann Gottfried Zinn (1727-1759) who described this structure in his Descriptio anatomica oculi humani (Anatomical Description of the Human Eye, 1755).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24697862", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 536, 
          "offsetInEndSection": 683, 
          "text": "It arose at the annulus of Zinn, passing forwards between the inferior rectus muscle and lateral rectus muscle, and insert directly on the sclera. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22336122", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1007, 
          "offsetInEndSection": 1133, 
          "text": "Drilling was continued toward the annulus of Zinn (AZ) and optic nerve superiorly and over the intracavernous ICA posteriorly.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21772799", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 498, 
          "offsetInEndSection": 811, 
          "text": "Measurements before and after resection of the ACP included the length of C6 segment of the ICA on its lateral aspect; C6 segment length on its medial aspect; and medial length of the optic nerve from the optic chiasm to falciform ligament (before ACP resection) then to the annulus of Zinn (after ACP resection).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16917665", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 200, 
          "offsetInEndSection": 499, 
          "text": "The muscles, situated between the optic nerve and the lateral rectus muscle, originated from the annulus of Zinn and branched off two heads; one inserted into the medial inferior side of the superior rectus muscle and the other inserted into the central superior side of the inferior rectus muscle. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16955671", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 404, 
          "offsetInEndSection": 603, 
          "text": " In 30 cadavers, the superior division of the oculomotor nerve was severed en bloc 1.5 cm anterior to the annulus of Zinn with the levator palpebrae superioris (LPS) and the superior rectus muscles. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11601571", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 357, 
          "offsetInEndSection": 474, 
          "text": "The optic canal was subsequently removed en bloc, beginning at the annulus of Zinn and extending to the optic chiasm.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17667093", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 609, 
          "text": "PURPOSE: To describe a combined transcranial-orbital approach for en bloc resection of optic nerve gliomas with preservation of the annulus of Zinn that minimizes recurrence and prevents postoperative paralytic ptosis.DESIGN: A retrospective, noncomparative, interventional case series.STUDY POPULATION: All patients who underwent optic nerve glioma resections using this technique with the authors between 1994 and 2010.PROCEDURE: A transcranial-orbital approach is used to resect the intracranial segment of the optic nerve glioma from 2 mm anterior to the chiasm to the posterior extent of annulus of Zinn.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22581081", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1274, 
          "offsetInEndSection": 1565, 
          "text": "No patients had tumor recurrence or developed postoperative paralytic ptosis.CONCLUSIONS: The combined transcranial-orbital approach with preservation of the annulus of Zinn is a safe and effective way to remove optic nerve gliomas and ensure tumor clearance while avoiding paralytic ptosis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22581081", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 562, 
          "text": "To describe a combined transcranial-orbital approach for en bloc resection of optic nerve gliomas with preservation of the annulus of Zinn that minimizes recurrence and prevents postoperative paralytic ptosis.A retrospective, noncomparative, interventional case series.All patients who underwent optic nerve glioma resections using this technique with the authors between 1994 and 2010.A transcranial-orbital approach is used to resect the intracranial segment of the optic nerve glioma from 2 mm anterior to the chiasm to the posterior extent of annulus of Zinn", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22581081", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 663, 
          "offsetInEndSection": 798, 
          "text": "Through a superior orbitotomy exposure, the entire retrobulbar segment of the tumor is transected from the globe to the annulus of Zinn", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22581081", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 800, 
          "offsetInEndSection": 1194, 
          "text": "A simulation of the procedure in a cadaver and en bloc resection of the orbital apex are performed to demonstrate the subdural plane of dissection within the annulus of Zinn.Postoperative outcome measures include: health of the ipsilateral globe, paralytic ptosis, postoperative complications, and tumor recurrence.Eleven patients underwent resection of optic nerve gliomas using this technique", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22581081", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1196, 
          "offsetInEndSection": 1473, 
          "text": "No patients had tumor recurrence or developed postoperative paralytic ptosis.The combined transcranial-orbital approach with preservation of the annulus of Zinn is a safe and effective way to remove optic nerve gliomas and ensure tumor clearance while avoiding paralytic ptosis", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22581081", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 412, 
          "offsetInEndSection": 575, 
          "text": "The orbital surface of the medial rectus and inferior rectus are exposed from the annulus of Zinn to a position close to where the muscles penetrate Tenons capsule", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8827557", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 413, 
          "offsetInEndSection": 579, 
          "text": "The orbital surface of the medial rectus and inferior rectus are exposed from the annulus of Zinn to a position close to where the muscles penetrate Tenon's capsule. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8827557", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 200, 
          "offsetInEndSection": 498, 
          "text": "The muscles, situated between the optic nerve and the lateral rectus muscle, originated from the annulus of Zinn and branched off two heads; one inserted into the medial inferior side of the superior rectus muscle and the other inserted into the central superior side of the inferior rectus muscle.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16955671", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 339, 
          "offsetInEndSection": 456, 
          "text": "The optic canal was subsequently removed en bloc, beginning at the annulus of Zinn and extending to the optic chiasm.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17667093", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 862, 
          "offsetInEndSection": 1114, 
          "text": "The distance from the annulus of Zinn to the trochlea was the same in both eyes.The findings for our patients, particularly in those who underwent additional high resolution MRI, did not provide evidence of a lack of CN IV as a cause of Brown syndrome.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25744329", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 82, 
          "text": "Should the annular tendon of the eye be named 'annulus of Zinn' or 'of Valsalva'?", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24697862", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 864, 
          "offsetInEndSection": 944, 
          "text": "The distance from the annulus of Zinn to the trochlea was the same in both eyes.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25744329", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 340, 
          "offsetInEndSection": 457, 
          "text": "The optic canal was subsequently removed en bloc, beginning at the annulus of Zinn and extending to the optic chiasm.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17667093", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 666, 
          "offsetInEndSection": 802, 
          "text": "Through a superior orbitotomy exposure, the entire retrobulbar segment of the tumor is transected from the globe to the annulus of Zinn.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22581081", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is the indication for SLCO1B1 genotyping?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/27595674", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25181036", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26131212", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25150868", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25563221"
      ], 
      "triples": [], 
      "ideal_answer": [
        "HMG Co-A reductase inhibitors, commonly known as statins, also display wide interindividual variability in plasma concentration, response and toxicity due in part to polymorphisms in transporter genes, including SLCO1B1 and ABCG2.  The SLCO1B1*5 variant is a risk factor for statin side effects and exhibits statin-specific effects: highest with simvastatin/atorvastatin and lowest with pravastatin/rosuvastatin."
      ], 
      "exact_answer": [
        [
          "Statin treatment"
        ]
      ], 
      "concepts": [], 
      "type": "factoid", 
      "id": "58bbc0fc22d300530900001c", 
      "snippets": [
        {
          "offsetInBeginSection": 264, 
          "offsetInEndSection": 509, 
          "text": "including the well-known genetic variant associated with statin-associated muscle symptoms-solute carrier organic anion transporter family, member 1B1 (SLCO1B1) rs4149056-also increase the risk of statin-associated muscle symptoms in FH patients", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27595674", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 112, 
          "text": "Statin-associated muscle symptoms and SLCO1B1 rs4149056 genotype in patients with familial hypercholesterolemia.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27595674", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 1834, 
          "offsetInEndSection": 2075, 
          "text": "Similarly, HMG Co-A reductase inhibitors, commonly known as statins, also display wide interindividual variability in plasma concentration, response and toxicity due in part to polymorphisms in transporter genes, including SLCO1B1 and ABCG2.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25181036", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 146, 
          "text": "Association of SLCO1B1 gene polymorphisms with toxicity response of high dose methotrexate chemotherapy in childhood acute lymphoblastic leukemia.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26131212", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 610, 
          "offsetInEndSection": 775, 
          "text": " development of SLCO1B1 genotyping to avoid statin induced adverse drug reactions is discussed as a model case for transporter pharmacogenetics clinical development.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25150868", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 306, 
          "text": "Statin adherence is often limited by side effects. The SLCO1B1*5 variant is a risk factor for statin side effects and exhibits statin-specific effects: highest with simvastatin/atorvastatin and lowest with pravastatin/rosuvastatin. The effects of SLCO1B1*5 genotype guided statin therapy (GGST) are unknown", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25563221", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "List available circular RNA prediction tools.", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26657634"
      ], 
      "triples": [], 
      "ideal_answer": [
        "circRNA_finder, find_circ, CIRCexplorer, CIRI, and MapSplice."
      ], 
      "exact_answer": [
        [
          "circRNA_finder"
        ], 
        [
          "find_circ"
        ], 
        [
          "CIRCexplorer"
        ], 
        [
          "CIRI"
        ], 
        [
          "MapSplice"
        ]
      ], 
      "concepts": [], 
      "type": "list", 
      "id": "588f220e3b87a8a73800000d", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 1119, 
          "text": "CircRNAs are novel members of the non-coding RNA family. For several decades circRNAs have been known to exist, however only recently the widespread abundance has become appreciated. Annotation of circRNAs depends on sequencing reads spanning the backsplice junction and therefore map as non-linear reads in the genome. Several pipelines have been developed to specifically identify these non-linear reads and consequently predict the landscape of circRNAs based on deep sequencing datasets. Here, we use common RNAseq datasets to scrutinize and compare the output from five different algorithms; circRNA_finder, find_circ, CIRCexplorer, CIRI, and MapSplice and evaluate the levels of bona fide and false positive circRNAs based on RNase R resistance. By this approach, we observe surprisingly dramatic differences between the algorithms specifically regarding the highly expressed circRNAs and the circRNAs derived from proximal splice sites. Collectively, this study emphasizes that circRNA annotation should be handled with care and that several algorithms should ideally be combined to achieve reliable predictions.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26657634", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which disease is treated with Nusinersen?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26823478", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26865511", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27939059"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Nusinersen us used for treatment of Spinal Muscular Atrophy."
      ], 
      "exact_answer": [
        [
          "Spinal Muscular Atrophy", 
          "SMA"
        ]
      ], 
      "concepts": [
        "http://www.disease-ontology.org/api/metadata/DOID:4", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=diseases_category", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004194"
      ], 
      "type": "factoid", 
      "id": "589185cc621ea6ff7e00000b", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 102, 
          "text": "Intrathecal Injections in Children With Spinal Muscular Atrophy: Nusinersen Clinical Trial Experience.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26823478", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 284, 
          "text": "Nusinersen (ISIS-SMNRx or ISIS 396443) is an antisense oligonucleotide drug administered intrathecally to treat spinal muscular atrophy. We summarize lumbar puncture experience in children with spinal muscular atrophy during a phase 1 open-label study of nusinersen and its extension.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26823478", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 99, 
          "text": "Results from a phase 1 study of nusinersen (ISIS-SMN(Rx)) in children with spinal muscular atrophy.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26865511", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 465, 
          "text": "OBJECTIVE: To examine safety, tolerability, pharmacokinetics, and preliminary clinical efficacy of intrathecal nusinersen (previously ISIS-SMNRx), an antisense oligonucleotide designed to alter splicing of SMN2 mRNA, in patients with childhood spinal muscular atrophy (SMA).METHODS: Nusinersen was delivered by intrathecal injection to medically stable patients with type 2 and type 3 SMA aged 2-14 years in an open-label phase 1 study and its long-term extension. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26865511", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1422, 
          "offsetInEndSection": 1695, 
          "text": "CONCLUSIONS: Results from this study support continued development of nusinersen for treatment of SMA.CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that in children with SMA, intrathecal nusinersen is not associated with safety or tolerability concerns.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26865511", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 115, 
          "text": "Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27939059", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 626, 
          "text": "BACKGROUND: Nusinersen is a 2'-O-methoxyethyl phosphorothioate-modified antisense drug being developed to treat spinal muscular atrophy. Nusinersen is specifically designed to alter splicing of SMN2 pre-mRNA and thus increase the amount of functional survival motor neuron (SMN) protein that is deficient in patients with spinal muscular atrophy.METHODS: This open-label, phase 2, escalating dose clinical study assessed the safety and tolerability, pharmacokinetics, and clinical efficacy of multiple intrathecal doses of nusinersen (6 mg and 12 mg dose equivalents) in patients with infantile-onset spinal muscular atrophy. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27939059", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 3149, 
          "offsetInEndSection": 3289, 
          "text": "Results informed the design of an ongoing, sham-controlled, phase 3 clinical study of nusinersen in infantile-onset spinal muscular atrophy.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27939059", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 124, 
          "text": "Nusinersen is a 2'-O-methoxyethyl phosphorothioate-modified antisense drug being developed to treat spinal muscular atrophy.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27939059", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 136, 
          "text": "Nusinersen (ISIS-SMNRx or ISIS 396443) is an antisense oligonucleotide drug administered intrathecally to treat spinal muscular atrophy.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26823478", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 136, 
          "offsetInEndSection": 283, 
          "text": "We summarize lumbar puncture experience in children with spinal muscular atrophy during a phase 1 open-label study of nusinersen and its extension.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26823478", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 124, 
          "offsetInEndSection": 333, 
          "text": "Nusinersen is specifically designed to alter splicing of SMN2 pre-mRNA and thus increase the amount of functional survival motor neuron (SMN) protein that is deficient in patients with spinal muscular atrophy.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27939059", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 263, 
          "text": "To examine safety, tolerability, pharmacokinetics, and preliminary clinical efficacy of intrathecal nusinersen (previously ISIS-SMNRx), an antisense oligonucleotide designed to alter splicing of SMN2 mRNA, in patients with childhood spinal muscular atrophy (SMA).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26865511", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 103, 
          "text": "Intrathecal Injections in Children With Spinal Muscular Atrophy: Nusinersen Clinical Trial Experience.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26823478", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 1396, 
          "offsetInEndSection": 1485, 
          "text": "Results from this study support continued development of nusinersen for treatment of SMA.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26865511", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 100, 
          "text": "Results from a phase 1 study of nusinersen (ISIS-SMN(Rx)) in children with spinal muscular atrophy.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26865511", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 116, 
          "text": "Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27939059", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 3105, 
          "offsetInEndSection": 3245, 
          "text": "Results informed the design of an ongoing, sham-controlled, phase 3 clinical study of nusinersen in infantile-onset spinal muscular atrophy.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27939059", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1486, 
          "offsetInEndSection": 1630, 
          "text": "This study provides Class IV evidence that in children with SMA, intrathecal nusinersen is not associated with safety or tolerability concerns..", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26865511", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 137, 
          "offsetInEndSection": 284, 
          "text": "We summarize lumbar puncture experience in children with spinal muscular atrophy during a phase 1 open-label study of nusinersen and its extension.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26823478", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which disease the London mutation involved in?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/22171952", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21389247", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20523046", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16426772", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19771217", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15380017", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24145776", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16467370", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17431643", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15314265", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20409323", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25108425", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20025930", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23747045", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17215062", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24524897", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27421117", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15197738", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10525535", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10500121"
      ], 
      "triples": [], 
      "ideal_answer": [
        "London mutation that is the missense mutation in exon 17 of the amyloid precursor protein gene on chromosome 21 (Val717Ile) is involved in Alzheimer's Disease."
      ], 
      "exact_answer": [
        [
          "Alzheimer's Disease", 
          "AD"
        ]
      ], 
      "concepts": [
        "http://www.disease-ontology.org/api/metadata/DOID:4", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=diseases_category", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D009154", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D017354", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D020125", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004194", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016564", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000544"
      ], 
      "type": "factoid", 
      "id": "58b6978822d300530900000a", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 248, 
          "text": "In the present study, we used a new training paradigm in the intelliCage automatic behavioral assessment system to investigate cognitive functions of the transgenic mice harboring London mutation of the human amyloid precursor protein (APP.V717I). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22171952", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 914, 
          "offsetInEndSection": 1092, 
          "text": "The novel approach to study the transgenic mice cognitive abilities presented in this paper offers new insight into cognitive dysfunctions of the Alzheimer's disease mouse model.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22171952", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 856, 
          "text": "One major hallmark of Alzheimer's disease (AD) is the massive loss of synapses that occurs at an early clinical stage of the disease. In this study, we characterize alterations in spine density and the expression of synapse-associated immediate early gene Arc (activity-regulated cytoskeleton-associated protein) in the hippocampal CA1 regions of two different amyloid precursor protein (APP) transgenic mouse lines before plaque development and their connection to performance in hippocampus-dependent memory tests. The density of mushroom-type spines was reduced by 34% in the basal dendrites proximal to the soma of CA1 pyramidal neurons in 5.5-month-old Tg2576 mice, carrying the Swedish mutation, compared with wild-type littermates. A similar reduction of 42% was confirmed in the same region of 8-month-old APP/Lo mice, carrying the London mutation.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21389247", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 161, 
          "text": "The London APP mutation (Val717Ile) associated with early shifting abilities and behavioral changes in two Italian families with early-onset Alzheimer's disease.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20523046", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 145, 
          "offsetInEndSection": 310, 
          "text": "We describe 2 Italian families showing the missense mutation in exon 17 of the amyloid precursor protein gene on chromosome 21 (Val717Ile), known as London mutation.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20523046", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 319, 
          "offsetInEndSection": 579, 
          "text": "In 1 family, this mutation was responsible for AD in 3 out of 7 siblings and it is also present in a fourth sibling who has only shown signs of executive dysfunction so far. Two subjects of the other family with AD diagnosis were carriers of the same mutation.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20523046", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 73, 
          "offsetInEndSection": 628, 
          "text": "A pathological hallmark in the brain of an AD patient is extracellular amyloid plaques formed by accumulated beta-amyloid protein (Abeta), a metabolic product of amyloid precursor protein (APP). Studies have revealed a strong genetic linkage in the early-onset familial form (<60 years old) of AD. For example, some mutant APPs are transmitted dominantly and are segregated with inheritance of early onset AD. These mutants facilitate Abeta production. The \"Swedish\" mutations (APP(SW)) and the \"London\" mutation (APP(LON)) are examples of these mutants. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16426772", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1258, 
          "offsetInEndSection": 1487, 
          "text": "The sequences that are effective to silence APP(SW) and APP(LON) as identified in this study may be useful in both in vivo and in vitro studies to investigate the pathophysiological role of APP(SW) and APP(LON) in AD development.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16426772", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 333, 
          "offsetInEndSection": 638, 
          "text": "Here, we show ASP-RNAi against the Swedish- and London-type amyloid precursor protein (APP) variants related to familial Alzheimer's disease using two reporter alleles encoding the Photinus and Renilla luciferase genes and carrying mutant and wild-type allelic sequences in their 3'-untranslated regions. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19771217", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 341, 
          "text": "Transgenic mice over-expressing a mutated form of the human amyloid precursor protein (APP, 695 isoform) bearing a mutation associated with Alzheimer's disease (V642I, so-called London mutation, hereafter APPLd2) and wild-type controls were studied at age periods (3 and 10 months) prior to the overt development of neuritic amyloid plaques.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15380017", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 521, 
          "offsetInEndSection": 622, 
          "text": "The \"Swedish\" mutations (APP(SW)) and the \"London\" mutation (APP(LON)) are examples of these mutants.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16426772", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 125, 
          "text": "Allele-specific silencing of Alzheimer's disease genes: the amyloid precursor protein genes with Swedish or London mutations.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16426772", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 455, 
          "text": "Mutations in the amyloid precursor protein gene were the first to be recognized as a cause of Alzheimers disease (AD).We describe 2 Italian families showing the missense mutation in exon 17 of the amyloid precursor protein gene on chromosome 21 (Val717Ile), known as London mutation.In 1 family, this mutation was responsible for AD in 3 out of 7 siblings and it is also present in a fourth sibling who has only shown signs of executive dysfunction so far", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20523046", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 159, 
          "text": "The London APP mutation (Val717Ile) associated with early shifting abilities and behavioral changes in two Italian families with early-onset Alzheimers disease", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20523046", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 415, 
          "offsetInEndSection": 584, 
          "text": "We analyzed the cytotoxic mechanisms of the London-type AbetaPP mutant, V642I-AbetaPP, in primary cortical neurons utilizing an adenovirus-mediated gene transfer system.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15197738", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1806, 
          "offsetInEndSection": 2003, 
          "text": "We demonstrate that the APP-London and PS1 mutations have additive effects on the increased secretion of betaA4(1-42) relative to betaA4(1-40), indicating that both mutations operate independently.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10525535", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1193, 
          "offsetInEndSection": 1323, 
          "text": "Pathogenic mutations in APP at codon 717 (APP \"London\") lead to an increased proportion of Abeta 1-42 being produced and secreted.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10500121", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 526, 
          "offsetInEndSection": 627, 
          "text": "The \"Swedish\" mutations (APP(SW)) and the \"London\" mutation (APP(LON)) are examples of these mutants.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16426772", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 126, 
          "text": "Allele-specific silencing of Alzheimer's disease genes: the amyloid precursor protein genes with Swedish or London mutations.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16426772", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 120, 
          "offsetInEndSection": 285, 
          "text": "We describe 2 Italian families showing the missense mutation in exon 17 of the amyloid precursor protein gene on chromosome 21 (Val717Ile), known as London mutation.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20523046", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 162, 
          "text": "The London APP mutation (Val717Ile) associated with early shifting abilities and behavioral changes in two Italian families with early-onset Alzheimer's disease.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20523046", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 246, 
          "offsetInEndSection": 341, 
          "text": "Such cleavage is promoted by the Swedish and London mutations (APPSwe/Lon) inside the APP gene.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20025930", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1029, 
          "offsetInEndSection": 1121, 
          "text": "We also show that the Swedish and London mutations reduce the amount of APP in the lysosome.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20409323", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1375, 
          "offsetInEndSection": 1479, 
          "text": "This rapid transit to the lysosome is blocked by the presence of either the London or Swedish mutations.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20409323", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Define lncRNA.", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26207516", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27729273", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26166759", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26004516", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25994219", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26142536"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Long noncoding RNAs (lncRNAs) represent a newly discovered class of regulatory molecules that impact a variety of biological processes in cells and organ systems. In humans, it is estimated that there may be more than twice as many lncRNA genes than protein-coding genes. However, only a handful of lncRNAs have been analyzed in detail.\nLong non-coding RNAs (lncRNAs) are emerging as key molecules in cancers, yet their potential molecular mechanisms are not well understood.\nlong noncoding RNAs (lncRNAs), the largest family of noncoding transcripts, have emerged as common regulators of many cellular stressors; including heat shock, metabolic deprivation and DNA damage."
      ], 
      "concepts": [], 
      "type": "summary", 
      "id": "58bc696b02b8c60953000005", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 264, 
          "text": "Protein-coding genes account for only 2% of the human genome, whereas the vast majority of transcripts are noncoding RNAs including long noncoding RNAs. LncRNAs are involved in the regulation of a diverse array of biological processes, including cancer progression", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26207516", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 208, 
          "offsetInEndSection": 336, 
          "text": "Recently, aberrant expression of long noncoding RNAs (lncRNAs) has been considered as a primary feature of many types of cancer.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27729273", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 336, 
          "text": "Long noncoding RNAs (lncRNAs) represent a newly discovered class of regulatory molecules that impact a variety of biological processes in cells and organ systems. In humans, it is estimated that there may be more than twice as many lncRNA genes than protein-coding genes. However, only a handful of lncRNAs have been analyzed in detail.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26166759", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 154, 
          "text": "Genomic imprinting has been a great resource for studying transcriptional and post-transcriptional-based gene regulation by long noncoding RNAs (lncRNAs).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26004516", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 11, 
          "offsetInEndSection": 150, 
          "text": "Long non-coding RNAs (lncRNAs) are emerging as key molecules in cancers, yet their potential molecular mechanisms are not well understood. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25994219", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 706, 
          "offsetInEndSection": 904, 
          "text": "long noncoding RNAs (lncRNAs), the largest family of noncoding transcripts, have emerged as common regulators of many cellular stressors; including heat shock, metabolic deprivation and DNA damage. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26142536", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "How many microorganisms are present in human normal gut?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26613639", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26627987", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26908163", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26945826"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Human gut microbiota is home to 10 to 100 trillions microorganisms."
      ], 
      "exact_answer": [
        [
          "10 to 100 trillions microorganisms."
        ]
      ], 
      "concepts": [], 
      "type": "factoid", 
      "id": "58bc347422d300530900001e", 
      "snippets": [
        {
          "offsetInBeginSection": 267, 
          "offsetInEndSection": 494, 
          "text": ". A major breakthrough in understanding the etiology of neurological disorders is the recent insight on the role of the gut microbiota (GM). Human GM also referred to as the \"forgotten organ\" is home to 10(13-14) microorganisms", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26613639", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 129, 
          "text": "The gut microbiome comprises the collective genome of the trillions of microorganisms residing in our gastrointestinal ecosystem.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26627987", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 655, 
          "offsetInEndSection": 847, 
          "text": "The gut microbiome (i.e. the 100 trillion symbiotic microorganisms which inhabit the mammalian gastrointestinal tract) influences numerous aspects of host metabolism, development and immunity.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26908163", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 127, 
          "text": "The microorganisms inhabiting the human gut are abundant (10(14) cells) and diverse (approximately 500 species per individual).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26945826", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is the role of 3,4-diaminobenzoic acid derivatives in the immune system?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25635706"
      ], 
      "triples": [], 
      "ideal_answer": [
        "3,4-diaminobenzoic acid derivatives are inhibitors of the oxytocinase subfamily of M1 aminopeptidases with immune-regulating properties. Cell-based analysis indicated that the lead compounds can be effective in downregulating macrophage activation induced by lipopolysaccharide and interferon-\u03b3 as well as cross-presentation by bone marrow-derived dendritic cells."
      ], 
      "exact_answer": [
        [
          "Inhibition of the oxytocinase subfamily of M1 aminopeptidases with immune-regulating properties."
        ]
      ], 
      "concepts": [
        "http://www.biosemantics.org/jochem#http://www.biosemantics.org/jochem#:4258378", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D007107", 
        "http://www.biosemantics.org/jochem#4258378", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D007154"
      ], 
      "type": "factoid", 
      "id": "5887fe7d3b87a8a738000008", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 135, 
          "text": "3,4-diaminobenzoic acid derivatives as inhibitors of the oxytocinase subfamily of M1 aminopeptidases with immune-regulating properties.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25635706", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 1029, 
          "text": "Members of the oxytocinase subfamily of M1 aminopeptidases (ERAP1, ERAP2, and IRAP) play important roles in both the adaptive and innate human immune responses. Their enzymatic activity can contribute to the pathogenesis of several major human diseases ranging from viral and parasitic infections to autoimmunity and cancer. We have previously demonstrated that diaminobenzoic acid derivatives show promise as selective inhibitors for this group of aminopeptidases. In this study, we have thoroughly explored a series of 3,4-diaminobenzoic acid derivatives as inhibitors of this class of enzymes, achieving submicromolar inhibitors for ERAP2 (IC50 = 237 nM) and IRAP (IC50 = 105 nM). Cell-based analysis indicated that the lead compounds can be effective in downregulating macrophage activation induced by lipopolysaccharide and interferon-\u03b3 as well as cross-presentation by bone marrow-derived dendritic cells. Our results indicate that this class of inhibitors may be useful for the targeted downregulation of immune responses.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25635706", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 134, 
          "text": "3,4-diaminobenzoic acid derivatives as inhibitors of the oxytocinase subfamily of M1 aminopeptidases with immune-regulating properties", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25635706", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 160, 
          "text": "Members of the oxytocinase subfamily of M1 aminopeptidases (ERAP1, ERAP2, and IRAP) play important roles in both the adaptive and innate human immune responses.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25635706", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 136, 
          "text": "3,4-diaminobenzoic acid derivatives as inhibitors of the oxytocinase subfamily of M1 aminopeptidases with immune-regulating properties.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25635706", 
          "endSection": "title"
        }
      ]
    }, 
    {
      "body": "Can NADPH oxidase be inhibited by apocynin and diphenylene iodonium?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25666589", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25920934", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24037962", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24794531", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21693104", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23229789", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12424096", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20860666", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16393992", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17904225", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15271858", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17662968", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18195159", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12867501", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17962358", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19819434", 
        "http://www.ncbi.nlm.nih.gov/pubmed/3800872", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17341601", 
        "http://www.ncbi.nlm.nih.gov/pubmed/2121828", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11755128", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19892012", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17046555", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15308331", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20698853", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22503982", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16741139", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19281832", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21159852", 
        "http://www.ncbi.nlm.nih.gov/pubmed/1324836", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15845907", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15346654", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22134950", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26728380"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Yes, nicotinamide adenine dinucleotide phosphate (NADPH) oxidase can be inhibited by apocynin or diphenylene iodonium (DPI)."
      ], 
      "exact_answer": "yes", 
      "concepts": [
        "http://www.biosemantics.org/jochem#http://www.biosemantics.org/jochem#:4276074", 
        "http://www.biosemantics.org/jochem#http://www.biosemantics.org/jochem#:4251947", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D019255", 
        "http://www.biosemantics.org/jochem#4270191", 
        "http://amigo.geneontology.org/amigo/term/GO:0043020", 
        "http://amigo.geneontology.org/amigo/term/GO:0016174"
      ], 
      "type": "yesno", 
      "id": "58a5924060087bc10a000020", 
      "snippets": [
        {
          "offsetInBeginSection": 637, 
          "offsetInEndSection": 968, 
          "text": "Ang II treatment also led to a significant increment in intracellular reactive oxygen species generation, which could be fully abolished by nicotinamide adenine dinucleotide phosphate (NADPH) oxidase inhibitors apocynin or diphenylene iodonium, indicating that Ang II enhanced oxidative stress via a NADPH oxidase-dependent manner.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25666589", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1220, 
          "offsetInEndSection": 1390, 
          "text": "NOX inhibitors (diphenylene iodonium (DPI) or apocynin) were able to achieve similar results to that of ML-7 except no effect on MLCK activity and MLC20 phosphorylation. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25920934", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1211, 
          "offsetInEndSection": 1375, 
          "text": "Significant reductions of AII effects on podocyte TRPC6 were also observed after pretreatment with NADPH oxidase inhibitors apocynin or diphenylene iodonium (DPI). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24037962", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 930, 
          "offsetInEndSection": 1216, 
          "text": "Furthermore, inhibition of NOX-mediated ROS production with apocynin, diphenylene iodonium (DPI) or NOX2 docking sequence (Nox2ds)-tat peptide during these first 4h of PE stimulation significantly inhibited PE-induced hypertrophy of H9c2 cells, both after 24 and 48h of PE stimulation. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24794531", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 603, 
          "offsetInEndSection": 820, 
          "text": "Remarkably, Ang-II induced reactive oxygen species (ROS) via a NAD(P)H oxidase-dependent mechanism, as shown by inhibition of ROS production via the NAD(P)H oxidase inhibitors diphenylene iodonium (DPI) and apocynin. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21693104", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 998, 
          "offsetInEndSection": 1194, 
          "text": "Moreover, NADPH oxidase activation by beta CD (145.5+/-9.0%; control: 98.6+/-1.6%) was also abrogated by the NADPH oxidase inhibitors apocynin (100.4+/-3.2%) and diphenylene iodonium (9.5+/-3.3%).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18195159", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 627, 
          "offsetInEndSection": 870, 
          "text": "We used structurally diverse NADPH oxidase inhibitors, aminoethyl-benzenesulfonylfluoride (AEBSF, 100-1000microM), apocynin (100-1000microM), and diphenylene iodonium (DPI, 3-30microM), to inhibit intrinsic NADPH oxidase activity in N27 cells.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17904225", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 972, 
          "offsetInEndSection": 1149, 
          "text": "Paraquat-induced ROS production was inhibited by NADPH oxidase inhibitors, apocynin and diphenylene iodonium (DPI), but not the xanthine/xanthine oxidase inhibitor, allopurinol.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17662968", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 174, 
          "offsetInEndSection": 453, 
          "text": "With the use of dihydroethidium as a superoxide indicator, C(2)-ceramide was found to increase superoxide production in the endothelial cells of small coronary arteries, which was inhibited by the NADPH oxidase inhibitors N-vanillylnonanamide, apocynin, and diphenylene iodonium.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12424096", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 902, 
          "offsetInEndSection": 1057, 
          "text": "The contractile responses to U46619 in isolated PA were inhibited by PEG-catalase and the NADPH oxidase inhibitors diphenylene iodonium (DPI) and apocynin.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17341601", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 587, 
          "offsetInEndSection": 732, 
          "text": "The effects of diphenylene iodonium (DPI) and apocynin, inhibitors of NADPH oxidase, on key parameters of PSC activation were evaluated in vitro.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17962358", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1084, 
          "offsetInEndSection": 1250, 
          "text": "These effects could be inhibited by diphenylene iodonium and apocynin, indicating a self-cycle regulated by NADPH oxidase in microglial activation in response to oA\u00e2.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23229789", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 101, 
          "text": "Diphenylene iodonium is an inhibitor of the respiratory burst-generating NADPH oxidase of phagocytes.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2121828", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 628, 
          "offsetInEndSection": 861, 
          "text": "NADPH oxidase inhibitors [diphenylene iodonium (DPI) and apocynin (4-hydroxy-3-methoxy-acetophenone)] prevented the microglial activation induced by oA\u00e2, suggesting that NADPH oxidase activation was involved in microglial activation.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23229789", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 517, 
          "offsetInEndSection": 693, 
          "text": "In addition, inhibitors of NADPH oxidase (diphenylene iodonium or apocynin) also prevented microglia proliferation, suggesting that this may be the source of hydrogen peroxide.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16393992", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 632, 
          "offsetInEndSection": 861, 
          "text": "Inhibitors of NADPH oxidase (diphenylene iodonium, apocynin, D-(+)-neopterine) also significantly blunted the generation of reactive oxygen species, activation of K(+), Cl(-)-cotransport and apoptosis induced by N-ethylmaleimide.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11755128", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 175, 
          "offsetInEndSection": 454, 
          "text": "With the use of dihydroethidium as a superoxide indicator, C(2)-ceramide was found to increase superoxide production in the endothelial cells of small coronary arteries, which was inhibited by the NADPH oxidase inhibitors N-vanillylnonanamide, apocynin, and diphenylene iodonium.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12424096", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 182, 
          "text": "NADPH-dependent superoxide production by the solubilized oxidase of neutrophils was inhibited 36% by diphenylene iodonium at a 1:1 stoichiometry with the enzyme flavoprotein content.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3800872", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1084, 
          "offsetInEndSection": 1249, 
          "text": "These effects could be inhibited by diphenylene iodonium and apocynin, indicating a self-cycle regulated by NADPH oxidase in microglial activation in response to oA\u03b2", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23229789", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 540, 
          "offsetInEndSection": 941, 
          "text": "Moreover, CSE-regulated COX-2, PGE(2), and IL-6 generation was inhibited by pretreatment with TLR4 Ab; inhibitors of c-Src (PP1), NADPH oxidase (diphenylene iodonium chloride and apocynin), p38 MAPK (SB202190), MEK1/2 (U0126), JNK1/2 (SP600125), and NF-kappaB (helenalin); a ROS scavenger (N-acetyl-l-cysteine); and transfection with siRNA of TLR4, MyD88, TRAF6, Src, p47(phox), p38, p42, JNK2, or p65", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19892012", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 631, 
          "offsetInEndSection": 747, 
          "text": "Treatment of the cells with the NADPH oxidase inhibitors, apocynin and diphenylene iodonium, inhibited these effects", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17046555", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 175, 
          "offsetInEndSection": 453, 
          "text": "With the use of dihydroethidium as a superoxide indicator, C(2)-ceramide was found to increase superoxide production in the endothelial cells of small coronary arteries, which was inhibited by the NADPH oxidase inhibitors N-vanillylnonanamide, apocynin, and diphenylene iodonium", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12424096", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 394, 
          "offsetInEndSection": 745, 
          "text": "UVB irradiation generated ROS in a dose-dependent manner, and this was significantly inhibited by diphenylene iodonium (DPI), apocynin (Apo) and neopterine (Neo), inhibitors of the NADPH oxidase, and indomethacin (Indo), a cyclooxygenase (COX) inhibitor, but not by the mitochondrial electron transport inhibitors and other cytosolic enzyme inhibitors", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15308331", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 802, 
          "offsetInEndSection": 1121, 
          "text": "In RBA-1 cells, JEV induced MMP-9 expression and promoter activity, which was inhibited by pretreatment with inhibitors of NADPH oxidase (diphenylene iodonium chloride or apocynin), MAPKs (U0126, SB203580 or SP600125) and a ROS scavenger (N-acetylcysteine), or transfection with siRNAs of p47(phox) , ERK1, JNK2 and p38", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20698853", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 750, 
          "offsetInEndSection": 955, 
          "text": "Such discharge of Dectin-1-reactive \u03b2-glucan from macrophage cells was inhibited by either NADPH oxidase inhibitors (apocynin and diphenylene iodonium) or radical scavengers (N-acetyl cysteine and MCI-186)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22503982", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 902, 
          "offsetInEndSection": 1056, 
          "text": "The contractile responses to U46619 in isolated PA were inhibited by PEG-catalase and the NADPH oxidase inhibitors diphenylene iodonium (DPI) and apocynin", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17341601", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1213, 
          "offsetInEndSection": 1385, 
          "text": "ANG II further increased superoxide production in LP only, and this was inhibited by coincubation with diphenylene iodonium or apocynin (inhibitor of NADPH oxidase complex)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16741139", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 411, 
          "offsetInEndSection": 973, 
          "text": "Our results showed that IL-1beta enhanced HTSMCs-monocyte adhesion through up-regulation of VCAM-1, which was inhibited by pretreatment with selective inhibitors of PKCalpha (G\u00f66976), c-Src (PP1), NADPH oxidase [diphenylene iodonium (DPI) and apocynin (APO)], intracellular calcium chelator (BAPTA/AM), PI-PLC (U73122), CaM (calmidazolium chloride), CaM kinase II (KN62), p300 (garcinol), NF-kappaB (Bay11-7082), HDAC (trichostatin A), and ROS scavenger [N-acetyl-L-cysteine (NAC)] or transfection with siRNAs of MyD88, PKCalpha, Src, p47(phox), p300, and HDAC4.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19281832", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 388, 
          "offsetInEndSection": 640, 
          "text": "Here we show that cAMP-dependent decidualization can be attenuated or enhanced upon treatment of primary cultures with a nicotinamide adenine dinucleotide phosphate (NADPH) oxidase inhibitor (diphenylen iodonium) or activator (apocynin), respectively. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21159852", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 175, 
          "offsetInEndSection": 455, 
          "text": "With the use of dihydroethidium as a superoxide indicator, C(2)-ceramide was found to increase superoxide production in the endothelial cells of small coronary arteries, which was inhibited by the NADPH oxidase inhibitors N-vanillylnonanamide, apocynin, and diphenylene iodonium. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12424096", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 622, 
          "offsetInEndSection": 1011, 
          "text": "The inhibition of NAD(P)H oxidase by apocynin and diphenylene iodonium, and of the mitochondrial electron transport system at complex II by thenoyltrifluoroacetone (TTFA), significantly inhibited both AGE-induced ROS production and VCAM-1 expression, whereas these effects were potentiated by rotenone and antimycin A, specific inhibitors of mitochondrial complex I and III, respectively. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15845907", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 977, 
          "offsetInEndSection": 1155, 
          "text": "Paraquat-induced ROS production was inhibited by NADPH oxidase inhibitors, apocynin and diphenylene iodonium (DPI), but not the xanthine/xanthine oxidase inhibitor, allopurinol. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17662968", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 631, 
          "offsetInEndSection": 749, 
          "text": "Treatment of the cells with the NADPH oxidase inhibitors, apocynin and diphenylene iodonium, inhibited these effects. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17046555", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 218, 
          "offsetInEndSection": 626, 
          "text": "The G6PD inhibitor DHEA and the inhibitors of NADPH oxidase apocynin and diphenylene iodonium (DPI) prevented both superoxide generation and capacitation in human spermatozoa, but whereas DPI and DHEA inhibited PPP, apocynin did not influence it, suggesting that PPP activation during capacitation is not a response to increased oxidative stress but exerts a role by supplying reducing equivalents to oxygen.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19819434", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 586, 
          "offsetInEndSection": 809, 
          "text": "Ang II induced a time-dependent increase in Rac1 activation and O(2)(*-) production in Neuro-2A cells, and this was abolished by pretreatment with AdN17Rac1 or the NADPH oxidase inhibitors apocynin or diphenylene iodonium. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15271858", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 977, 
          "offsetInEndSection": 1154, 
          "text": "Paraquat-induced ROS production was inhibited by NADPH oxidase inhibitors, apocynin and diphenylene iodonium (DPI), but not the xanthine/xanthine oxidase inhibitor, allopurinol.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17662968", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 802, 
          "offsetInEndSection": 1122, 
          "text": "In RBA-1 cells, JEV induced MMP-9 expression and promoter activity, which was inhibited by pretreatment with inhibitors of NADPH oxidase (diphenylene iodonium chloride or apocynin), MAPKs (U0126, SB203580 or SP600125) and a ROS scavenger (N-acetylcysteine), or transfection with siRNAs of p47(phox) , ERK1, JNK2 and p38.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20698853", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1084, 
          "offsetInEndSection": 1250, 
          "text": "These effects could be inhibited by diphenylene iodonium and apocynin, indicating a self-cycle regulated by NADPH oxidase in microglial activation in response to oA\u03b2.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23229789", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 631, 
          "offsetInEndSection": 748, 
          "text": "Treatment of the cells with the NADPH oxidase inhibitors, apocynin and diphenylene iodonium, inhibited these effects.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17046555", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 394, 
          "offsetInEndSection": 746, 
          "text": "UVB irradiation generated ROS in a dose-dependent manner, and this was significantly inhibited by diphenylene iodonium (DPI), apocynin (Apo) and neopterine (Neo), inhibitors of the NADPH oxidase, and indomethacin (Indo), a cyclooxygenase (COX) inhibitor, but not by the mitochondrial electron transport inhibitors and other cytosolic enzyme inhibitors.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15308331", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 750, 
          "offsetInEndSection": 956, 
          "text": "Such discharge of Dectin-1-reactive \u03b2-glucan from macrophage cells was inhibited by either NADPH oxidase inhibitors (apocynin and diphenylene iodonium) or radical scavengers (N-acetyl cysteine and MCI-186).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22503982", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 411, 
          "offsetInEndSection": 910, 
          "text": "Our results showed that IL-1beta enhanced HTSMCs-monocyte adhesion through up-regulation of VCAM-1, which was inhibited by pretreatment with selective inhibitors of PKCalpha (G\u00f66976), c-Src (PP1), NADPH oxidase [diphenylene iodonium (DPI) and apocynin (APO)], intracellular calcium chelator (BAPTA/AM), PI-PLC (U73122), CaM (calmidazolium chloride), CaM kinase II (KN62), p300 (garcinol), NF-kappaB (Bay11-7082), HDAC (trichostatin A), and ROS scavenger [N-acetyl-L-cysteine (NAC)] or transfection w", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19281832", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 540, 
          "offsetInEndSection": 942, 
          "text": "Moreover, CSE-regulated COX-2, PGE(2), and IL-6 generation was inhibited by pretreatment with TLR4 Ab; inhibitors of c-Src (PP1), NADPH oxidase (diphenylene iodonium chloride and apocynin), p38 MAPK (SB202190), MEK1/2 (U0126), JNK1/2 (SP600125), and NF-kappaB (helenalin); a ROS scavenger (N-acetyl-l-cysteine); and transfection with siRNA of TLR4, MyD88, TRAF6, Src, p47(phox), p38, p42, JNK2, or p65.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19892012", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 142, 
          "text": "The use of diphenylene iodonium, an inhibitor of NADPH oxidase, to investigate the antimicrobial action of human monocyte derived macrophages.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2121828", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 628, 
          "offsetInEndSection": 861, 
          "text": "NADPH oxidase inhibitors [diphenylene iodonium (DPI) and apocynin (4-hydroxy-3-methoxy-acetophenone)] prevented the microglial activation induced by oA\u03b2, suggesting that NADPH oxidase activation was involved in microglial activation.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23229789", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 930, 
          "offsetInEndSection": 1215, 
          "text": "Furthermore, inhibition of NOX-mediated ROS production with apocynin, diphenylene iodonium (DPI) or NOX2 docking sequence (Nox2ds)-tat peptide during these first 4h of PE stimulation significantly inhibited PE-induced hypertrophy of H9c2 cells, both after 24 and 48h of PE stimulation.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24794531", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 434, 
          "offsetInEndSection": 664, 
          "text": "We compared the pharmacological profiles of the commonly used NADPH oxidase inhibitors, diphenylene iodonium (DPI), apocynin and 4-(2-amino-ethyl)-benzolsulphonyl-fluoride (AEBSF), as well as the novel triazolo pyrimidine VAS3947.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20860666", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 694, 
          "offsetInEndSection": 939, 
          "text": "IL-1beta and TNF-alpha rapidly stimulated the rate of hydrogen peroxide produced by isolated microglia, and this was inhibited by diphenylene iodonium, implying that the cytokines were acting directly on microglia to stimulate the NADPH oxidase.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16393992", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1062, 
          "offsetInEndSection": 1224, 
          "text": "The fractions achieved the same effects that known NADPH oxidase inhibitors, such as diphenylene iodonium and apocynin, but they presented better hydrosolubility.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22134950", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 586, 
          "offsetInEndSection": 808, 
          "text": "Ang II induced a time-dependent increase in Rac1 activation and O(2)(*-) production in Neuro-2A cells, and this was abolished by pretreatment with AdN17Rac1 or the NADPH oxidase inhibitors apocynin or diphenylene iodonium.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15271858", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Viliuisk encephalomyelitis is diagnosed in which geographical area?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24586232", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20010208", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19618339", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18379734", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15182325", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18252102", 
        "http://www.ncbi.nlm.nih.gov/pubmed/1393513", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9223130", 
        "http://www.ncbi.nlm.nih.gov/pubmed/7848104", 
        "http://www.ncbi.nlm.nih.gov/pubmed/2894813"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Viliuisk encephalomyelitis (VE) is an endemic neurological disease in Northeast Siberia and generally considered to be a chronic encephalomyelitis of unknown origin actually spreading in the Sakha (Yakutian) Republic."
      ], 
      "exact_answer": [
        [
          "Northeast Siberia"
        ]
      ], 
      "concepts": [
        "http://www.disease-ontology.org/api/metadata/DOID:640", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004679"
      ], 
      "type": "factoid", 
      "id": "588f9f83ed9bbee70d000004", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 229, 
          "text": "BACKGROUND: Viliuisk encephalomyelitis (VE) is an endemic neurological disease in Northeast Siberia and generally considered to be a chronic encephalomyelitis of unknown origin actually spreading in the Sakha (Yakutian) Republic.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24586232", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 139, 
          "text": "Communicating hydrocephalus following eosinophilic meningitis is pathogenic for chronic Viliuisk encephalomyelitis in Northeastern Siberia.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24586232", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 62, 
          "text": "Epidemiology of Viliuisk encephalomyelitis in Eastern Siberia.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20010208", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 245, 
          "offsetInEndSection": 350, 
          "text": ". An epidemic of this disease has been spreading throughout the Yakut Republic of the Russian Federation.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20010208", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 502, 
          "offsetInEndSection": 729, 
          "text": "METHODS: Detailed clinical, pathologic, laboratory, and epidemiologic studies have identified 414 patients with definite Viliuisk encephalomyelitis in 15 of 33 administrative regions of the Yakut Republic between 1940 and 1999.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20010208", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 70, 
          "text": "Viliuisk encephalomyelitis in Eastern Siberia - analysis of 390 cases.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19618339", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 114, 
          "text": "Viliuisk encephalomyelitis (VE) is a unique disease occurring in the Yakut (Sakha) population of Eastern Siberia. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19618339", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 99, 
          "text": "Viliuisk encephalomyelitis in Northeastern Siberia is not caused by Borrelia burgdorferi infection.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18379734", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 167, 
          "text": "Viliuisk encephalomyelitis (VE) is an endemic neurological disease in Northeastern Siberia and generally believed to be a chronic encephalomyelitis of unknown origin. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18379734", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 166, 
          "text": "Viliuisk encephalomyelitis (VE) is an endemic neurological disease in Northeastern Siberia and generally believed to be a chronic encephalomyelitis of unknown origin.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18379734", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 217, 
          "text": "Viliuisk encephalomyelitis (VE) is an endemic neurological disease in Northeast Siberia and generally considered to be a chronic encephalomyelitis of unknown origin actually spreading in the Sakha (Yakutian) Republic.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24586232", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 58, 
          "text": "Viliuisk encephalomyelitis in the Iakut people of Siberia.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1393513", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 727, 
          "offsetInEndSection": 983, 
          "text": "Initially identified in a small Yakut-Evenk population on the Viliui River of eastern Siberia, the disease subsequently spread through human contacts to new geographic areas, thus characterizing Viliuisk encephalomyelitis as an emerging infectious disease.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18252102", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 115, 
          "text": "Viliuisk encephalomyelitis (VE) is an unique neurological disease occurring in the Iakut (Sakha) people of Siberia.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9223130", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 124, 
          "text": "Viliuisk encephalomyelitis (VEM) appears to be endemic disease, affecting native population in Yakutia (Yakut, Even, Evenk).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7848104", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 534, 
          "text": "Viliuisk encephalomyelitis (VE) is an endemic neurological disease in Northeast Siberia and generally considered to be a chronic encephalomyelitis of unknown origin actually spreading in the Sakha (Yakutian) Republic.In search for the pathophysiology and causative agent of VE, we performed a cross-sectional study on clinical, serological and neuroimaging data on chronic VE patients during two medical expeditions to three villages within the Viliuiski river basin in the Republic of Sakha in 2000 and to the capital Yakutsk in 2006", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24586232", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 732, 
          "offsetInEndSection": 987, 
          "text": "Initially identified in a small Yakut-Evenk population on the Viliui River of eastern Siberia, the disease subsequently spread through human contacts to new geographic areas, thus characterizing Viliuisk encephalomyelitis as an emerging infectious disease", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18252102", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 112, 
          "text": "Viliuisk encephalomyelitis (VE) is a unique disease occurring in the Yakut (Sakha) population of Eastern Siberia", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19618339", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 98, 
          "text": "Viliuisk encephalomyelitis in Northeastern Siberia is not caused by Borrelia burgdorferi infection", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18379734", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 165, 
          "text": "Viliuisk encephalomyelitis (VE) is an endemic neurological disease in Northeastern Siberia and generally believed to be a chronic encephalomyelitis of unknown origin", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18379734", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 732, 
          "offsetInEndSection": 988, 
          "text": "Initially identified in a small Yakut-Evenk population on the Viliui River of eastern Siberia, the disease subsequently spread through human contacts to new geographic areas, thus characterizing Viliuisk encephalomyelitis as an emerging infectious disease.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18252102", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 535, 
          "text": "Viliuisk encephalomyelitis (VE) is an endemic neurological disease in Northeast Siberia and generally considered to be a chronic encephalomyelitis of unknown origin actually spreading in the Sakha (Yakutian) Republic.In search for the pathophysiology and causative agent of VE, we performed a cross-sectional study on clinical, serological and neuroimaging data on chronic VE patients during two medical expeditions to three villages within the Viliuiski river basin in the Republic of Sakha in 2000 and to the capital Yakutsk in 2006.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24586232", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 447, 
          "offsetInEndSection": 926, 
          "text": "IgG antibodies to HTLV-I were measured in the sera and/or cerebrospinal fluid from 82 Guamanian patients with amyotrophic lateral sclerosis and parkinsonism-dementia, 164 Guamanian normal controls, 10 patients with kuru from the Eastern Highlands of Papua New Guinea, 4 patients with Viliuisk encephalomyelitis from the Iakut region of eastern Siberia, 45 Italian patients with multiple sclerosis, and 56 patients with polymyositis (49 from the United States and 7 from Jamaica).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2894813", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 193, 
          "text": "Viliuisk encephalomyelitis (VE), a progressive neurological disorder with a fatal outcome usually in several months to 6 yrs after disease onset, is seen only among the Iakut people of Siberia.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1393513", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 559, 
          "offsetInEndSection": 731, 
          "text": "Transmission to unrelated persons was documented in a densely populated region around the city of Yakutsk in which Viliuisk encephalomyelitis had not been previously known.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18252102", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 732, 
          "offsetInEndSection": 989, 
          "text": "Initially identified in a small Yakut-Evenk population on the Viliui River of eastern Siberia, the disease subsequently spread through human contacts to new geographic areas, thus characterizing Viliuisk encephalomyelitis as an emerging infectious disease..", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18252102", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 63, 
          "text": "Epidemiology of Viliuisk encephalomyelitis in Eastern Siberia.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20010208", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 59, 
          "text": "Viliuisk encephalomyelitis in the Iakut people of Siberia.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1393513", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 71, 
          "text": "Viliuisk encephalomyelitis in Eastern Siberia - analysis of 390 cases.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19618339", 
          "endSection": "title"
        }
      ]
    }, 
    {
      "body": "What are Septins?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/27044893", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26700173", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26780475", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27048593", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24367716", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20885997", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21082023", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25217462", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25957401", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15214843", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18826657", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23204191", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18541672", 
        "http://www.ncbi.nlm.nih.gov/pubmed/14517318", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20517926", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25575596", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27473901", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22767579", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10607590", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11238387", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8791410", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18586950", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24664283", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21824004", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22815479", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17922164", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21883761", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8636235"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Septins are an evolutionarily conserved family of GTP-binding proteins. They are involved in diverse processes including cytokinesis, apoptosis, infection, neurodegeneration and neoplasia. In yeast, septins assemble into a highly ordered array of filaments at the mother bud neck in Saccharomyces cerevisiae cells. Septins have been implicated in a diverse range of cancers, including gastric cancer, but the underlying mechanisms remain unclear.", 
        "Septins are an evolutionarily conserved family of GTP-binding proteins. discover that septins, a component of the cytoskeleton, recognize membrane curvature at the micron scale, a common morphological hallmark of eukaryotic cellular processes. eptins are a family of cytoskeletal GTP-binding proteins that assemble into membrane-associated hetero-oligomers and organize scaffolds for recruitment of cytosolic proteins or stabilization of membrane proteins. "
      ], 
      "concepts": [
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D058112"
      ], 
      "type": "summary", 
      "id": "58a327bf60087bc10a000011", 
      "snippets": [
        {
          "offsetInBeginSection": 154, 
          "offsetInEndSection": 325, 
          "text": "discover that septins, a component of the cytoskeleton, recognize membrane curvature at the micron scale, a common morphological hallmark of eukaryotic cellular processes.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27044893", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 189, 
          "text": "Septins are an evolutionarily conserved family of GTP-binding proteins. They are involved in diverse processes including cytokinesis, apoptosis, infection, neurodegeneration and neoplasia. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26700173", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1, 
          "offsetInEndSection": 346, 
          "text": "eptins are a family of cytoskeletal GTP-binding proteins that assemble into membrane-associated hetero-oligomers and organize scaffolds for recruitment of cytosolic proteins or stabilization of membrane proteins. Septins have been implicated in a diverse range of cancers, including gastric cancer, but the underlying mechanisms remain unclear. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27048593", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 282, 
          "offsetInEndSection": 386, 
          "text": "nidulans septins contain the highly conserved GTP binding and coiled-coil domains seen in other septins.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11238387", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 54, 
          "text": "The septins: roles in cytokinesis and other processes.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8791410", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 126, 
          "text": "The septins are a novel family of proteins that were first recognized in yeast as proteins associated with the neck filaments.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8791410", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 72, 
          "text": "Septin9 is involved in septin filament formation and cellular stability.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21824004", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 703, 
          "offsetInEndSection": 881, 
          "text": "Here, we review these findings and discuss emerging mechanisms by which septins promote cell asymmetry in fungi and animals.<CopyrightInformation>\u00a9 2011 John Wiley & Sons A/S.</C", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21883761", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 632, 
          "offsetInEndSection": 749, 
          "text": "These observations together with conserved sequence motifs identify the septins as members of the GTPase superfamily.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8636235", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 160, 
          "text": "BACKGROUND: Septins belong to the GTPase superclass of proteins and have been functionally implicated in cytokinesis and the maintenance of cellular morphology.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21082023", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 175, 
          "text": "Septins are important components of the cytoskeleton that are highly conserved in eukaryotes and play major roles in cytokinesis, patterning, and many developmental processes.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24664283", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 376, 
          "offsetInEndSection": 480, 
          "text": "The septins also appear to be involved in various other aspects of the organization of the cell surface.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8791410", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 88, 
          "text": "Septins are a family of eukaryotic GTP binding proteins conserved from yeasts to humans.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24367716", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 12, 
          "offsetInEndSection": 157, 
          "text": "Septins are a highly conserved family of GTP-binding proteins involved in multiple cellular functions, including cell division and morphogenesis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20885997", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 96, 
          "text": "Septin proteins are conserved structural proteins that often demarcate regions of cell division.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25217462", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 183, 
          "text": "Septins are GTP-binding proteins that form filaments and higher-order structures on the cell cortex of eukaryotic cells and associate with actin and microtubule cytoskeletal networks.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25957401", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 212, 
          "text": "Septins are guanosine-5'-triphosphate-binding proteins involved in wide-ranging cellular processes including cytokinesis, vesicle trafficking, membrane remodelling and scaffolds, and with diverse binding partners", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24768753", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 2058, 
          "offsetInEndSection": 2178, 
          "text": "Septins are a group of GTP-binding proteins that can organize into heteromeric complexes and then into large filaments. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25293760", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 137, 
          "text": "Septins are a conserved family of GTPases that regulate important cellular processes such as cell wall integrity, and septation in fungi.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26051489", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 318, 
          "text": "Septins are a cytosolic GTP-binding protein family first characterized in yeast, but gaining increasing recognition as critical protagonists in higher eukaryotic cellular events. Mammalian septins have been associated with cytokinesis and exocytosis, along with contributing to the development of neurological disorder", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15214843", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 176, 
          "offsetInEndSection": 326, 
          "text": "Septins are a family of proteins that assemble a ring structure at the mother-daughter neck during vegetative growth, where they control cytokinesis. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18826657", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 233, 
          "text": "Septins are a class of GTP-binding proteins conserved throughout many eukaryotes. Individual septin subunits associate with one another and assemble into heteromeric complexes that form filaments and higher-order structures in vivo. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23204191", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 79, 
          "text": "The septins are a conserved family of GTP-binding, filament-forming proteins. I", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14517318", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 280, 
          "text": "The septins are filament-forming, GTP-binding proteins that are conserved from yeast to humans. Septins assemble into higher-order structures such as rings, bars, and gauzes with diverse functions including serving as membrane diffusion barriers and scaffolds for cell signaling. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20517926", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 144, 
          "text": "Septins are a family of 14 cytoskeletal proteins that dynamically form hetero-oligomers and organize membrane microdomains for protein complexes", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25575596", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 319, 
          "text": "Septins are highly conserved and essential eukaryotic cytoskeletal proteins that interact with the inner plasma membrane. They are involved in essential functions requiring cell membrane remodeling and compartmentalization, such as cell division and dendrite morphogenesis, and have been implicated in numerous diseases", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27473901", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 141, 
          "text": "Septins are conserved GTP-binding proteins that assemble into heteromeric complexes that form filaments and higher-order structures in cells.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22767579", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 11, 
          "offsetInEndSection": 122, 
          "text": " Septins are members of a conserved family of GTPases found in organisms as diverse as budding yeast and mammal", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10607590", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 148, 
          "text": "Septins are a family of conserved proteins that are essential for cytokinesis in a wide range of organisms including fungi, Drosophila and mammals. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16857012", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 108, 
          "text": "The human genome codes for 13 members of a family of filament-forming GTP-binding proteins known as septins.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23163726", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 140, 
          "text": "Septins are evolutionary conserved cytoskeletal GTPases forming heteropolymer complexes involved in cytokinesis and other cellular processes", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12023038", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 72, 
          "text": "Septins comprise a conserved family of GTPases important in cytokinesis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22815479", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 225, 
          "text": "Septins are a highly conserved family of GTP-binding cytoskeletal proteins implicated in multiple cellular functions, including membrane transport, apoptosis, cell polarity, cell cycle regulation, cytokinesis, and oncogenesis", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17922164", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is the drug target for Simtuzumab?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23821193", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27939076", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27232579", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26085906"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Simtuzumab is a humanized monoclonal antibody drug that targets LOXL2", 
        " these results suggest that loxl2 could be an appealing target for treatment of scar formation after glaucoma surgery, and point to the potential therapeutic benefits of simtuzumab, a humanized monoclonal antibody derived from gs-607601.", 
        " These results suggest that LOXL2 could be an appealing target for treatment of scar formation after glaucoma surgery, and point to the potential therapeutic benefits of simtuzumab, a humanized monoclonal antibody derived from GS-607601."
      ], 
      "exact_answer": [
        [
          "LOXL2"
        ]
      ], 
      "concepts": [], 
      "type": "factoid", 
      "id": "58a644e560087bc10a000027", 
      "snippets": [
        {
          "offsetInBeginSection": 1530, 
          "offsetInEndSection": 1767, 
          "text": " These results suggest that LOXL2 could be an appealing target for treatment of scar formation after glaucoma surgery, and point to the potential therapeutic benefits of simtuzumab, a humanized monoclonal antibody derived from GS-607601.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23821193", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1490, 
          "offsetInEndSection": 1725, 
          "text": "These results suggest that LOXL2 could be an appealing target for treatment of scar formation after glaucoma surgery, and point to the potential therapeutic benefits of simtuzumab, a humanized monoclonal antibody derived from GS-607601", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23821193", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1534, 
          "offsetInEndSection": 1770, 
          "text": "These results suggest that LOXL2 could be an appealing target for treatment of scar formation after glaucoma surgery, and point to the potential therapeutic benefits of simtuzumab, a humanized monoclonal antibody derived from GS-607601.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23821193", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1296, 
          "offsetInEndSection": 1458, 
          "text": "Other potential agents will be silent information regulator protein Sirtuin and antifibrotic monoclonal antibody Simtuzumab against lysyl oxidase like molecule 2.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26085906", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1491, 
          "offsetInEndSection": 1727, 
          "text": "These results suggest that LOXL2 could be an appealing target for treatment of scar formation after glaucoma surgery, and point to the potential therapeutic benefits of simtuzumab, a humanized monoclonal antibody derived from GS-607601.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23821193", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 294, 
          "offsetInEndSection": 446, 
          "text": " aim of this study was to study the safety and tolerability of simtuzumab, a monoclonal antibody directed against lysyl oxidase-like 2 (LOXL2) enzyme, i", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27232579", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is Dravet syndrome?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/27264139", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22848613", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25666511", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23762420", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26995069", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21719429", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22104018", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24665294", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19203856", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25778844", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23517304", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25243660", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26017580", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21504428", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20184819", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20184820", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12503502", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19589774", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24254932"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Dravet syndrome is one of the most severe epilepsy syndromes of early childhood, and is associated with high morbidity and mortality. The typical presentation is characterized by hemiclonic or generalized clonic seizures triggered by fever during the first year of life, followed by myoclonic, absence, focal and generalized tonic-clonic seizures.", 
        "dravet syndrome is one of the most severe epilepsy syndromes of early childhood, and it comes with very high morbidity and mortality.", 
        "Dravet syndrome is one of the most severe epilepsy syndromes of early childhood, and it comes with very high morbidity and mortality. The typical presentation is characterized by hemiclonic or generalized clonic seizures triggered by fever during the first year of life, followed by myoclonic, absence, focal and generalized tonic-clonic seizures.", 
        "Dravet syndrome is one of the most severe epilepsy syndromes of early childhood, and it comes with very high morbidity and mortality.", 
        "Dravet syndrome is one of the most severe epilepsy syndromes of early childhood, and it comes with very high morbidity and mortality. It is likely that Dravet syndrome is underdiagnosed in adults with treatment-resistant epilepsy."
      ], 
      "exact_answer": [
        [
          "A severe epilepsy of chidhood"
        ]
      ], 
      "concepts": [
        "http://www.disease-ontology.org/api/metadata/DOID:0060171", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004831"
      ], 
      "type": "factoid", 
      "id": "58bca08702b8c6095300000a", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 347, 
          "text": "Dravet syndrome is one of the most severe epilepsy syndromes of early childhood, and it comes with very high morbidity and mortality. The typical presentation is characterized by hemiclonic or generalized clonic seizures triggered by fever during the first year of life, followed by myoclonic, absence, focal and generalized tonic-clonic seizures.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27264139", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 57, 
          "text": "BACKGROUND: Dravet syndrome is a severe form of epilepsy.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22848613", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 108, 
          "text": "Dravet syndrome, a severe infantile epilepsy syndrome, is typically resistant to anti-epileptic drugs (AED).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25243660", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 110, 
          "text": "Dravet syndrome is an epilepsy syndrome of infantile onset, frequently caused by SCN1A mutations or deletions.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21719429", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 91, 
          "text": "Dravet syndrome is an epileptic encephalopathy characterized by multiple types of seizures.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23517304", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 154, 
          "offsetInEndSection": 364, 
          "text": "Haploinsufficiency of the voltage-gated sodium channel Nav1.1 causes Dravet syndrome, an intractable childhood-onset epilepsy with hyperactivity, cognitive deficit, autistic-like behaviours, and premature death", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26017580", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1555, 
          "offsetInEndSection": 1814, 
          "text": "Thus, the multi-faceted phenotypes of Dravet syndrome can be genetically dissected, revealing synergy in causing epilepsy, premature death and deficits in long-term spatial memory, but interneuron-specific effects on hyperactivity and autistic-like behaviours", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26017580", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 159, 
          "text": "Dravet syndrome, or as it was called in the past severe myoclonic epilepsy in infancy, is a drug-resistant epilepsy first described by Charlotte Dravet in 1978", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21504428", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 45, 
          "text": "Dravet syndrome is a severe form of epilepsy.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22848613", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 543, 
          "text": "Severe myoclonic epilepsy in infants (SMEI), also known as Dravet syndrome, is a rare, refractory form of epilepsy, for whose treatment stiripentol (STP) has been recently licensed for add-on use.To evaluate the efficacy and tolerability of STP and other antiepileptic drug treatments (including ketogenic diet) as therapy for patients with SMEI.We searched the Cochrane Epilepsy Group Specialised Register (15 May 2013), the Cochrane Central Register of Controlled Trials (CENTRAL, Issue 4 of 12, The Cochrane Library, April 2013), MEDLINE (1", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24254932", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 144, 
          "text": "Dravet syndrome is a severe infantile-onset epileptic encephalopathy associated with mutations in the sodium channel alpha-1 subunit gene SCN1A.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25778844", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 100, 
          "text": "Dravet syndrome is a rare form of epilepsy largely refractory to current antiepileptic medications. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25666511", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 12, 
          "offsetInEndSection": 122, 
          "text": "Dravet syndrome is a rare epileptic encephalopathy characterized by treatment-resistant polymorphic seizures. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26995069", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 150, 
          "text": "Dravet syndrome is a severe form of epileptic encephalopathy characterized by early onset epileptic seizures followed by ataxia and cognitive decline.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23148524", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 11, 
          "offsetInEndSection": 147, 
          "text": "Dravet syndrome is a severe form of intractable pediatric epilepsy with a high incidence of SUDEP: Sudden Unexpected Death in epilepsy. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24155976", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 11, 
          "offsetInEndSection": 151, 
          "text": "Dravet syndrome or severe myoclonic epilepsy of infancy (SMEI) is a baleful epileptic encephalopathy that begins in the first year of life. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24665294", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 445, 
          "offsetInEndSection": 574, 
          "text": "Dravet syndrome is a severe infantile onset epilepsy syndrome with multiple seizure types, developmental slowing and poor outcome", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19203856", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 89, 
          "text": "Dravet syndrome is an intractable epileptic syndrome beginning in the first year of life.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23103419", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 72, 
          "text": "Dravet syndrome is an epileptic syndrome of infancy and early childhood.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20184819", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 52, 
          "text": "Dravet syndrome is an epileptic syndrome of infancy.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20184820", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 141, 
          "offsetInEndSection": 211, 
          "text": "patients with severe myoclonic epilepsy of infancy (Dravet's syndrome)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12503502", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 12, 
          "offsetInEndSection": 179, 
          "text": "Dravet syndrome is a severe infantile epileptic encephalopathy caused in approximately 80% of cases by mutations in the voltage gated sodium channel subunit gene SCN1A", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19589774", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What makes telomerase a good drug target?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26771897", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26742579", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25550449", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25744732", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23558965", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12689331", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24053596", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27118336", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18763067", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21208462", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25256442", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16112419", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21802433", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24109558", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16549043", 
        "http://www.ncbi.nlm.nih.gov/pubmed/14594517", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11342355", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22044621", 
        "http://www.ncbi.nlm.nih.gov/pubmed/14649329", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27657809", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12750550", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12678727", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10857992"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Telomerase, a ribonucleoprotein enzyme is considered as a universal therapeutic target of cancer because of its preferential expression in cancer cells and its presence in 90 % of tumors. Human telomerase is absent in most normal tissues, but is abnormally activated in all major cancer cells.", 
        " telomerase, a ribonucleoprotein enzyme is considered as a universal therapeutic target of cancer because of its preferential expression in cancer cells and its presence in 90 % of tumors.", 
        "Human telomerase is absent in most normal tissues, but is abnormally activated in all major cancer cells. Telomerase enables tumor cells to maintain telomere length, allowing indefinite replicative capacity.", 
        " Telomerase, a ribonucleoprotein enzyme is considered as a universal therapeutic target of cancer because of its preferential expression in cancer cells and its presence in 90 % of tumors. ", 
        "Human telomerase is absent in most normal tissues, but is abnormally activated in all major cancer cells. Telomerase enables tumor cells to maintain telomere length, allowing indefinite replicative capacity. telomerase is believed to be necessary for cancer cells to grow without limit"
      ], 
      "concepts": [
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D019098", 
        "http://www.biosemantics.org/jochem#4221288"
      ], 
      "type": "summary", 
      "id": "58bc9dbb02b8c60953000009", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 207, 
          "text": "Human telomerase is absent in most normal tissues, but is abnormally activated in all major cancer cells. Telomerase enables tumor cells to maintain telomere length, allowing indefinite replicative capacity.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26742579", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 261, 
          "offsetInEndSection": 338, 
          "text": "telomerase is believed to be necessary for cancer cells to grow without limit", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26742579", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 317, 
          "offsetInEndSection": 506, 
          "text": " Telomerase, a ribonucleoprotein enzyme is considered as a universal therapeutic target of cancer because of its preferential expression in cancer cells and its presence in 90 % of tumors. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25744732", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1072, 
          "offsetInEndSection": 1231, 
          "text": "Interestingly, almost 100 % of adenocarcinoma, including breast cancer cells, expresses telomerase which makes it a good target for telomerase-related therapy.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23558965", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 319, 
          "text": "The observation that the enzyme telomerase is up-regulated in 80-90% of cancer cells isolated from primary human tumors but is absent in neighboring cells of healthy tissue has resulted in significant efforts to validate telomerase as an anticancer drug target and to develop effective approaches toward its inhibition.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24053596", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 134, 
          "text": "Telomerase plays an important role in cell proliferation and carcinogenesis and is believed to be a good target for anti-cancer drugs.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18763067", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 144, 
          "text": "In contrast to cancer cells, most normal human cells have no or low telomerase levels which makes it an attractive target for anti-cancer drugs.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25256442", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 171, 
          "text": "Telomerase activity is repressed in normal human somatic cells, but is activated in most cancers, suggesting that telomerase may be an important target for cancer therapy.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16112419", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 303, 
          "offsetInEndSection": 471, 
          "text": "Telomerase is expressed in more than 85% of cancer cells, making it a nearly universal cancer marker, while the majority of normal somatic cells are telomerase negative", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21802433", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 156, 
          "offsetInEndSection": 304, 
          "text": "The activity of telomerase is highly associated with carcinogenesis which makes the enzyme an attractive biomarker in cancer diagnosis and treatment", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24109558", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 321, 
          "text": "The human telomerase reverse transcriptase (hTERT) is expressed in more than 85% of tumor cells but is usually not found in normal cells, which makes hTERT as an ideal tumor-associate antigen (TAA) to develop potential vaccine specifically destroying cancers without impairing normal tissues in human cancer immunotherapy", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16549043", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 120, 
          "offsetInEndSection": 219, 
          "text": "The differential expression of telomerase in cancer cells makes it an attractive therapeutic target", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14594517", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 166, 
          "offsetInEndSection": 385, 
          "text": "The evidence that telomerase is also present in normal B cells at different levels according to their differentiation and activation state makes the study of telomerase activity in B cell tumors particularly interesting", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11342355", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 334, 
          "offsetInEndSection": 477, 
          "text": "Telomerase is up-regulated in the majority of cancer cells and is essential for their survival, making it a potential anti-cancer drug target. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22044621", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 145, 
          "text": "In contrast to cancer cells, most normal human cells have no or low telomerase levels which makes it an attractive target for anti-cancer drugs. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25256442", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 554, 
          "offsetInEndSection": 718, 
          "text": "As normal cells have a considerable telomere reserve, even in elderly humans, this makes telomerase an attractive and potentially selective anti-cancer drug target.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14649329", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 158, 
          "text": "The expression of telomerase in approximately 85% of cancers and its absence in the majority of normal cells makes it an attractive target for cancer therapy.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27657809", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 765, 
          "offsetInEndSection": 919, 
          "text": "Moreover, since telomerase is not or slightly expressed in normal cells, it has been postulated that drugs targeting telomerase would induce low toxicity.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10857992", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 290, 
          "offsetInEndSection": 443, 
          "text": "Telomerase is expressed in most cancer cells, but not in normal somatic cells, suggesting that telomerase is an attractive target for cancer chemotherapy", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12689331", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 119, 
          "offsetInEndSection": 299, 
          "text": "elomerase, a special reverse transcriptase, has been recognized as a common factor in most tumor cells, and in turn a distinctive characteristic with respect to non-malignant cells", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27118336", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 706, 
          "offsetInEndSection": 823, 
          "text": "Telomerase is detected in the majority of prostate cancers, but not in normal or benign prostatic hyperplasia tissue.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15369445", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 148, 
          "offsetInEndSection": 403, 
          "text": "The catalytic component of telomerase in humans, hTERT, is upregulated in nearly 90% of all cancers, making it the most widely expressed marker of malignancy. With the exception of germ cells and stem cells, hTERT is undetectable in somatic human tissues.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12750550", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 146, 
          "offsetInEndSection": 320, 
          "text": "he notion that telomerase is reactivated in 80-90% of human cancers has led to the proposal of telomerase as a promising therapeutic target for novel anticancer interventions", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12678727", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is DENdb?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26342387"
      ], 
      "triples": [], 
      "ideal_answer": [
        "DENdb is a centralized on-line repository of predicted enhancers derived from multiple human cell-lines. DENdb integrates enhancers predicted by five different methods generating an enriched catalogue of putative enhancers for each of the analysed cell-lines. DENdb provides information about the overlap of enhancers with DNase I hypersensitive regions, ChIP-seq regions of a number of transcription factors and transcription factor binding motifs, means to explore enhancer interactions with DNA using several chromatin interaction assays and enhancer neighbouring genes. DENdb is designed as a relational database that facilitates fast and efficient searching, browsing and visualization of information."
      ], 
      "concepts": [
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D030561"
      ], 
      "type": "summary", 
      "id": "587f90fa8ce3255b64000002", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 45, 
          "text": "DENdb: database of integrated human enhancers", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26342387", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 332, 
          "offsetInEndSection": 1050, 
          "text": "We developed DENdb, a centralized on-line repository of predicted enhancers derived from multiple human cell-lines. DENdb integrates enhancers predicted by five different methods generating an enriched catalogue of putative enhancers for each of the analysed cell-lines. DENdb provides information about the overlap of enhancers with DNase I hypersensitive regions, ChIP-seq regions of a number of transcription factors and transcription factor binding motifs, means to explore enhancer interactions with DNA using several chromatin interaction assays and enhancer neighbouring genes. DENdb is designed as a relational database that facilitates fast and efficient searching, browsing and visualization of information. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26342387", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 46, 
          "text": "DENdb: database of integrated human enhancers.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26342387", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 330, 
          "offsetInEndSection": 445, 
          "text": "We developed DENdb, a centralized on-line repository of predicted enhancers derived from multiple human cell-lines.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26342387", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 912, 
          "offsetInEndSection": 1044, 
          "text": "DENdb is designed as a relational database that facilitates fast and efficient searching, browsing and visualization of information.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26342387", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 445, 
          "offsetInEndSection": 599, 
          "text": "DENdb integrates enhancers predicted by five different methods generating an enriched catalogue of putative enhancers for each of the analysed cell-lines.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26342387", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 599, 
          "offsetInEndSection": 912, 
          "text": "DENdb provides information about the overlap of enhancers with DNase I hypersensitive regions, ChIP-seq regions of a number of transcription factors and transcription factor binding motifs, means to explore enhancer interactions with DNA using several chromatin interaction assays and enhancer neighbouring genes.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26342387", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 332, 
          "offsetInEndSection": 446, 
          "text": "We developed DENdb, a centralized on-line repository of predicted enhancers derived from multiple human cell-lines", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26342387", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 448, 
          "offsetInEndSection": 601, 
          "text": "DENdb integrates enhancers predicted by five different methods generating an enriched catalogue of putative enhancers for each of the analysed cell-lines", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26342387", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 603, 
          "offsetInEndSection": 915, 
          "text": "DENdb provides information about the overlap of enhancers with DNase I hypersensitive regions, ChIP-seq regions of a number of transcription factors and transcription factor binding motifs, means to explore enhancer interactions with DNA using several chromatin interaction assays and enhancer neighbouring genes", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26342387", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 917, 
          "offsetInEndSection": 1048, 
          "text": "DENdb is designed as a relational database that facilitates fast and efficient searching, browsing and visualization of information", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26342387", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1050, 
          "offsetInEndSection": 1142, 
          "text": "Database URL: http://www.cbrc.kaust.edu.sa/dendb/.<CopyrightInformation>\u00a9 The Author(s) 2015", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26342387", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 47, 
          "text": "DENdb: database of integrated human enhancers.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26342387", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 1050, 
          "offsetInEndSection": 1101, 
          "text": "Database URL: http://www.cbrc.kaust.edu.sa/dendb/..", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26342387", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 332, 
          "offsetInEndSection": 447, 
          "text": "We developed DENdb, a centralized on-line repository of predicted enhancers derived from multiple human cell-lines.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26342387", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 917, 
          "offsetInEndSection": 1049, 
          "text": "DENdb is designed as a relational database that facilitates fast and efficient searching, browsing and visualization of information.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26342387", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 448, 
          "offsetInEndSection": 602, 
          "text": "DENdb integrates enhancers predicted by five different methods generating an enriched catalogue of putative enhancers for each of the analysed cell-lines.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26342387", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 603, 
          "offsetInEndSection": 916, 
          "text": "DENdb provides information about the overlap of enhancers with DNase I hypersensitive regions, ChIP-seq regions of a number of transcription factors and transcription factor binding motifs, means to explore enhancer interactions with DNA using several chromatin interaction assays and enhancer neighbouring genes.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26342387", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "List scales that are used for scoring of patients with spinal metastasis?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24120144", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25869337", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26713145", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25085251", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24869611", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24912121", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23179121", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26160329", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24212518", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27584676", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27080411", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18787846", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27018903", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21223698", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26602195"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Tokuhashi, Tomita, Bauer, and Oswestry scores are used for survival prediction of patients with spinal metastases."
      ], 
      "exact_answer": [
        [
          "Tokuhashi"
        ], 
        [
          "Tomita"
        ], 
        [
          "Bauer"
        ], 
        [
          "Oswestry"
        ]
      ], 
      "concepts": [
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D009362"
      ], 
      "type": "list", 
      "id": "589a245878275d0c4a000025", 
      "snippets": [
        {
          "offsetInBeginSection": 556, 
          "offsetInEndSection": 682, 
          "text": "METHODS: Outcomes of surgery, prognostic factors for survival, and relevance of Tomita and Tokuhashi scores were investigated.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24120144", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 98, 
          "text": "PURPOSE: To assess variability in the use of Tomita and modified Bauer scores in spine metastases.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25869337", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1111, 
          "offsetInEndSection": 1213, 
          "text": "Only the Tomita scoring system was shown to be an independent prognostic factor for overall survival. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26713145", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1359, 
          "offsetInEndSection": 1462, 
          "text": ".CONCLUSION: The Tomita scoring system represents a practicable and highly predictive prognostic tool. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26713145", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 154, 
          "text": "Analysis of the predictive role and new proposal for surgical strategies based on the modified Tomita and Tokuhashi scoring systems for spinal metastasis.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25085251", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 95, 
          "offsetInEndSection": 276, 
          "text": "We also aimed to evaluate the validity of the prognostic scores in the Tomita and Tokuhashi systems and discuss several aspects to improve the predictive accuracy of these systems. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25085251", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1527, 
          "offsetInEndSection": 1612, 
          "text": "CONCLUSIONS: Tomita scores more accurately predicted survival than Tokuhashi scores. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25085251", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 128, 
          "text": "A comparison of the modified Tokuhashi and Tomita scores in determining prognosis for patients afflicted with spinal metastasis.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24869611", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 103, 
          "offsetInEndSection": 215, 
          "text": " It is for this reason that scoring systems, such as the modified Tokuhashi and Tomita scores, have been created", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24869611", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1417, 
          "offsetInEndSection": 1497, 
          "text": "The modified Tokuhashi score had better accuracy in determining actual survival.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24869611", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 142, 
          "offsetInEndSection": 316, 
          "text": "Tokuhashi, Tomita, Bauer, and Oswestry scores have been devised for survival prediction; however, none of these systems have been evaluated in nasopharyngeal carcinoma (NPC).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24912121", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 2366, 
          "offsetInEndSection": 2491, 
          "text": "All four scoring systems could be used to prognosticate these patients. The modified Tokuhashi score is the best in doing so.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24912121", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1292, 
          "offsetInEndSection": 1399, 
          "text": "Primary tumor type and Tokuhashi score independently predicted survival in patients with spinal metastases.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23179121", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1586, 
          "offsetInEndSection": 1710, 
          "text": " Primary tumor type and Tokuhashi scoring independently predicted survival in patients with spinal metastases after surgery.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23179121", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 977, 
          "offsetInEndSection": 1133, 
          "text": "A predictive score was then developed and compared against that of the modified Bauer score alone in terms of prognosticating 1-year survival after surgery.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26160329", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 2301, 
          "offsetInEndSection": 2456, 
          "text": "Our predictive score performed better than the modified Bauer alone and may be used to predict survival after surgical intervention for metastatic disease.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26160329", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 142, 
          "text": "Tokuhashi Scoring System has limited applicability in the majority of patients with spinal cord compression secondary to vertebral metastasis.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24212518", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 141, 
          "text": "Tokuhashi Scoring System has limited applicability in the majority of patients with spinal cord compression secondary to vertebral metastasis", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24212518", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 121, 
          "offsetInEndSection": 704, 
          "text": "Tokuhashi, Tomita, Bauer, and Oswestry scores have been devised for survival prediction; however, none of these systems have been evaluated in nasopharyngeal carcinoma (NPC).To investigate the accuracy of these scoring systems in predicting survival and to identify prognostic factors for survival of the patients with spinal metastases from NPC.Retrospective analysis of the patients with spinal metastases from NPC who were treated in our institution.The study included 87 patients with spinal metastases from NPC.The primary outcome measure was the survival time of these patients", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24912121", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 2083, 
          "offsetInEndSection": 2267, 
          "text": "Predictive value of survival by modified Tokuhashi score was the highest among all four scoring systems.Patients with spinal metastases from NPC have relatively good survival prognosis", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24912121", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1748, 
          "offsetInEndSection": 1994, 
          "text": "The data of the present study emphasize that the original Bauer score and a modified Bauer score without scoring for pathologic fracture seem to be practicable and highly predictive preoperative scoring systems for patients with spinal metastases", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18787846", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 423, 
          "text": "A retrospective study of 180 patients with lung cancer spinal metastases, wherein prognostic score-predicted survival was compared with actual survival.To evaluate and compare the accuracy of prognostic scoring systems in lung cancer spinal metastases.The modified Tokuhashi, Tomita, modified Bauer, and Oswestry scores are currently used to guide decisions regarding operative treatment of patients with spinal metastases.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27018903", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 180, 
          "text": "To evaluate the predictive values of Tokuhashi score, revised Tokuhashi score and Tomita score systems for life expectancy and treatment options in patients with spinal metastasis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21223698", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 129, 
          "text": "A comparison of the modified Tokuhashi and Tomita scores in determining prognosis for patients afflicted with spinal metastasis.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24869611", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 1789, 
          "offsetInEndSection": 1975, 
          "text": "The combination of Tokuhashi score and Tomita score may be applied to better predict postoperative survival prognosis and guide the surgical options for patients with spinal metastasis..", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21223698", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 291, 
          "offsetInEndSection": 441, 
          "text": "reported a composite model taking into account a modified Bauer score, preoperative albumin, and ambulatory status of patients with spinal metastasis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27080411", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Does NADPH oxidase 5 require any subunit for function?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/21319793", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15994299"
      ], 
      "triples": [], 
      "ideal_answer": [
        "No, NADPH oxidase 5 (NOX5) does not require any subunits for function."
      ], 
      "exact_answer": "no", 
      "concepts": [
        "http://www.uniprot.org/uniprot/NOX5_HUMAN", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D019255", 
        "http://www.uniprot.org/uniprot/NOXO1_HUMAN", 
        "http://www.biosemantics.org/jochem#4270191", 
        "http://amigo.geneontology.org/amigo/term/GO:0016174", 
        "http://amigo.geneontology.org/amigo/term/GO:0016175"
      ], 
      "type": "yesno", 
      "id": "58a5add260087bc10a000022", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 90, 
          "text": "Nox5 forms a functional oligomer mediated by self-association of its dehydrogenase domain.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21319793", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 290, 
          "offsetInEndSection": 399, 
          "text": " While Nox1-4 require regulatory subunits, including p22phox, Nox5 activity does not depend on any subunits. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21319793", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1566, 
          "offsetInEndSection": 1678, 
          "text": " Thus, Nox5 forms a catalytically active oligomer in the membrane that is mediated by its dehydrogenase domain. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21319793", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 652, 
          "offsetInEndSection": 934, 
          "text": "Coexpression of specific Nox catalytic subunits (Nox1, Nox2, Nox3, Nox4, or Nox5) along with their corresponding regulatory subunits (NOXO1/NOXA1 for Nox1; p47phox/p67phox/Rac for Nox2; NOXO1 for Nox3; no subunits for Nox4 or Nox5) resulted in marked production of reactive oxygen. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15994299", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What are the side effects during statins administration in patients with atherosclerosis?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25644328", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26575138", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26490078", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24788803", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24840269", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21267417", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27878791", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21972203", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12891851", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22913216", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21796961", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19039148", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17042673", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25678839", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23299641", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18585718", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24601937", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25936326"
      ], 
      "triples": [], 
      "ideal_answer": [
        "The side effects during statins administration in patients with atherosclerosis are:\n1) Myopathy\n2) Transaminase elevations\n3) Diabetes mellitus \n4) Renal and neurologic adverse effects."
      ], 
      "exact_answer": [
        [
          "Myopathy"
        ], 
        [
          "Transaminase elevations"
        ], 
        [
          "Diabetes mellitus"
        ], 
        [
          "Renal adverse effects"
        ], 
        [
          "Neurologic adverse effects"
        ]
      ], 
      "concepts": [], 
      "type": "list", 
      "id": "589c4c9078275d0c4a000040", 
      "snippets": [
        {
          "offsetInBeginSection": 1081, 
          "offsetInEndSection": 1224, 
          "text": "A history of side effects was reported by 40 (19.5%) of the patients, and mainly consisted of muscle complaints and gastrointestinal symptoms. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25644328", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 56, 
          "text": "Treatment Options for Statin-Associated Muscle Symptoms.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26575138", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 383, 
          "offsetInEndSection": 457, 
          "text": "Muscle symptoms are a clinically relevant side effect of statin treatment.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26575138", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 641, 
          "offsetInEndSection": 727, 
          "text": "At least 5% of patients taking statins have statin-associated muscle symptoms (SAMS). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26575138", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 237, 
          "text": "Muscle problems and other adverse symptoms associated with statin use are frequent reasons for non-adherence and discontinuation of statin therapy, which results in inadequate control of hyperlipidemia and increased cardiovascular risk. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26490078", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 632, 
          "offsetInEndSection": 838, 
          "text": "It was estimated that rosuvastatin-associated absolute hazards of muscle-, liver- and renal-related adverse effects are lower than the corresponding vascular benefits in moderate vascular risk individuals. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24788803", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1654, 
          "offsetInEndSection": 1856, 
          "text": "Rosuvastatin-induced proteinuria appears to be of tubular origin, not relating to kidney injury. Rosuvastatin increases the risk of new-onset diabetes by dose-dependently impairing insulin sensitivity. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24788803", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 469, 
          "offsetInEndSection": 736, 
          "text": "Statins are associated with myopathy, transaminase elevations, and an increased risk of incident diabetes mellitus among some patients; connections between statins and other processes, such as renal and neurologic function, have also been studied with mixed results. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24840269", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 371, 
          "offsetInEndSection": 696, 
          "text": "Muscle symptoms are a clinically relevant side effect of statin treatment.This review is based on pertinent publications retrieved by a selective literature search, and on the current recommendations of the European Atherosclerosis Society.At least 5% of patients taking statins have statin-associated muscle symptoms (SAMS).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26575138", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1018, 
          "offsetInEndSection": 1239, 
          "text": "Nevertheless, patients may develop side effects such as muscle pain and weakness years after starting statin therapy; however, the absolute number of patients affected by statin myopathy increases with treatment duration.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23299641", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1122, 
          "offsetInEndSection": 1311, 
          "text": "Better understanding of the molecular mechanisms involved in statin-induced myopathy may help identify patient groups susceptible to statins' side effects, thereby increasing their safety..", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18585718", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Entresto is composed of which two drugs?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26642078", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26992459", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27284124", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27804100", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27697814", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27378659", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26466333", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26976916", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26417173", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26975167", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26873495"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Entresto is composed of sacubitril and valsartan. It is newly FDA-approved medication that dually inhibits angiotensin and neprilysin, in the treatment of heart failure."
      ], 
      "exact_answer": [
        [
          "sacubitril"
        ], 
        [
          "valsartan"
        ]
      ], 
      "concepts": [], 
      "type": "list", 
      "id": "58962ed178275d0c4a000006", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 342, 
          "text": "The PARADIGM-HF study, a large outcome trial in heart failure and reduced ejection fraction (HFrEF), has recently shown improved cardiovascular outcomes with sacubitril/valsartan (Entresto\u00ae, Novartis), still commonly referred to as LCZ696, compared to ACE-inhibitor therapy, possibly leading us to a new era for heart failure (HF) treatment. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26642078", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 387, 
          "offsetInEndSection": 627, 
          "text": "This article reviews the background, current knowledge and data supporting the use of sacubitril/valsartan (Entresto(\u00ae) ), the newly FDA-approved medication that dually inhibits angiotensin and neprilysin, in the treatment of heart failure.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26992459", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 167, 
          "text": "\u25bc Sacubitril valsartan (Entresto-Novartis) is a new oral drug licensed for the treatment of symptomatic chronic heart failure in adults with reduced ejection fraction.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27284124", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 114, 
          "text": "Rhabdomyolysis After Coadministration of Atorvastatin and Sacubitril/Valsartan (Entresto\u2122) in a 63-Year-Old Woman.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27804100", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 367, 
          "text": "A 63-year-old woman previously stable on a regimen of atorvastatin 40\u00a0mg daily, carvedilol 25\u00a0mg twice daily, digoxin 0.125\u00a0mg daily, furosemide 40\u00a0mg daily, spironolactone 25\u00a0mg daily, rivaroxaban 15\u00a0mg daily, and enalapril 20\u00a0mg twice daily for heart failure developed rhabdomyolysis 26\u00a0days after enalapril was stopped and sacubitril/valsartan (Entresto\u2122) started.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27804100", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 319, 
          "text": "Sacubitril/valsartan [LCZ696 (Entresto), Novartis Pharmaceuticals Corp.] is the first in a new class of drugs that combines neprilysin inhibition with angiotensin II receptor antagonism, the combination of which acts to increase endogenous natriuretic peptides while inhibiting the renin-angiotensin-aldosterone system.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26466333", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 295, 
          "offsetInEndSection": 669, 
          "text": "In July 2015, the US Food and Drug Administration approved the first of a new class of drugs for the treatment of heart failure: Valsartan/sacubitril (formerly known as LCZ696 and currently marketed by Novartis as Entresto) combines the angiotensin receptor blocker valsartan and the neprilysin inhibitor prodrug sacubitril in a 1:1 ratio in a sodium supramolecular complex.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26976916", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 221, 
          "text": "Sacubitril/valsartan (Entresto) for chronic heart failure; brexpiprazole (Rexulti) for major depressive disorder and schizophrenia; and lumacaftor/ivacaftor (Orkambi) for cystic fibrosis involving specific CFTR mutations.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26417173", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 191, 
          "text": "Sacubritil\u2217valsartan (Entresto, Novartis, still commonly referred to as LCZ696) is a combination drug described as a new class of dual-acting angiotensin receptor-neprilysin inhibitor (ARNi).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27378659", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 251, 
          "text": "The molecular combination of sacubitril and valsartan (Entresto) is a new drug for reducing the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection fraction.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26975167", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 457, 
          "text": "\u25bc Sacubitril valsartan (Entresto-Novartis) is a new oral drug licensed for the treatment of symptomatic chronic heart failure in adults with reduced ejection fraction.(1) It is described as an angiotensin receptor neprilysin inhibitor and contains the neprilysin inhibitor, sacubitril and the angiotensin II receptor antagonist, valsartan.(1-3) Here, we review the evidence for sacubitril valsartan and consider its place in the management of heart failure.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27284124", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is the doRiNA database?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/22086949", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25416797"
      ], 
      "triples": [], 
      "ideal_answer": [
        "doRina is a database of RNA interactions in post-transcriptional regulation."
      ], 
      "concepts": [
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D030561", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012323"
      ], 
      "type": "summary", 
      "id": "588f365194c1512c50000003", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 74, 
          "text": "doRiNA: a database of RNA interactions in post-transcriptional regulation.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22086949", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 394, 
          "offsetInEndSection": 1242, 
          "text": " We provide a database that supports the quest for deciphering this regulatory code. Within doRiNA, we are systematically curating, storing and integrating binding site data for RBPs and miRNAs. Users are free to take a target (mRNA) or regulator (RBP and/or miRNA) centric view on the data. We have implemented a database framework with short query response times for complex searches (e.g. asking for all targets of a particular combination of regulators). All search results can be browsed, inspected and analyzed in conjunction with a huge selection of other genome-wide data, because our database is directly linked to a local copy of the UCSC genome browser. At the time of writing, doRiNA encompasses RBP data for the human, mouse and worm genomes. For computational miRNA target site predictions, we provide an update of PicTar predictions.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22086949", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 97, 
          "text": "DoRiNA 2.0--upgrading the doRiNA database of RNA interactions in post-transcriptional regulation.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25416797", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 1050, 
          "offsetInEndSection": 1140, 
          "text": "At the time of writing, doRiNA encompasses RBP data for the human, mouse and worm genomes.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22086949", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 475, 
          "offsetInEndSection": 584, 
          "text": "Within doRiNA, we are systematically curating, storing and integrating binding site data for RBPs and miRNAs.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22086949", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 73, 
          "text": "doRiNA: a database of RNA interactions in post-transcriptional regulation", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22086949", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 479, 
          "offsetInEndSection": 587, 
          "text": "Within doRiNA, we are systematically curating, storing and integrating binding site data for RBPs and miRNAs", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22086949", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1059, 
          "offsetInEndSection": 1148, 
          "text": "At the time of writing, doRiNA encompasses RBP data for the human, mouse and worm genomes", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22086949", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 479, 
          "offsetInEndSection": 589, 
          "text": "Within doRiNA, we are systematically curating, storing and integrating binding site data for RBPs and miRNAs. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22086949", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1059, 
          "offsetInEndSection": 1150, 
          "text": "At the time of writing, doRiNA encompasses RBP data for the human, mouse and worm genomes. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22086949", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 479, 
          "offsetInEndSection": 588, 
          "text": "Within doRiNA, we are systematically curating, storing and integrating binding site data for RBPs and miRNAs.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22086949", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1059, 
          "offsetInEndSection": 1149, 
          "text": "At the time of writing, doRiNA encompasses RBP data for the human, mouse and worm genomes.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22086949", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 98, 
          "text": "DoRiNA 2.0--upgrading the doRiNA database of RNA interactions in post-transcriptional regulation.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25416797", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 75, 
          "text": "doRiNA: a database of RNA interactions in post-transcriptional regulation.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22086949", 
          "endSection": "title"
        }
      ]
    }, 
    {
      "body": "Is NSD-1015 an inhibitor of Aromatic L-Amino Acid Decarboxylase?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26830512", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23940784", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22841861", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20408420", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19168057", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17066255", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24084697", 
        "http://www.ncbi.nlm.nih.gov/pubmed/6811255", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8836582", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10619466", 
        "http://www.ncbi.nlm.nih.gov/pubmed/7616241", 
        "http://www.ncbi.nlm.nih.gov/pubmed/1997008", 
        "http://www.ncbi.nlm.nih.gov/pubmed/3917287", 
        "http://www.ncbi.nlm.nih.gov/pubmed/3103858", 
        "http://www.ncbi.nlm.nih.gov/pubmed/904693", 
        "http://www.ncbi.nlm.nih.gov/pubmed/2414683", 
        "http://www.ncbi.nlm.nih.gov/pubmed/2426412", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20501080", 
        "http://www.ncbi.nlm.nih.gov/pubmed/7664818", 
        "http://www.ncbi.nlm.nih.gov/pubmed/323424", 
        "http://www.ncbi.nlm.nih.gov/pubmed/1663587", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15927700", 
        "http://www.ncbi.nlm.nih.gov/pubmed/1470299", 
        "http://www.ncbi.nlm.nih.gov/pubmed/2320657", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11135014", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16292508", 
        "http://www.ncbi.nlm.nih.gov/pubmed/7692885", 
        "http://www.ncbi.nlm.nih.gov/pubmed/6164221", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12658372", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8371833", 
        "http://www.ncbi.nlm.nih.gov/pubmed/1348847", 
        "http://www.ncbi.nlm.nih.gov/pubmed/6746835", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8287902", 
        "http://www.ncbi.nlm.nih.gov/pubmed/1436125", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11343835", 
        "http://www.ncbi.nlm.nih.gov/pubmed/6432557", 
        "http://www.ncbi.nlm.nih.gov/pubmed/7889269", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8511717", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8361951", 
        "http://www.ncbi.nlm.nih.gov/pubmed/1904482", 
        "http://www.ncbi.nlm.nih.gov/pubmed/6780662", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8096696", 
        "http://www.ncbi.nlm.nih.gov/pubmed/7690229"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Yes, NSD-1015 is an ihnibitor of Aromatic L-Amino Decarboxylase."
      ], 
      "exact_answer": "yes", 
      "concepts": [
        "http://www.biosemantics.org/jochem#http://www.biosemantics.org/jochem#:4251263", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D001142", 
        "http://www.biosemantics.org/jochem#4251263", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D065105", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D024322", 
        "http://amigo.geneontology.org/amigo/term/GO:0004058"
      ], 
      "type": "yesno", 
      "id": "589c334e78275d0c4a00003d", 
      "snippets": [
        {
          "offsetInBeginSection": 1341, 
          "offsetInEndSection": 1550, 
          "text": "When pretreated with a central AADC inhibitor (NSD-1015), further application of l-dopa failed to increase the motoneuron activity although the expression of DA in the AADC cells was not completely inhibited. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26830512", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 609, 
          "offsetInEndSection": 739, 
          "text": "Inhibition of Ddc by AADC inhibitor NSD-1015 or anti-sense morpholino oligonucleotides (MO) reduced brain volume and body length. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23940784", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 399, 
          "offsetInEndSection": 577, 
          "text": "We evaluated this in vivo by reverse dialysis of the aromatic-l-amino-acid decarboxylase (EC 4.1.1.28) inhibitor NSD-1015 (20\u03bcM) and selected concentrations of l- or d-tyrosine. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22841861", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1, 
          "offsetInEndSection": 296, 
          "text": "Neurochemical study of effects of the new anxiolytic drugs afobazol and ladasten on the synthesis and metabolism of monoamines and their metabolites in the brain structures of Wistar rat on the model of monoamine synthesis blockade induced by aromatic amino acid decarboxylase inhibitor NSD-1015", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20408420", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 401, 
          "text": "To establish the neurotransmitter role(s) of L-3,4-dihydroxyphenylalanine (DOPA) in its own right, we attempted to clarify whether i.p. injection of a DOPA antagonist, DOPA cyclohexyl ester (CHE), would antagonize the behavioral responses of conscious rats to DOPA in the presence of 3-hydroxybenzylhydrazine (NSD-1015) (100 mg/kg i.p.), a central aromatic L-amino acid decarboxylase (AADC) inhibitor.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19168057", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 245, 
          "offsetInEndSection": 459, 
          "text": "TH and TPH activities were determined in tissue extracts by measuring the accumulation of L-Dopa and 5-HTP respectively, following the administration of the aromatic L-amino acid decarboxylase inhibitor, NSD-1015. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17066255", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 342, 
          "text": "Results of a neurochemical study of the effects of the new anxiolytic drugs afobazole and ladasten on the synthesis and metabolism of monoamines and their metabolites determined by HPLC on the model of monoamine synthesis blockade induced by NSD-1015 (aromatic L-amino acid decarboxylase) in the brain structures of Wistar rats are reported. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20408420", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1339, 
          "offsetInEndSection": 1397, 
          "text": ". When pretreated with a central AADC inhibitor (NSD-1015)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26830512", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 815, 
          "offsetInEndSection": 848, 
          "text": "NSD 1015 (general AADC inhibitor)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24084697", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 202, 
          "offsetInEndSection": 289, 
          "text": "monoamine synthesis blockade induced by NSD-1015 (aromatic L-amino acid decarboxylase) ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20408420", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 448, 
          "offsetInEndSection": 520, 
          "text": "the aromatic-l-amino-acid decarboxylase (EC 4.1.1.28) inhibitor NSD-1015", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22841861", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 386, 
          "text": "An accumulation of L-dihydroxyphenylalanine (DOPA) in the median eminence of female rats treated with 3-hydroxybenzylhydrazine (NSD 1015), and inhibitor of aromatic L-amino acid decarboxylase (DOPA decarboxylase) activity, was associated with a decreased concentration of dopamine in the median eminence and pronounced reduction in the release of dopamine into hypophysial portal blood.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6811255", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 787, 
          "offsetInEndSection": 1019, 
          "text": "6S-BH4 increased extracellular DOPA levels in the presence of NSD 1015, an inhibitor of aromatic L-amino acid decarboxylase (an index of in vivo tyrosine hydroxylase activity), to an extent similar to the increase induced by 6R-BH4.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7616241", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 515, 
          "offsetInEndSection": 774, 
          "text": "5-HT synthesis was estimated by measuring the accumulation of the 5-HT precursor, 5-hydroxytryptophan (5-HTP), in the neurointermediate lobe of male Long-Evans rats following the administration of NSD 1015, an inhibitor of aromatic L-amino acid decarboxylase.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3103858", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 804, 
          "offsetInEndSection": 1062, 
          "text": "Monoamine synthesis was studied in different parts of the brain by measuring the accumulated dopa and 5-hydroxytryptophan (5-HTP), 30 min after NSD 1015 (3-hydroxybenzylhydrazine HCl, 100 mg/kg) an inhibitor of aromatic L-amino-acid decarboxylase, given i.p.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/904693", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 377, 
          "text": "HPLC coupled with electrochemical detection was used to make concurrent measurements of the rate of accumulation of 5-hydroxytryptophan and 3,4-dihydroxyphenylalanine in selected brain regions (striatum, nucleus accumbens, septum, medial periventricular hypothalamus) and thoracic spinal cords of rats treated with NSD 1015, an inhibitor of aromatic-L-amino-acid decarboxylase.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3917287", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 551, 
          "text": "The activity of 5-hydroxytryptaminergic neurons has been estimated from measurements of: concentrations of 5-hydroxyindoleacetic acid; the ratio of the concentrations of 5-hydroxyindoleacetic acid to 5-hydroxytryptamine; the rate of accumulation of 5-hydroxytryptophan following the administration of an aromatic L-amino acid decarboxylase inhibitor (e.g., NSD 1015); the rate of accumulation of 5-hydroxytryptamine, and the rate of decline of 5-hydroxyindoleacetic acid following the administration of a monoamine oxidase inhibitor (e.g., pargyline).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2426412", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1006, 
          "offsetInEndSection": 1183, 
          "text": "The accumulation of dopa (3,4-dihydroxyphenylalanine) after administration of NSD 1015 to inhibit aromatic l-amino acid decarboxylase was determined as an index of NE synthesis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20501080", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 148, 
          "text": "The central aromatic amino acid DOPA decarboxylase inhibitor, NSD-1015, does not inhibit L-DOPA-induced circling in unilateral 6-OHDA-lesioned-rats.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11135014", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 184, 
          "text": "The centrally acting aromatic amino acid dopa decarboxylase (AADC) inhibitor, 3-hydroxybenzyl hydrazine (NSD-1015), is widely used to study the neurotransmitter-like actions of L-DOPA.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11135014", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 115, 
          "text": "The aromatic amino acid decarboxylase inhibitor, NSD-1015, increases release of dopamine: response characteristics.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1470299", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 450, 
          "offsetInEndSection": 549, 
          "text": "The aromatic amino acid decarboxylase inhibitor NSD 1015 markedly increased the dopa concentration.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6164221", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 343, 
          "text": "Using a microdialysis technique, the rat striatum was perfused with NSD-1015, an inhibitor of aromatic L-amino acid decarboxylase, and the amount of L-3,4-dihydroxyphenylalanine (L-DOPA) and 5-hydroxytryptophan (5-HTP) accumulating in dialysate was measured as an index of in vivo activities of tyrosine hydroxylase and tryptophan hydroxylase.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7692885", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 308, 
          "offsetInEndSection": 489, 
          "text": "Also, we studied the effect of MnCl2 on extracellular levels of l-Dopa in the presence of aromatic amino acid decarboxylase (AADC) inhibitor 3-hydroxybencilhydracine-HCl (NSD 1015).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16292508", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 102, 
          "offsetInEndSection": 283, 
          "text": "The role of L-DOPA itself was investigated by administering several doses of an aromatic L-amino acid decarboxylase inhibitor, NSD 1015, prior to 100 mg/kg L-DOPA to 5-day-old rats.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8836582", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 387, 
          "text": "An accumulation of L-dihydroxyphenylalanine (DOPA) in the median eminence of female rats treated with 3-hydroxybenzylhydrazine (NSD 1015), and inhibitor of aromatic L-amino acid decarboxylase (DOPA decarboxylase) activity, was associated with a decreased concentration of dopamine in the median eminence and pronounced reduction in the release of dopamine into hypophysial portal blood. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6811255", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 298, 
          "text": "[Neurochemical study of effects of the new anxiolytic drugs afobazol and ladasten on the synthesis and metabolism of monoamines and their metabolites in the brain structures of Wistar rat on the model of monoamine synthesis blockade induced by aromatic amino acid decarboxylase inhibitor NSD-1015].", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20408420", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 149, 
          "text": "DOPA was measured in the anterior pituitary and hypothalamic-hypophysial portal blood after treatment with NSD-1015, a DOPA decarboxylase inhibitor. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1348847", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 116, 
          "text": "Central action of an inhibitor of brain dopa-decarboxylase, NSD-1015, on cyanamide-induced alcohol drinking in rats.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2320657", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 102, 
          "offsetInEndSection": 284, 
          "text": "The role of L-DOPA itself was investigated by administering several doses of an aromatic L-amino acid decarboxylase inhibitor, NSD 1015, prior to 100 mg/kg L-DOPA to 5-day-old rats. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8836582", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 185, 
          "text": "The centrally acting aromatic amino acid dopa decarboxylase (AADC) inhibitor, 3-hydroxybenzyl hydrazine (NSD-1015), is widely used to study the neurotransmitter-like actions of L-DOPA. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11135014", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 643, 
          "offsetInEndSection": 944, 
          "text": "Furthermore, the ethanol-induced enhancement of 3,4-dihydroxyphenylalanine accumulation in the mesolimbic dopamine terminal area after NSD 1015 (an inhibitor of l-aromatic amino acid decarboxylase) was completely antagonized by mecamylamine in doses (3.0 and 6.0 mg/kg) that exerted no effects per se.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8287902", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 271, 
          "offsetInEndSection": 630, 
          "text": "The acetylcholinesterase inhibitor physostigmine (0.5 mg/kg s.c.) enhanced L-dihydroxyphenylalanine (DOPA) and 3,4-dihydroxyphenylacetic acid (DOPAC) levels in both the corpus striatum and limbic areas (nucleus accumbens) after inhibition of aromatic amino acid decarboxylase with NSD-1015, indicating an enhanced synthesis of dopamine in these brain regions.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1436125", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1021, 
          "offsetInEndSection": 1376, 
          "text": "Estradiol benzoate-treated rats had significantly lower anterior pituitary DOPA accumulation after intraperitoneal administration of 3,4-hydroxybenzyl-hydrazine dihydrochloride (NSD-1015), an irreversible inhibitor of L-aromatic amino acid decarboxylase whereas methylene blue did not affect anterior pituitary DOPA accumulation when compared to controls.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11343835", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 260, 
          "offsetInEndSection": 433, 
          "text": "The accumulation of dihydroxyphenylalanine (DOPA) following administration of the L-aromatic amino acid decarboxylase inhibitor, NSD 1015, was used to estimate DA synthesis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6432557", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1016, 
          "offsetInEndSection": 1189, 
          "text": "Inhibition of PE synthesis by i.p. injection of the aromatic L-amino acid decarboxylase inhibitor, NSD 1015, produced a reversal of the effects of MDL 72,145 and Ro 19-6327.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7889269", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 275, 
          "offsetInEndSection": 482, 
          "text": "After 42 hr of abstinence, rats were challenged with either cocaine (15 mg/kg, ip) or saline, followed by the aromatic L-amino acid decarboxylase inhibitor 3-hydroxybenzylhydrazine (NSD-1015; 100 mg/kg, ip).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8511717", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 304, 
          "offsetInEndSection": 633, 
          "text": "Following motor activity observations, the cerebral aromatic L-amino acid decarboxylase inhibitor NSD-1015 (100 mg kg-1 intraperitoneally) was administered and 30 min. later the animals were decapitated for subsequent analysis of the accumulated forebrain DOPA and 5-HTP levels, as an estimate of the rate of monoamine synthesis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8361951", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 566, 
          "offsetInEndSection": 834, 
          "text": "The utility of this technique was demonstrated by comparing the effects on the scans of halothane and pentobarbital anesthesia and by the administration of NSD 1015, a peripheral and central inhibitor of L-aromatic amino-acid decarboxylase, between back-to-back scans.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1904482", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 351, 
          "offsetInEndSection": 571, 
          "text": "Addition of the aromatic amino acid decarboxylase inhibitor, 3-hydroxybenzylhydrazine (NSD 1015), prevented the formation of N-acetylcompounds from L-[3H]tyrosine, without resulting in an accumulation of label in L-DOPA.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6780662", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 272, 
          "text": "The effects of the peripheral aromatic amino acid decarboxylase (AADC) inhibitors, carbidopa and benserazide, and the central AADC inhibitor, 3-hydroxybenzylhydrazine (NSD-1015) on peripheral and brain monoamine oxidase (MAO) A and B activity were investigated in the rat.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12658372", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 847, 
          "offsetInEndSection": 1105, 
          "text": "Although the putative role of NSD-1015 is as an aromatic amino acid decarboxylase inhibitor, the present results demonstrate that, either as a result of this function and/or in addition to this role, NSD-1015 is a potent activator of the release of dopamine.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1470299", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 116, 
          "text": "The aromatic amino acid decarboxylase inhibitor, NSD-1015, increases release of dopamine: response characteristics.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1470299", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 149, 
          "text": "The central aromatic amino acid DOPA decarboxylase inhibitor, NSD-1015, does not inhibit L-DOPA-induced circling in unilateral 6-OHDA-lesioned-rats.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11135014", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 472, 
          "offsetInEndSection": 697, 
          "text": "The L-aromatic amino acid decarboxylase inhibitor, NSD-1015 (3-hydroxybenzylhydrazine dihydrochloride) was then given ICV twice daily in a volume of 5.0 microliters in the following doses: 0.005, 0.01, 0.1 and 1.0 micrograms.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2320657", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 847, 
          "offsetInEndSection": 1106, 
          "text": "Although the putative role of NSD-1015 is as an aromatic amino acid decarboxylase inhibitor, the present results demonstrate that, either as a result of this function and/or in addition to this role, NSD-1015 is a potent activator of the release of dopamine..", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1470299", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Is pseudouridine a RNA modification?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25616362", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15659360", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20106954"
      ], 
      "triples": [], 
      "ideal_answer": [
        "Yes, pseudouridine (\u03a8) is the most abundant of>150 nucleoside modifications in RNA."
      ], 
      "exact_answer": "yes", 
      "concepts": [], 
      "type": "yesno", 
      "id": "58bbb77e22d3005309000017", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 79, 
          "text": "Pseudouridine (\u03a8) is the most abundant of>150 nucleoside modifications in RNA. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25616362", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 292, 
          "text": "The number and position of the pseudouridines of Haloarcula marismortui and Deinococcus radiodurans large subunit RNA have been determined by a combination of total nucleoside analysis by HPLC-mass spectrometry and pseudouridine sequencing by the reverse transcriptase method and by LC/MS/MS.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15659360", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 109, 
          "text": "Pseudouridine is the most abundant of more than 100 chemically distinct natural ribonucleotide modifications.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20106954", 
          "endSection": "abstract"
        }
      ]
    }
  ]
}